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  symptoms	  
	   2.6.2.2.5	  	  	  Management	  of	  restenosis	  
	   	   	  	  	  	  	  	  2.6.2.2.5.1	  	  	  Symptomatic	  restenoses	  	  
	   	   	  	  	  	  	  	  2.6.2.2.5.2	  	  	  Asymptomatic	  restenoses	  	  
	   	   	  	  	  	  	  	  2.6.2.2.5.3	  	  	  Redo	  endarterectomy	  or	  stenting?	  
	   	   	  
	  
2.7	  	  Management	  of	  concurrent	  coronary	  and	  cardiac	  disease	  
2.7.1	  	  	  Is	  carotid	  disease	  a	  cause	  of	  stroke	  during	  cardiac	  surgery?	  
2.7.2	  	  	  What	  is	  the	  value	  of	  screening	  patients	  prior	  to	  cardiac	  surgery?	  
2.7.3	  	  	  Are	  carotid	  interventions	  indicated	  in	  cardiac	  surgery	  patients?	  
2.7.4	  	  	  What	  surgical/endovascular	  options	  are	  available?	  
2.7.5	  	  	  Managing	  patients	  with	  unstable	  coronary	  artery	  disease	  
	  
	  
2.8	  	  	  Carotid	  disease	  and	  major	  non-­‐cardiac	  surgery	  
2.8.1	  	  	  Prevalence	  of	  stroke	  after	  major	  non-­‐cardiac	  surgery	  
2.8.2	  	  	  Prediction	  of	  stroke	  after	  major	  non-­‐cardiac	  surgery	  
2.8.3	  	  	  Timing	  of	  major	  surgery	  after	  recent	  stroke	  
2.8.4	  	  	  Is	  there	  a	  role	  for	  prophylactic	  carotid	  endarterectomy	  or	  stenting?	  
	  
	  
2.9	   Occlusive	   disease	   of	   proximal	   common	   carotid	   and	   innominate	  
arteries	   	  
2.9.1	  	  Introduction	  
2.9.2	  	  Clinical	  presentation	  
2.9.3	  	  Indications	  for	  revascularization	  
2.9.4	  	  Endovascular	  versus	  open	  reconstruction	  
2.9.5	  	  Open	  revascularisation:	  cervical	  versus	  transthoracic	  reconstruction	  
2.9.6	  	  Tandem	  proximal	  inflow	  and	  internal	  carotid	  artery	  disease	  
	  
	  
2.10	  	  Unresolved	  issues	  relating	  to	  managing	  carotid	  artery	  disease	  
	  
Section	  3:	  Management	  of	  vertebral	  artery	  disease	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3.1	  	  Introduction	  	  	  	   	   	   	   	   	  
3.1.1	  	  	  Burden	  of	  vertebrobasilar	  stroke	  
3.1.2	  	  	  Aetiology	  of	  vertebrobasilar	  stroke	  
3.1.3	  	  	  Symptoms	  attributable	  to	  vertebral	  artery	  disease	  
3.1.4	  	  	  Imaging	  strategies	  in	  vertebral	  artery	  disease	  	  
	  
	  
3.2	  	  Secondary	  prevention	  in	  asymptomatic	  patients	  
	  
3.2.1	  	  Optimal	  medical	  therapy	  
3.2.1.1	  	  Risk	  factor	  control	  
3.2.1.2	  	  Antiplatelet	  therapy	  
3.2.1.3	  	  Lipid	  lowering	  therapy	   	  
3.2.1.4	  	  Treatment	  of	  hypertension	  
3.2.1.5.	  Treatment	  in	  diabetic	  patients	   	   	  
	  
	  
3.2.2	  	  	  Screening	  for	  asymptomatic	  vertebral	  artery	  disease	  
	  
3.2.3	  	  	  Interventions	  for	  asymptomatic	  vertebral	  artery	  disease	  
	  
3.3	  	  	  Tertiary	  prevention	  in	  recently	  symptomatic	  patients	  
3.3.1	  	  	  	  	  Optimal	  medical	  therapy	  
3.3.2	  	  	  	  	  Interventions	  in	  recently	  symptomatic	  patients	  with	  VA	  stenoses	  
3.3.2.1	  	  Role	  of	  vertebral	  revascularisation	  in	  ‘positional	  vertigo	  
3.3.3	  	  Open	  surgical	  management	  
3.3.4	  	  	  Endovascular	  treatment	  	  
3.3.4.1	  	  	  Stents	  vs	  medical	  therapy	  
3.3.4.2	  	  	  Adjuvant	  medical	  therapy	  
	   	   3.3.4.3	  	  	  Access	  
	   	   3.3.4.4	  	  	  Choice	  of	  wires,	  access	  catheters,	  stent	  design	  
	   	   3.3.4.5	  	  	  Cerebral	  protection	  devices	  
	   	   3.3.4.6	  	  	  Predilatation	  
	  
3.4	  	  	  Complications	  after	  vertebral	  interventions	  
3.4.1	  	  	  Complications	  after	  surgical	  reconstructions	  
3.4.2	  	  	  Complications	  after	  endovascular	  interventions	  
3.4.3	  	  	  Restenosis	  after	  vertebral	  revascularisations	  
	  
	  
3.5	  	  Surveillance	  strategies	  after	  vertebrobasilar	  reconstructions	  
	  
3.6:	  Unresolved	  issues	  relating	  to	  vertebral	  artery	  disease	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What	  have	  the	  2017	  guidelines	  added	  to	  the	  2009	  Guidelines?	  
	  
 Updated	   analysis	   of	   evidence	   supporting	   the	   prevention	   of	   stroke	   in	   patients	  with	  
asymptomatic	  and	  symptomatic	  carotid	  disease.	  
	  
 New	  section	   incorporating	  evidence	  supporting	  the	  prevention	  of	  stroke	   in	  patients	  
with	  atherosclerotic	  vertebral	  artery	  disease.	  
	  
 New	  sections	  on	  screening	  for	  asymptomatic	  carotid	  disease	  and	  the	  potential	  role	  of	  
carotid	  interventions	  in	  preventing	  dementia	  
	  
 New	  section	  on	  the	  evidence	  supporting	  rapid	  interventions	  in	  recently	  symptomatic	  
patients	  and	  the	  timing	  of	  interventions	  after	  thrombolysis	  
	  
 New	   section	   on	   the	   evidence	   supporting	   patching,	   shunting,	   endarterectomy	  
method,	   protamine	   reversal,	   treatment	   of	   coils	   and	   kinks,	   antegrade	   versus	  
retrojugular	  exposure,	  sinus	  nerve	  blockade	  and	  the	  role	  of	  monitoring.	  
	  
 New	  section	  on	   the	  evidence	   supporting	   various	   carotid	   artery	   stenting	   techniques	  
including	   adjuvant	   medical	   therapy,	   wires,	   catheters	   and	   stents	   and	   cerebral	  
protections	  devices.	  
	  
 New	   section	   on	   the	   evidence	   for	   managing	   complications	   following	   carotid	  
interventions	   including	   stroke,	   hypotension,	   hypertension,	   haematoma,	   patch	  
infection,	  restenosis.	  
	  
 New	  section	  on	  the	  management	  of	  concurrent	  carotid	  and	  cardiac	  disease	  
	  
 New	   section	   on	   the	   management	   of	   patients	   with	   asymptomatic	   carotid	   stenoses	  
undergoing	  major	  non-­‐cardiac	  surgical	  procedures.	  
	  
 New	  section	  on	  managing	  patients	  with	  occlusive	  disease	  of	   the	  proximal	   common	  








AAA	   	   abdominal	  aortic	  aneurysm	  
ACAS	   	   Asymptomatic	  Carotid	  Atherosclerosis	  Study	  
ACE	   	   Angiotensin	  Converting	  Enzyme	  
ACES	   	   asymptomatic	  carotid	  emboli	  study	  
ACS	   	   asymptomatic	  carotid	  stenosis	  
ACSRS	   	   Asymptomatic	  Carotid	  Stenosis	  and	  Risk	  of	  Stroke	  
ACST-­‐1	   	   Asymptomatic	  Carotid	  Surgery	  Trial	  (first	  trial)	  
ACST-­‐2	   	   Asymptomatic	  Carotid	  Surgery	  Trial	  (second	  trial)	  
ACT-­‐1	   	   Asymptomatic	  Carotid	  Trial	  (first	  trial)	  
ACTRIS	   	   Asymptomatic	  Carotid	  artery	  Stenosis	  at	  higher	  risk	  than	  average	  risk	  of	  ipsilateral	  stroke	  
AF	   	   atrial	  fibrillation	  
AHA	   	   American	  Heart	  Association	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AMBDAP	   AMBulatory	  Dual	  Anti-­‐Platelet	  
ARR	   	   absolute	  risk	  reduction	  
ARWMC	  	   age-­‐related	  white-­‐matter	  change	  
Bd	   	   bis	  die	  (twice	  daily)	  
BMS	   	   bare	  metal	  stent	  
BMT	   	   best	  medical	  therapy	  
BP	   	   blood	  pressure	  
CABG	   	   Coronary	  Artery	  Bypass	  Graft	  
CAD	   	   coronary	  artery	  disease	  
CAPRIE	   	   Clopidogrel	  versus	  Aspirin	  in	  Patients	  at	  Risk	  of	  Ischaemic	  Events	  
CAPTURE	   Carotid	  stent	  systems	  and	  embolic	  protection	  systems	  
CARE	   	   Carotid	  Artery	  Revascularization	  and	  Endarterectomy	  
CAS	   	   carotid	  artery	  stenting	  
CAVATAS	   Carotid	  and	  Vertebral	  Artery	  Transluminal	  Angioplasty	  Study	  
CCA	  	   	   common	  carotid	  artery	  
CCB	   	   calcium	  channel	  blocker	  
CCF	   	   congestive	  cardiac	  failure	  
CEA	   	   carotid	  endarterectomy	  
CEMRA	   	   contrast	  enhanced	  magnetic	  resonance	  angiography	  
CETC	   	   carotid	  Endarterectomy	  Trialists	  Collaboration	  
CFA	   	   common	  femoral	  artery	  
CHANCE	  	   Clopidogrel	  in	  High-­‐risk	  patients	  with	  Acute	  Nondisabling	  Cerebrovascular	  Events	  
CHARISMA	   Clopidogrel	  for	  High	  Atherothrombotic	  Risk	  and	  Ischemic	  Stabilization,	  Management,	  and	  
Avoidance	  	  
CI	   	   Confidence	  Interval	  
CMS	   	   Centre	  for	  Medicare	  and	  Medicaid	  Services	  
CNI	   	   cranial	  nerve	  injury	  
COPD	   	   Chronic	  obstructive	  pulmonary	  disease	  
CPD	   	   cerebral	  protection	  device	  
CREST	   	   Carotid	  Revascularization	  versus	  Stenting	  Trial	  
CSN	   	   carotid	  sinus	  nerve	  
CSTS	   	   Carotid	  Stent	  Trialists	  Collaboration	  
CT	   	   computerised	  tomography	  
CTA	   	   computerised	  tomography	  angiography	  
CVR	   	   cerebral	  vascular	  reserve	  
DAPT	   	   dual	  antiplatelet	  therapy	  
DES	   	   drug	  eluting	  stent	  
DSA	   	   digital	  subtraction	  angiography	  
DUS	   	   Duplex	  ultrasound	  
DWI	   	   diffusion	  weighted	  imaging	  
ECA	   	   external	  carotid	  artery	  
EC	  IC	   	   extracranial	  intracranial	  
ECST	   	   European	  Carotid	  Surgery	  Trial	  
EDV	   	   end-­‐diastolic	  velocity	  
EEG	   	   electroencephalography	  
EJVES	   	   European	  Journal	  of	  Vascular	  and	  Endovascular	  Surgery	  
ENT	   	   Ear	  Nose	  and	  Throat	  Surgeon	  
ESC	   	   European	  Society	  of	  Cardiology	  
ESPRIT	   	   European-­‐Australasian	  Stroke	  Prevention	  in	  Reversible	  Ischaemia	  Trial	  
ESPS-­‐2	   	   European	  Stroke	  Prevention	  Study-­‐2	  
ESVS	   	   European	  Society	  of	  Vascular	  Surgery	  
EVA-­‐3S	   	   Endarterectomy	  versus	  Stenting	  in	  patients	  with	  Symptomatic	  Severe	  carotid	  Stenosis	  
FLAIR	   	   Fluid-­‐attenuated	  inversion	  recovery	  
GA	   	   general	  anaesthesia	  
GALA	   	   General	  Anaesthesia	  versus	  Local	  Anaesthesia	  
GC	   	   Guideline	  Committee	  
HDU	   	   high	  dependency	  unit	  
HR	   	   Hazard	  ratio	  
HS	   	   hyperperfusion	  syndrome	  
HTA	   	   Health	  Technology	  Assessment	  
HRQoL	   	   Health	  Related	  Quality	  of	  Life	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ICA	   	   internal	  carotid	  artery	  
ICH	   	   intracerebral	  haemorrhage	  
ICSS	   	   International	  Carotid	  Stenting	  Study	  
IMT	   	   intima	  media	  thickness	  
ISR	   	   instent	  restenosis	  
IVT	   	   intravenous	  thrombolysis	  
LDL	   	   low	  density	  lipoprotein	  
LMWH	   	   low	  molecular	  weight	  heparin	  
LRA	   	   locoregional	  anaesthesia	  
MCA	   	   middle	  cerebral	  artery	  
MDT	   	   multi-­‐disciplinary	  team	  
MES	   	   microembolic	  signals	  
MI	   	   myocardial	  infarction	  
MMSE	   	   Mini	  Mental	  State	  Examination	  
MRA	   	   magnetic	  resonance	  angiography	  
MRI	   	   magnetic	  resonance	  imaging	  
NASCET	   	   North	  American	  Symptomatic	  Carotid	  Endarterectomy	  Trial	  
NICE	   	   National	  Institute	  for	  Health	  and	  Care	  Excellence	  
NSQIP	   	   National	  Surgical	  Quality	  Improvement	  Program	  
NSTEMI	   	   non	  ST	  elevation	  myocardial	  infarction	  
OR	   	   Odds	  Ratio	  
PAD	   	   peripheral	  arterial	  disease	  
PCA	   	   posterior	  cerebral	  artery	  
PPI	   	   proton	  pump	  inhibitor	  
PRoFESS	  	   Prevention	  Regimen	  for	  Effectively	  Avoiding	  Second	  Strokes	  
PSV	   	   peak	  systolic	  velocity	  
PTA	   	   percutaneous	  transluminal	  angioplasty	  
PTFE	   	   Polytetrafluoroethylene	  
RASP	   	   rapid	  access	  stroke	  prevention	  
RCT	   	   randomised	  controlled	  trial	  
rTPA	   	   recombinant	  Tissue	  Plasminogen	  Activator	  
RR	   	   relative	  risk	  
RRI	   	   relative	  risk	  increase	  
RRR	   	   relative	  risk	  reduction	  
SAPPHIRE	   Stenting	  &	  Angioplasty	  with	  Protection	  in	  Patients	  at	  High	  Risk	  for	  Endarterectomy	  
SAMMPRIS	   Stenting	  and	  Aggressive	  Medical	  Management	  for	  Preventing	  Recurrent	  Stroke	  and	  Intracranial	  
Stenosis	  
SVS	   	   Society	  of	  Vascular	  Surgery	  
SPACE	   	   Stent	  Protected	  Angioplasty	  versus	  Carotid	  Endarterectomy	  
SPARCL	   	   Stroke	  Prevention	  by	  Aggressive	  Reduction	  in	  Cholesterol	  Levels	  
SSYLVIA	   	   Stenting	  of	  Symptomatic	  Atherosclerotic	  Lesions	  in	  the	  Vertebral	  or	  Intracranial	  Arteries	  
SVACS	   	   Symptomatic	  Veterans	  Affairs	  Carotid	  Study	  
TIA	   	   Transient	  ischaemic	  attack	  
TCD	   	   Transcranial	  Doppler	  
USPSTF	   	   US	  Preventive	  Services	  Taskforce	  
VACS	   	   Veteran’s	  Affairs	  Co-­‐operative	  Study	  
VA	   	   vertebral	  artery	  
VAST	   	   Vertebral	  Artery	  Stenting	  Trial	  
VIST	   	   Vertebral	  Artery	  Ischaemia	  Stenting	  Trial	  
VSGNE	   	   The	  Vascular	  Surgery	  Group	  of	  New	  England	  
WG	   	   Writing	  Group
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Section	  1:	  Methodology	  and	  Grading	  of	  Recommendations	  	  
1.1	  Purpose	  of	  these	  Guidelines	  	  
The	  European	  Society	  of	  Vascular	  Surgery	  (ESVS)	  has	  prepared	  guidelines	  for	  treating	  patients	  
with	   atherosclerotic	   carotid	   and	   vertebral	   artery	   (VA)	   disease.	   It	   does	   not	   include	   non-­‐
atherosclerotic	   conditions	   such	   as	   fibromuscular	   dysplasia,	   dissection,	   arteritis	   or	   trauma.	  
Potential	  users	  include	  vascular	  surgeons,	  neurologists,	  stroke	  physicians,	  angiologists,	  primary	  
care	  physicians,	  cardiologists	  and	   interventional	  radiologists.	  Guidelines	  promote	  standards	  of	  
care,	  based	  on	  evidence.	  However,	  they	  should	  not	  be	  viewed	  as	  the	  legal	  standard	  of	  care.	  This	  
document	   is	   a	   ’guiding	   principle’	   and	   care	   given	   depends	   upon	   the	   individual	   patient	  
(presentation,	  comorbidities,	  age)	  and	  treatment	  setting	  (techniques	  available,	  local	  expertise).	  	  
	  
1.2	  Writing	  Group	  
Writing	  Group	  (WG)	  members	  were	  selected	  by	  the	  ESVS	  to	  represent	  clinicians	  involved	  in	  the	  
treatment	  of	  carotid	  and	  VA	  disease.	  WG	  members	  provided	  disclosure	  statements	   regarding	  
relationships	   that	   might	   be	   perceived	   as	   real	   or	   potential	   conflicts	   of	   interest,	   which	   are	  
available	   at	   ESVS	   headquarters.	   WG	   members	   received	   no	   financial	   support	   from	   any	  
pharmaceutical,	  device,	  or	  surgical	  industry.	  	  
	  
1.3	  Evidence	  Collection	  	  
The	  WG	   held	   an	   introductory	   meeting	   in	   Copenhagen	   in	   November	   2014,	   where	   the	   list	   of	  
topics	   and	   author	   tasks	   were	   allocated.	   The	   WG	   agreed	   a	   literature	   search	   strategy	   using	  
Medline,	  Embase,	  Cardiosource	  Clinical	  Trials	  Database	  and	  the	  Cochrane	  Library	  databases	  up	  
to	  December	  31st	  2016.	  Reference	  checking	  and	  journal	  hand	  searching	  added	  other	  literature.	  
Only	   peer-­‐reviewed,	   published	   literature	   and	   studies	   presenting	   predefined	   outcomes	   were	  
considered.	  The	  selection	  process	  followed	  the	  ’pyramid	  of	  evidence’,	  with	  systematic	  reviews	  
and	   meta-­‐analyses	   at	   the	   top,	   then	   randomised	   controlled	   trials	   (RCTs),	   then	   observational	  
studies.	  Case	  reports	  and	  abstracts	  were	  excluded,	  leaving	  expert	  opinion	  at	  the	  bottom.	  	  
	  
1.4	  Recommendations	  
The	  European	  Society	  of	  Cardiology	  (ESC)	  system	  was	  used	  for	  grading	   levels	  of	  evidence	  and	  
class	  of	  	  recommendation.	  The	  letter	  A,	  B,	  or	  C	  reflects	  the	  level	  of	  evidence	  (Figure	  1)	  and	  each	  
recommendation	   was	   graded	   class	   I,	   IIa,	   IIb,	   or	   III	   (Figure	   2).	   WG	   members	   reviewed	   each	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chapter	  of	  the	  evolving	  guideline	  on	  several	  occasions.	  Following	  preparation	  of	  the	  first	  draft,	  
WG	   members	   participated	   in	   a	   teleconference	   where	   the	   wording/grading	   of	   each	  
recommendation	  was	  reviewed.	  If	  there	  was	  not	  unanimous	  agreement,	  discussions	  were	  held	  
to	  decide	  how	  a	  consensus	  might	  be	  achieved.	  If	  this	  failed,	  then	  the	  wording,	  grade	  and	  level	  
of	  evidence	  was	  secured	  via	  a	  majority	  vote	  of	  the	  WG	  members.	  
	  
Figure	  1.	  Level	  of	  evidence.	  	  
Level	  of	  Evidence	  A	   Data	  derived	  from	  multiple	  randomised	  clinical	  trials	  or	  meta-­‐analyses	  
Level	  of	  Evidence	  B	   Data	   derived	   from	   a	   single	   randomised	   clinical	   trial	   or	   large	   non-­‐
randomised	  studies	  




Figure	  2.	  Class	  of	  Recommendation.	  	  
	  
Class	  I	   Evidence	  and/or	  general	  agreement	  that	  a	  given	  treatment	  
or	  procedure	  is	  beneficial,	  useful,	  effective	  
Class	  II	   Conflicting	   evidence	   and/or	   a	   divergence	   of	   opinion	   about	  
the	  usefulness/efficacy	  of	  the	  given	  treatment	  or	  procedure	  
Class	  IIa	   Weight	   of	   evidence/opinion	   is	   in	   favour	   of	  
usefulness/efficacy	  
Class	  IIb	   Usefulness/efficacy	   is	   less	   well	   established	   by	  
evidence/opinion	  
Class	  III	   Evidence	  or	  general	  agreement	  that	  the	  given	  treatment	  or	  
procedure	  is	  not	  useful/effective,	  and	  in	  some	  cases	  may	  be	  
harmful	  
	  
1.5	  Review	  process	  and	  update	  of	  guidelines	  
The	   guidelines	   underwent	   external	   review	  by	  Guideline	   Committee	   (GC)	  members	   and	   other	  
independent	  experts	  in	  the	  field	  of	  cerebrovascular	  disease.	  Each	  draft	  was	  revised	  according	  to	  
reviewer	   suggestions	   and	   the	   final	   document	   submitted	   to	   the	   European	   Journal	   of	   Vascular	  
and	  Endovascular	  Surgery	  (EJVES)	  in	  June	  2017.	  The	  GC	  proposes	  that	  these	  guidelines	  should	  




1.6	  	  Definition	  of	  primary,	  secondary	  and	  tertiary	  prevention	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The	  WG	  adopted	  the	  prevention	  classification	  proposed	  by	  the	  Institute	  of	  Work	  and	  Health1.	  
Primary	  prevention	  aims	  to	  prevent	  carotid	  and	  VA	  disease	  from	  ever	  developing	  (outside	  the	  
scope	   of	   these	   guidelines).	   Secondary	   prevention	   aims	   at	   reducing	   the	   clinical	   impact	   of	  
asymptomatic	  carotid	  and	  VA	  stenoses	  (ie.	  stenoses	  are	  present	  and	  the	  aim	  is	  to	  prevent	  them	  
from	  causing	  a	  transient	  ischaemic	  attack	  (TIA)	  or	  stroke).	  The	  goal	  of	  tertiary	  prevention	  is	  to	  
reduce	   the	   risk	   of	   recurrent	   TIA	   or	   stroke	   in	   patients	   who	   present	   with	   a	   TIA	   or	   stroke	  
secondary	  to	  carotid	  or	  VA	  stenoses.	  
	  
	  
Section	  2:	  Management	  of	  Carotid	  disease	  
2.1	  	  Introduction	  	  
2.1.1	  Burden	  of	  stroke	  
In	   a	   European	   population	   of	   715	  million,	   about	   1.4	  million	   strokes	   occur	   each	   year2.	   Stroke	  
causes	  1.1	  million	  deaths	  annually	  in	  Europe,	  making	  it	  the	  second	  commonest	  cause	  of	  death3.	  
Over	   half	   of	   stroke	   survivors	   remain	   dependent	   on	   others	   for	   some	   aspect	   of	   everyday	  
activities4.	  	  Stroke	  imposes	  an	  enormous	  financial	  burden	  on	  health	  systems	  and	  caregivers.	  In	  
Europe,	  annual	  stroke	  costs	  exceed	  38	  billion	  Euros3.	  	  
	  
	  
2.1.2	  Definition	  of	  stroke	  and	  transient	  ischaemic	  attack	  
For	  three	  decades,	  a	  stroke	  diagnosis	  has	  been	  based	  on	  the	  World	  Health	  Organisation	  (WHO)	  
definition	   of	   a	   focal,	   occasionally	   global,	   loss	   of	   neurological	   function	   lasting	   >24	   hours	   (or	  
leading	  to	  death)	  and	  which	  has	  a	  vascular	  aetiology.	  A	  TIA	  was	  defined	  in	  a	  similar	  manner,	  but	  
the	  duration	  was	  <24	  hours5.	  	  	  
Brain	  imaging	  with	  magnetic	  resonance	  imaging	  (MRI)	  has	  shown	  that	  many	  TIA	  patients	  have	  
evidence	  of	  acute	  infarction	  (particularly	  where	  symptoms	  lasted	  several	  hours)	  and	  this	  led	  to	  
proposals	  that	  the	  classical	  definitions	  of	  stroke/TIA	  should	  be	  revised.	  One	  revised	  definition	  of	  
TIA	   proposed	   by	   the	   American	   Heart	   Association	   (AHA)	   is	   “a	   brief	   episode	   of	   neurologic	  
dysfunction	   resulting	   from	   focal	   temporary	   cerebral	   ischaemia,	   which	   is	   not	   associated	   with	  
acute	  cerebral	  infarction”.	  Ischaemic	  stroke	  is	  “an	  episode	  of	  neurologic	  dysfunction	  caused	  by	  
focal	   cerebral	   or	   retinal	   infarction,	  where	   infarction	   is	   defined	   as	   brain,	   or	   retinal	   cell	   death	  
attributable	  to	  ischaemia,	  based	  on	  neuropathologic,	  neuroimaging,	  and/or	  clinical	  evidence	  of	  
permanent	   injury”.	   Silent	   infarction	   is	   defined	   as	   “imaging	   or	   neuropathological	   evidence	   of	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cerebral/retinal	   infarction	  without	   a	   history	   of	   acute	   neurological	   dysfunction	   attributable	   to	  
the	   lesion”	   6.	   This	   ‘tissue-­‐based’	   definition	   of	   TIA	   is	   not	   applied	   in	   all	   healthcare	   settings,	  
especially	  outside	   the	  USA,	  because	   the	  definition	   is	  dependent	  on	   the	   type	  of	  neuroimaging	  
performed	  (computed	  tomography	  (CT),	  MRI)	  and	  the	  availability	  and	  timing	  of	  such	   imaging.	  
Accordingly,	  the	  clinical	  (WHO)	  definition	  has	  been	  used	  throughout	  these	  guidelines5.	  
	  
2.1.3	  Aetiology	  of	  carotid	  territory	  ischaemic	  stroke	  
The	   principal	   causes	   of	   ischaemic,	   carotid	   territory	   stroke	   are	   thromboembolism	   from	   the	  
internal	   carotid	   artery	   (ICA)	   or	  middle	   cerebral	   artery	   (MCA)	   (25%);	   small	   vessel	   intracranial	  
disease	  (25%);	  cardiac	  embolism	  (20%),	  other	  specified	  rarer	  causes	  (5%)	  and	  unknown	  causes	  
despite	   investigation	   (25%)7.	   Overall,	   about	   10-­‐15%	   of	   all	   strokes	   	   follow	   thromboembolism	  
from	  a	  previously	  (unheralded)	  asymptomatic	  ICA	  stenosis	  >50%8.	  	  
	  
	  
2.1.4	  Methods	  for	  measuring	  carotid	  artery	  stenosis	  severity	  
The	   European	   Carotid	   Surgery	   Trial	   (ECST)9	   and	   the	   North	   American	   Symptomatic	   Carotid	  
Endarterectomy	  Trial	  (NASCET)10	  used	  different	  methods	  for	  measuring	  stenosis	  severity	  (figure	  
3).	  Both	  used	  minimum	  residual	  luminal	  diameter	  as	  the	  numerator.	  In	  ECST,	  the	  denominator	  
was	  the	  estimated	  vessel	  diameter	  where	  the	  residual	  luminal	  diameter	  was	  measured	  (usually	  
the	  carotid	  bulb).	  In	  NASCET,	  the	  denominator	  was	  the	  diameter	  of	  a	  disease	  free	  ICA	  segment	  
above	  the	  stenosis,	  where	  the	  vessel	  walls	  were	  approximately	  parallel.	  Each	  method	  provides	  
different	  measures	  of	  stenosis	  severity	  and	  this	  has	  been	  a	  source	  of	  confusion	  as	  to	  whether	  
interventions	  should	  be	  based	  on	  ‘50%’	  or	  ‘70%’	  thresholds.	  	  
	  
A	  50%	  NASCET	  stenosis	  is	  equivalent	  to	  a	  75%	  ECST	  stenosis.	  A	  70%	  NASCET	  stenosis	  equates	  to	  
an	   85%	   ECST	   stenosis11.	   Some	   units	   remain	   uncertain	   about	   which	  measurement	  method	   is	  
being	   used,	   which	   could	   lead	   to	   inappropriate	   patient	   selection	   (or	   exclusion)	   from	  
interventions12.	  The	  NASCET	  measurement	  method	  has	  been	  adopted	  by	   the	  WG	  throughout	  
these	  guidelines,	  unless	  stipulated	  otherwise.	  	  
There	   is	  one	   situation	  where	   the	  ECST	  measurement	  method	  has	   important	  advantages	  over	  
NASCET.	   The	  NASCET	  method	   does	   not	   allow	   a	   reliable	  measurement	   of	   stenosis	   severity	   in	  
patients	   with	   large	   volume	   plaques	   within	   dilated	   carotid	   bulbs.	   Here,	   the	   residual	   luminal	  
diameter	  may	  be	  similar	  or	  slightly	  less	  than	  that	  of	  the	  distal	  ICA.	  In	  this	  situation,	  the	  NASCET	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measurement	  method	  will	  record	  a	  <50%	  stenosis,	  while	  the	  ECST	  method	  will	  measure	  this	  as	  
being	   >70%.	   In	   this	   rare	   situation,	   recently	   symptomatic	   patients	  with	   large	   volume	   plaques	  
consistent	  with	  an	  ECST	  >70%	  stenosis	  should	  be	  considered	  for	  revascularisation.	  
	  
Figure	  3:	  ECST	  and	  NASCET	  methods	  for	  measuring	  stenosis	  severity	  	  
	  
	  
Reproduced	   with	   permission	   from	   Rothwell	   PM,	   Eliasziw	  M,	   Gutnikov	   SA,	   Fox	   AJ,	   Taylor	   DW,	  Mayberg	  MR,	  Warlow	   CP,	  
Barnett	   HJM	   for	   the	   Carotid	   Trialists	   Collaboration.	   Analysis	   of	   pooled	   data	   from	   the	   randomised	   controlled	   trials	   of	  




2.1.5	  Imaging	  strategies	  in	  carotid	  artery	  disease	  
When	   ECST/NASCET	   were	   randomizing	   patients,	   everyone	   underwent	   intra-­‐arterial	  
angiography.	   This	   has	   now	   been	   abandoned	   because	   of	   angiography-­‐related	   stroke.	   In	   the	  
Asymptomatic	   Carotid	   Atherosclerosis	   Study	   (ACAS),	   the	   30-­‐day	   death/stroke	   rate	   was	   2.3%	  
after	  CEA,	  but	  about	  half	  of	  these	  strokes	  (1.2%)	  were	  angiographic	  related13.	  	  
	  
Duplex	   ultrasound	   (DUS)	   is	   usually	   the	   first-­‐line	   imaging	   modality	   due	   to	   its	   low	   cost	   and	  
accessibility.	  B-­‐mode	  imaging	  is	  combined	  with	  colour	  flow,	  as	  well	  as	  the	  ability	  to	  undertake	  
Doppler	   flow	   velocity	   measurements.	   Table	   1	   details	   DUS	   criteria	   for	   defining	   stenosis	  
thresholds	  using	  peak	  systolic	  velocity	  (PSV),	  end-­‐diastolic	  velocity	  (EDV)	  and	  their	  ratios	  in	  the	  
ICA	  and	  common	  carotid	  artery	  (CCA),	  based	  on	  the	  NASCET	  measurement	  method14.	  	  
	  
	  







PSVICA/PSVCCA	  ratio	   St	  Mary’s	  ratio
15	  
PSVICA/EDVCCA	  
<50%	   <12516	   <216	   <8	  
50-­‐69%	   >12516	   2.0-­‐416	   8-­‐10	  
60-­‐69%	   	   	   11-­‐13	  
70-­‐79%	   >23016	   >416	   14-­‐21	  
80-­‐89%	   	   	   22-­‐29	  
>90%	  but	  not	  near	  
occlusion	  
>40016	   >517	   >30	  
near-­‐occlusion	   high,	  low	  –	  string	  flow	   variable	   variable	  
occlusion	   no	  flow	   not	  applicable	   not	  applicable	  
Reproduced	   with	   permission	   from	   Oates	   C,	   Naylor	   AR,	   Hartshorne	   T,	   Charles	   SM,	   Humphries	   K,	   Aslam	   M,	  
Khodabaksh	   P.	   Reporting	   carotid	   ultrasound	   investigations	   in	   the	   United	   Kingdom	   Eur	   J	   Vasc	   Endovasc	   Surg	  
2009;37:251-­‐261	  
	  
The	  advantage	  of	  computed	  tomographic	  angiography	  (CTA)	  and	  MR	  angiography	  (MRA)	  is	  the	  
ability	   to	   simultaneously	   image	   the	  aortic	   arch,	   supra-­‐aortic	   trunks,	   carotid	  bifurcation,	  distal	  
ICA	  and	   the	   intracranial	   circulation,	  which	  are	  mandatory	   if	   a	  patient	   is	   being	   considered	   for	  
carotid	  artery	  stenting	  (CAS).	  Contrast	  enhanced	  MRA	  (CEMRA)	  has	  a	  higher	  accuracy	  than	  non-­‐
contrast	   MRA	   techniques	   (time	   of	   flight),	   but	   requires	   administration	   of	   a	   paramagnetic	  
contrast	   agent	   such	   as	   gadolinium.	   In	   a	   Health	   Technology	   Assessment	   (HTA)	  meta-­‐analysis,	  
DUS,	   MRA,	   and	   CTA	   were	   equivalent	   for	   detecting	   significant	   ICA	   stenoses18.	   Catheter	  
angiography	  is	  now	  rarely	  required,	  unless	  there	  are	  discrepancies	  on	  non-­‐invasive	  imaging.	  The	  
HTA	  advise	   that	  where	  centres	   rely	  on	  DUS	  alone	  prior	   to	  CEA,	   the	  patient	  should	  undergo	  a	  
second	  corroborative	  DUS	  scan,	  preferably	  by	  a	  second	  operator.	  
	  
Recommendation	  1	   Class	   Level	   References	  
Duplex	   ultrasound	   (as	   first-­‐line),	   computed	   tomographic	  
angiography	   and/or	   magnetic	   resonance	   angiography	   are	  
recommended	   for	   evaluating	   the	   extent	   and	   severity	   of	  
extracranial	  carotid	  stenoses.	  




Recommendation	  2	   Class	   Level	   References	  
When	   carotid	   endarterectomy	   is	   being	   considered,	   it	   is	  
recommended	  that	  Duplex	  ultrasound	  stenosis	  estimation	  be	  
corroborated	   by	   computed	   tomographic	   angiography	   or	  
magnetic	   resonance	   angiography,	   or	   by	   a	   repeat	   Duplex	  
ultrasound	  performed	  by	  a	  second	  operator.	  
I	   A	   18	  
	  
	  
Recommendation	  3	   Class	   Level	   References	  
When	   carotid	   stenting	   is	   being	   considered,	   it	   is	   I	   A	   18	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recommended	  that	  any	  Duplex	  ultrasound	  study	  be	  followed	  
by	   computed	   tomographic	   angiography	   or	   magnetic	  
resonance	   angiography	   which	   will	   provide	   additional	  




Recommendation	  4	   Class	   Level	   References	  
It	  is	  recommended	  that	  units	  who	  base	  management	  
decisions	  on	  Duplex	  ultrasound	  stenosis	  measurement	  
should	  state	  which	  measurement	  method	  is	  being	  used.	  




Recommendation	  5	   Class	   Level	   References	  
Intra-­‐arterial	   digital	   subtraction	   angiography	   should	   not	   be	  
performed	  in	  patients	  being	  considered	  for	  revascularisation,	  
unless	  there	  are	  significant	  discrepancies	  during	  non-­‐invasive	  
imaging.	  	  




2.1.6	  Role	  of	  the	  multi-­‐disciplinary	  team	  	  
Where	   possible,	   decisions	   regarding	   carotid	   interventions	   should	   involve	   a	   multidisciplinary	  
team	   (MDT)	   including	   neurologists/stroke	   physicians,	   vascular	   surgeons,	   and	   interventional	  
radiologists.	   Evidence	   suggests	   that	   MDTs	   increase	   the	   proportion	   of	   patients	   undergoing	  
urgent	  CEA	  (4%	  vs	  22%,	  p<0.0001)19,	  but	  it	  is	  important	  that	  urgent	  decisions	  can	  be	  made	  by	  at	  
least	   two	   MDT	   members	   if	   meetings	   only	   occur	   weekly.	   Outcomes	   after	   CEA/CAS	   vary	  
according	  to	  who	  performs	  the	  assessment.	  Rothwell	  observed	  that	  peri-­‐operative	  stroke	  rates	  
after	   CEA	   were	   7.7%	   when	   patients	   were	   assessed	   by	   a	   neurologist,	   vs	   2.3%	   where	   the	  
operating	  surgeon	  adjudicated	  outcomes20.	  A	  German	  Carotid	  Stenting	  Registry	  also	  observed	  
that	  neurologist	  assessment	  resulted	  in	  higher	  rates	  of	  transient	  (8.2%	  vs	  5.1%)	  and	  permanent	  
(3.3%	   vs.	   0.9%)	   neurological	   deficits	   following	   CAS,	   compared	   with	   when	   assessments	   were	  
undertaken	  by	  the	  Interventionist21.	  	  
	  
Recommendation	  6	   Class	   Level	   References	  
Multi-­‐disciplinary	   assessment	   is	   recommended	   to	   achieve	  
consensus	  regarding	  the	  indication	  and	  optimal	  treatment	  of	  
patients	  by	  carotid	  endarterectomy	  or	  carotid	  stenting.	  
I	   C	   19	  
	  
Recommendation	  7	   Class	   Level	   References	  
Independent	   assessment	   after	   carotid	   interventions	   is	  
recommended	  to	  audit	  procedural	  risks	  





2.2	  Secondary	  prevention	  in	  asymptomatic	  patients	  
2.2.1	  Optimal	  Medical	  Therapy	  
2.2.1.1	  	  Risk	  factor	  assessment	  
In	  a	  pooled	  analysis	  of	  four	  population	  based	  screening	  cohorts,	  smoking	  was	  associated	  with	  a	  
significant	   increase	   in	   the	   prevalence	   of	   a	   >50%	   ICA	   stenosis	   (Odds	   Ratio	   (OR)	   2.3	   (95%	  
confidence	  interval	  (CI)	  1.8-­‐2.8))	  and	  of	  a	  >70%	  stenosis	  (OR	  3.0	  (95%CI	  2.1-­‐4.4))22.	  About	  5%	  of	  
males	  aged	  >65	  years	  who	  are	  current	  smokers	  have	  a	  >50%	  ICA	  stenosis	  on	  DUS	  screening23	  
and	  smoking	  has	  been	  shown	  to	  increase	  plaque	  progression24.	  In	  a	  meta-­‐analysis	  of	  32	  studies,	  
smoking	   was	   associated	   with	   a	   significant	   increase	   in	   late	   ischaemic	   stroke	   (Relative	   Risk	  
Increase	   (RRI)	   1.9	   (95%CI	   1.7-­‐2.2))25.	   In	   a	  meta-­‐analysis,	   moderate	   or	   high	   levels	   of	   physical	  
activity	  were	  associated	  with	  a	  25%	  relative	  risk	  reduction	  (RRR)	  in	  ischaemic	  stroke26,	  possibly	  
via	  reductions	  in	  blood	  pressure	  (BP),	  	  body	  weight	  and	  other	  effects	  on	  risk	  factors.	  Finally,	  in	  a	  
meta-­‐analysis	  of	  25	  studies	  involving	  2	  million	  people,	  obesity	  was	  associated	  with	  a	  significant	  
increase	  in	  stroke	  prevalence	  (RRI	  1.64	  (95%CI	  1.36-­‐1.99))27.	  
	  
Recommendation	  8	   Class	   Level	   References	  
A	   healthy	   diet,	   smoking	   cessation	   and	   physical	   activity	   are	  
recommended	   for	   all	   patients	   with	   asymptomatic	   carotid	  
disease	  
I	   C	   	  
	  
	  
2.2.1.2	  	  Antiplatelet	  therapy	  
There	   is	   conflicting	   opinion	   regarding	   antiplatelet	   therapy	   in	   asymptomatic	   patients,	   due	   to	  
concerns	  that	   inappropriate	  therapy	  could	   increase	  the	  risk	  of	  major	  bleeding	  events	  without	  
reducing	   stroke	   risk.	   In	   the	   Asymptomatic	   Cervical	   Bruit	   study,	   patients	   with	   >50%	  
asymptomatic	  ICA	  stenoses	  were	  randomized	  to	  325mg	  aspirin	  versus	  placebo	  (table	  2).	  After	  a	  
median	  2.3	  years	  follow-­‐up,	  there	  was	  no	  difference	  in	  ‘any	  ischaemic	  events’	  or	  ‘any	  death’28.	  
By	  contrast,	  the	  Asymptomatic	  Carotid	  Emboli	  Study	  (ACES)	  reported	  that	  antiplatelet	  therapy	  
was	   an	   independent	   predictor	   of	   lower	   rates	   of	   ‘ipsilateral	   stroke/TIA’	   and	   ‘any	  
stroke/cardiovascular	  death’	  in	  patients	  with	  asymptomatic	  70-­‐99%	  stenoses29.	  	  
	  
However,	  up	   to	   two-­‐thirds	  of	  asymptomatic	  patients	  have	   subclinical	   coronary	  artery	  disease	  
(CAD)30.	  In	  a	  systematic	  review	  of	  17	  natural	  history	  studies	  reporting	  5-­‐year	  all-­‐cause	  mortality	  
in	   11,391	   patients	   with	   >50%	   asymptomatic	   ICA	   stenoses,	   63%	   of	   late	   deaths	   were	   cardiac,	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representing	  an	  average	  cardiac-­‐related	  mortality	  of	  2.9%	  per	  year31.	  In	  addition,	  a	  multicentre	  
review	  of	  stroke	  severity	  and	  outcomes,	  stratified	  for	  whether	  patients	  were	  taking	  aspirin	  prior	  
to	   stroke	   onset,	   observed	   that	   pre-­‐existing	   aspirin	   users	   had	   reduced	   stroke	   severity	   at	  
presentation	  and	  improved	  functional	  outcomes	  at	  discharge,	  even	  though	  aspirin	  had	  failed	  to	  
prevent	   their	   stroke.	   This	   beneficial	   effect	   was	   only	   seen	   in	   patients	   with	   large	   artery	  
atherosclerotic	  strokes,	  as	  opposed	  to	  cardioembolic	  or	  lacunar	  strokes32.	  Park’s	  data	  were	  not	  
included	  in	  table	  2	  because	  a	  small	  proportion	  had	  experienced	  a	  remote	  TIA/stroke	  in	  the	  past	  
and	  were	  not,	  therefore,	  truly	  asymptomatic.	  	  	  
In	  the	  Clopidogrel	  for	  High	  Atherothrombotic	  Risk	  and	  Ischemic	  Stabilization,	  Management	  and	  
Avoidance	  (CHARISMA)	  study,	  where	  7%	  had	  an	  asymptomatic	  50-­‐99%	  ICA	  stenosis,	  there	  was	  
no	  evidence	  that	  dual	  antiplatelet	  therapy	  (DAPT)	  conferred	  any	  benefit	  over	  single	  antiplatelet	  
therapy33.	   In	  a	  meta-­‐analysis	  of	  the	  primary	  prevention	  trials,	  aspirin	  allocation	  yielded	  a	  12%	  
RRR	   in	   serious	   vascular	   events,	   due	   mainly	   to	   a	   reduction	   of	   about	   a	   fifth	   in	   non-­‐fatal	  
myocardial	   infarction	   (MI)	   (0.18%	  vs	  0.23%	  per	  year,	  p<0.0001).	  The	  net	  effect	  on	  stroke	  was	  
not	  significant	  (0.20%	  vs	  0.21%	  per	  year,	  p=0.4:	  haemorrhagic	  stroke	  0.04%	  vs	  0.03%,	  p=0.05;	  
other	  stroke	  0.16%	  vs	  0.18%	  per	  year,	  p=0.08)	  ATT	  2009.	  Accordingly,	  monotherapy	  with	  aspirin	  
remains	  the	  first-­‐line	  antiplatelet	  agent	  in	  asymptomatic	  patients,	  with	  clopidogrel	  reserved	  for	  
patients	  who	  are	  aspirin	  intolerant.	  
	  
Table	   2:	   effect	   of	   antiplatelet	   therapy	  on	   stroke	   prevention	   in	   patients	  with	   asymptomatic	  
carotid	  stenoses.	  
	  
Study	   ICA	  stenosis,	  	  
n=	  
antiplatelet	  strategy	  
endpoint	   outcomes	  
antiplatelet	  vs	  no	  
antiplatelet	  
Asymptomatic	  	  
Carotid	  Bruit	  	  
Study28	  
	  
50-­‐99%,	  n=	  372	  
	  
randomised	  to	  325mg	  
enteric	  coated	  aspirin	  
vs	  placebo	  
annual	  rate	  of	  TIA,	  
stroke,	  unstable	  angina,	  
MI	  or	  death	  from	  any	  
cause	  at	  a	  mean	  of	  2.3yrs	  
	  
annual	  rate	  of	  TIA,	  stroke,	  
unstable	  angina,	  MI	  at	  a	  
mean	  of	  2.3yrs	  














antiplatelet	  vs	  no	  
antiplatelet	  therapy*	  
2	  yr	  risk	  of	  ipsilateral	  
stroke	  or	  TIA	  
	  
2	  year	  risk	  of	  stroke	  or	  any	  
cardiovascular	  death	  
HR	  0.45	  (95%CI	  0.31-­‐0.66)	  
p<0.001	  
	  
HR	  0.13	  (95%CI	  0.06-­‐0.27)	  
p<0.001	  
*	  95%	  of	  patients	  took	  antiplatelet	  therapy	  during	  sequential	  follow-­‐up	  
	  
Recommendation	  9	   Class	   Level	   References	  
 20 
Low	   dose	   aspirin	   (75-­‐325mg)	   is	   recommended	   in	  
patients	   with	   asymptomatic	   carotid	   stenoses	   for	   the	  
prevention	   of	   late	   myocardial	   infarction	   and	   other	  
cardiovascular	  events.	  
I	   A	   	  
29,34	  
	  
Recommendation	  10	   Class	   Level	   References	  
Clopidogrel	   75mg	   daily	   should	   be	   considered	   in	  












2.2.1.3	  	  Lipid	  lowering	  therapy	  
In	   a	  post-­‐hoc	   analysis	   of	   patients	   randomised	  within	   the	   Asymptomatic	   Carotid	   Surgery	   Trial	  
(ACST-­‐1)	  who	  were	   on	   lipid-­‐lowering	   therapy,	   the	   10-­‐year	   risk	   of	   stroke/death	  was	   13.4%	   in	  
best	   medical	   therapy	   (BMT)	   patients	   and	   7.6%	   after	   CEA.	   However,	   in	   patients	   not	   taking	  
statins,	  the	  10-­‐year	  stroke	  risk	  was	  24.1%	  in	  BMT	  patients,	  versus	  17.9%	  after	  CEA,	  suggesting	  
that	  statins	  reduced	  long-­‐term	  stroke	  in	  patients	  with	  asymptomatic	  stenoses35.	  With	  regard	  to	  
dosage	  and/or	  intensity	  of	  statin	  therapy,	  there	  is	  insufficient	  data	  from	  carotid	  stenosis	  studies	  
in	   asymptomatic	   patients.	   However,	   evidence-­‐based	   treatment	   goals	   from	   studies	   involving	  
patients	   with	   symptomatic	   and	   asymptomatic	   cardiovascular	   disease	   advise	   high-­‐intensity	  
statin	  treatment	  goals,	  including	  a	  low-­‐density	  lipoprotein	  (LDL)	  level	  of	  <1.8	  mmol/l	  (70mg/dl)	  
or	  a	  50%	  reduction	  of	  LDL	  by	  either	  40-­‐80mg	  atorvastatin	  or	  20-­‐40mg	  rosuvastatin36-­‐38.	  A	  2013	  
Cochrane	  review	  of	  18	  RCTs	  (56,934	  patients)	  on	  the	  role	  of	  statins	  in	  the	  primary	  prevention	  of	  
cardiovascular	   disease,	   observed	   significant	   reductions	   in	   all-­‐cause	   mortality,	   fatal/non-­‐fatal	  
stroke	  and	  revascularisation	  procedures	  in	  patients	  randomised	  to	  statins39.	  	  
	  
Because	   of	   the	   increased	   risk	   of	   cardiovascular	   complications	   and	   the	   generally	   low	   rate	   of	  
serious	   adverse-­‐effects	   associated	   with	   statins,	   it	   seems	   reasonable	   to	   apply	   the	   same	  
recommendation	   to	   patients	  with	   symptomatic	   carotid	   disease	   (section	   2.3.2.3).	   The	   role	   of	  
statin	   therapy	   in	   reducing	   the	   peri-­‐operative	   risk	   of	   stroke/death	   following	   CEA	   and	   CAS	   is	  
discussed	  in	  sections	  2.3.2.3.2	  and	  2.3.2.3.3.	  
	  
Recommendation	  11	   Class	   Level	   References	  
Statin	   therapy	   is	   recommended	   for	   the	   longterm	  
prevention	   of	   stroke,	   myocardial	   infarction	   and	  
other	   cardiovascular	   events	   in	   patients	   with	  
asymptomatic	  carotid	  disease.	  






2.2.1.4	  	  Management	  of	  hypertension	  
Hypertension	  is	  associated	  with	  an	  increased	  risk	  of	  carotid	  disease40.	  Treatment	  in	  older	  adults	  
with	   ICA	   stenoses	   (compared	   with	   placebo)	   reduces	   stenosis	   progression	   (14%	   vs	   31%)	   and	  
promotes	   regression	   (32%	   vs	   0%)41.	   Regression	   of	   carotid	   intima-­‐media	   thickness	   (IMT)	   has	  
been	   attributed	   to	   reductions	   in	   carotid	   pulse	   pressure42.	   The	   European	   Lacidipine	   Study	   on	  
Atherosclerosis,	   which	   compared	   lacidipine	   (calcium	   channel	   blocker	   (CCB))	   with	   atenolol,	  
observed	  that	  lacidipine	  was	  associated	  with	  greater	  reductions	  in	  carotid	  IMT	  progression	  and	  
fewer	   atherosclerotic	   plaques,	   despite	   smaller	   falls	   in	   BP,	   suggesting	   an	   independent,	   anti-­‐
atherosclerotic	  action43.	  Similar	  results	  have	  been	  obtained	  for	  Angiotensin	  Converting	  Enzyme	  
(ACE)	   inhibitors,	  however	  CCBs	   reduce	   IMT	  progression	  more	   than	  diuretics,	  beta-­‐blockers	  or	  
ACE	  inhibitors44.	  	  
	  
No	   RCT	   has	   evaluated	   anti-­‐hypertensive	   therapy	   on	   stroke	   prevention	   in	   patients	   with	  
asymptomatic	  carotid	  stenoses	  (ACS).	  However,	  a	  meta-­‐analysis	  of	  25	  BP	  RCTs	  in	  patients	  with	  
no	  history	  of	  vascular	  disease	  reported	  significant	  reductions	  in	  late	  stroke	  (RRR	  45%	  (95%CI	  35-­‐
55)45,	   with	   stroke	   reduction	   being	   proportional	   to	   reductions	   in	   systolic	   BP45.	   In	   a	   RCT	   of	  
Chinese	  hypertensive	  patients	  without	   a	   history	  of	   stroke/MI,	   enalapril	   and	   folic	   acid	   (versus	  
enalapril	   alone),	   reduced	   the	   risk	   of	   first	   stroke46.	   In	   practice,	   BP	   should	   be	   maintained	  
<140/90mmHg	   in	   patients	   with	   ACS47.	   The	   European	   Society	   of	   Cardiology	   (ESC)	   /European	  
Society	   for	   Hypertension	   advise	   that	   the	   target	   for	   end-­‐diastolic	   BP	   should	   be	   85mmHg	   in	  
patients	  with	  diabetes48.	  
	  
Recommendation	  12	   Class	   Level	   References	  
Antihypertensive	   treatment	   is	   recommended	   for	  
patients	   with	   hypertension	   and	   asymptomatic	  
extracranial	   internal	   carotid	   artery	   stenoses	   to	  
maintain	  long	  term	  blood	  pressure	  <140/90mmHg	  




2.2.1.5	  	  Treatment	  in	  diabetic	  patients	  
Diabetes	   is	   associated	  with	  an	   increased	   risk	  of	  ACS22,	   as	  well	   as	  hypertension	  and	  abnormal	  
lipid	  profiles.	  However,	  neither	  plaque	  burden	  nor	  plaque	   instability	  are	   increased	   in	  diabetic	  
patients49.	   Diabetes	   doubles	   the	   risk	   of	   stroke	   and	   20%	   of	   diabetic	   patients	   will	   die	   from	   a	  
stroke50.	  In	  meta-­‐analyses,	  however,	  there	  is	  no	  evidence	  that	  tight	  glycaemic	  control	  reduces	  
stroke	  risk51,	  but	   it	  will	  reduce	  other	  diabetes-­‐related	  complications	  eg.	  microangiopathy.	   In	  a	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study	  of	   type	   II	  diabetic	  patients	  who	   received	   risk	   factor	  advice	  and	   took	   statin,	  antiplatelet	  
and	   anti-­‐hypertensive	   therapy	   (as	   appropriate),	   there	  was	   a	   60%	   reduction	   in	   cardiovascular	  
events	  (Hazard	  Ratio	  (HR)	  0.41	  (95%CI	  0.25-­‐0.69),	  p<0.001)	  and	  cardiovascular	  deaths	  (HR	  0.43	  
(95%CI	  0.19-­‐0.94),	  p=0.04)52.	  The	  UK	  Prospective	  Diabetes	  Study	  observed	  that	  tight	  BP	  control	  
(mean	   BP	   144/82mmHg)	  was	   associated	  with	   a	   44%	  RRR	   in	   stroke	   ((95%CI	   11-­‐65),	   p=0.013),	  
compared	  with	  patients	  who	  had	  less	  tight	  BP	  control	  (mean	  BP	  154/87mmHg)53.	  Accordingly,	  
the	  ESC/European	  Society	  for	  Hypertension	  advise	  that	  the	  target	  for	  end-­‐diastolic	  BP	  should	  be	  
85mmHg	  in	  patients	  with	  diabetes48.	  
	  
Recommendation	  13	   Class	   Level	   References	  
In	   diabetic	   patients	   with	   asymptomatic	   carotid	  
stenoses,	  strict	  glycaemic	  control	  is	  recommended	  
I	   C	   	  
	  
Recommendation	  14	   Class	   Level	   References	  
In	   diabetic	   patients	   with	   asymptomatic	   carotid	  
stenoses,	   the	   target	   blood	   pressure	   should	   be	  
<140/85mmHg	  





2.2.1.6	  Adherence	  to	  optimal	  medical	  therapy	  
	  
In	  patients	  with	   carotid	  disease,	   there	   is	   a	  paucity	  of	  data	   relating	   to	   the	  potentially	   adverse	  
effect	   of	   non-­‐adherence	   with	   antiplatelet/antithrombotic	   therapy	   and	   medications	   for	  
hypertension,	  diabetes	  mellitus	  and	  dyslipidaemia.	   	  This	  was	  never	  evaluated	  in	  the	   landmark	  
RCTs9,10,13,35,54.	  In	  a	  single	  centre	  study,	  114	  patients	  with	  TIA	  or	  ischaemic	  stroke	  were	  recruited	  
via	   a	   rapid	   access	   stroke	   prevention	   (RASP)	   or	   inpatient	   vascular	   neurology	   service	   between	  
2006	   and	   2009	   and	   followed-­‐up	   for	   a	   median	   of	   630	   days55.	   The	   proportion	   continuing	  
medications	   prescribed	   at	   the	   initial	   RASP	   clinic	   assessment	   or	   hospital	   admission	   and	   who	  
were	   also	   taking	   these	   medications	   at	   their	   last	   follow-­‐up	   was	   94%	   for	   aspirin,	   73%	   for	  
dipyridamole	  MR,	  81%	  for	  clopidogrel,	  88%	  for	  statins	  and	  90%	  for	  antihypertensives.	  Overall,	  
99%	  reported	  that	  they	  were	  fully	  adherent	  to	  prescribed	  medications	  the	  preceding	  day,	  while	  
11%	  reported	  they	  had	  missed	  at	  least	  one	  medication	  over	  the	  preceding	  14	  days.	  Half	  of	  the	  
patients	  in	  this	  study	  (54%)	  reported	  that	  they	  never	  forgot	  to	  take	  their	  medications55.	  
	  
Studies	   in	   CAD	  or	   heart	   failure	  patients	   report	   better	   clinical	   outcomes	   in	   those	  who	   remain	  
adherent	   to	   their	   prescribed	  medications	   than	   those	  who	  were	   not56.	   It	   has	   been	   suggested	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that	  adherence	  to	  antihypertensive	  medications	  has	  important	  implications	  for	  primary	  stroke	  
prevention	   in	   the	  general	  population57,	  where	   ‘real	  world’	   compliance	  may	  be	  worse	   than	   in	  
RCTs58.	  Statins	  have	  the	  widest	  variation	  in	  compliance	  to	  treatment,	  possibly	  because	  of	  side-­‐
effects59.	  This	  may	  contribute	  to	  the	  fact	  that	  many	  patients	  may	  not	  achieve	  pre-­‐defined	  LDL-­‐
Cholesterol	   reduction	   targets,	   thereby	   predisposing	   them	   to	   recurrent	   or	   new	   cardiovascular	  
events.	   The	   same	   may	   also	   be	   true	   for	   aspirin	   plus	   dipyridamole	   (because	   of	   dypiridamol-­‐
induced	  headache),	  but	  this	  can	  be	  reduced	  by	  dose	  escalation	  during	  treatment	  initiation.	  	  
	  
In	  patients	  with	  ACS,	  adherence	  to	  medications	  may	  be	  significantly	  reduced	  in	  the	  presence	  of	  
undiagnosed	   cognitive	   impairment,	   which	   also	   has	   implications	   for	   monitoring	   medication	  
usage60.	   	   Other	   predictors	   of	   poor	   compliance	   include	   psychological	   problems	   (particularly	  
depression),	   asymptomatic	   disease,	   inadequate	   follow-­‐up	   or	   discharge	   planning,	   medication	  
side	  effects,	  a	  patient’s	   lack	  of	  belief	   in	   the	  benefits	  of	  medical	   treatment,	  a	  patient’s	   lack	  of	  
insight	   into	   the	   illness,	   poor	   provider–patient	   relationships,	   presence	   of	   barriers	   to	   care	   or	  
medications,	   missed	   appointments,	   complexity	   of	   treatment,	   and	   cost	   of	   medication,	   co-­‐
payment,	  or	  both61.	  In	  a	  simulation	  model	  in	  patients	  with	  asymptomatic	  carotid	  stenosis,	  long-­‐
term	  survival	  was	  significantly	  better	   for	  patients	  who	  remained	  adherent	   to	  BMT,	  compared	  




2.2.2	  	  Screening	  for	  Asymptomatic	  Carotid	  Stenoses	  	  	  	  	  	  	  	  	  	  	  	  
	  
According	   to	  Wilson	   and	   Jungner,	   the	   rationale	   for	   screening	   requires	   that:	   (i)	   the	   condition	  
being	  prevented	  is	  important,	  has	  a	  latent	  phase	  and	  its	  natural	  history	  is	  fully	  understood;	  (ii)	  
there	  is	  a	  reliable	  screening	  test	  that	  is	  acceptable	  to	  the	  population	  in	  question;	  (iii)	  there	  is	  an	  
accepted	  treatment	  for	  screen	  positive	  patients	  and	  an	  agreed	  policy	  for	  whom	  to	  treat	  and	  (iv)	  
the	  intervention	  for	  screen	  positive	  patients	  should	  be	  cost-­‐effective63.	  	  
	  
2.2.2.1	  	  Is	  stroke	  important	  to	  prevent?	  
In	   Europe,	   stroke	   causes	  1.1	  million	  deaths	   annually3.	   It	   is	   the	   commonest	   cause	  of	   acquired	  
disability	   in	  adults,	  with	  more	   than	  half	  of	  all	   stroke	  survivors	  being	  dependent	  on	  others	   for	  
everyday	   activities4.	   Stroke	   costs	   health	   providers	   in	   Europe	   38	   billion	   Euros	   per	   year3	   and	  
successful	  prevention	  strategies	  could	  have	  enormous	  clinical,	  social	  and	  financial	  benefits.	  It	  is,	  
therefore,	  a	  very	  important	  condition	  to	  prevent.	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2.2.2.2	  	  	  Unheralded	  stroke	  and	  asymptomatic	  carotid	  stenoses	  
	  
About	  10-­‐15%	  of	  all	  first-­‐ever	  stroke	  patients	  will	  experience	  an	  unheralded	  ischaemic,	  carotid	  
territory	   stroke	   following	   thromboembolism	   from	   a	   previously	   untreated,	   asymptomatic	  
significant	  carotid	  stenosis8.	  	  
	  
2.2.2.3	  	  Is	  Duplex	  ultrasound	  reliable	  for	  diagnosing	  stenosis	  severity?	  
The	  US	  Preventive	   Services	   Taskforce	   (USPSTF)	   concluded	   that	  DUS	  was	  widely	   available	   and	  
non-­‐invasive,	  with	  a	  sensitivity	  of	  94%	  and	  a	  specificity	  of	  92%	  for	  diagnosing	  a	  60-­‐99%	  carotid	  
stenosis64.	  However,	  USPSTF	  observed	  that	  the	  accuracy	  of	  DUS	  varied	  considerably	  (especially	  
in	   inexperienced	   hands)	   and	   that	   its	   indiscriminate	   use	   in	   low	   prevalence	   populations	   could	  
result	  in	  a	  low	  positive	  predictive	  value	  due	  to	  a	  large	  number	  of	  false	  positives.	  USPSTF	  cited	  
an	  example	  where	   screening	  100,000	   adults	  with	   a	   60-­‐99%	   stenosis	   prevalence	  of	   1%	  would	  
yield	  893	  true	  positives	  and	  7920	  false	  positives.	  Even	  if	  all	  false	  positive	  tests	  underwent	  MRA	  
corroboration,	  792	  patients	  with	  false	  positive	  stenoses	  might	  still	  be	  considered	  candidates	  for	  
CEA/CAS	  (ie	  almost	  as	  many	  as	  the	  893	  true	  positives)64.	  The	  USPSTF	  concluded	  that	  if	  reliable	  
risk	  stratification	  tools	  were	  available	  to	  distinguish	  persons	  who	  were	  more	  likely	  to	  have	  an	  
ACS,	   thereby	   allowing	   identification	   of	   a	   subset	   of	   the	   population	  with	   a	   higher	   prevalence,	  
then	   the	   ratio	   of	   true	   positives	   to	   false	   positives	   for	   DUS	   screening	   (with	   or	   without	  
confirmatory	  testing)	  would	  improve64.	  	  
	  
2.2.2.4	  	  Prevalence	  of	  asymptomatic	  carotid	  disease?	  
Using	  DUS,	  the	  prevalence	  of	  asymptomatic	  moderate	  (>50%)	  and	  severe	  (>70%)	  stenoses	  in	  a	  
population	  of	  23,706	  people	   (mean	  age	  61	  years,	   46%	  male)	   recruited	   from	   four	  population-­‐
based	   cohort	   studies	   (Malmö	   Diet	   and	   Cancer	   Study,	   Tromsø	   Study,	   Carotid	   Atherosclerosis	  
Progression	   Study	   and	   the	   Cardiovascular	   Health	   Study)	   was	   2.0%	   and	   0.5%	   respectively22.	  
Table	  3	  details	  the	  prevalence	  of	  >50%	  and	  >70%	  ACS,	  stratified	  for	  age	  and	  gender22.	  Assuming	  
that	   patients	   aged	   >80	   years	   with	   asymptomatic	   stenoses	   do	   not	   benefit	   from	   CEA	   (section	  
2.2.3.1.4.1),	  the	  yield	  for	  finding	  patients	  with	  >70%	  stenoses	  through	  unselected	  screening	  of	  
patients	  aged	  <80	  years	  would	  be	  <2%22,	  i.e.	  not	  enough	  to	  be	  cost-­‐	  or	  clinically-­‐effective.	  	  
	  
	  
Table	  3:	  Prevalence	  of	  asymptomatic	  >50%	  and	  >70%	  in	  the	  general	  population,	  stratified	  for	  
gender	  and	  age*	  
	  
	  	  	  	  	  Age	   stenosis	   males	   females	  
 25 
>50%	   0.2%	   0.0%	  <50	  years	  
>70%	   0.1%	   0.0%	  
>50%	   0.7%	   0.5%	  50-­‐59	  years	  
>70%	   0.2%	   0.1%	  
>50%	   2.3%	   2.0%	  60-­‐69	  years	  
>70%	   0.8%	   0.2%	  
>50%	   6.0%	   3.6%	  70-­‐79	  years	  
>70%	   2.1%	   1.0%	  
>50%	   7.5%	   5.0%	  >80	  years	  
>70%	   3.1%	   0.9%	  
*	  Based	  on	  analyses	  from	  de	  Weerd	  et	  al22.	  
	  
2.2.2.5	  	  Can	  a	  ‘high-­‐risk	  for	  stenosis’	  cohort	  be	  identified?	  
A	   predictive	   model	   was	   developed	   by	   Greco,	   involving	   a	   self-­‐selected	   cohort	   of	   2,885,257	  
patients	  who	  paid	  to	  have	  a	  carotid	  DUS	  via	  the	  Lifeline	  Screening	  company,	  where	  66%	  were	  
female	  and	  20%	  were	  <55	  years65.	  Overall,	  71,004	  (2.4%)	  had	  a	  >50%	  ACS.	  Half	  the	  cohort	  were	  
used	  to	  develop	  the	  scoring	  system,	  which	  identified	  increasing	  age,	  smoking	  history,	  history	  of	  
PAD,	   CAD,	   high	   BP,	   diabetes,	   abdominal	   aortic	   aneurysm	   (AAA)	   and	   high	   cholesterol	   as	  
independent	   predictors	   of	   a	   >50%	   carotid	   stenosis.	   African	   Americans,	   Asians	   and	   Hispanic	  
participants	   had	   a	   low	   prevalence	   of	   ACS	   and	   this	   was	   factored	   into	   the	  model,	   which	   was	  
tested	  on	   the	  second	  half	  of	   the	  cohort.	  With	  a	  score	  of	  11-­‐15,	  <2%	  of	  screened	  participants	  
had	  a	  >50%	  ACS,	  increasing	  to	  4%	  in	  those	  with	  a	  score	  of	  21	  and	  6%	  for	  those	  whose	  score	  was	  
25.	  Screening	  those	  with	  the	  lowest	  ‘useful	  score’	  of	  11	  identified	  100%	  of	  subjects	  with	  an	  ACS	  
>50%	  at	  a	  cost	  of	  41	  screenings	  per	  >50%	  ACS	  detected.	  This	  study	  provided	  no	  data	  on	  their	  
ability	  to	  identify	  a	  cohort	  with	  an	  increased	  likelihood	  of	  having	  a	  >70%	  stenosis,	  which	  is	  the	  
more	  clinically	  important	  stenosis	  threshold65.	  	  
	  
	  
2.2.2.6	  Potential	  benefits	  of	  ‘selective	  screening’	  	  
	  
Screening	   for	   ACS	   could	   enable	   risk	   factor	   modification	   and	   BMT	   for	   all	   screened	   patients	  
(irrespective	  of	  stenosis	  severity	  or	  whether	  they	  undergo	  CEA/CAS)	  and	  this	  could	  contribute	  
towards	  preventing	  MI	  and	  cardiac	  deaths,	  which	  are	  commoner	  than	  late	  stroke66.	  In	  ACST-­‐1,	  
40%	  of	  patients	  aged	  <75	  years	  at	   trial	  entry	  died	  within	  10	  years,	  with	  55%	  of	  deaths	  being	  
cardiac35.	  In	  a	  recent	  systematic	  review	  and	  meta-­‐analysis,	  17	  studies	  reported	  late	  mortality	  in	  
11,391	  patients	  with	  an	  ACS	  >50%31.	  Overall,	  5-­‐year	  mortality	  was	  24%	  (95%	  CI	  20.5-­‐26.8).	  Two-­‐
 26 
thirds	  of	  late	  deaths	  were	  the	  result	  of	  heart	  disease.	  Accordingly,	  risk	  factor	  modification	  and	  
implementation	  of	  BMT	  in	  patients	  with	  screen	  detected	  ACS	  could	  significantly	  reduce	  cardiac	  
morbidity	  and	  mortality.	  
	  
2.2.2.7	  Harm	  associated	  with	  screening?	  
Patients	  might	  undergo	  an	  unnecessary	  intervention	  following	  a	  false	  positive	  screen	  and	  suffer	  
a	  stroke	  after	  CEA	  or	  CAS.	  This	  was	  one	  the	  main	  concerns	  of	  the	  USPSTF64.	  	  
	  
2.2.2.8	  	  Harm	  associated	  with	  carotid	  interventions?	  
	  
All	  RCTs	  involving	  CEA	  or	  CAS	  in	  asymptomatic	  patients	  reported	  30-­‐day	  death/stroke	  rates	  <3%	  
(section	   2.2.3.1.3).	   However,	   most	   surgeons/interventionists	   were	   credentialed	   before	  
randomising	  patients	  and	  40%	  of	  surgeon	  applicants	  in	  ACAS	  were	  rejected	  following	  review	  of	  
their	   track	   record67.	   Several	   audits	   and	   registries	   of	   ‘real	   world’	   practice	   suggest	   that	   many	  
surgeons/interventionists	  do	  not	  achieve	  death/stroke	  rates	  <3%	  in	  asymptomatic	  patients68-­‐70.	  	  	  
	  
2.2.2.9	  Does	  screening	  prevent	  fatal	  or	  nonfatal	  ipsilateral	  stroke?	  
	  
There	  is	  no	  evidence	  that	  population	  screening	  reduces	  stroke	  and	  there	  have	  been	  no	  RCTs	  of	  
the	  benefits	  of	  screening	  versus	  no	  screening	  for	  ACS.	  	  
	  
2.2.2.10	  	  Who	  advocates	  population	  or	  selective	  screening?	  
The	   AHA	   recommends	   against	   screening	   low-­‐risk	   populations,	   but	   did	   not	   define	   who	   they	  
meant71.	   The	   Society	   for	   Vascular	   Surgery	   (SVS)	   advise	   that	   screening	   for	   ACS	   should	   be	  
considered	  in	  selected	  patients	  with	  multiple	  risk	  factors,	  provided	  that	  ‘patients	  are	  fit	  for	  and	  
willing	   to	   consider	  a	   carotid	   intervention	   if	   a	   significant	   stenosis	   is	  discovered’.	   Such	  patients	  
might	  include	  those	  with	  PAD	  (regardless	  of	  age),	  patients	  aged	  >65	  years	  with	  a	  history	  of	  one	  
or	  more	  of	  CAD,	  smoking,	  or	  hypercholesterolemia72.	  The	  ‘14	  Society’	  Guidelines	  advise	  against	  
routine	  screening	  of	  low-­‐risk	  patients,	  but	  advise	  that	  screening	  might	  be	  considered	  in	  people	  
without	   clinical	   evidence	   of	   atherosclerosis	   who	   had	   >2	   risk	   factors	   including;	   hypertension,	  
hyperlipidemia,	  tobacco	  smoking,	  a	  family	  history	  of	  stroke	  and	  ‘early	  onset’	  atherosclerosis73.	  
Using	  the	  SVS	  screening	  criteria	  described	  above,	  Thapar	  determined	  that	  screening	  all	  60-­‐year	  
old	  UK	  claudicants	  with	  a	  ‘one	  off’	  DUS	  would	  cost	  £17	  million	  (€20	  million).	  If	  all	  patients	  with	  
a	  70-­‐99%	  stenosis	  then	  underwent	  CEA,	  this	  would	  prevent	  about	  230	  strokes	  annually	   in	  the	  
UK,	  which	  represents	  only	  0.2%	  of	  the	  annual	  UK	  stroke	  burden74.	  In	  practice,	  143	  claudicants	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would	  need	  to	  be	  screened	  to	  identify	  20	  with	  a	  70-­‐99%	  stenosis	  for	  CEA,	  in	  order	  to	  prevent	  
one	  stroke	  at	  10	  years.	  This	  would	  cost	  £76,000	  (€88,300)	  per	  stroke	  prevented74.	  
	  
The	   USPSTF	   has	   recommended	   against	   screening	   for	   ACS	   on	   the	   basis	   that	   RCTs	   may	   have	  
overestimated	   benefits	   and	   used	   highly	   selected	   surgeons,	   while	   DUS	   screening	   (even	   with	  
MRA	  corroboration)	  might	  lead	  to	  a	  large	  number	  of	  false	  positive	  patients	  being	  diagnosed	  as	  
having	   a	   significant	   ACS.	   They	   also	   noted	   that	   (i)	  medical	   therapy	   in	   the	   RCTs	  was	   outdated	  
(section	  2.2.3.1.5),	   (ii)	   stroke	   rates	  have	  probably	  declined	  over	   recent	  decades,	  and	   that	   (iii)	  
‘real	  world’	  stroke	  risks	  may	  have	  been	  under	  reported64.	  	  
	  
Recommendation	  15	   Class	   Level	   References	  
Routine	  population	  screening	  for	  asymptomatic	  carotid	  stenosis	  
is	  not	  recommended	  	  
III	   C	   64	  
	  
	  
Recommendation	  16	   Class	   Level	   References	  
Selective	   screening	   for	   asymptomatic	   carotid	   stenoses	   may	   be	  
considered	   in	   patients	   with	   multiple	   vascular	   risk	   factors	   to	  
optimise	   risk	   factor	   control	   and	   medical	   therapy	   in	   order	   to	  
reduce	   late	   cardiovascular	  morbidity	  and	  mortality,	   rather	   than	  
for	  identifying	  candidates	  for	  invasive	  carotid	  interventions.	  	  
IIb	   C	   	  
	  
2.2.3	  Interventions	  in	  asymptomatic	  patients	  
2.2.3.1	  	  	  Randomised	  Trials	  comparing	  endarterectomy	  with	  medical	  therapy	  	  	  
The	   Veteran’s	   Affairs	   Co-­‐operative	   Study	   (VACS),	   ACAS	   and	   ACST-­‐1	   compared	   CEA	   plus	  
contemporary	  BMT,	  versus	  BMT	  alone	  in	  5,526	  patients	  who	  were	  recruited	  from	  Europe	  and	  
North	   America.	   VACS	   randomised	  males	   with	   50-­‐99%	   stenoses	   (n=444)	   between	   1983-­‐1987,	  
with	  follow-­‐up	  to	  199175.	  All	  underwent	  intra-­‐arterial	  angiography	  prior	  to	  randomisation.	  ACAS	  
randomised	   1662	   patients	   aged	   <80	   years	   with	   60-­‐99%	   stenoses	   between	   1987-­‐1993,	   with	  
follow-­‐up	  out	   to	   199713.	   ACAS	  patients	   had	   to	  have	   reported	  no	  previous	   ipsilateral	   cerebral	  
events	   at	   any	   time.	   All	   were	   screened	   by	   DUS	   (with	   an	   inclusion	   cut-­‐off	   corresponding	   to	   a	  
≥60%	   stenosis)	   and	   those	   randomised	   to	   CEA	   then	   underwent	   intra-­‐arterial	   angiography.	  
Patients	  randomised	  to	  BMT	  did	  not	  undergo	  angiography.	  Any	  angiographic	  related	  strokes	  in	  
patients	   randomised	   to	   CEA	  were	   included	  within	   the	   ‘intention	   to	   treat’	   analysis	   of	   surgical	  
morbidity	   and	   mortality.	   Patients	   with	   bilateral	   ACS	   had	   the	   side	   with	   the	   tightest	   stenosis	  
treated	  in	  the	  trial.	  If	  there	  were	  bilateral	  equal	  stenoses,	  the	  left	  ICA	  was	  designated	  the	  ‘trial’	  
artery.	  About	  40%	  of	  surgeons	  who	  applied	  to	   join	  ACAS	  were	  excluded	  following	  a	  review	  of	  
their	   track	   record67.	   ACST-­‐1	   randomised	   3120	   patients	  with	   70-­‐99%	   stenoses	   between	   1993-­‐
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2003,	  with	  follow-­‐up	  extending	  to	  2008.	  ACST-­‐1	  had	  no	  age	  limit	  and	  20%	  were	  aged	  >75	  years	  
at	  trial	  entry.	  Pre-­‐randomisation	  angiography	  was	  not	  required	  for	  either	  trial	  arm54.	  
	  
2.2.3.1.1	  Medical	  therapy	  in	  the	  randomised	  trials	  
In	  VACS,	  650mg	  of	  aspirin	   (daily)	  was	   taken	  by	  55%	  of	  patients,	  while	  27%	  took	   lower	  doses.	  
Antihypertensive	   therapy	   was	   less	   commonly	   used	   in	   VACS	   and	   no	   patient	   received	   statins.	  
During	  ACAS	  and	  ACST-­‐1,	  the	  use	  of	  BP	  and	  antithrombotic	  treatments	   increased.	  ACST-­‐1	  and	  
ACAS	  included	  patients	  who	  took	  fibrates	  and	  statins,	  though	  ACST-­‐1	  had	  longer	  follow-­‐up	  and	  
more	  robust	  evidence	  about	  statin	  use	   (13%	  ACAS	  patients	  were	  on	   lipid-­‐lowering	  therapy	  at	  
entry	  vs	  32%	  in	  ACST-­‐1).	  	  
	  
2.2.3.1.2	  	  Outcomes	  of	  randomised	  trials	  
Table	  4	  summarises	  the	  30-­‐day	  risks	  of	  death/stroke	  after	  CEA	  in	  the	  RCTs.	  Approximately	  half	  
of	   the	   peri-­‐operative	   strokes	   in	   CEA	   patients	   randomised	   within	   VACS	   and	   ACAS	   followed	  
angiography13,75.	  Table	  4	  also	  details	  late	  ‘ipsilateral’	  and	  ‘any’	  stroke	  rates	  (including	  the	  peri-­‐
operative	   risk).	  Overall,	   VACS	  observed	  no	  difference	   in	   ‘ipsilateral’	   or	   ‘any’	   stroke	   (including	  
the	  peri-­‐operative	  risk)	  at	  4	  years75.	  By	  contrast,	  ACAS	  and	  ACST	  observed	  that	  CEA	  conferred	  
significant	   reductions	   in	   ‘any’	   stroke	   (including	   the	   peri-­‐operative	   risk),	   while	   ACAS	   reported	  
that	   CEA	   significantly	   reduced	   the	   5-­‐year	   rate	   of	   ‘ipsilateral’	   stroke13,35.	   The	   ACAS	   and	   ACST	  
trials	  were	   pivotal	   in	   developing	   international	   practice	   guidelines,	  most	   of	  which	   advise	   that	  
CEA	   should	   be	   performed	  with	   a	   30-­‐day	   death/stroke	   rate	   <3%	   and	   that	   the	   patient	   should	  
have	  a	  predicted	  survival	  >5	  years13,35.	  
	  
Table	  4:	  peri-­‐operative	  and	  late	  outcomes	  following	  CEA	  and	  BMT	  in	  VACS,	  ACAS	  and	  ACST	  	  
	  
Ipsilateral	  stroke	  plus	  	  	  
perioperative	  death/stroke	  







CEA+BMT	   BMT	  alone	   CEA+BMT	   BMT	  alone	  
VACS75	   4.6%*	   	  	  	  7.0%	  at	  4	  yrs	   	  	  	  9.4%	  at	  4yrs	   	  	  	  10.4%	  at	  4yrs	   	  	  	  12.0%	  at	  4yrs	  
ACAS13	   2.3%*	   	  	  	  5.1%	  at	  5yrs	   	  	  	  11%	  at	  5yrs	   	  	  	  12.4%	  at	  5yrs	   	  	  	  17.8%	  at	  5yrs	  
ACST-­‐135	   2.8%	   Not	  available	   Not	  available	   	  	  	  6.4%	  at	  5yrs	   	  	  	  11.8%	  at	  5yrs	  
*	  includes	  strokes	  occurring	  after	  diagnostic	  angiography	  as	  well	  
	  
2.2.3.1.3	  	  Important	  subgroup	  analyses	  	  
2.2.3.1.3.1	  	  Effect	  of	  age	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ACST-­‐1	  published	  outcomes	  stratified	  for	  age	  (<65	  years	  (n=912);	  65-­‐74	  years	  (n=1558);	  and	  >75	  
years	  (n=650),	  but	  the	  long-­‐term	  analyses	  excluded	  peri-­‐operative	  deaths/strokes.	  CEA	  patients	  
aged	  <65	  years	  had	  a	  5-­‐year	  risk	  of	  ‘any’	  stroke	  of	  1.8%	  versus	  9.6%	  after	  BMT	  (Absolute	  Risk	  
Reduction	   (ARR)	   7.8%	   (95%CI	   4.3-­‐11.3)).	   CEA	   patients	   aged	   65-­‐74	   years	   had	   a	   5-­‐year	   risk	   of	  
‘any’	   stroke	   of	   2.2%	   versus	   9.7%	   after	   BMT	   (ARR	   7.5%	   (95%CI	   4.7-­‐10.3)),	  while	   CEA	   patients	  
aged	   >75	   years	   had	   a	   5.5%	   risk	   of	   ‘any’	   stroke	   at	   5-­‐years	   versus	   8.8%	   after	   BMT	   (ARR	   3.3%	  
(95%CI	  1.9-­‐8.4))35.	  Half	  of	  all	  patients	  aged	  >75	  who	  were	  randomised	  to	  CEA	  were	  dead	  within	  
5-­‐years	  and	  once	  the	  peri-­‐operative	  risks	  (3.7%	  in	  patients	  aged	  >75	  years)	  were	  included,	  there	  
was	   no	   evidence	   that	   CEA	   conferred	   any	   benefit	   in	   patients	   aged	   >7535.	   However,	   if	   it	  were	  
possible	  to	  develop	  imaging	  algorithms	  for	  identifying	  patients	  at	  higher	  risk	  of	  experiencing	  a	  
stroke	  on	  BMT	  (section	  2.2.3.1.5),	  it	  is	  possible	  that	  a	  higher	  risk	  subgroup	  of	  patients	  aged	  >75	  
years	  with	  a	  predicted	  life	  expectancy	  >5	  years	  might	  benefit	  from	  intervention.	  
	  
2.2.3.1.3.2	  	  Gender	  
An	  early	  meta-­‐analysis	  of	  pooled	  data	  from	  ACAS	  and	  ACST-­‐1	  reported	  that	  males	  randomised	  
to	  BMT	  were	  twice	  as	  likely	  to	  suffer	  a	  stroke	  at	  5-­‐years	  (OR	  2.04	  (95%CI	  1.5-­‐2.8))69.	  However,	  
at	   5	   years,	   CEA	   conferred	   no	  benefit	   in	   females	   (OR	   0.96	   (95%CI	   0.63-­‐1.45)).	   	   After	   10-­‐years	  
follow-­‐up,	  ACST-­‐1	  reported	  that	  females	  now	  gained	  a	  similar	  benefit	  to	  men	  (ARR	  5.8%	  (95%CI	  
1.1-­‐11.4)	   p=0.05)35.	   Reasons	   for	   the	   lack	   of	   apparent	   benefit	   in	  women	   at	   5-­‐years	  were	   that	  
whilst	  their	  hazard	  from	  CEA	  was	  similar	  to	  men,	  the	  ‘background’	  stroke	  risk	  (without	  surgery)	  
was	  lower,	  so	  benefit	  took	  longer	  to	  accrue.	  
	  
2.2.3.1.3.3	  	  Stenosis	  severity	  
Unlike	   symptomatic	  patients	   in	  ECST/NASCET	   (section	  2.3.3),	  ACST-­‐1	  and	  ACAS	   reported	   that	  
increasing	  stenosis	  severity	  (including	  bilateral	  stenoses	  and	  contralateral	  occlusion)	  were	  not	  
associated	   with	   increased	   rates	   of	   late	   stroke	   in	   patients	   randomised	   to	   BMT13,35.	   A	   meta-­‐
analysis	  involving	  41	  studies	  (6	  RCTS,	  35	  observational	  studies),	  reported	  that	  ipsilateral	  stroke	  
risk	   was	   1.9/100	   person	   years	   in	   patients	   with	   50-­‐70%	   stenoses	   at	   baseline,	   compared	  with	  
2.1/100	  person	  years	  in	  those	  with	  70-­‐99%	  stenoses	  (p=0.427)76.	  
	  
	  
2.2.3.1.4	  	  	  Controversy	  over	  ‘modern’	  medical	  therapy	  
ACAS,	   ACST-­‐1	   and	   VACS	   are	   the	   only	   RCTs	   to	   compare	   CEA	   with	   BMT,	   but	   they	   recruited	  
patients	   from	   1983-­‐2003	   when,	   for	  most	   of	   the	   time,	   the	   concept	   of	   ‘BMT’	   did	   not	   include	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statins	   and	  a	   greater	  proportion	  of	  patients	   smoked.	   Some	  now	  question	  whether	   their	  data	  
remain	  relevant	  in	  the	  modern	  era77.	  Several	  studies	  suggest	  that	  the	  annual	  risk	  of	  stroke	  may	  
be	  less	  than	  when	  ACAS	  and	  ACST-­‐1	  were	  recruiting.	  In	  a	  meta-­‐analysis	  of	  41	  studies,	  the	  rate	  
of	   ipsilateral	  stroke	  was	  2.3/100	  person	  years	   in	  studies	  completing	  recruitment	  before	  2000,	  
compared	   with	   1.0/100	   person	   years	   in	   studies	   completing	   between	   2000-­‐2010	   (p<0.001)76.	  
The	  39%	  decline	   in	   ipsilateral	  stroke	  per	  decade	  was	  attributed	  to	   improvements	   in	  BMT	  and	  
smoking	   cessation.	   In	   studies	  where	   >25%	   of	   participants	   took	   statins,	   ipsilateral	   stroke	  was	  
1.2/100	  person	   years,	   compared	  with	  2.3/100	  person	   years	  where	  <25%	  of	  participants	   took	  
statins	   (p=0.009)76.	   Another	   review	   has	   reported	   that	   the	   temporal	   trend	   towards	   declining	  
annual	  stroke	  rates	  in	  medically	  treated	  patients	  was	  consistent	  across	  all	  grades	  of	  stenosis	  at	  
baseline	  (50-­‐99%,	  60-­‐99%	  and	  70-­‐99%)	  and	  was	  also	  apparent	  in	  ACAS	  and	  ACST78.	  
	  	  
In	  1995,	  ACAS	  reported	  a	  17.5%	  five-­‐year	  risk	  of	  ‘any’	  stroke	  in	  patients	  with	  a	  60-­‐99%	  stenosis	  
who	   were	   treated	   medically	   (3.5%	   per	   year).	   The	   five-­‐year	   risk	   of	   ‘any	   stroke’	   in	   patients	  
randomised	  to	  medical	  therapy	  then	  decreased	  to	  11.8%,	  when	  ACST	  reported	  its	  first	  five-­‐year	  
data	  in	  2004	  (2.4%	  per	  year).	  When	  ACST	  reported	  its	  second	  five-­‐year	  data	  (ie	  years	  5-­‐10),	  the	  
five-­‐year	   risk	  of	  any	   stroke	  on	  medical	   therapy	  had	  declined	   to	  7.2%	   (1.4%	  per	  year),	  part	  of	  
which	   may	   be	   attributable	   to	   the	   fact	   that	   a	   proportion	   of	   patients	   randomised	   to	   BMT	  
underwent	  deferred	  CEA13,35,54,79.	  The	  same	  phenomenon	  was	  evident	   in	  the	  5-­‐year	   incidence	  
of	   ipsilateral	  stroke	   in	  medically	  treated	  patients.	  ACAS	  reported	  a	  five-­‐year	  rate	  of	   ipsilateral	  
stroke	   of	   11.0%	   in	  medically	   treated	   patients	   in	   1995	   (2.2%	   per	   year).	   By	   2004,	   when	   ACST	  
reported	  its	  first	  five-­‐year	  data,	  the	  5-­‐year	  risk	  of	  ipsilateral	  stroke	  had	  fallen	  to	  5.3%	  (1.1%	  per	  
year).	  When	  ACST	  reported	   its	  10-­‐year	  data,	   the	  rate	  of	   ipsilateral	  stroke	  for	  the	  second	  five-­‐
year	  period	  had	  decreased	  even	  further	  to	  3.6%	  (0.7%	  per	  year)13,35,54,79.	  Overall,	  this	  represents	  
a	  60%	  decline	  in	  annual	  stroke	  rates	  between	  1995	  and	  2010.	  It	  could	  be	  argued	  that	  patients	  
at	   ‘high	  risk	  for	  stroke’	   in	  ACST	  might	  already	  have	  had	  outcome	  events	   in	  the	  first	   five	  years	  
and	  were	  thus	  censored	  from	  further	  trial	  follow-­‐up,	  potentially	  leaving	  ‘lower	  risk’	  patients	  in	  
the	   5-­‐10	   year	   cohort.	   However,	   the	   decline	   at	   5	   and	   10	   years	   in	   ACST	   exactly	   parallels	   the	  
decline	   in	  the	  five-­‐year	  rates	  of	   ‘any’	  stroke	   in	  two	  entirely	   independent	  cohorts	  observed	  by	  
ACAS	  in	  1995	  and	  ACST-­‐1	  in	  2004.	  
	  
Awareness	  that	  the	  risk	  of	  stroke	  in	  asymptomatic	  patients	  treated	  medically	  may	  be	  less	  than	  
previously	  thought	  has	  led	  to	  calls	  for	  RCTs	  evaluating	  management	  strategies	  in	  asymptomatic	  
patients	  to	  include	  an	  additional	  limb	  for	  BMT.	  The	  second	  Stent	  Protected	  Angioplasty	  versus	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Carotid	  Endarterectomy	  	  trial	  (SPACE)-­‐2)	  planned	  to	  randomise	  patients	  to	  CEA,	  CAS	  and	  BMT,	  
but	  was	   abandoned	   after	   randomising	   only	   513	   patients	   because	   of	   slow	   recruitment80.	   The	  
second	  Carotid	  Revascularization	  versus	  Stenting	  Trial	   trial	   (CREST-­‐2)	  has	   started	   randomising	  
asymptomatic	  patients	   to	  CEA	  vs	  BMT	  and	  CAS	  vs	  BMT,	  while	   the	   second	  ECST	   trial	   (ECST-­‐2)	  
includes	  a	  medical	  limb	  for	  asymptomatic	  patients.	  The	  French	  randomised	  trial	  (Asymptomatic	  
Severe	  Atherosclerotic	  Carotid	  Artery	  Stenosis	  at	  Higher-­‐than-­‐average	  Risk	  of	  Ipsilateral	  Stroke	  	  
(ACTRIS))	  has	  not	  yet	  started	  but	  will	  compare	  BMT	  versus	  CEA/CAS	  in	  asymptomatic	  patients	  
who	  exhibit	   one	  or	  more	   features	   suggestive	   of	   them	  being	   at	   higher	   risk	   of	   suffering	   a	   late	  
ipsilateral	   stroke81	   (section	   2.2.3.1.5).	   The	   second	   ACST	   trial	   (ACST-­‐2)	   has	   been	   randomising	  
asymptomatic	  patients	  to	  CEA	  or	  CAS	  and	  should	  complete	  recruitment	  in	  2019.	  It	  is	  hoped	  that	  
as	  many	  vascular	  surgeons	  and	  interventionists	  as	  possible	  will	  support	  these	  RCTs.	  
	  
2.2.3.1.5	  	  Who	  is	  at	  	  ‘higher-­‐risk	  for	  stroke’	  on	  medical	  therapy?	  
The	   AHA	   has	   repeatedly	   advised	   that	   only	   ‘highly-­‐selected’	   asymptomatic	   patients	   should	  
undergo	   CEA71,82,	   but	   have	   never	   defined	   what	   ‘highly-­‐selected’	   means.	   An	   alternative	  
interpretation	  of	  ACST-­‐1	  is	  that	  (at	  ten	  years),	  only	  46	  strokes	  will	  be	  prevented	  at	  5-­‐years	  per	  
1000	  CEAs	  (ie	  95%	  of	  all	  CEAs	  were	  ultimately	  unnecessary).	  This,	  along	  with	  evidence	  that	  the	  
annual	   risk	   of	   stroke	   on	   BMT	   may	   be	   declining,	   suggests	   that	   there	   is	   a	   need	   to	   develop	  
clinical/imaging	  algorithms	  for	  identifying	  a	  smaller,	  but	  higher-­‐risk	  for	  stroke	  cohort	  in	  whom	  
CEA/CAS	  might	  be	   targeted.	   This	   is	   important	   as	  multi-­‐state	   audits	   suggest	   that	  CEA	   is	   being	  
performed	  in	  asymptomatic	  patients	  with	  30-­‐day	  death/stroke	  rates	  that	  frequently	  exceed	  the	  
3%	   threshold83.	   In	   addition,	   a	   recent	   systematic	   review	   observed	   that	   9/21	   (43%)	   registries	  
reported	  30-­‐day	  death/stroke	  rates	  that	  exceeded	  3%	  after	  CAS70.	  
Accordingly,	   an	   uncritical	   recommendation	   to	   revascularise	   ‘highly-­‐selected’	   patients	  without	  
defining	   who	   these	   patients	   might	   be,	   cannot	   be	   justified.	   	   It	   is	   inevitable	   that	   a	   smaller	  
subgroup	  with	  clinical	  and/or	  imaging	  features	  that	  make	  them	  ‘higher	  risk	  for	  stroke’	  on	  BMT	  
will	  benefit	  from	  carotid	  revascularisation.	  Whilst	  awaiting	  data	  from	  CREST-­‐2,	  ECST-­‐2,	  ACST-­‐2	  
and	  ACTRIS	  and	  the	  development	  of	  validated	  algorithms	  for	  patient	  selection,	  the	  presence	  of	  
one	   or	   more	   clinical	   and/or	   imaging	   features	   such	   as	   silent	   infarction	   on	   CT/MRI,	   stenosis	  
progression,	   large	   plaque	   area,	   large	   juxta-­‐luminal	   black	   area	   (JBA)	   on	   computerised	   plaque	  
analysis,	   plaque	   echolucency,	   intra-­‐plaque	   haemorrhage	   on	   MRI,	   impaired	   cerebral	   vascular	  
reswerve	  (CVR)	  and	  spontaneous	  embolisation	  on	  transcranial	  Doppler	  (TCD)	  monitoring,	  might	  
be	  useful	  for	  selecting	  ‘higher-­‐risk	  for	  stroke’	  patients	  for	  revascularization	  (table	  5).	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Table	  5:	  Clinical/Imaging	  features	  associated	  with	  an	  increased	  risk	  of	  late	  stroke	  in	  patients	  
with	  asymptomatic	  50-­‐99%	  stenoses	  treated	  medically.	  
	  
Imaging/Clinical	  Parameter	  
and	  stenosis	  severity	  
Type	  of	  study	  
Annual	  rate	  




silent	  infarction	  on	  CT84	  
multi-­‐centre,	  observational	  
60-­‐99%	  stenoses	  
Yes	  =	  3.6%	  
No	  	  =	  1.0%	  
3.0	  (1.46-­‐6.29)	  
p=0.002	  
stenosis	  progression85	  	  
multicentre,	  observational	  
50-­‐99%	  stenoses	  
regression	  	  	  =	  0.0%	  
unchanged	  	  =	  1.1%	  








Progression	  1	  stenosis	  grade	  





plaque	  area	  on	  computerized	  plaque	  
analysis	  (70-­‐99%)87	  
multicentre,observational	  
<40	  mm2	  	  	  	  	  	  	  	  =	  1.0%	  
40-­‐80	  mm2	  	  =	  1.4%	  	  
>80	  mm2	  	  	  	  	  	  	  	  	  	  	  =	  4.6%	  	  
HR	  1.0	  
2.08	  (95%CI	  1.05-­‐4.12)**	  
5	  	  5.81	  (95%CI	  2.67-­‐12.67)**	  




<4	  mm2	  	  	  	  	  	  =	  0.4%	  
4-­‐8	  mm2	  	  	  	  =	  1.4%	  
8-­‐10	  mm2	  =	  3.2%	  
>10	  mm2	  	  	  	  	  =	  5.0%	  
trend	  p<0.001	  
intra-­‐plaque	  haemorrhage	  on	  MRI89	  	  
meta-­‐analysis	  
50-­‐99%	  stenoses	  






Yes	  vs	  No	   OR	  6.14	  
(95%CI1.27-­‐29.5)	  
p=0.02	  
plaque	  lucency	  on	  Duplex	  US91	  
meta-­‐analysis	  
50-­‐99%	  stenoses	  
predominantly	  echolucent	  4.2%	  




spontaneous	  embolisation	  on	  TCD92	  	  
meta-­‐analysis	  
50-­‐99%	  stenoses	  
Yes	  vs	  No	   OR	  7.46	  
(95%CI	  2.24-­‐24.89)	  
p=0.001	  
spontaneous	  embolisation	  plus	  
uniformly	  or	  predominantly	  
echolucent	  	  plaque93	  
multicentre	  (observational)	  
70-­‐99%	  stenoses	  
Yes	  	  =	  	  8.9%	  




contralateral	  TIA/stroke94	  	  
multicentre	  (observational),	  	  
50-­‐99%	  stenoses	  	  
Yes	  =	  3.4%	  









2.2.3.2	  	  	  Randomised	  trials	  comparing	  endarterectomy	  with	  stenting	  
2.2.3.2.1	  	  	  ‘Average	  risk	  for	  surgery’	  asymptomatic	  patients	  
 33 
Five	   RCTs	   have	   published	   outcomes	   comparing	   CEA	   with	   CAS	   in	   ‘average-­‐risk	   for	   CEA’	  
patients80,95-­‐98.	   Lexington,	   Mannheim,	   SPACE-­‐2	   and	   the	   Asymptomatic	   Carotid	   Trial	   (ACT-­‐1)	  
randomised	  asymptomatic	  patients	  from	  the	  outset.	  CREST-­‐1	  was	  originally	  a	  symptomatic	  RCT,	  
but	  a	  protocol	  change	  enabled	  them	  to	  randomise	  asymptomatic	  patients	  because	  of	  sluggish	  
recruitment.	  Table	  6	  details	  30-­‐day	  death/stroke	  rates	  from	  the	  5	  RCTs.	  A	  meta-­‐analysis	  of	  data	  
from	   four	  of	   the	   five	  RCTs	   in	   table	  6	   (Lexington	  was	  excluded	  as	   there	  were	  no	  early	  or	   late	  
strokes),	  observed	  a	  30-­‐day	  death/stroke	  rate	  of	  1.6%	  after	  CEA	  (95%CI	  1.02-­‐2.45)	  versus	  2.7%	  
(95%CI	  2.1-­‐3.6%)	  after	  CAS	   (OR	  1.71	   (95%CI	  0.99-­‐2.94);	  p=0.0553).	  Figure	  4	  provides	  a	  Forest	  
plot	  of	  this	  meta-­‐analysis.	  
	  
Table	   6:	   30-­‐day	   morbidity	   and	   mortality	   in	   randomised	   trials	   comparing	   CEA	   and	   CAS	   in	  
asymptomatic	  patients.	  
Lexington95	   CREST-­‐196	   ACT-­‐197	   SPACE-­‐280	   Mannheim98	  	  
30-­‐day	  






















death/stroke	   0%	   0%	   1.4%	   2.5%	   1.7%	   2.9%	   2.0%	   2.5%	   0.0%	   1.5%	   2.9%	  
death/disabling	  
stroke	  
0%	   0%	   0.3%	   0.5%	   0.6%	   0.6%	   	   	   	   	   	  
death/stroke/	  
MI	  
0%	   0%	   3.6%	   3.5%	   2.6%	   3.3%	   	   	   	   1.5%	   2.9%	  
	  
	  
Figure	   4:	   Forest	   Plot	   comparing	   30-­‐day	   death/stroke	   in	   four	   randomised	   trials	   comparing	  
carotid	  endarterectomy	  versus	  carotid	  artery	  stenting	  in	  asymptomatic	  patients	  
	  
	  
In	   the	  Lexington	  RCT,	  no	   strokes	  or	   recurrent	   stenoses	  were	   reported	  at	  4-­‐years.	   In	  CREST-­‐1,	  
the	  4-­‐year	  rate	  of	  ipsilateral	  stroke	  (including	  the	  peri-­‐operative	  risk)	  was	  8%	  following	  CAS,	  vs	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6.7%	   after	   CEA.	   Restenosis	   (>70%)	  was	   6.7%	   at	   4-­‐years	   after	   CAS	   and	   6.2%	   after	   CEA96.99.	   In	  
ACT-­‐1,	  including	  peri-­‐operative	  stroke/death/MI,	  the	  1-­‐year	  rate	  of	  ipsilateral	  stroke	  was	  3.8%	  
after	  CAS	  versus	  3.4%	  after	  CEA.	  The	  5-­‐year	  rate	  of	   ipsilateral	  stroke	  (excluding	  peri-­‐operative	  
events)	   was	   2.2%	   after	   CAS	   and	   2.7%	   after	   CEA	   (p=0.51).	   The	   5-­‐year	   rate	   of	   ‘any’	   stroke	  
(excluding	  peri-­‐operative	  events)	  was	  6.9%	  after	  CAS,	  vs	  5.3%	  after	  CEA.	  At	  one-­‐year,	  freedom	  
from	  ‘target-­‐lesion’	  revascularization	  was	  99.4%	  after	  CAS	  and	  97.4%	  after	  CEA97.	  	  
	  
Despite	  protocol	  amendments,	  SPACE-­‐2	  stopped	  in	  2015	  after	  recruiting	  513	  patients80.	  The	  30-­‐
day	  stroke/death	  rate	  was	  1.97%	  in	  203	  patients	  randomised	  to	  CEA	  vs	  2.54%	  in	  197	  patients	  
randomised	  to	  CAS.	  No	  strokes	  occurred	  <30-­‐days	  of	   randomisation	   in	  the	  113	  BMT	  patients.	  
Follow-­‐up	   will	   continue	   to	   5-­‐years,	   with	   data	   being	   available	   for	   future	   meta-­‐analyses.	   In	  
Mannheim’s	   RCT,	   there	   were	   no	   late	   strokes	   at	   a	   mean	   follow-­‐up	   of	   26	   months;	   3/68	   CEA	  
patients	  (4.4%)	  developed	  a	  70-­‐99%	  restenosis,	  versus	  1/68	  (1.5%)	  after	  CAS98.	  	  
	  
Only	   experienced	   and	   credentialed	   CAS	   interventionists	   participated	   in	   CREST	   and	   ACT-­‐1.	   In	  
ACT-­‐1	   (the	   largest	   completed	   trial	   to	   date),	   the	   2.9%	   rate	   of	   death/stroke	   after	   CAS	   just	   fell	  
within	   the	   accepted	   3%	   risk	   threshold,	   which	   many	   now	   believe	   to	   be	   too	   high,	   given	   the	  
apparent	  reductions	  in	  stroke	  on	  BMT	  (section	  2.2.3.1.5).	   In	  addition,	  because	  of	  the	  learning	  
curve	  associated	  with	  CAS,	  as	  well	  as	  it	  being	  performed	  in	  low	  numbers	  by	  multiple	  specialties	  
with	  different	  patient	  selection	  criteria100,	   there	  are	  concerns	  as	  to	  whether	  the	  death/stroke	  
rates	  following	  CAS	  in	  RCTs	  can	  be	  replicated	  in	  ‘real	  world’	  practice.	  Whilst	  some	  national	  CAS	  
registries	  have	  published	  death/stroke	  rates	  <3%101,102,	  others	  have	  reported	  wide	  variations	  in	  
practice.	  In	  a	  review	  of	  19,381	  CAS	  procedures	  in	  the	  USA,	  there	  was	  a	  four-­‐fold	  variation	  in	  in-­‐
hospital	   death/stroke,	   despite	   adjusting	   for	   case-­‐mix100.	   A	   systematic	   review	   of	   large	  
administrative	  dataset	  registries	  (>1.5	  million	  procedures)	  found	  that	  40%	  of	  registries	  reported	  
death/stroke	   rates	   after	   CAS	   in	   excess	   of	   3%	   in	   asymptomatic	   patients,	   while	   14%	   reported	  
death/stroke	   rates	   >5%70.	   In	   some	   large	   registries,	   the	   median	   annual	   number	   of	   CAS	  
procedures	  in	  asymptomatic	  patients	  may	  only	  be	  1–2	  per	  interventionist,	  which	  is	  known	  to	  be	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The	   Stenting	   and	   Angioplasty	   With	   Protection	   in	   Patients	   at	   HIgh	   Risk	   for	   Endarterectomy	  
(SAPPHIRE)	  study	  randomised	  334	  patients	  deemed	  ‘high-­‐risk	  for	  CEA’	  to	  either	  CEA	  or	  CAS.	  The	  
criteria	   for	  defining	  a	   ‘high-­‐risk	   for	  CEA’	  asymptomatic	  patient	   included	  an	  asymptomatic	  70-­‐
99%	  stenosis	  in	  the	  presence	  of	  one	  or	  more	  of:	  clinically	  significant	  cardiac	  disease	  (congestive	  
heart	  failure,	  abnormal	  stress	  test,	  or	  need	  for	  open-­‐heart	  surgery);	  severe	  pulmonary	  disease;	  
contralateral	   carotid	   occlusion;	   contralateral	   laryngeal-­‐nerve	   palsy;	   previous	   radical	   neck	  
surgery,	  cervical	  radiation	  therapy;	  recurrent	  stenosis	  after	  CEA	  and	  age	  >80	  years104.	  However,	  
the	  majority	  of	  SAPPHIRE	  patients	  were	  asymptomatic	  (70%),	  in	  whom	  the	  30-­‐day	  death/stroke	  
rate	  was	  5.8%	  after	  CAS	  and	  6.1%	  after	  CEA104.	  At	  these	  levels	  of	  risk,	  none	  would	  gain	  benefit	  
in	  terms	  of	  late	  stroke	  prevention,	  suggesting	  they	  should	  be	  treated	  medically.	  
	  
An	  algorithm	  for	  managing	  asymptomatic	  patients	  with	  carotid	  disease	  is	  presented	  in	  Figure	  5.	  
	  
Figure	   5	   Algorithm	   detailing	   management	   strategies	   in	   patients	   with	   symptomatic	   and	  
asymptomatic	  atherosclerotic	  extracranial	  carotid	  artery	  stenoses	  
	  
	  
Green	  boxes	  denote	  Level	  I	  recommendations,	  yellow	  boxes	  denote	  level	  IIa	  and	  IIb	  recomendations	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*	   	   ‘High-­‐risk	   for	   CEA’	   criteria	   might	   include	   clinically	   significant	   cardiac	   disease;	   severe	   pulmonary	   disease;	  
contralateral	  carotid	  occlusion;	  contralateral	  laryngeal-­‐nerve	  palsy;	  previous	  radical	  neck	  surgery,	  cervical	  radiation	  
therapy,	  recurrent	  stenosis	  after	  CEA.	  
**imaging/clinical	   criteria	   that	  might	   confer	   an	   increased	   risk	   of	   stroke	   on	   BMT	   include	   silent	   infarction	   on	   CT,	  
stenosis	   progression,	   large	   plaque	   area,	   large	   JBA,	   plaque	   echolucency,	   intra-­‐plaque	   haemorrhage	   on	   MRI,	  
impaired	  CVR,	  spontaneous	  embolisation	  on	  TCD,	  history	  of	  contralateral	  TIA	  (table	  5)	  
Figure	  5	  reproduced	  with	  permission	  from	  The	  2017	  European	  Society	  of	  Cardiology	  Guidelines	  on	  the	  diagnosis	  and	  
treatment	  of	  peripheral	  arterial	  diseases	   in	  collaboration	  with	  the	  European	  Society	  of	  Vascular	  Surgery	  covering	  
atherosclerotic	  disease	  of	  extracranial,	  vertebral,	  mesenteric,	  renal,	  upper	  and	  lower	  extremity	  arteries.	  Eur	  J	  Vasc	  
Endovasc	  Surg	  (2017	  IN	  PRESS).	  	  
	  
Recommendation	  17	   Class	   Level	   References	  
In	   ‘average	   surgical	   risk’	   patients	   with	   an	   asymptomatic	   60-­‐99%	  
stenosis,	   carotid	   endarterectomy	   should	   be	   considered	   in	   the	  
presence	   of	   one	   or	   more	   imaging	   characteristics	   that	   may	   be	  
associated	  with	  an	  increased	  risk	  of	  late	  ipsilateral	  stroke*,	  provided	  
documented	   perioperative	   stroke/death	   rates	   are	   <3%	   and	   the	  
patient’s	  life	  expectancy	  exceeds	  5	  years.	  
IIa	   B	   13,35,54,	   84-­‐
94,	  96,97	  
	  
Recommendation	  18	   Class	   Level	   References	  
In	   ‘average	   surgical	   risk’	   patients	   with	   an	   asymptomatic	   60-­‐99%	  
stenosis	  in	  the	  presence	  of	  one	  or	  more	  imaging	  characteristics	  that	  
may	  be	  associated	  with	  an	   increased	  risk	  of	   late	   ipsilateral	  stroke*,	  
carotid	   stenting	   may	   be	   an	   alternative	   to	   carotid	   endarterectomy,	  
provided	  documented	  perioperative	  stroke/death	  rates	  are	  <3%	  and	  
the	  patient’s	  life	  expectancy	  exceeds	  5	  years	  
IIb	   B	   80,84-­‐94,	  
95,96,	  97,98	  
	  
Recommendation	  19	   Class	   Level	   References	  
Carotid	   stenting	   may	   be	   considered	   in	   selected	   asymptomatic	  
patients	  who	  have	  been	  deemed	  by	   the	  multi-­‐disciplinary	   team	   to	  
be	   ‘high-­‐risk	   for	   surgery’	   and	   who	   have	   an	   asymptomatic	   60-­‐99%	  
stenosis	  in	  the	  presence	  of	  one	  or	  more	  imaging	  characteristics	  that	  
may	  be	  associated	  with	  an	  increased	  risk	  of	  late	  ipsilateral	  stroke*,	  
provided	  documented	  procedural	  risks	  are	  <3%	  and	  the	  patient’s	  life	  
expectancy	  exceeds	  5	  years	  
IIb	   B	   84-­‐94,	  104,	  
105	  
 
*	   imaging/clinical	   criteria	   that	  might	   confer	   an	   increased	   risk	   of	   stroke	   on	   BMT	   include	   silent	   infarction	   on	   CT,	  
stenosis	   progression,	   large	   plaque	   area,	   large	   JBA,	   plaque	   echolucency,	   intra-­‐plaque	   haemorrhage	   on	   MRI,	  





2.2.3.3	  	  Carotid	  revascularisation	  to	  prevent	  dementia	  
	  
2.2.3.3.1	  	  Alzheimer’s,	  Vascular	  and	  ‘Mixed’	  dementias	  
Worldwide,	  44	  million	  people	  have	  dementia.	  	  In	  2012,	  the	  cost	  of	  treating	  dementia	  in	  the	  UK	  
exceeded	  £23	  billion	   (27	  billion	  Euros).	   In	  20%	  of	  dementia	   sufferers,	   the	  underlying	  cause	   is	  
atherosclerosis	  or	  other	  occlusive	  diseases	  affecting	  cerebral	  blood	  vessels	  (vascular	  dementia),	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while	   20-­‐30%	   have	   a	   mixture	   of	   vascular	   dementia	   and	   Alzheimer’s	   disease.	   Important	   risk	  
factors	  for	  dementia	  include	  poor	  diet,	  mid-­‐life	  hypertension,	  hypercholesterolaemia,	  diabetes,	  
smoking	  and	  excess	  alcohol	  intake106.	  	  	  
	  
2.2.3.3.2	  Dementia	  and	  Carotid	  disease	  
Cognitive	  impairment	  is	  relatively	  common	  in	  stroke	  patients,	  attributed	  to	  the	  site	  and	  extent	  
of	   the	  underlying	  brain	   injury.	  However,	   there	  has	  been	   interest	   in	  whether	   there	   is	  a	   causal	  
association	  between	  ACS	  and	  cognitive	  impairment.	  In	  a	  recent	  systematic	  review,	  9	  out	  of	  10	  
observational	   studies	   reported	   a	   significant	   association	   between	   ACS	   and	   cognitive	  
impairment107.	  However,	  many	  of	   the	   risk	   factors	   for	  ACS	  are	   the	   same	  as	   for	  dementia.	  The	  
Baltimore	  Longitudinal	  Study	  of	  Ageing	  observed	  that	  patients	  in	  the	  upper	  quintile	  of	  carotid	  
IMT	  or	  who	  had	  bilateral	  carotid	  plaques	  (of	  any	  severity)	  had	  a	  doubling	  of	  dementia	  rates	  at	  
14	   years,	   compared	   to	  patients	   in	   the	   lower	  quintiles108.	   In	   the	   Framingham	  Offspring	   Study,	  
which	   included	  1975	  participants	  who	  were	   free	  of	  stroke	  and	  dementia	  at	   the	  time	  of	  study	  
entry,	  ICA	  IMT	  thickness	  (but	  not	  CCA	  IMT	  thickness)	  was	  associated	  with	  MRI	  derived	  indices	  of	  
brain	  ischaemia	  as	  well	  as	  cognitive	  impairment109.	  	  
	  
Buratti	  undertook	  serial	  DUS	   in	  159	  patients	  with	  bilateral,	  70-­‐99%	  ACS	  over	  a	  3-­‐year	  period.	  
Cognitive	   decline	   was	   lowest	   in	   patients	   with	   no	   evidence	   of	   impaired	   CVR	   at	   baseline,	  
becoming	   more	   apparent	   in	   patients	   with	   unilateral	   CVR	   impairment.	   The	   highest	   levels	   of	  
cognitive	   impairment	  were	   in	   patients	  with	   bilaterally	   impaired	   CVR110.	   Similar	   findings	  were	  
reported	   by	   Balucani	   in	   a	   cohort	   of	   333	   asymptomatic	   patients	   with	   unilateral	   (n=150),	   or	  
bilateral	  (n=127)	  carotid	  stenoses	  >60%	  and	  patients	  with	  no	  carotid	  stenosis	  (n=56)	  who	  acted	  
as	   controls.	   Patients	   with	   unilateral	   or	   bilateral	   ACS	   were	   more	   likely	   to	   have	   cognitive	  
impairment,	  compared	  to	  with	  those	  with	  no	  stenoses111.	  Cognitive	  impairment	  was	  maximal	  in	  
patients	  with	   impaired	  CVR.	   Interestingly,	   there	  was	  no	  difference	   in	  cognitive	   impairment	   in	  
controls	  compared	  with	  patients	  with	  bilateral	  ACS	  who	  had	  no	  evidence	  of	  impaired	  CVR.	  	  
	  
In	   the	   Cardiovascular	   Health	   Study	   Group,	   a	   high-­‐grade	   stenosis	   of	   the	   left	   ICA	   (>75%)	   was	  
associated	  with	   cognitive	   decline	   using	   the	  modified	  Mini-­‐Mental	   State	   Examination	   (MMSE)	  
test,	  which	  is	  more	  specific	  for	  testing	  dominant	  hemisphere	  cognitive	  function112.	  The	  Tromso	  
study	  also	  observed	  that	  the	  presence	  of	  a	  carotid	  stenosis	   (defined	  as	  >35%)	  was	  associated	  
with	  impaired	  neuropsychological	  performance113.	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2.2.3.3.3	  	  How	  might	  carotid	  stenoses	  cause	  cognitive	  decline?	  
Cognitive	   decline	   may	   be	   due	   to	   ‘silent	   embolisation’,	   with	   the	   development	   of	   multiple	  
infarctions	  and	  increasing	  subcortical	  deep	  white	  matter	  and	  cortical	  lesions,	  which	  have	  been	  
associated	   with	   cognitive	   impairment114.	   Chronic	   hypoperfusion,	   especially	   in	   patients	   with	  
impaired	   CVR,	   may	   also	   be	   responsible.	   However,	   an	   alternative	   explanation	   may	   be	   that	  
because	   patients	  with	   ACS	   share	   the	   same	   risk	   factors	   as	   those	  who	   develop	   dementia,	   the	  
presence	  of	  ACS	  may	  simply	  be	  a	  risk	  marker,	  rather	  than	  a	  cause	  of	  cognitive	  decline.	  
	  
In	  the	  Cardiovascular	  Health	  Study,	  the	  persistence	  of	  a	  significant	  association	  between	  severe	  
left	  sided	  ACS	  and	  impaired	  cognitive	  function,	  after	  adjustment	  for	  the	  presence	  of	  right	  sided	  
carotid	   stenoses,	  was	   interpreted	  as	  meaning	   that	   the	  association	   could	  not	  be	  attributed	   to	  
underlying	  vascular	  risk	  factors	  or	  atherosclerosis	  in	  general112.	  However,	  interpretation	  of	  the	  
data	   was	   limited	   by	   the	   small	   number	   of	   patients	   with	   severe	   stenoses	   (n=35).	   Silent	  
embolisation	  has	  long	  been	  associated	  with	  cognitive	  decline,	  but	  the	  evidence	  supporting	  this	  
is	   limited.	   In	   the	   Tromso	   study,	   impaired	   cognition	   could	   not	   be	   attributed	   to	   embolization,	  
because	  there	  was	  no	  increase	  in	  silent	  ischaemic	  lesions	  on	  MRI113.	  	  
	  
In	  a	  series	  of	  projects	  from	  Manchester	  UK,	  spontaneous	  embolisation	  on	  TCD	  was	  detected	  in	  
43%	  of	  patients	  with	  Alzheimer’s	  disease	  and	  45%	  with	  vascular	  dementia115.	  The	  presence	  of	  
microemboli	  was	  associated	  with	  faster	  deterioration	  in	  cognitive	  function	  during	  two	  years	  of	  
surveillance.	  However,	  only	  8%	  of	  Alzheimer	  patients	  had	  ACS	  on	  DUS,	  compared	  with	  21%	  of	  
vascular	   dementia	   patients.	   Microemboli	   were	   associated	   with	   elevated	   BP	   and	   a	   high	  
prevalence	  of	  venous	  to	  arterial	  shunts	  (detected	  in	  26%	  of	  dementia	  patients),	  which	  may	  be	  
indicative	   of	   an	   underlying	   patent	   foramen	   ovale116.	   The	   investigators	   identified	   >50%	   ICA	  
stenoses	  in	  only	  13%	  of	  dementia	  patients	  who	  had	  microemboli	  on	  TCD,	  compared	  with	  14%	  
of	   patients	  without	   emboli.	   By	   contrast,	   a	   venous	   to	   arterial	   shunt	  was	   identified	   in	   24%	   of	  
dementia	   patients	   who	   were	   microemboli	   negative,	   compared	   with	   49%	   who	   were	  
microemboli	  positive116.	   In	   the	  Manchester	  series,	  a	  >70%	  stenosis	  was	  present	   in	  only	  2%	  of	  
dementia	  patients	  who	  were	  microemboli	  positive,	  compared	  with	  0%	  of	  microemboli	  negative	  
patients116.	   In	  addition,	   in	  a	   series	  of	  96	  healthy	  older	  people	   (median	  age	  77	  years)	  with	  no	  
history	  of	  dementia	  or	   stroke,	  microemboli	  were	  detected	   in	  12%116.	   In	   this	  cohort,	   cognitive	  
decline	  over	   a	   2.5-­‐year	   period	  was	  not	   associated	  with	  microemboli	   after	   correcting	   for	   age,	  
gender	   and	   baseline	   cognition116.	   These	   data,	   therefore,	   support	   Johnston’s	   hypothesis	   that	  
silent	  embolisation	  from	  an	  underlying	  ACS	  is	  unlikely	  to	  be	  an	  important	  cause	  of	  dementia112.	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There	   is	   probably	   more	   evidence	   supporting	   the	   hypothesis	   that	   chronic	   hypoperfusion	   in	  
association	  with	  impaired	  CVR	  is	  associated	  with	  a	  higher	  prevalence	  of	  cognitive	  impairment.	  
As	  a	  carotid	  stenosis	  becomes	  more	  severe,	  patients	  with	   inadequate	  collateralisation	  via	  the	  
circle	   of	   Willis	   compensate	   by	   progressive	   dilatation	   of	   arteries/arterioles	   in	   the	   ipsilateral	  
hemisphere.	   This	   maintains	   cerebral	   blood	   flow,	   but	   a	   point	   is	   reached	   where	   the	   vessels	  
cannot	  vasodilate	  any	  more;	   ie.	   they	  are	  now	   in	  a	   state	  of	   impaired	  CVR	  with	  no	  capacity	   to	  
compensate	  any	  further.	  CVR	  can	  be	  measured	  in	  several	  ways.	  One	  method	  is	  to	  measure	  the	  
increase	   in	  MCA	  velocities	   using	   TCD	  at	   baseline	   and	   then	  after	   breath	  holding	   (which	   raises	  
CO2	   levels),	   or	   the	   inhalation	   of	   5%	  CO2,	   or	   by	   the	   administration	   of	   acetazolamide.	   Patients	  
with	  exhausted	  CVR	  cannot	  increase	  their	  MCA	  velocities,	  because	  they	  are	  already	  maximally	  
vasodilated.	   Interestingly,	   Fearn	   observed	   that	   CEA	   was	   able	   to	   improve	   post-­‐operative	  
cognitive	  function	  in	  patients	  who	  had	  evidence	  of	  impaired	  pre-­‐operative	  CVR117.	  	  	  
	  
2.2.3.3.4	  	  Do	  carotid	  interventions	  improve	  cognition?	  
It	  is	  hypothesised	  that	  CEA/CAS	  have	  the	  potential	  to	  improve	  cognitive	  function	  by	  increasing	  
brain	  perfusion,	  as	  well	  as	  by	  removing	  a	  source	  of	  embolisation.	  In	  a	  systematic	  review	  of	  15	  
studies	  on	  the	  effect	  of	  CEA	  on	  cognitive	  function,	  there	  was	  no	  change	  in	  cognitive	  function	  in	  
six	  studies,	  there	  was	  a	  deterioration	  in	  five	  studies	  and	  an	  improvement	  in	  four.	  Four	  studies	  
reported	  on	   the	  effect	  of	  CAS	  on	  cognitive	   function,	  with	  no	  change	   in	   cognition	  post-­‐CAS	   in	  
one	   study,	   while	   in	   three,	   there	   was	   an	   improvement118.	   A	   subsequent	   systematic	   review	  
compared	  changes	  in	  post-­‐operative	  cognitive	  function	  after	  CEA	  vs	  CAS119.	  Six	  studies	  reported	  
no	  difference,	  three	  reported	  that	  cognitive	  function	  deteriorated	  more	  significantly	  after	  CAS	  
(than	  CEA),	  whereas	  in	  one	  study,	  cognitive	  function	  deteriorated	  after	  both	  CEA	  and	  CAS	  with	  
the	  effect	  being	  more	  persistent	  after	  CEA119.	  
	  
To	  date,	  there	   is	  no	  compelling	  evidence	  that	  carotid	   interventions	  either	   improve	  or	  prevent	  
cognitive	   impairment.	  However,	   there	  are	  a	  number	  of	   reasons	  why	  a	  beneficial	  effect	  might	  
have	   been	  missed	   including	   a	   ‘learning	   effect’	   through	   repeated	   patient	   testing;	   the	   type	   of	  
neuropsychological	  test	  employed;	  the	  lack	  of	  involvement	  of	  a	  specialised	  neuropsychologist;	  
the	  hemisphere	  being	  tested	  (MMSE	  mainly	  tests	  dominant	  hemispheric	  function);	  the	  type	  of	  
patient	   (symptomatic/asymptomatic);	   a	   lack	   of	   controls;	   short	   duration	   of	   follow-­‐up	   (most	  
studies	   focused	   on	   the	   early	   peri-­‐operative	   period);	   small	   sample	   size	   and	   underpowered	  
studies;	  and	  the	  lack	  of	  standardised	  timing	  of	  post-­‐operative	  assessments	  .	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Further	  data	  will	  be	  forthcoming	  from	  CREST-­‐2,	  which	  is	  randomising	  asymptomatic	  patients	  to	  
CEA	  or	  CAS	  versus	  BMT	  and	  which	  plans	  to	  include	  serial	  cognitive	  function	  testing.	  In	  addition,	  
ACST-­‐1	  (with	  extended	  follow-­‐up	  to	  22	  years	  in	  some	  patients)	  is	  comparing	  rates	  of	  dementia	  
between	  patients	  who	  underwent	  CEA	  with	  those	  who	  remained	  on	  medical	  treatment	  alone.	  	  
	  
Recommendation	  20	   Class	   Level	   References	  
Until	  a	  causal	  association	  between	  severe	  asymptomatic	  carotid	  
stenoses	  and	  cognitive	  decline	  has	  been	  established,	  carotid	  
interventions	  are	  not	  recommended	  for	  the	  prevention	  of	  
cognitive	  impairment	  in	  patients	  with	  severe	  asymptomatic	  
carotid	  stenoses	  




2.3	  Tertiary	  prevention	  in	  recently	  symptomatic	  patients	  
2.3.1	  	  Symptoms	  attributable	  to	  carotid	  artery	  disease	  
For	   the	   purpose	   of	   these	   guidelines,	   the	   term	   ‘symptomatic’	   refers	   to	   any	   patient	   who	   has	  
suffered	   a	   carotid	   territory	   symptom	   within	   the	   preceding	   6	   months.	   Carotid	   territory	  
symptoms	   include	   (i)	  hemi-­‐sensory	   impairment	   (numbness,	  paraesthesia	  of	   face/arm/leg);	   (ii)	  
hemi-­‐motor	   deficits	   (weakness	   of	   face/arm/leg,	   or	   limb	   clumsiness),	   and	   (iii)	   higher	   cortical	  
dysfunction	  (dysphasia/aphasia,	  visuospatial	  problems).	  Most	  symptoms	  are	  “negative”	  (ie	  loss	  
of	  function),	  but	  occasionally	  a	  ‘limb-­‐shaking’	  TIA	  can	  occur,	  characterized	  by	  involuntary	  limb	  
movements	   due	   to	   haemodynamic	   failure	   in	   patients	   with	   severe	   carotid	   stenoses	   (or	  
occlusion).	  ‘Crescendo	  TIAs’	  involve	  multiple	  TIAs	  within	  a	  short	  time	  period,	  with	  full	  recovery	  
in	   between.	   The	   exact	   number	   and/or	   frequency	   has	   never	   been	   defined,	   but	   >3	   events	   in	  
seven	  days	  would	   seem	  reasonable.	   ‘Stroke-­‐in-­‐evolution’	   refers	   to	  a	   fluctuating	  deficit	   (never	  
fully	  back	  to	  normal)	  or	  a	  progressively	  worsening	  neurological	  deficit.	  	  
	  
Amaurosis	   Fugax	   (transient	   monocular	   blindness)	   refers	   to	   transient	   impairment	   or	   loss	   of	  
vision	   in	   one	   eye.	   Occasionally,	   visual	   loss	   can	   be	   permanent	   due	   to	   retinal	   infarction	  
(analogous	  to	  stroke).	  Patients	  with	  retinal	  infarction	  are	  still	  candidates	  for	  revascularisation	  in	  
order	   to	   prevent	   hemispheric	   stroke.	   Ocular	   ischaemia	   syndrome	   is	   rare	   and	   involves	   a	  
spectrum	  of	  clinical	  findings	  secondary	  to	  chronic	  ocular	  hypoperfusion	  (progressive	  visual	  loss,	  
pain,	  dilated	  conjunctival/episcleral	  vessels,	  rubeosis	  iridis,	  narrowing	  of	  retinal	  arteries,	  retinal	  
haemorrhages	  and	  microaneurysms).	   In	   rare	  patients,	   entering	  a	  brightly	   lit	   room	  will	   trigger	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transient	   visual	   loss	   or	   ‘whiteout’	   of	   vision120.	   Ocular	   ischaemia	   syndrome	   is	   nearly	   always	  
associated	  with	  severe	  extracranial	   ICA	  stenotic/occlusive	  disease,	  although	  if	  collateralisation	  
via	  the	  circle	  of	  Willis	  is	  extremely	  poor,	  it	  may	  occur	  in	  patients	  with	  50%	  stenoses120.	  The	  main	  
differential	   diagnoses	   are	   diabetic	   retinopathy	   and	   central	   retinal	   vein	   occlusion.	   Treatment	  
involves	   local	   ophthalmic	   measures	   to	   control	   anterior	   segment	   inflammation,	   raised	   intra-­‐
ocular	  pressures	  and	  neovascular	  glaucoma.	  Medical	  treatment	  should	  focus	  on	  traditional	  risk	  
factor	  control	  and	  optimal	  medical	  therapy,	  while	  the	  aim	  of	  CEA	  is	  to	  try	  and	  prevent	  further	  
deterioration	   in	   visual	   acuity	   by	   preventing	   further	   neovascularisation,	   which	   is	   prone	   to	  
haemorrhage	   onto	   the	   retinal	   surface.	   Carotid	   endarterectomy	   is	   probably	   less	   likely	   to	   be	  
successful	   in	   patients	   who	   already	   have	   neovascularisation-­‐related	   glaucoma	   or	   iris	  
neovascularisation,	  as	  this	  indicates	  more	  severe	  longer-­‐term	  ocular	  hypoperfusion120.	  
	  
2.3.2.	  	  	  Optimal	  medical	  therapy	  	  
2.3.2.1	  	  Risk	  factor	  control	  
The	  control	  of	  modifiable	  risk	  factors	  including	  smoking,	  exercise,	  diet	  and	  obesity	  are	  the	  same	  
as	  for	  section	  2.2.1.1.	  
	  
Recommendation	  21	   Class	   Level	   References	  
A	   healthy	   diet,	   smoking	   cessation	   and	   physical	   activity	   are	  
recommended	   for	   all	   patients	   with	   symptomatic	   carotid	  
disease	  
I	   C	   	  
	  
	  
2.3.2.2	  	  Antiplatelet	  therapy	  
2.3.2.2.1	  	  Antiplatelet	  therapy	  as	  tertiary	  prevention	  
Table	  7	  summarises	  key	  RCT	  findings	  regarding	  roles	  for	  mono	  or	  DAPT	  in	  patients	  with	  TIA	  or	  
ischaemic	   stroke,	   including	   the	  European	  Stroke	  Prevention	  Study-­‐2	   (ESPS-­‐2),	   the	  Clopidogrel	  
versus	   Aspirin	   in	   Patients	   at	   Risk	   of	   Ischaemic	   Events	   (CAPRIE),	   the	   European-­‐Australasian	  
Stroke	  Prevention	  in	  Reversible	  Ischaemia	  Trial	  (ESPRIT),	  the	  Prevention	  Regimen	  for	  Effectively	  
Avoiding	  Second	  Strokes	   (PRoFESS)	  and	   the	  Clopidogrel	   in	  High-­‐risk	  patients	  with	  Acute	  Non-­‐
disabling	  Cerebrovascular	  Events	  (CHANCE)121-­‐125.	  These	  studies	  were	  not	  focussed	  on	  patients	  
with	  symptomatic	  moderate	  or	  severe	  carotid	  stenoses,	  but	  it	  is	  reasonable	  to	  extrapolate	  the	  
data	   to	   such	   patients	   in	   the	   absence	   of	   large	   studies	   in	   patients	   with	   symptomatic	   carotid	  
disease.	  NICE	  (National	  Institute	  for	  Health	  and	  Care	  Excellence)	  concluded	  that	  in	  patients	  with	  
stroke	   or	   TIA,	   clopidogrel	   should	   be	   the	   first-­‐line	   antiplatelet	   agent,	   followed	   by	   aspirin	   and	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dipyridamole	  (if	  clopidogrel	  intolerant),	  followed	  by	  aspirin	  monotherapy,	  followed	  by	  modified	  
release	  dipyridamole	  monotherapy,	  if	  aspirin	  and	  clopidogrel	  intolerant126.	  
	  
Table	   7:	   RCTs	   of	   antiplatelet	   therapy	   for	   tertiary	   prevention	   in	   patients	   with	   TIA	   and/or	  	  
minor	  ischaemic	  stroke	  	  
	  

































dipyridamole	  200mg	  bd	  
vs	  
aspirin	  25mg	  bd	  
vs	  
aspirin	  25mg	  bd	  plus	  















relative	  risk	  reduction	  (all	  p<0.05)	  
dipyridamole	  vs	  placebo:	  16%	  	  
	  
aspirin	  vs	  placebo:	  18%	  
	  
aspirin	  +	  dipyridamole	  	  vs	  placebo:	  
37%	  
	  
aspirin	  +	  dipyridamole	  vs	  
dipyridamole:	  25%	  
	  











stroke	  <6	  mths	  









30-­‐325mg	  daily	  and	  








or	  MI/	  vascular	  
death	  
aspirin	  and	  dipyridamole	  vs	  aspirin	  




aspirin	  and	  dipyridamole	  vs.	  aspirin	  









stroke,	  MI	  	  
or	  PAD	  







325mg	  daily	  	  
	  
ischaemic	  stroke,	  
MI	  or	  vascular	  
death	  
RRR	  with	  clopidogrel	  vs	  aspirin	  for	  
overall	  vascular	  disease	  population	  
=	  8.7	  %	  (p=0.043)	  
	  
RRR	  with	  clopidogrel	  vs	  aspirin	  for	  










stroke	  <4	  mths	  




aspirin	  25mg	  bd	  +	  
dipyridamole	  200mg	  bd	  
vs	  







stroke	  /	  MI	  or	  	  
vascular	  death	  
	  
aspirin	  and	  dipyridamole	  vs	  
clopidogrel	  (HR	  1.01	  (95%	  CI	  0.92-­‐
1.11),	  p	  =	  0.8)	  
	  
	  
aspirin	  and	  dipyridamole	  vs	  

















75-­‐300mg	  aspirin	  on	  day	  1,	  
then	  75mg	  aspirin	  for	  21d	  
PLUS	  clopidogrel	  300mg,	  
then	  clopidogrel	  75mg	  for	  
90	  days	  
vs.	  
75-­‐300mg	  aspirin	  on	  day	  1,	  




defined	  TIA	  or	  
haemorhagic	  
stroke	  at	  90	  days	  
	  
	  
aspirin	  and	  clopidogrel	  vs	  aspirin	  
HR	  0.68(	  	  95%CI	  0.57-­‐	  0.81)	  	  
p	  <	  0.01	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Most	   of	   the	   trials	   in	   table	   7	   recruited	   patients	   some	   time	   after	   the	   index	   event.	   This	   is	  
important	  as	  observational	  studies	  suggest	  that	  the	  risk	  of	  recurrent	  stroke	  is	  highest	  in	  the	  first	  
few	  days/weeks	  after	  symptom	  onset	  (section	  2.3.5).	  Accordingly,	  there	  is	  considerable	  interest	  
in	   a	   role	   for	  DAPT	   in	   the	  early	   time	  period	  after	   symptom	  onset	   (especially	   the	   first	   7	  days).	  
Spontaneous	  microembolic	   signals	   (MES),	  detected	  using	  TCD,	  are	  a	   recognised	  marker	  of	  an	  
increased	  risk	  of	  recurrent	  stroke	   in	  symptomatic	  patients92.	  Table	  8	  details	  the	  findings	  from	  
several	   RCTs	   and	   observational	   studies,	   which	   evaluated	   the	   role	   of	   DAPT	   in	   reducing	  
spontaneous	   embolisation	   in	   symptomatic	   patients.	   The	   importance	   of	   starting	   antiplatelet	  
therapy	  early	  was	  illustrated	  in	  a	  meta-­‐analysis	  of	  12	  RCTs	  (n=15,778)	  comparing	  aspirin	  with,	  
where	   aspirin	   was	   started	   in	   the	   first	   few	   days	   after	   symptom	   onset.	   Aspirin	   reduced	   the	   6	  
week	  risk	  of	  recurrent	  stroke	  by	  60%	  (HR	  0.42	  (95%CI	  0.32-­‐0.55),	  p<0.0001)	  and	  the	  prevalence	  
of	  disabling	  or	  fatal	  stroke	  by	  70%	  (HR	  0.29	  (95%CI	  0.2-­‐0.42),	  p<0.0001)	  127.	  	  
	  
	  
Table	  8:	  antiplatelet	  strategies	  for	  reducing	  recurrent	  stroke	  and	  spontaneous	  embolisation	  in	  

























daily	  for	  4	  weeks	  
pre-­‐op	  plus	  a	  
single	  75mg	  dose	  
of	  clopidogrel	  12	  
hours	  pre-­‐op	  	  
	  
After	  3	  hours	  of	  post-­‐operative	  TCD	  monitoring,	  aspirin	  
+	  clopidogrel	  was	  associated	  with	  a	  tenfold	  reduction	  in	  
the	  proportion	  of	  patients	  with	  >20	  emboli	  detected:	  
	  















aspirin	  75mg	  daily	  
+	  clopidogrel	  
300mg	  on	  day	  1,	  
followed	  by	  75mg	  
of	  clopidogrel	  
daily	  until	  day	  7	  	  
vs	  
aspirin	  75mg	  daily	  
At	  7	  days,	  aspirin	  +	  clopidogrel	  was	  associated	  with	  a	  
significant	  reduction	  in	  proportion	  of	  patients	  with	  
persisting	  embolisation:	  
	  	  













daily	  for	  7	  days	  	  
vs	  	  
aspirin	  75–160mg	  
daily	  for	  7	  days	  +	  
clopidogrel	  
300mg	  on	  day	  1,	  
followed	  by	  75mg	  
of	  clopidogrel	  
daily	  for	  6	  days	  	  
aspirin	  +	  clopidogrel	  associated	  with	  significant	  
reductions	  in	  persistent	  embolisation:	  
	  
at	  day	  2	  (31%	  vs.	  54%,	  p	  =	  0.025)	  	  
at	  day	  7	  (23%	  vs.	  51%,	  p	  =	  0.006)	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Phase-­‐2	   trials	   support	   the	   hypothesis	   that	   aspirin+clopidogrel	   might	   be	   more	   effective	   than	  
either	  alone	   in	  early	   stroke	  prevention.	  The	  CHANCE	   trial125	   recruited	  5,170	  patients	   in	  China	  
within	   24-­‐hours	   of	   suffering	   a	   minor	   stroke	   or	   high-­‐risk	   TIA,	   who	   were	   randomised	   to	  
clopidogrel	  (300mg,	  then	  75mg	  daily	  for	  90	  days)	  plus	  aspirin	  (75	  mg	  daily	  for	  first	  21	  days)	  or	  
aspirin	  alone	  (75mg	  daily	  for	  90	  days).	  	  A	  ‘high-­‐risk	  TIA’	  patient	  was	  defined	  as	  having	  an	  ABCD2	  
score	   >4,	   (based	   on	  Age,	  Blood	   pressure,	  Clinical	   features,	  Duration	   of	   TIA,	   and	   presence	   or	  
absence	   of	   Diabetes)133.	   There	   was	   a	   significant	   (32%)	   RRR	   in	   recurrent	   stroke	   in	   patients	  
receiving	   DAPT,	   versus	   aspirin	   alone	   (8.2%	   vs	   11.7%,	   p<0.001),	   with	   no	   excess	   risk	   of	  
moderate/severe	   haemorrhage	   (0.3%	   in	   both	   groups).	   A	   subgroup	   analysis	   involving	   >1000	  
subjects	  with	  imaging	  observed	  that	  the	  benefit	  conferred	  by	  DAPT	  was	  particularly	  marked	  in	  
patients	  with	  extracranial	  ICA	  or	  MCA	  stenoses134.	  A	  meta-­‐analysis,	  which	  included	  the	  CHANCE	  
data,	   reported	   that	   in	   patients	   with	   acute,	   non-­‐cardioembolic	   ischaemic	   stroke/TIA,	   DAPT	  
conferred	  a	  31%	  RRR	  in	  stroke,	  compared	  with	  monotherapy135.	  	  
	  
Further	   data	   supporting	   a	   beneficial	   role	   for	   DAPT	   in	   the	   early	   time	   period	   after	   onset	   of	  
symptoms	   comes	   from	   analyses	   of	   recurrent	   TIA/stroke	   rates	   prior	   to	   urgent	   CEA.	   In	   audits	  
involving	   220	   symptomatic	   patients	  with	   ipsilateral	   50-­‐99%	   ICA	   stenoses	  who	  were	   admitted	  
within	   5-­‐days	   of	   symptom	   onset,	   13%	   suffered	   recurrent	   TIA/stroke	   in	   the	   2-­‐3	   day	   period	  
between	   transfer	   from	   the	   daily	   TIA	   Clinic	   to	   undergoing	   CEA,	   despite	   being	   preloaded	  with	  












then	  75mg	  daily	  +	  
dipyridamole	  




then	  75mg	  daily	  	  +	  
300mg	  
clopidogrel,	  then	  
75mg	  daily	  for	  30	  
days]	  
	  
At	  48	  hours,	  there	  was	  a	  similar	  reduction	  in	  the	  
frequency	  of	  microembolisation	  for:	  	  
	  
Aspirin	  +	  Dipyridamole	  (75.5%)	  







CEA	  within	  8	  days	  
of	  symptom	  onset,	  
compared	  with	  





then	  75mg	  daily	  +	  
75mg	  clopidogrel	  
12	  hours	  pre-­‐op	  	  
vs	  
aspirin	  300mg,	  





starting	  aspirin	  and	  clopidogrel	  48-­‐72	  hours	  pre-­‐op	  
(compared	  with	  12	  hours	  pre-­‐op)	  was	  associated	  with	  
significant	  reductions	  in:	  
	  
	  recurrent	  TIA/stroke	  prior	  to	  CEA	  (3%	  vs	  13%	  	  
(OR	  0.20	  (95%CI	  0.06-­‐0.66)	  p=0.01)	  
	  
spontaneous	  embolisation	  (5%	  vs	  21%	  	  
(OR	  0.24	  (95%CI	  0.09-­‐0.66)	  p=0.0047)	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aspirin)	  prior	  to	  transfer	  to	  the	  surgical	  unit	  (once	  parenchymal	  haemorrhage	  was	  excluded	  on	  
CT/MRI)	   was	   associated	   with	   significant	   reductions	   in	   spontaneous	   embolisation	   from	   21%	  
down	   to	   5%	   	   (OR	   0.24	   (95%CI	   0.09-­‐0.66)	   p=0.0047)	   and	   a	   significant	   reduction	   in	   recurrent	  
events	   prior	   to	   CEA,	   down	   from	   13%	   to	   3%	   (OR	   0.20	   (95%CI	   0.06-­‐0.66)	   p=0.01)132.	   A	   similar	  
reduction	  in	  recurrent	  events	  following	  early	   introduction	  of	  DAPT	  prior	  to	  expedited	  CEA	  has	  
been	  reported	  by	  a	  Danish	  group138.	  
	  
2.3.2.2.2	  Antiplatelet	  therapy	  during	  carotid	  endarterectomy	  
Boysen	   reported	   that	   starting	   antiplatelet	   therapy	   after	   CEA	   did	   not	   reduce	   late	   stroke,	  
compared	  with	   patients	   receiving	   placebo139.	   In	   an	   RCT,	   Lindblad	   demonstrated	   that	   starting	  
75mg	   aspirin	   prior	   to	   CEA	   reduced	   disabling	   stroke	   without	   increasing	   bleeding	  
complications140.	  Kretschmer	  showed	  that	   long-­‐term	  aspirin	  therapy	  after	  CEA	  was	  associated	  
with	  significantly	  better	  long-­‐term	  survival141.	  	  
In	   NASCET,	   patients	  were	   advised	   to	   take	   1300mg	   aspirin	   daily142.	   In	   an	   unplanned	  post-­‐hoc	  
analysis,	  patients	  taking	  81-­‐325mg	  of	  aspirin	  had	  a	  30-­‐day	  stroke/death	  rate	  of	  6.9%	  compared	  
with	  1.8%	   in	   those	   taking	  650-­‐1300mg	  doses142,	   suggesting	   that	  higher	  dose	  aspirin	  might	  be	  
beneficial.	   The	   Aspirin	   and	   Carotid	   Endarterectomy	   trial	   thereafter	   randomised	   2849	   CEA	  
patients	  to	  81mg,	  325mg,	  650mg	  or	  1300mg	  of	  aspirin	  throughout	  the	  peri-­‐operative	  period143.	  
Aspirin	  doses	  of	  81-­‐325mg	  were	   termed	   ‘low	  dose’,	  whereas	  650-­‐1300mg	  were	   termed	   ‘high	  
dose’.	   The	   risk	   of	   stroke,	   MI	   or	   death	   at	   30-­‐days	   was	   non-­‐significantly	   lower	   in	   patients	  
randomised	  to	  low-­‐dose	  (5.4%)	  vs	  high-­‐dose	  aspirin	  (7.0%,	  p=0.07).	  However,	  it	  was	  noted	  that	  
the	  data	  were	  biased	  by	  the	  inclusion	  of	  patients	  taking	  >650mg	  aspirin	  before	  randomisation,	  
alongside	   patients	   who	   only	   started	   aspirin	   the	   day	   before	   CEA.	   In	   an	   efficacy	   analysis	   that	  
excluded	  the	  latter,	  the	  risk	  of	  stroke,	  MI	  or	  death	  at	  30-­‐days	  was	  3.7%	  on	  low	  dose	  versus	  8.2%	  
on	  high	  dose	  aspirin	  (p=0.002).	  
	  
Increasing	  embolisation	  on	  TCD	  in	  the	  early	  post-­‐operative	  period	  after	  CEA	  increases	  the	  risk	  
of	   post-­‐operative	   thrombotic	   stroke144.	   A	   small	   RCT	   (n=22)	   reported	   that	   pre-­‐operative	  
treatment	   with	   aspirin	   plus	   dipyridamole	   was	   associated	   with	   a	   significant	   reduction	   in	   the	  
accumulation	   of	   indium-­‐labelled	   platelets	   to	   the	   endarterectomy	   zone	   in	   the	   first	   few	   hours	  
after	   CEA,	   compared	   with	   placebo145.	   In	   a	   larger	   RCT,	   Payne	   demonstrated	   that	   regular	  
administration	  of	  150mg	  aspirin	  daily	  plus	  a	  single	  75mg	  dose	  of	  clopidogrel	   the	  night	  before	  
surgery	   significantly	   reduced	  embolisation	   rates	   in	   the	   first	   three	  hours	   after	   CEA,	   compared	  
with	  aspirin	  plus	  placebo	  (OR	  0.1	  (95%CI	  0.01-­‐0.77),	  p=0.01)128.	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2.3.2.2.3	  	  Antiplatelet	  therapy	  during	  carotid	  artery	  stenting	  
Virtually	   every	   guideline	   recommends	   that	  CAS	  patients	   should	   receive	  DAPT	   throughout	   the	  
peri-­‐operative	   period.	   However,	   this	   is	   largely	   based	   on	   experience	   from	   the	   coronary	  
literature,	  with	  no	  data	  from	  large	  RCTs	  in	  CAS	  patients.	   Intimal	   injury	  after	  CAS	  releases	  pro-­‐
coagulant	   factors	   and	   exposes	   subendothelial	   collagen,	   which	   acts	   as	   a	   nidus	   for	   platelet	  
adhesion	   and	   secondary	   thrombus	   formation.	   Meta-­‐analyses	   of	   RCTs	   suggested	   that	   aspirin	  
plus	   clopidogrel	  were	  as	  effective	  as	  aspirin	  and	   ticlopidine	   in	  preventing	   in-­‐stent	   thrombosis	  
after	   coronary	   artery	   stenting146.	   In	   the	   only	   RCT	   in	   CAS	   patients,	   aspirin	   plus	   heparin	   was	  
associated	  with	  significantly	  more	  peri-­‐operative	  neurological	  events	  (25	  vs.	  0%,	  p=0.02),	  and	  a	  
non-­‐significantly	   higher	   risk	   of	   bleeding	   complications	   compared	   with	   aspirin	   plus	  
clopidogrel147.	  No	  RCT	  has	   randomised	  CAS	  patients	   to	  aspirin	  and	  clopidogrel	  vs.	  aspirin	  and	  
dipyridamole.	  	  Notwithstanding	  this,	  most	  investigators	  advise	  at	  least	  four	  weeks	  of	  treatment	  
with	  aspirin	  and	  clopidogrel	  after	  CAS147.	  	  
	  
2.3.2.2.4	  	  When	  to	  prescribe	  gastric	  protection	  medications?	  
There	   was	   a	   substantial	   reduction	   in	   gastrointestinal	   bleeding	   when	   clopidogrel	   was	   co-­‐
prescribed	  with	   a	   proton	  pump	   inhibitor	   (PPI)148.	   However,	   studies	   suggest	   that	   PPIs	   such	   as	  
Omeprazole	  may	   reduce	   the	   effectiveness	   of	   clopidogrel149,150.	   Accordingly,	   current	   advice	   is	  
that	   in	   the	   absence	   of	   risk	   factors,	   it	   is	   reasonable	   to	   prescribe	   clopidogrel	   without	   a	   PPI.	  
However,	  if	  the	  patient	  has	  one	  or	  more	  of	  the	  risk	  factors,	  they	  should	  be	  prescribed	  an	  agent	  
for	   gastric	   protection	   along	   with	   clopidogrel.	   These	   risk	   factors	   include	   a	   prior	   history	   of	  
gastrointestinal	  bleeding,	  older	  age,	  helicobacter	  pylori	  infection,	  concomitant	  use	  of	  aspirin,	  or	  
other	   non-­‐steroidal	   anti-­‐inflammatory	   agents,	   anticoagulants,	   selective	   serotonin	   re-­‐uptake	  
inhibitors	  and	  steroids151.	   In	  these	  circumstances,	  one	  could	  empirically	  consider	  ranitidine	  as	  
an	   agent	   for	   gastric	   protection.	   If	   a	   PPI	   is	   preferred,	   then	   it	   may	   be	   preferable	   to	   use	  
pantoprazole,	  which	  does	  not	  appear	  to	  interact	  with	  clopidogrel150.	  
	  
Recommendation	  22	   Class	   Level	   References	  
Antiplatelet	   therapy	   is	   recommended	   in	  
symptomatic	   patients	   with	   50-­‐99%	   stenoses	   not	  
undergoing	   carotid	   endarterectomy	   or	   carotid	  
stenting.	   First	   choice	   therapy	   is	   clopidogrel	   75mg	  
daily	   or	   aspirin	   75mg	   daily	   plus	   modified	   release	  
dipyridamole	  200mg	  bd.	  If	  intolerant	  of	  dipyridamole	  
or	   clopidogrel,	   aspirin	   monotherapy	   (75-­‐325mg)	  
should	  be	  used.	  If	  aspirin	  and	  clopidogrel	  intolerant,	  
use	  dipyridamole	  MR	  200mg	  bd.	  	  
I	   A	   121-­‐124,126,131	  
 47 
	  
Recommendation	  23	   Class	   Level	   References	  
It	   is	   recommended	   that	   all	   patients	   undergoing	  
carotid	   endarterectomy	   should	   receive	   antiplatelet	  
therapy	   throughout	   the	   peri-­‐operative	   period	   and	  
also	  in	  the	  long	  term	  
I	   B	   140,141	  
	  
	  
Recommendation	  24	   Class	   Level	   References	  
Low-­‐dose	   aspirin	   (75-­‐325mg	   daily)	   is	   recommended	  
rather	   than	   higher	   doses	   (>625mg	  daily)	   in	   patients	  
undergoing	  carotid	  endarterectomy	  	  
I	   B	   143	  
	  
	  
Recommendation	  25	   Class	   Level	   References	  
Early	   institution	   of	   aspirin+clopidogrel	   (or	   aspirin	  
plus	   modified	   release	   dipyridamole)	   after	   transient	  
ischaemic	  attack	  or	  minor	  stroke	  may	  be	  considered	  
to	   reduce	   early	   recurrent	   events	   in	   patients	   with	   a	  
>50%	   carotid	   stenosis	   awaiting	   carotid	  
endarterectomy.	  
IIb	   C	   125,129,131,132,138	  
	  
	  
Recommendation	  26	   Class	   Level	   References	  
It	  is	  recommended	  that	  patients	  undergoing	  carotid	  
stenting	  should	  receive	  dual	  antiplatelet	  therapy	  with	  
aspirin	  (75-­‐325mg	  daily)	  and	  clopidogrel	  (75mg	  daily).	  
Clopidogrel	   should	  be	  started	  at	   least	  3	  days	  prior	   to	  
stenting	   or	   as	   a	   single	   300mg	   loading	   dose	   in	   urgent	  
cases.	  Aspirin	  and	  clopidogrel	  should	  be	  continued	  for	  
at	  least	  4	  weeks	  after	  stenting	  and	  then	  optimal	  long-­‐
term	   secondary	   preventive	   antiplatelet	   therapy	  
should	  be	  continued	  indefinitely.	  	  	  	  
I	   B	   147	  
	  
Recommendation	  27	   Class	   Level	   References	  
Long-­‐term	   aspirin	   plus	   clopidogrel	   therapy	   is	   not	  
recommended	   in	   patients	   undergoing	   carotid	  
endarterectomy	  or	   carotid	   stenting	  unless	   indicated	  
for	  cardiac	  reasons	  
III	   C	   152,153	  
	  
	  
Recommendation	  28	   Class	   Level	   References	  
Concurrent	   gastro-­‐protection	   treatment	   or	   proton	  
pump	   inhibition	   with	   pantoprazole	   should	   be	  
considered	   in	   patients	   prescribed	   clopidogrel	   who	  
have	  one	  or	  more	  factors	  that	  increase	  the	  patient’s	  
risk	   of	   gastrointestinal	   bleeding	   (prior	   history	   of	  
gastrointestinal	   bleeding,	   older	   age,	   helicobacter	  
pylori	  infection,	  concomitant	  use	  of	  aspirin,	  or	  other	  
non-­‐steroidal	   anti-­‐inflammatory	   agents,	  
anticoagulants,	   selective	   serotonin	   re-­‐uptake	  
inhibitors	  and	  steroids).	  






2.3.2.3	  	  Lipid-­‐lowering	  treatment	  
Most	   of	   the	   available	   data	   comes	   from	   RCTs	   that	   included	   carotid	   stenosis	   patients	   within	  
larger	  cohorts	  of	  patients	  with	  vascular	  disease.	  	  
	  
2.3.2.3.1	  	  Statins	  as	  tertiary	  prevention	  	  
SPARCL	   included	  4,731	  patients	  with	   a	  prior	   TIA/stroke	  1-­‐6	  months	  before	   randomisation,	   of	  
whom	  966	   had	   a	  median	   ICA	   stenosis	   of	   51%154.	  Within	   30-­‐days	   of	   screening,	   patients	  were	  
randomised	  to	  80mg	  atorvastatin	  or	  placebo.	  The	  primary	  end-­‐point	  was	  time	  to	  fatal	  or	  non-­‐
fatal	   stroke.	   Patients	  with	   carotid	   stenoses	  who	  were	   randomised	   to	   atorvastatin	   had	   a	   33%	  
RRR	   in	   fatal/non-­‐fatal	   stroke,	   as	   well	   as	   a	   42%	   RRR	   in	   cardiovascular	   events154.	   A	   subgroup	  
analysis	   from	   the	  Heart	   Protection	   Study	   included	  3280	  patients	  with	   a	   TIA,	   or	   non-­‐disabling	  
ischaemic	   stroke154	   who	  were	   randomised	   to	   40mg	   of	   simvastatin	   daily	   (n=1055)	   or	   placebo	  
(n=1052).	   The	   mean	   interval	   from	   most	   recent	   TIA/stroke	   was	   4.3	   years	   and	   patients	   were	  
excluded	  if	  they	  had	  been	  hospitalised	  for	  stroke	  within	  6-­‐months.	  Simvastatin	  conferred	  a	  20%	  
RRR	  in	  stroke,	  MI	  or	  vascular	  death	  (p=0.001).	  
	  
Recommendation	  29	   Class	   Level	   References	  
Statin	  therapy	  is	  recommended	  for	  the	  prevention	  of	  
longterm	   stroke,	   myocardial	   infarction	   and	   other	  
cardiovascular	   events	   in	   patients	  with	   symptomatic	  
carotid	  disease.	  




2.3.2.3.2	  	  Statins	  during	  carotid	  surgery	  
Several	  studies	  have	  reported	  that	  statin	  therapy	  (started	  pre-­‐operatively)	  was	  associated	  with	  
significant	  reductions	   in	  30-­‐day	  death/stroke156-­‐158.	  This	  may	  be	  mediated	  via	  their	  pleiotropic	  
effects	   in	   reducing	   inflammation	   associated	   with	   oxidised	   lipoprotein,	   direct	   plaque	  
stabilisation	  and	  a	  general	  reduction	  in	  the	  inflammatory	  response	  to	  surgery159.	  Interestingly,	  
patients	   receiving	   statin	   therapy	   prior	   to	   CEA	   may	   have	   significantly	   lower	   rates	   of	   pre-­‐
operative	   spontaneous	   embolisation,	   than	   those	   not	   taking	   statins160.	   However,	   in	   a	   2013	  
Cochrane	   review	   on	   the	   role	   of	   peri-­‐operative	   statin	   therapy	   for	   improving	   outcomes	   after	  
‘non-­‐cardiac	   vascular	   surgery	   procedures’	   the	   findings	   were	   inconclusive.	   This	   was	   probably	  
because	   of	   the	   relatively	   small	   number	   of	   patients	  who	   had	   not	   been	   taking	   statins	   prior	   to	  
their	  operation161.	   In	  a	  much	   larger,	  multicentre	  study	   involving	  15,478	  patients	  undergoing	  a	  
variety	   of	   vascular,	   general	   surgical,	   thoracic,	   gynaecological	   and	   urological	   procedures,	  
multivariable	  logistic	  modelling	  observed	  that	  patients	  who	  started	  statins	  pre-­‐operatively	  had	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significant	  reductions	  in	  30-­‐day	  myocardial	  injury,	  stroke	  or	  death162.	  Patients	  prescribed	  statin	  
therapy	   should	   not	   have	   this	  medication	  withdrawn	  acutely,	   because	   this	  may	  be	   associated	  
with	  significant	  increases	  in	  peri-­‐operative	  cardiovascular	  morbidity	  and	  mortality163.	  
	  
2.3.2.3.3	  	  Statins	  during	  carotid	  artery	  stenting	  
As	  with	  CEA	  (section	  2.3.2.3.2),	  studies	  have	  reported	  that	  statin	  therapy	  started	  prior	  to	  CAS	  
was	  associated	  with	  significant	  reductions	  in	  30-­‐day	  risks164-­‐166.	  Groschel	  reported	  that	  30-­‐day	  
death/stroke/MI	  risk	  was	  significantly	   lower	  in	  CAS	  patients	  who	  were	  pretreated	  with	  statins	  
(4%),	  versus	  15%	  in	  patients	  who	  were	  not	  on	  statins	  (OR	  0.23	  (95%CI	  0.05-­‐0.99),	  p=0.049)164.	  A	  
similar	   finding	   was	   reported	   by	   Reiff	   who	   observed	   that	   pre-­‐operative	   statin	   therapy	   was	  
associated	  with	  significant	  reductions	  in	  peri-­‐operative	  death/stroke/MI	  (6.8%)	  versus	  13.9%	  in	  
those	   not	   starting	   stains	   pre-­‐CAS	   (OR	   0.31	   (95%CI	   0.3-­‐0.71),	   p=0.006)166.	   Finally,	   Verzini	  
observed	  that	  pre-­‐treatment	  with	  statins	  was	  associated	  with	  a	  significant	  reduction	  in	  30-­‐day	  
death/stroke,	  compared	  with	  no	  statin	  therapy	  (OR	  0.33	  (95%CI	  0.13-­‐0.80),	  p=0.016)165.	  Statin	  
usage	  has	  not	  been	  evaluated	  in	  RCTs,	  but	  the	  evidence	  would	  suggest	  that	  pre-­‐treatment	  with	  
statins	  prior	  to	  undergoing	  CAS	  is	  desirable.	  
	  
Recommendation	  30	   Class	   Level	   References	  
It	   is	  recommended	  that	  patients	  start	  statin	  therapy	  
prior	  to	  endarterectomy	  or	  stenting	  and	  that	  statins	  
should	   not	   be	   stopped	   during	   the	   peri-­‐operative	  
period	  and	  should	  be	  continued	  long	  term.	  	  
I	   B	   156-­‐159,162,164-­‐166	  
	  
	  
2.3.2.4	  	  Hypertension	  
2.3.2.4.1	  	  Tertiary	  	  prevention	  in	  patients	  with	  symptomatic	  carotid	  stenoses	  
No	   RCT	   has	   evaluated	   the	   role	   of	   anti-­‐hypertensive	   therapy	   in	   patients	   with	   symptomatic	  
carotid	  stenoses.	  However,	  a	  meta-­‐analysis	  of	  13	  BP	  treatment	  trials	  in	  patients	  with	  a	  history	  
of	  stroke	  reported	  a	  significant	  RRR	   in	  stroke	  with	  antihypertensive	  therapy	  (34%	  (95%	  CI	  15-­‐
32))45.	   A	   recent	   Cochrane	   review	   concluded	   that	   there	   was	   insufficient	   evidence	   to	   support	  
lowering	  BP	  during	  the	  acute	  phase	  of	  stroke,	  because	  there	  was	  no	  improvement	  in	  functional	  
outcome167.	   In	   addition,	   in	   recently	   symptomatic	   patients	  with	   severe	   bilateral	   ICA	   stenoses,	  
aggressive	  BP	  lowering	  before	  revascularization	  may	  not	  be	  advisable168.	  However,	   in	  patients	  
being	   considered	   for	   early	   CEA,	   a	   balance	   must	   be	   struck.	   This	   is	   because	   a	   systolic	   BP	  
>180mmHg	   was	   an	   independent	   predictor	   for	   stroke	   after	   CEA	   in	   ECST169.	   Accordingly,	   it	   is	  
reasonable	   to	   perform	   an	   urgent	   CEA	   in	   symptomatic	   patients	   whose	   pre-­‐operative	   BP	   is	  
<180mmHg.	  Symptomatic	  patients	  with	  a	  pre-­‐operative	  BP	  >180mmHg	  should	   receive	  urgent	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antihypertensive	  treatment	  in	  order	  to	  reduce	  this	  to	  <180mmHg	  before	  proceeding	  with	  CEA.	  
Persisting	  or	  worsening	  hypertension	  after	  CEA	  should	  be	  actively	  treated	  post-­‐operatively,	  as	  
post–CEA	  hypertension	   is	  associated	  with	  an	   increased	  risk	  of	  hyperperfusion	  syndrome	  (HS),	  
intracranial	   haemorrhage	   (ICH),	   bleeding	   complications	   and	   cardiac	   events	   in	   the	   early	   post-­‐
operative	  period170.	  This	  will	  be	  discussed	  in	  section	  2.6.1.3.3.	  	  
	  
Recommendation	  31	   Class	   Level	   References	  
Antihypertensive	   treatment	   is	   recommended	   for	  
patients	   with	   hypertension	   and	   symptomatic	  
extracranial	   internal	   carotid	   artery	   carotid	   stenoses	  
to	  maintain	  long	  term	  blood	  pressure	  <140/90mmHg	  
I	   A	   45,47	  
	  
Recommendation	  32	   Class	   Level	   References	  
Caution	  should	  be	  exercised	  in	  significantly	  reducing	  
blood	   pressure	   immediately	   prior	   to	   carotid	  
endarterectomy	  or	  stenting	  in	  the	  early	  period	  after	  
onset	   of	   symptoms,	   but	   uncontrolled	   hypertension	  
(>180/90mmHg)	  should	  be	  treated.	  	  





2.3.2.5	  	  Treatment	  in	  diabetic	  patients	  
The	   management	   of	   patients	   with	   diabetes	   is	   the	   same	   as	   for	   asymptomatic	   patients	   (See	  
section	  2.2.1.5).	  
Recommendation	  33	   Class	   Level	   References	  
In	   diabetic	   patients	   with	   symptomatic	   carotid	  
stenoses,	  strict	  glycaemic	  control	  is	  recommended	  
I	   C	   	  
	  
Recommendation	  34	   Class	   Level	   References	  
In	   diabetic	   patients	   with	   symptomatic	   carotid	  
stenoses,	   the	   target	   blood	   pressure	   should	   be	  
<140/85mmHg	  
I	   B	   48	  
	  
2.3.2.6	  Compliance	  with	  medications	  
This	  subject	  has	  been	  reviewed	  in	  section	  2.2.1.6.	  	  
	  
2.3.3	  Randomized	  trials	  comparing	  endarterectomy	  with	  medical	  therapy	  
The	   three	   most	   important	   RCTs	   comparing	   CEA	   with	   BMT	   were	   NASCET,	   ECST	   and	   the	  
Symptomatic	   Veterans	   Affairs	   Co-­‐operative	   Study	   (SVACS)	   Trial9,10,171.	   The	   SVACS	   trial	   was	  
discontinued	  following	  publication	  of	  NASCET/ECST	  in	  1991.	  NASCET	  randomised	  2905	  patients	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who	  reported	  symptoms	  within	  the	  preceding	  6	  months	  and	  who	  had	  30-­‐99%	  carotid	  stenoses	  
to	  BMT	  or	  CEA	  (plus	  BMT).	  ECST	  randomized	  3024	  patients	  who	  reported	  symptoms	  within	  the	  
preceding	   6	   months	   and	   who	   had	   0-­‐99%	   stenoses	   to	   BMT	   or	   CEA	   (plus	   BMT).	   In	   order	   to	  
standardise	  stenosis	  measurement	  for	  individual	  patient	  meta-­‐analyses,	  the	  pre-­‐randomisation	  
angiograms	   for	   the	   6092	   patients	   randomised	   within	   NASCET,	   ECST	   and	   SVACS	   were	  
remeasured	   using	   the	   NASCET	   method	   (table	   9).	   CEA	   (plus	   BMT)	   did	   not	   prevent	   stroke	   in	  
recently	  symptomatic	  patients	  with	  <50%	  stenoses.	  CEA	  conferred	  significant	  benefit	  in	  patients	  
with	  moderate	  (50-­‐69%)	  and	  severe	  (70-­‐99%)	  stenoses	  (table	  9).	  The	  benefit	  conferred	  by	  CEA	  
increased	  with	  increasing	  stenosis	  severity,	  with	  the	  exclusion	  of	  ‘near-­‐occlusion’.	  Patients	  with	  
chronic	  near	  occlusion	  (defined	  as	  a	  95-­‐99%	  stenosis	  with	  distal	  ICA	  collapse	  or	  a	  narrow	  calibre	  
lumen	  with	  ‘trickle	  flow’)	  gained	  no	  obvious	  benefit	  from	  CEA172,173.	  
	  
	  
Table	  9:	   individual	  patient	  meta-­‐analysis	  of	  the	  5-­‐year	  risk	  of	  any	  stroke	  (including	  the	  peri-­‐
operative	  risk)	  from	  pooled	  ESCT,	  NASCET	  and	  SVACS	  Trial	  data*	  
	  
5yr	  risk	  of	  any	  stroke	  
(inc	  peri-­‐operative)	  stenosis	  
severity	  
(NASCET)	  












no	  of	  strokes	  
prevented	  per	  
1000	  CEAs	  	  
@	  5yrs	  
0-­‐30%	   1746	   18.4%	   15.7%	   -­‐2.7%	   no	  benefit	   no	  benefit	   none	  
30-­‐49%	   1429	   22.8%	   25.5%	   +2.7%	   no	  benefit	   no	  benefit	   27	  
50-­‐69%	   1549	   20.0%	   27.8%	   +7.8%	   28%	   13	   78	  
70-­‐99%	   1095	   17.1%	   32.7%	   +15.6%	   48%	   6	   156	  
near	  
occlusion	  
262	   22.4%	   22.3%	   -­‐0.1%	   no	  benefit	   no	  benefit	   none	  
	  
(*)	  data	  derived	  from	  the	  Carotid	  Endarterectomy	  Trialists	  Collaboration172-­‐174.	  	  
ARR	  =	  Absolute	  Risk	  Reduction	  in	  stroke;	  RRR	  =	  Relative	  Risk	  Reduction	  in	  stroke;.	  NNT	  =	  number	  needed	  to	  treat	  to	  
prevent	  one	  stroke	  at	  5	  years	  
	  
Because	   of	   the	   large	   number	   of	   randomised	   patients	   within	   ECST,	   NASCET	   and	   SVACS,	   it	   is	  
possible	   to	   perform	   meaningful	   subgroup	   analyses	   to	   establish	   who	   gained	   greater	   (lesser)	  
benefit	  from	  CEA175.	  The	  principle	  findings	  are	  summarised	  in	  table	  10.	  Clinical	  predictors	  of	  an	  
increased	   stroke	   risk	   on	   BMT	   include;	   increasing	   age,	   male	   gender,	   recent	   symptoms,	   a	  
hemispheric	   TIA/stroke,	   a	   cortical	   stroke	   and	   increasing	   medical	   co-­‐morbidities.	   Imaging	  
predictors	  of	  an	  increased	  risk	  of	  stroke	  on	  BMT	  include;	  irregular	  stenoses,	  increasing	  stenosis	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severity	   (but	   not	   subocclusion),	   contralateral	   occlusion,	   tandem	   intracranial	   stenoses	   and	   a	  
failure	  to	  recruit	  intracranial	  collaterals.	  	  
	  
Table	  10:	  Clinical	  and	   Imaging	   features	   that	  were	  predictive	  of	  a	   significant	   increase	   in	   late	  
stroke	  in	  patients	  with	  50-­‐99%	  stenoses	  randomised	  within	  ECST	  and	  NASCET	  
	  
CLINICAL	  FEATURES	   IMAGING	  FEATURES	  
Increasing	  Age	  172,173,176	  
5y	  ARR	  in	  ipsilateral	  stroke	  conferred	  by	  CEA	  	  
<65y	  =	  5.6%;	  	  65-­‐75y	  =	  8.6%;	  	  >75y	  =	  19.2%	  
Irregular	  vs	  Smooth	  Plaques173	  
5y	  ARR	  in	  ipsilateral	  stroke	  conferred	  by	  CEA	  
smooth	  =	  8%;	  	  irregular	  =	  17%	  
Recency	  of	  Symptoms173	  
5y	  ARR	  in	  ipsilateral	  stroke	  conferred	  by	  CEA	  
<2w=18.5%;	  	  	  	  	  	  	  	  	  2-­‐4w=9.8%;	  	  
4-­‐12w=5.5%;	  	  	  	  	  	  	  >12w=0.8%	  
Increasing	  Stenosis	  Severity172	  
5y	  ARR	  in	  ipsilateral	  stroke	  conferred	  by	  CEA	  
50-­‐69%=4%;	  60-­‐69%=5.9%;	  70-­‐79%=15.8%;	  80-­‐
99%=17.7%;	  90-­‐99%=32.4%;	  	  
near-­‐occlusion=0.1%	  
Males	  vs	  Females174	  
5y	  ARR	  in	  ipsilateral	  stroke	  conferred	  by	  CEA	  
males	  =	  11%;	  	  females	  =	  2.8%	  
Contralateral	  Occlusion173	  
5y	  ARR	  in	  ipsilateral	  stroke	  conferred	  by	  CEA	  
Contralat	  occlusion	  =	  24%;	  	  no	  occlusion	  =	  13%	  
Hemispheric	  vs	  Ocular	  Symptoms173	  
5y	  ARR	  in	  ipsilateral	  stroke	  conferred	  by	  CEA	  
ocular	  =	  5%;	  	  TIA	  =	  15%;	  	  stroke	  =	  18%	  
Tandem	  intracranial	  disease178	  
3y	  risk	  of	  ipsilateral	  stroke	  in	  medically	  treated	  
patients	  with	  tandem	  intracranial	  disease	  
increased	  with	  extracranial	  ICA	  stenosis	  severity	  
50-­‐69%	  =	  19%;	  	  70-­‐84%	  =	  29%;	  	  85-­‐99%	  =	  45%	  
Cortical	  vs	  Lacunar	  Stroke177	  
3y	  ARR	  in	  ipsilateral	  stroke	  conferred	  by	  CEA	  
non-­‐lacunar	  stroke	  =	  15%;	  	  lacunar	  stroke	  =	  9%	  
no	  recruitment	  of	  collaterals179	  
2y	  ARR	  in	  ipsilateral	  stroke	  conferred	  by	  CEA	  
collaterals	  recruited	  =	  5%;	  no	  recruitment	  =	  19%	  
Increasing	  Medical	  co-­‐morbidities10	  
2y	  risk	  of	  ipsilateral	  stroke	  on	  BMT	  	  
0-­‐5	  co-­‐morbidities	  =	  17%;	  6	  =	  23%;	  7+	  =	  39%	  
	  
2y	  risk	  of	  ipsilateral	  stroke	  with	  CEA	  





2.3.4	  	  Randomised	  trials	  comparing	  endarterectomy	  with	  stenting	  
Eighteen	   RCTs	   (9492	   patients)	   have	   published	   outcomes	   comparing	   CEA	  with	   CAS	   or	   carotid	  
angioplasty	  since	  1998.	  Nine	  included	  symptomatic	  patients	  only180-­‐188,	  while	  four	  randomised	  
asymptomatic	  patients	  only80,95,97,98.	   Five	  RCTs	   included	  both	   symptomatic	   and	  asymptomatic	  
patients104,189-­‐192,	   but	   did	   not	   always	   stratify	   outcomes	   for	   symptom	   status.	   Meta-­‐analyses	  
combined	  data	  from	  all	  RCTs193,	  or	   focused	  on	  RCTs	  with	  >50	  patients194.	  Outcomes	  from	  the	  
four	  largest	  symptomatic	  RCTs	  comprise	  the	  main	  evidence	  base	  in	  these	  guidelines;	  including	  
the	  Endarterectomy	  versus	  Stenting	  in	  patients	  with	  Symptomatic	  Severe	  carotid	  Stenosis	  (EVA-­‐
3S),	  the	  SPACE	  trial,	  the	  International	  Carotid	  Stenting	  Study	  (ICSS)	  and	  CREST184,185,187,189.	  The	  
RCTs	  involving	  symptomatic	  patients	  used	  a	  6	  month	  threshold	  for	  inclusion.	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2.3.4.1	  	  30-­‐day	  procedural	  risks	  
2.3.4.1.1	  	  Principle	  outcomes	  
Table	  11	  details	  30-­‐day	  risks	  following	  CEA	  and	  CAS	  in	  RCTs	  that	  randomised	  >500	  symptomatic	  
patients184,185,187,189,	  while	  Table	  12	  summarises	  statistically	  significant	  differences	  between	  CEA	  
and	  CAS	  in	  symptomatic	  patients.	  	  
	  
Table	   11:	   30-­‐day	   risks	   following	   CEA	   and	   CAS	   in	   trials	   that	   randomised	   >500	   recently	  
symptomatic	  patients	  into	  EVA-­‐3S,	  SPACE,	  ICSS	  and	  CREST184,185,187,189	  
	  
EVA-­‐3S184	   SPACE185	   ICSS187	   CREST189	  















	  	  	  n=668	  
death	   1.2%	   0.8%	   0.9%	   1.0%	   0.8%	   2.3%	   	   	  
any	  	  stroke	   3.5%	   9.2%	   6.2%	   7.2%	   4.1%	   7.7%	   3.2%	   5.5%	  
Ipsilateral	  stroke	   	   	   5.1%	   6.4%	   3.5%	   6.8%	   	   	  
disabling	  	  stroke	   0.4%	   2.7%	   2.9%	   4.1%	   2.3%	   2.0%	   0.9%	   1.2%	  
death/any	  	  stroke	   3.9%	   9.6%	   6.5%	   7.4%	   4.7%	   8.5%	   3.2%	   6.0%	  
disabling	  stroke/death	   1.5%	   3.4%	   3.8%	   5.1%	   3.2%	   4%	   	   	  
clinical	  MI	   0.8%	   0.4%	   	   	   0.5%	   0.4%	   	   	  
death/stroke/MI	   	   	   	   	   5.2%	   8.5%	   5.4%	   6.7%	  
cranial	  nerve	  injury	   7.7%	   1.1%	   	   	   5.3%	   0.1%	   5.1%	   0.5%	  
	  
	  
Table	  12:	   summary	  of	   statistically	   significant	   finding	   in	   the	  peri-­‐operative	  period	   from	  RCTs	  





Hazard	  Ratio	  (95%CI)	  
any	  stroke	   1.81	  (1.40-­‐2.34)	  favouring	  CEA195	  
death/stroke	  	   1.72	  (1.29-­‐2.31)	  favouring	  CEA195	  
death/stroke	  (males)	   1.86	  (1.19-­‐2.91)	  favouring	  CEA195	  
death/stroke	  (females)	   1.53	  (1.02-­‐2.29)	  favouring	  CEA195	  
death/stroke/MI	   1.44	  (1.15-­‐1.80)	  favouring	  CEA195	  
cranial	  nerve	  palsy	   0.08	  (0.04-­‐0.14)	  favouring	  CAS195	  
myocardial	  infarction	   0.44	  (0.23-­‐0.87)	  favouring	  CAS195	  
severe	  haematoma	   0.37	  (0.18-­‐0.77)	  favouring	  CAS195	  
	  
*	  HR	  and	  95%	  CIs	  less	  than	  1.0	  favour	  CAS.	  HR	  and	  95%	  CIs	  greater	  than	  1.0	  favour	  CEA	  
	  
The	   higher	   rates	   of	   peri-­‐operative	   stroke	   after	   CAS	  were	   largely	   due	   to	   higher	   rates	   of	   non-­‐
disabling	   stroke.	   There	   was	   no	   difference	   in	   30-­‐day	   death/disabling	   stroke	   in	   symptomatic	  
patients	  (HR	  1.28	  (95%CI	  0.93-­‐1.77))195.	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2.3.4.1.2	  	  Outcomes	  stratified	  for	  age	  
An	  individual	  patient	  meta-­‐analysis	  of	  ICSS,	  CREST,	  EVA-­‐3S,	  SPACE	  data	  in	  symptomatic	  patients	  
showed	   a	   strong	   association	   between	   increasing	   age	   and	   higher	   rates	   of	   death/stroke	   after	  
CAS,	  but	  not	  after	  CEA	  (table	  13).	  	  The	  age	  effect	  started	  to	  become	  apparent	  in	  patients	  aged	  
60-­‐65,	  while	  CEA	  was	  clinically	  superior	  to	  CAS	  in	  patients	  aged	  >70	  years	  (HR	  2.09	  (95%CI	  1.32-­‐
2.32)196.	   Increasing	  age	  had	  no	  effect	  on	  30-­‐day	  death/stroke	  rates	  after	  CEA196.	   Interestingly,	  
the	  same	  finding	  (no	  association	  between	  age	  and	  procedural	  risk	  after	  CEA)	  was	  reported	  by	  
NASCET	  in	  2001176.	  	  
	  
Table	  13:	   relationship	  between	  age	  and	  30-­‐day	   rates	  of	  death/stroke	  after	  CEA	  and	  CAS	   in	  
symptomatic	  patients	  randomised	  within	  ICSS,	  CREST,	  EVA-­‐3S,	  SPACE196	  	  
	  




CAS	  Vs	  CEA	  	  
HR	  (95%CI)***	  
<60	  years	   1.0**	   1.0	  **	   0.62	  (0.31-­‐1.23)	  
60-­‐64	  years	   1.79	  (0.89-­‐3.60)	   1.01	  (0.34-­‐1.9)	   1.07	  (0.56-­‐2.01)	  
65-­‐69	  years	   2.16	  (1.13-­‐4.13)	   	  	  0.81	  (0.43-­‐1.52)	   1.61	  (0.90-­‐2.88)	  
70-­‐74	  years	   4.01	  (2.19-­‐7.32)	   1.20	  (0.68-­‐2.13)	   2.09	  (1.32-­‐2.32)	  
75-­‐79	  years	   3.94	  (2.14-­‐7.28)	   1.29	  (0.74-­‐2.25)	   1.91	  (1.21-­‐3.01)	  
>80	  years	   4.15	  (2.20-­‐7.84)	   1.09	  (0.57-­‐2.10)	   2.43	  (1.35-­‐4.38)	  
	  
*	  	  	  	  	  Hazard	  Ratio	  (95%CI)	  	  
**	  	  	  All	  HR	  age	  based	  calculations	  compared	  against	  age	  <60	  years	  
***	  age	  based	  HR	  calculation	  for	  CAS	  compared	  with	  CEA.	  If	  HR	  is	  <1.0,	  CAS	  is	  associated	  with	  lower	  peri-­‐	  	  	  
operative	  death/stroke.	  If	  HR	  is	  >1.0,	  CAS	  is	  associated	  with	  higher	  rates	  of	  peri-­‐operative	  stroke/death	  	  
	  
2.3.4.2	  	  Long-­‐term	  outcomes	  in	  the	  randomised	  trials	  
2.3.4.2.1	  	  Late	  ipsilateral	  stroke	  
A	  2015	  meta-­‐analysis	  reported	  that	  CAS	  was	  associated	  with	  a	  significantly	  increased	  risk	  of	  late	  
ipsilateral	  stroke	  and/or	  peri-­‐procedural	  stroke/death	  (OR	  1.45	  (95%	  CI	  1.20-­‐1.75))194.	  However,	  
most	  strokes	  after	  CAS	  occurred	   in	   the	  peri-­‐operative	  period.	  CREST,	   ICSS,	  SPACE	  and	  EVA-­‐3S	  
have	  now	  shown	  that	  once	  the	  30-­‐day	  peri-­‐operative	  period	  has	  elapsed,	  late	  ipsilateral	  stroke	  
rates	   are	   no	   different	   between	   CEA	   and	   CAS,	   ie	   CAS	   appears	   durable	   after	   30-­‐days	   has	  
elapsed185,197-­‐199.	  Accordingly,	  the	  key	  consideration	  in	  deciding	  whether	  to	  recommend	  CEA	  or	  
CAS	   in	   individual	  patients	  will	  be	   to	   identify	   features	  which	   increase	  or	   lessen	   the	  procedural	  
risk	  (eg.	  recency	  of	  symptoms,	  surgeon/interventionist	  experience,	  patient	  age,	  plaque	  length,	  
sequential	  plaque,	  heavily	  calcified	  plaques,	  tortuous	  arteries,	  overall	  burden	  of	  cardiovascular	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risk,	   nature	   of	   presenting	   event,	   crescendo	   symptoms,	   contralateral	   occlusion,	   likelihood	   of	  
overlying	   thrombus,	   type	   III	   arch,	   bovine	   arch,	   arch	   atheroma	   and	   (of	   course)	   patient	  
preference).	  For	  a	  more	  detailed	  review	  of	  factors	  associated	  with	  higher	  procedural	  risks	  after	  
CEA	  and	  CAS,	  see	  sections	  2.6.1.1.3	  and	  2.6.1.2.2.	  
	  
2.3.4.2.2	  	  Quality	  of	  life	  
Health	  Related	  Quality	  of	   life	   (HRQoL)	  was	  assessed	  among	  2,502	  CREST	  patients200.	  CAS	  was	  
associated	  with	  better	  HRQoL	  in	  the	  post-­‐operative	  period	  (compared	  with	  CEA),	  especially	  for	  
physical	  limitation	  and	  pain	  (p=0.01).	  These	  differences	  were	  significant	  at	  4-­‐weeks,	  but	  not	  at	  
1-­‐year.	   Using	   disease-­‐specific	   scales,	   CAS	   patients	   reported	   fewer	   problems	   with	   driving,	  
eating/swallowing,	  neck	  pain	  and	  headaches,	  but	  greater	  difficulty	  with	  walking	  and	  leg	  pain	  (p	  
<0.05).	  However,	   by	   1-­‐year,	   there	  was	   no	   difference	   in	   any	  HRQoL	  measure.	   Peri-­‐procedural	  
stroke	   was	   associated	   with	   poorer	   one-­‐year	   HRQoL	   scores	   across	   all	   SF-­‐36	   domains,	   while	  
periprocedural	  MI	  and	  CNI	  were	  not.	  
	  
2.3.4.2.3	  	  Survival	  following	  peri-­‐operative	  stroke	  or	  myocardial	  infarction	  
A	  meta-­‐analysis	   of	   seven	   observational	   studies	   and	   two	   RCTs	   (5,959	   patients)	   observed	   that	  
CAS	  was	   associated	  with	   a	   significant	   reduction	   in	   ECG	  diagnosed	  MI	  or	   non-­‐ST	  elevation	  MI	  
(NSTEMI)	  with	  troponin	  elevation	  (OR	  0.37	  (95	  %	  CI	  0.22–0.61)),	  p=0.0001201.	  The	  significance	  
of	   peri-­‐operative	   MI	   (especially	   NSTEMI	   with	   biomarker	   elevation)	   has	   been	   a	   source	   of	  
controversy	  since	  its	   inclusion	  within	  the	  primary	  endpoint	   in	  SAPPHIRE	  and	  CREST104,189.	   	  The	  
rationale	   for	   including	  peri-­‐operative	  MI	  was	  because	  historical	   studies	  had	   suggested	   that	   it	  
was	  associated	  with	  poorer	  long-­‐term	  survival202.	  	  
	  
In	  a	  CREST	  subgroup	  analysis,	  patients	  suffering	  a	  peri-­‐operative	  MI	  faced	  a	  threefold	  increase	  
in	   late	  mortality	   (HR	   3.4	   (95%CI	   1.7-­‐6.0),	   p=0.001),	   whilst	   patients	   with	   biomarker	   elevation	  
alone	   faced	   a	   near	   fourfold	   increase	   in	   late	   death	   (HR	   3.6	   (95%CI	   1.5-­‐8.7),	   p=0.023)203.	  
However,	   poorer	   survival	   after	   suffering	   a	   peri-­‐operative	   MI	   must	   be	   balanced	   against	   the	  
findings	  of	  a	  further	  subgroup	  analysis	  from	  CREST204,	  which	  showed	  that	  the	  adjusted	  risk	  of	  
death	  at	  four-­‐years	  was	  significantly	  higher	  (by	  a	  factor	  of	  almost	  three)	  in	  patients	  suffering	  a	  
peri-­‐operative	  stroke	   (HR	  2.78	   (95%CI	  1.63–	  4.76).	   In	  a	  meta-­‐analysis,	  Vincent	  calculated	   that	  
CAS	  was	  associated	  with	  a	  0.3%	  absolute	  reduction	  in	  peri-­‐operative	  MI,	  which	  was	  offset	  by	  a	  
1.8%	  increase	  in	  peri-­‐operative	  stroke194.	  Accordingly,	  long-­‐term	  survival	  appears	  to	  be	  similarly	  
reduced	  in	  CEA	  or	  CAS	  patients	  suffering	  either	  a	  peri-­‐operative	  MI	  or	  stroke.	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An	  algorithm	  for	  managing	  recently	  symptomatic	  patients	  with	  carotid	  disease	  is	  presented	  in	  
figure	  5	  (section	  2.2.3.2.2).	  
	  
Recommendation	  35	   Class	   Level	   References	  
Carotid	  endarterectomy	  is	  recommended	  in	  patients	  reporting	  
carotid	  territory	  symptoms	  within	  the	  preceding	  6	  months	  and	  
who	  have	  a	  70-­‐99%	  carotid	  stenosis,	  provided	  the	  documented	  
procedural	  death/stroke	  rate	  is	  <6%.	  	  
I	  
	  
A	   172-­‐174,	  205	  	  
	  
Recommendation	  36	   Class	  
	  
Level	   References	  
Carotid	  endarterectomy	  should	  be	  considered	  in	  patients	  
reporting	  carotid	  territory	  symptoms	  within	  the	  preceding	  6	  
months	  and	  who	  have	  a	  70-­‐99%	  carotid	  stenosis,	  provided	  the	  
documented	  procedural	  death/stroke	  rate	  is	  <6%.	  	  
IIa	  
	  
A	   172-­‐174,205	  
	  
Recommendation	  37	   Class	   Level	   References	  
It	   is	   recommended	   that	   most	   patients	   who	   have	   suffered	  
carotid	  territory	  symptoms	  within	  the	  preceding	  6	  months	  and	  
who	  are	  aged	  >70	  years	  and	  who	  have	  50-­‐99%	  stenoses	  should	  
be	   treated	   by	   carotid	   endarterectomy,	   rather	   than	   carotid	  
stenting.	  
I	   A	   196	  
	  
Recommendation	  38	   Class	   Level	   References	  
When	   revascularisation	   is	   indicated	   in	   patients	   who	   have	  
suffered	   carotid	   territory	   symptoms	   within	   the	   preceding	   6	  
months	   and	   who	   are	   aged	   <70	   years,	   carotid	   stenting	   may	   be	  
considered	   an	   alternative	   to	   endarterectomy,	   provided	   the	  
documented	  procedural	  death/stroke	  rate	  is	  <6%.	  
IIb	   A	   196	  
	  
	  
Recommendation	  39	   Class	   Level	   References	  
Carotid	   endarterectomy	   and	   carotid	   stenting	   are	   not	  
recommended	   in	   symptomatic	   patients	   with	   a	   chronic	   internal	  
carotid	   near-­‐occlusion,	   unless	   associated	   with	   recurrent	  
ipsilateral	   symptoms	   (despite	   optimal	   medical	   therapy)	   and	  
following	  multi-­‐disciplinary	  team	  review.	  	  




2.3.5	  	  Timing	  of	  interventions	  after	  onset	  of	  symptoms	  	  
There	   is	  confusion	  over	  the	  definition	  of	   ‘first	  event’,	   ‘index	  event’	  and	  ‘most	  recent	  event205.	  
The	  ‘first	  event’	  is	  the	  first	  symptom	  to	  affect	  the	  patient.	  The	  ‘index	  event’	  is	  the	  symptom	  that	  
led	  the	  patient	  to	  seek	  medical	  advice.	  The	  ‘most	  recent	  event’	   is	  the	  symptom	  that	  occurred	  
most	  recently.	  These	  terms	  have	  been	  misused	  in	  the	  past206	  and	  must	  be	  interpreted	  carefully	  
when	  analysing	  the	  literature	  on	  the	  risks/benefits	  of	  intervening	  early.	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2.3.5.1	  	  Carotid	  endarterectomy	  
CEA	   has	   often	   been	   delayed	   because	   of	   a	   perception	   that	   this	   reduces	   procedural	   risk207.	  
However,	   there	   is	   increasing	   evidence	   that	   CEA	   confers	   maximum	   benefit	   if	   performed	   <14	  
days173,174	   and	   there	   is	   compelling	   evidence	   that	   the	   risk	   of	   early,	   recurrent	   stroke	   after	   TIA	  
onset	   may	   be	   much	   higher	   than	   previously	   thought.	   Contemporary	   natural	   history	   studies	  
report	  that	  the	  incidence	  of	  recurrent	  stroke	  after	  the	  index	  TIA	  ranges	  from	  5-­‐8%	  at	  48	  hours,	  
4-­‐17%	   at	   72	   hours,	   8-­‐22%	   at	   7	   days	   and	   11-­‐25%	   at	   14	   days	   (table	   14).	   Note	   that	   recurrent	  
stroke	  rates	  at	  14	  days	  are	  similar	  to	  those	  observed	  at	  5-­‐years	  in	  patients	  randomised	  to	  BMT	  
in	  ECST,	  NASCET	  and	  VA,	  suggesting	  that	  most	  patients	  destined	  to	  suffer	  an	  early	  stroke	  after	  
onset	  of	  symptoms	  were	  never	  randomised	  within	  these	  landmark	  RCTs.	  
	  
Table	  14:	  Risk	  of	  stroke	  in	  the	  early	  time	  period	  after	  the	  index	  TIA	  in	  patients	  with	  50-­‐99%	  
carotid	  stenoses	  compared	  with	  pooled	  data	  from	  the	  randomised	  trials	  
	  
	   48	  hours	   72	  hours	   7	  days	   14	  days	   5	  years	  
ECST+NASCET+VA	  
‚BMT’	  patients173	  
	   	   	   	   21%	  
Fairhead208	   	   	   	   20%	   	  
Purroy209	   	   	   10%	   	   	  
Ois210	   	   17%	   22%	   25%	   	  
Bonifati211	   8%	   	   	   	   	  
Johansson212	   5%	   	   8%	   11%	   	  
Mono213	   	   4%	   	   	   	  
Merwick214	   	   	   8%	   	   	  
Marnane215	   5%	   9%	   16%	   	   	  
	  
Few	  studies	  have	  reported	  risks	  after	  CEA,	  stratified	  for	  delay.	  In	  a	  single-­‐centre	  series	  involving	  
475	  patients	  from	  Leicester	  UK,	  30-­‐day	  death/stroke	  rate	  was	  2.4%	  when	  CEA	  was	  performed	  
<48	  hours	  of	  symptom	  onset,	  1.8%	  when	  CEA	  was	  performed	  at	  3-­‐7	  days,	  0.8%	  where	  CEA	  was	  
performed	  between	  8-­‐14	  days	  and	  0.7%	  when	  CEA	  was	  performed	  after	  14	  days216.	  An	  Austrian	  
audit,	   involving	   761	   patients,	   corroborated	   the	   Leicester	   findings,	   observing	   that	   CEA	   was	  
associated	  with	  a	  4.4%	  risk	  of	  death/stroke	  when	  performed	  <48	  hours	  of	  the	  index	  symptom;	  
1.8%	  when	  CEA	  was	  performed	  within	  3-­‐7	  days,	   4.4%	   for	  operations	  between	  8-­‐14	  days	   and	  
2.5%	  when	  >14	  days	  had	  elapsed217.	  Only	  three	  countries	  (worldwide)	  have	  published	  national	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audit	  data	  on	  the	  effect	  of	  delay	  to	  CEA	  on	  30-­‐day	  death/stroke	  rates	  after	  CEA.	  The	  principle	  
findings	  are	  detailed	  in	  tables	  15	  and	  16.	  	  
	  
Table	  15:	  Proportion	  of	  patients	  undergoing	  CEA	  in	  national	  audits	  within	  0-­‐2,	  3-­‐7,	  8-­‐14	  and	  
>15	  days	  after	  onset	  of	  symptoms	  
	  
































Only	  a	  minority	  underwent	  CEA	  <48	  hours	  (6%	  Sweden,	  3%	  UK	  and	  9%	  Germany).	  However,	  a	  
higher	  proportion	  underwent	  CEA	  <7	  days	  of	  symptom	  onset	  (37%	  Sweden,	  25%	  UK	  and	  43%	  
Germany),	  while	  63%	  underwent	  CEA	  within	  14	  days	   in	  Sweden,	   compared	   to	  52%	   in	   the	  UK	  
and	  72%	  in	  Germany.	  The	  median	  delay	  from	  symptom	  to	  undergoing	  CEA	  was	  12	  days	  in	  the	  
UK,	   9	   days	   in	   Germany	   and	   8	   days	   in	   Sweden218-­‐220.	   Table	   16	   details	   30-­‐day	   rates	   of	  
death/stroke	  in	  national	  audits,	  stratified	  for	  delay	  to	  surgery.	  
	  
Table	  16:	  30-­‐day	  death/stroke	  risks	  after	  CEA,	  stratified	  for	  delay	  from	  symptom	  onset	  to	  CEA	  
in	  national	  audits	  of	  practice	  
	  







































The	   paper	   associated	   with	   the	   most	   controversy	   was	   the	   2012	   Swedvasc	   Report,	   which	  
observed	  that	  when	  CEA	  was	  performed	  <48	  hours	  of	  the	  first	  symptom,	  30-­‐day	  death/stroke	  
was	  11.5%218.	  However,	  only	  148	  patients	  underwent	  CEA	  during	  this	  time	  period.	  Thereafter,	  
procedural	   risks	   were	   3.6%	   at	   3-­‐7	   days,	   4.0%	   at	   8-­‐14	   days	   and	   5.4%	   after	   14	   days	   had	  
elapsed218.	   By	   contrast,	   30-­‐day	   death/strokes	   rates	  were	   3%	   (Germany)	   and	   3.7%	   (UK)	  when	  
CEA	  was	  performed	  <48	  hours	  of	  symptom	  onset219,220.	  After	  48	  hours	  had	  elapsed,	  each	  of	  the	  




2.3.5.2	  	  	  Carotid	  artery	  stenting	  
Performing	  CAS	  in	  the	  early	  time	  period	  after	  symptom	  onset	  is	  controversial	  and	  the	  literature	  
contains	   conflicting	   data.	   A	   pooled	   series	   from	   four	   Industry-­‐sponsored	   registries	   (n=2104)	  
reported	  higher	  30-­‐day	   stroke	   rates	   (8.8%)	  when	  CAS	  was	  performed	  <14	  days,	   compared	   to	  
5.9%	  when	  CAS	  was	  performed	  >14	  days221.	  A	  doubling	  of	  stroke	  risk	  was	  also	  reported	  in	  the	  
CAPTURE	  Registry	  (n=3500)	  when	  CAS	  was	  performed	  <14	  days	  of	  symptom	  onset222.	  	  
The	   Carotid	   Stenosis	   Trialists’	   Collaboration	   (CSTC)	   has	   published	   an	   individual	   patient	   meta-­‐
analysis	   involving	  4138	   symptomatic	  patients	  who	  were	   randomised	   to	  CEA	  or	  CAS	  within	   the	  
four	   major	   multicentre	   RCTs	   (CREST,	   ICSS,	   EVA-­‐3S	   and	   SPACE)223.	   Only	   a	   relative	   minority	  
underwent	   CEA	   (11%)	   or	   CAS	   (14%)	   <48	   hours	   of	   symptom	  onset.	   Among	   patients	  who	  were	  
treated	  within	  7-­‐days	  of	  symptom	  onset,	  those	  treated	  by	  CAS	  were	  significantly	  more	  likely	  to	  
suffer	   an	   adverse	   outcome	   (30-­‐day	   death/stroke,	   30-­‐day	   any	   stroke,	   30-­‐day	   fatal	   or	   disabling	  
stroke),	   compared	   with	   CEA	   (table	   17).	   The	   CSTC	   concluded	   that	   for	   patients	   undergoing	   a	  
carotid	  intervention	  within	  7-­‐days	  of	  symptom	  onset,	  CEA	  was	  significantly	  safer	  than	  CAS223.	  	  In	  
an	  earlier	   individual	  patient	  meta-­‐analysis	  of	  procedural	  risks	   in	  recently	  symptomatic	  patients	  
randomised	  within	   EVA-­‐3S,	   SPACE	   and	   ICSS,	   patients	   undergoing	   CAS	  within	   8-­‐14	   days	   of	   the	  
most	  recent	  symptom	  incurred	  significantly	  higher	  30-­‐day	  death/stroke	  rates	  (8.1)	  versus	  3.4%	  
after	  CEA	  (p=0.04)224.	  	  
	  
Table	   17:	   30-­‐day	   outcomes	   following	   CEA	   and	   CAS,	   stratified	   for	   timing	   of	   the	   carotid	  
intervention	   after	   symptom	   onset	   in	   a	   pooled	   meta-­‐analysis	   of	   symptomatic	   patients	  




CEA	   CAS	  
OR	  (95%CI)	   p=	  
ANY	  STROKE/DEATH	  
<7	  days	   3/226	  (1.3%)	   24/287	  (8.4%)	   6.51	  (2.00-­‐21.21)	   0.002	  
>7	  days	   65/1819	  (3.6%)	   129/1806	  (7.1%)	   2.00	  (1.49-­‐2.67)	   <0.0001	  
ANY	  STROKE	  
<7	  days	   3/226	  (1.3%)	   23/287	  (8.0%)	   6.27	  (1.92-­‐20.44)	   0.002	  
>7days	   62/1819	  (3.4%)	   122/1806	  (6.8%)	   1.98	  (1.47-­‐2.67)	   <0.0001	  
FATAL/DISABLING	  STROKE	  
<7	  days	   1/226	  (0.4%)	   9/287	  (3.1%)	   8.29	  (1.07-­‐64.28)	   0.04	  
>7	  days	   26/1819	  (1.4%)	   46/1806	  (2.5%)	   1.77	  (1.10-­‐2.85)	   0.02	  
*	  based	  on	  data	  derived	  from	  Rantner	  et	  al223.	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Very	  few	  CAS	  studies	  have	  published	  30-­‐day	  death/stroke	  rates	  stratified	  for	  delays	  from	  most	  
recent	   symptom	   to	  undergoing	  CAS.	   Those	   that	  have	  published	  are	   summarised	   in	   (table	  18).	  
There	  are	  no	  data	  relating	  to	  outcomes	  after	  CAS	  using	  proximal	  flow	  reversal	  in	  large	  cohorts	  of	  
recently	  symptomatic	  patients,	  especially	  in	  the	  first	  seven	  days	  after	  symptom	  onset.	  	  
	  
Table	  18:	  30-­‐day	  death	  stroke	  risks	  following	  CAS,	  stratified	  for	  time	  from	  index	  symptom	  to	  
intervention	  




8-­‐14	  days	   >14	  	  
days	  
Setacci	  2010225	   1/26	  	  
(4.0%)	  
	   	   	  
Moratto	  2012226	   3/78	  	  
(3.8%)	  
	   	   	  
Al	  Mubarak	  1999227	   	   3/44	  	  
(6.8%)	  
	   	  

















However,	   surgeons/interventionists	   participating	   in	   the	   RCTs	  were	   credentialed	   and	  may	   not	  
represent	  ‘real	  world’	  practice.	  In	  a	  recent	  systematic	  review,	  Paraskevas	  observed	  that	  72%	  of	  
administrative	   dataset	   registries	   reported	   30-­‐day	   death/stroke	   rates	   in	   excess	   of	   the	   6%	  
threshold	  after	  CAS,	  while	  28%	  reported	  stroke	  rates	   in	  excess	  of	  10%70.	  Given	  that	   the	   term	  
‘recently	  symptomatic’	  includes	  any	  patient	  undergoing	  CAS/CEA	  <6	  months	  of	  symptom	  onset,	  
this	  would	   suggest	   that	   the	  majority	   of	   patients	   undergoing	   carotid	   interventions	  within	   the	  
first	  7-­‐14	  days	  period	  in	  'real	  world'	  practice	  would	  probably	  be	  better	  treated	  by	  CEA.	  
	  
Recommendation	  40	   Class	   Level	   References	  
When	  revascularisation	  is	  considered	  appropriate	  in	  
symptomatic	  patients	  with	  50-­‐99%	  stenoses,	  it	  is	  
recommended	  that	  this	  be	  performed	  as	  soon	  as	  possible,	  
preferably	  within	  14	  days	  of	  symptom	  onset	  	  
I	  
	  
A	   172,173	  
	  
	  
Recommendation	  41	   Class	   Level	   References	  
It	   is	   recommended	   that	   patients	   who	   are	   to	   undergo	  
revascularisation	   within	   the	   first	   14	   days	   after	   onset	   of	  
symptoms	   should	   undergo	   carotid	   endarterectomy,	   rather	  
than	  carotid	  stenting.	  	  





2.3.5.3	  	  	  Intervening	  in	  neurologically	  unstable	  patients	  
It	  is	  important	  to	  delay	  CEA	  in	  patients	  suffering	  a	  disabling	  stroke,	  as	  they	  face	  a	  higher	  risk	  of	  
haemorrhagic	  transformation	  of	  an	  infarct	  or	  ICH230,231.	  Patients	  with	  a	  significant	  neurological	  
deficit	  (modified	  Rankin	  >3),	  with	  an	  area	  of	  infarction	  exceeding	  one	  third	  of	  the	  MCA	  territory	  
and	   those	   who	   have	   altered	   consciousness	   should	   not	   undergo	   CEA	   until	   significant	  
neurological	  improvement	  has	  occurred.	  	  
	  
CEA	   in	   neurologically	   unstable	   patients	   (stroke-­‐in-­‐evolution,	   crescendo	   TIAs)	   carries	   a	   higher	  
than	  average	  procedural	  risk232.	  A	  meta-­‐analysis	  has	  reported	  that	  stroke/death	  rates	  after	  CEA	  
were	  20.2%	   	   (95%CI	  12.0-­‐28.4)	   in	  patients	  undergoing	  CEA	   for	   stroke	   in	  evolution	  and	  11.4%	  
(95%CI	   6.1-­‐16.7)	   in	   patients	   undergoing	   CEA	   for	   crescendo	   TIAs233.	   However,	   in	   selected	  
patients	   with	   an	   area	   of	   infarction	   involving	   less	   than	   one-­‐third	   of	   the	   MCA	   territory,	  
emergency	  CEA	  can	  be	  performed	  with	  2-­‐8%	  rates	  of	  death/stroke	  for	  stroke-­‐in-­‐evolution	  and	  
0-­‐2%	   for	   crescendo	   TIAs234-­‐236.	   	   These	   results	   compare	   favourably	   with	   the	   otherwise	   poor	  
natural	  history	  of	  these	  conditions.	  
	  
There	  are	  no	  RCT	  data	  for	  determining	  whether	  intravenous	  heparin	  administration	  is	  superior	  
to	  antiplatelet	  therapy	  in	  preventing	  early	  recurrent	  stroke	  in	  patients	  with	  stroke	  in	  evolution	  
or	  crescendo	  TIAs.	  In	  a	  series	  of	  144	  patients	  suffering	  a	  non-­‐disabling	  stroke	  and	  who	  had	  a	  50-­‐
99%	   stenosis	   and	   TCD	   evidence	   of	   embolisation,	   spontaneous	   embolisation	   rates	   were	  
diminished	  in	  patients	  started	  on	  antiplatelet	  therapy,	  but	  not	  in	  those	  receiving	  heparin237.	  	  In	  
two	   RCTs,	   comparing	   low	  molecular	   weight	   heparin	   (LMWH)	   versus	   aspirin	   monotherapy	   in	  
acute	   stroke	   patients	  where	   antiplatelet/antithrombotic	   therapy	  were	   commenced	  within	   48	  
hours	   of	   symptom	   onset,	   there	   was	   no	   evidence	   that	   LWMH	   conferred	   any	   benefit	   over	  
aspirin238,239.	  However,	  in	  a	  post-­‐hoc	  analysis	  looking	  specifically	  at	  the	  prevalence	  of	  neurologic	  
deterioration	  at	  10	  days,	  LMWH	  was	  associated	  with	  a	  significant	  reduction	  in	  ischaemic	  stroke	  
progression	   (5%),	   compared	   with	   aspirin	   (12.7%),	   (OR	   0.36	   (95%CI	   0.16-­‐0.81)),	   without	   an	  
excess	  risk	  of	  cerebral	  haemorrhage240.	  
	  
Other	   therapeutic	   strategies	   for	   reducing	   spontaneous	   microembolisation	   in	   patients	   with	  
recurrent	   TIAs	   or	   crescendo	   TIAs	   include;	   TCD	   titrated	   intravenous	   Dextran	   therapy241,	   or	  
Tirofiban	  (intravenous	  glycoprotein	  IIb/IIa	  receptor	  antagonist)242.	  Batchelder	  et	  al	  showed	  that	  
early	   institution	  of	   aspirin	   and	   clopidogrel	   (once	  parenchymal	  haemorrhage	  was	  excluded	  on	  
CT/MRI)	  was	  associated	  with	  significant	  reductions	  in	  spontaneous	  embolisation	  (21%	  down	  to	  
 62 
5%	  	  (OR	  0.20	  (95%CI	  0.06-­‐0.66)	  p=0.0047)	  and	  a	  significant	  reduction	  in	  recurrent	  events	  prior	  
to	  CEA,	  (13%	  down	  to	  3%	  ((OR	  0.20	  (95%CI	  0.06-­‐0.66)	  p=0.01))132.	  
	  
In	  the	  absence	  of	  quality	  evidence,	  it	  would	  seem	  reasonable	  to	  offer	  heparin	  (plus	  aspirin)	  or	  
dual	  antiplatelet	  therapy	  in	  patients	  with	  recurrent	  TIAs	  or	  crescendo	  TIAs	  prior	  to	  urgent	  CEA.	  	  
	  
Recommendation	  42	   Class	  
	  
Level	   References	  
Revascularisation	  should	  be	  deferred	  in	  patients	  with	  50-­‐
99%	  stenoses	  who	  suffer	  a	  disabling	  stroke	  (modified	  
Rankin	  score	  >3),	  whose	  area	  of	  infarction	  exceeds	  one	  
third	  of	  the	  ipsilateral	  middle	  cerebral	  artery	  territory,	  or	  
who	  have	  altered	  consciousness/drowsiness,	  to	  minimise	  
the	  risks	  of	  post-­‐operative	  parenchymal	  haemorrhage.	  	  
I	  
	  
C	   230,231	  
	  
Recommendation	  43	   Class	   Level	   References	  
Patients	  with	   50-­‐99%	   stenoses	  who	   present	  with	   stroke-­‐in-­‐
evolution	  or	  crescendo	  transient	  ischaemic	  attacks	  should	  be	  
considered	   for	   urgent	   carotid	   endarterectomy,	   preferably	  
<24	  hours.	  




2.3.6	  	  	  	  Timing	  of	  carotid	  interventions	  after	  intravenous	  thrombolysis	  
An	   important	   concern	   when	   performing	   CAS/CEA	   after	   intravenous	   thrombolysis	   (IVT)	   is	   an	  
increased	  risk	  of	   ICH	   following	  reperfusion	  of	   ischaemic	  cerebral	   tissue.	  A	   review	  of	  13	  series	  
(361	  patients),	  observed	  that	  the	  30-­‐day	  death/stroke	  rate	  was	  3.6%,	  while	  the	  prevalence	  of	  
ICH	  was	   2.5%243.	   These	   outcomes	   were	   not	   significantly	   different	   to	   historical	   series	   (where	  
thrombolysis	  was	  not	  used),	  suggesting	  publication	  bias	  (ie	  centres	  with	  poorer	  outcomes	  have	  
probably	   not	   published	   their	   results).	   To	   achieve	   such	   low	   procedural	   risks,	   strict	   selection	  
criteria	  for	  early	  CEA	  should	  be	  followed.	  These	  include;	  (1)	  rapid	  neurological	  recovery	  of	  the	  
patient	  after	   IVT	   (modified	  Rankin	  0-­‐2);	   (2)	   area	  of	   infarction	   less	   than	  one	   third	  of	   the	  MCA	  
territory;	   (3)	   recanalisation	  of	   a	   previously	  occluded	  MCA	  mainstem;	   (4)	   ICA	   stenosis	   50-­‐99%	  
and	   (5)	   no	   evidence	   of	   parenchymal	   haemorrhage	   or	   significant	   brain	   oedema243-­‐245.	   Careful	  
post-­‐operative	  BP	  monitoring	  is	  mandatory170	  (section	  2.6.1.3.3).	  Contraindications	  to	  early	  CEA	  
after	   IVT	   include:	   (1)	   severe	   persistent	   neurological	   deficit	   (modified	   Rankin	   score	   >3);	   (2)	  
anticipated	   high	   surgical	   risk;	   (3)	   the	   presence	   of	   parenchymal	   haemorrhage	   and	   previous	  
radical	   neck	   dissection	   or	   radiotherapy243.	   Given	   these	   strict	   selection	   criteria	   and	  
contraindications,	  only	  2-­‐6%	  of	  patients	  undergoing	  acute	  IVT	  may	  be	  eligible	  for	  CEA244,246.	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The	   optimal	   timing	   of	   CEA	   after	   IVT	   remains	   unknown,	   but	   antiplatelet	   and	   heparin	   therapy	  
should	   be	  withheld	   for	   24	   hours	   after	   cessation	   of	   IVT246,	   because	   of	   the	   heightened	   risk	   of	  
haemorrhagic	   complications	   during	   this	   time	   period.	   The	   literature	   review	   observed	   delays	  
ranging	  from	  48	  hours	  to	  8	  days,	  with	  one	  small	  study	  reporting	  higher	  rates	  of	  ICH	  if	  CEA	  was	  
performed	  <72	  hours	   of	   IVT	   completion247.	   The	   largest	   published	   series	   (202	   cases)	   reported	  
30-­‐day	   death/stroke	   rates	   of	   3.4%	   among	   patients	   who	   underwent	   CEA	   <14	   days	   of	   IVT,	  
compared	   with	   5.1%	   in	   those	   undergoing	   CEA	   <7	   days248.	   It	   is	   essential,	   however,	   that	   CEA	  
patients	  who	  undergo	  treatment	  within	  a	  few	  days	  of	  completing	   IVT	  are	  monitored	  carefully	  
and	  treated	  actively	  for	  post-­‐CEA	  hypertension	  (section	  2.6.1.3.3)170.	  
	  
Only	  one	  study	  (involving	  six	  patients)	  has	  reported	  outcomes	  following	  early	  CAS	  after	  IVT249.	  	  	  
	  
Recommendation	  44	   Class	   Level	   References	  
Early	   carotid	   endarterectomy	   (within	   14	   days)	   should	   be	  
considered	  after	  intravenous	  thrombolysis	  in	  symptomatic	  patients	  
if	  they	  make	  a	  rapid	  neurological	  recovery	  (Rankin	  0-­‐2),	  the	  area	  of	  
infarction	   is	   less	   than	   one	   third	   of	   the	   ipsilateral	  middle	   cerebral	  
artery	   territory,	   a	   previously	   occluded	   middle	   cerebral	   artery	  
mainstem	  has	   recanalised,	   there	   is	   a	   50-­‐99%	   carotid	   stenosis	   and	  
no	   evidence	   of	   parenchymal	   hemorrhage	   or	   significant	   brain	  
oedema	  
IIa	   C	   243-­‐245	  
	  
Recommendation	  45	   Class	   Level	   References	  
It	   is	   recommended	   that	   intravenous	   heparin	   and	   antiplatelet	  
therapy	  be	  withheld	  for	  24	  hours	  after	  completion	  of	   intravenous	  
thrombolysis,	  but	  antiplatelet	  therapy	  should	  then	  be	  commenced	  
before	  any	  carotid	  intervention	  is	  undertaken	  
I	   C	   246	  
	  
Recommendation	  46	   Class	   Level	   References	  
It	   is	   recommended	   that	   patients	   undergoing	   early	   carotid	  
interventions	   after	   thrombolysis	   should	   have	   post-­‐interventional	  
hypertension	   actively	   treated	   to	   reduce	   the	   risks	   of	   parenchymal	  
haemorrhage	  




2.3.7	  	  Timing	  of	  carotid	  interventions	  after	  intracranial	  endovascular	  therapies	  
	  
A	  meta-­‐analysis	  of	  five	  randomised	  trials	  reported	  that	  emergency	  endovascular	  treatment	  of	  
acute	   ischaemic	   stroke	   (mechanical	   thrombectomy	   (stent	   retrieval)	   and/or	   intra-­‐arterial	  
thrombolysis)	  was	   associated	  with	   a	   twofold	   improvement	   in	   functional	   outcome,	   compared	  
with	  patients	  randomized	  to	  BMT.	  Interestingly,	  endovascular	  therapy	  was	  not	  associated	  with	  
reduced	   mortality	   or	   an	   increased	   risk	   of	   symptomatic	   intracerebral	   hemorrhage250.	   A	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proportion	  of	  patients	  undergoing	  an	  emergency	  intracranial	  endovascular	  intervention	  will	  be	  
founf	   to	   have	   a	   significant	   extracranial	   ICA	   stenosis.	   	   There	   are	   currently	   no	   data	   to	   guide	  
clinicians	  as	  to	  whether	  adjuvant	  CEA	  or	  CAS	  should	  be	  performed	  as	  a	  synchronous	  or	  staged	  
intervention	   in	   these	   patients,	   but	   neurointerventionists	   were	   advised	   not	   to	   ‘routinely’	  
perform	  CAS	  at	  the	  time	  of	  mechanical	  thrombectomy	  in	  the	  ESCAPE	  trial251.	  In	  the	  Multicentre	  
Randomised	   Clinical	   Trial	   of	   Ischaemic	   Stroke	   in	   the	   Netherlands	   (Mr	   CLEAN)	   study,	   13%	   of	  
patients	   underwent	   stent	   retrieval	   plus	   simultaneous	   CAS,	   but	   no	   data	  were	   provided	   about	  




2.3.8	  	  	  Is	  there	  a	  subgroup	  with	  <50%	  stenosis	  who	  might	  benefit	  from	  surgery?	  
An	   individual	   patient	   meta-­‐analysis	   of	   symptomatic	   patients	   with	   <50%	   stenoses	   who	   were	  
randomised	  within	  ECST,	  NASCET	  and	  the	  VA	  Trials172-­‐173	  showed	  that	  CEA	  conferred	  no	  benefit	  
over	  BMT	  (section	  2.3.3).	  The	  five-­‐year	  risk	  of	  stroke	  in	  1746	  patients	  with	  <30%	  stenoses	  who	  
were	  randomised	  to	  CEA	  was	  18.4%,	  compared	  with	  15.7%	  on	  BMT.	  The	  five-­‐year	  risk	  of	  stroke	  
in	   1429	   patients	  with	   30-­‐49%	   stenoses	  who	  were	   randomised	   to	   CEA	  was	   22.8%,	   compared	  
with	   25.5%	   on	   BMT173.	   However,	   a	   small	   cohort	   of	   patients	   with	   <50%	   stenoses	   will	   still	  
continue	   to	   suffer	   recurrent	   symptoms	   (despite	   BMT).	   In	   a	   recent	   review	   of	   outcomes	   in	  
previously	   symptomatic	   patients	   with	   20-­‐49%	   stenoses	   at	   baseline,	   the	   risk	   of	   recurrent	  
ipsilateral	  stroke	  at	  3-­‐years	  was	  7.4%253.	  
	  
	  It	   is	   important	  to	  ensure	  that	  medical	  treatment	  really	  has	  really	  been	  optimised	  and	  that	  no	  
other	   cause	   for	   the	   recurrent	   TIAs	   can	   be	   identified.	   If	   symptoms	   persist,	   despite	   optimal	  
medical	  therapy,	  it	  may	  be	  reasonable	  to	  consider	  CEA/CAS,	  but	  this	  should	  not	  be	  undertaken	  
without	  independent	  neurologist	  or	  stroke	  physician	  review.	  	  
Recommendation	  47	   Class	   Level	   References	  
Carotid	   endarterectomy	  or	   carotid	   stenting	  may	  be	   considered	   in	  
recently	   symptomatic	   patients	   with	   <50%	   stenoses	   if	   they	   suffer	  
recurrent	   symptoms	   despite	   best	   medical	   therapy	   and	   following	  
multi-­‐disciplinary	  team	  review	  




2.3.9	  	  	  ‘High	  risk	  for	  surgery’	  symptomatic	  patients	  
In	  patients	  considered	  high-­‐risk	  for	  mortality/morbidity	  after	  CEA,	  CAS	  has	  been	  proposed	  as	  an	  
alternative.	   “High-­‐risk	   for	   CEA”	   is	   generally	   defined	   as	   anatomical	   and/or	   clinical	   factors	   that	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have	  the	  potential	  to	  increase	  complications	  following	  CEA,	  ranging	  from	  death,	  stroke,	  through	  
to	   cranial	   nerve	   injury	   (CNI).	   The	   concept	   of	   “high-­‐risk”	   is,	   however,	   open	   to	  misuse.	   This	   is	  
because	   being	   ‘high-­‐risk	   for	   CEA’	   can	   occasionally	   be	   misinterpreted	   as	   being	   ‘high-­‐risk	   for	  
stroke’254.	  Criteria	   that	  are	  currently	  used	  to	  define	  a	  patient	  as	  being	  “high-­‐risk	   for	  CEA”	  are	  
based	  on	  those	  adopted	  by	  SAPPHIRE104.	  SAPPHIRE	  advised	  that	  the	  patient	  should	  have	  carotid	  
territory	  symptoms	  within	  the	  preceding	  180	  days	  and	  have	  a	  50-­‐99%	  stenosis,	  plus	  at	  least	  one	  
of	  the	  following;	  clinically	  significant	  cardiac	  disease	  (congestive	  heart	  failure,	  abnormal	  stress	  
test,	   or	   need	   for	   open-­‐heart	   surgery);	   severe	   pulmonary	   disease;	   contralateral	   carotid	  
occlusion;	  contralateral	   laryngeal-­‐nerve	  palsy;	  previous	  radical	  neck	  surgery,	  cervical	  radiation	  
therapy;	   recurrent	   stenosis	   after	   CEA	   and	   age	   >80	   years.	  While	   severe	   cardiac	   or	   pulmonary	  
artery	   disease	  might	   increase	   the	   risk	   of	   CEA	   and	   the	   presence	   of	   a	   contralateral	   recurrent	  
laryngeal	  nerve	  palsy	  is	  an	  accepted	  contraindication	  to	  CEA,	  the	  validity	  of	  certain	  ‘high-­‐risk	  for	  
CEA’	   criteria	   are	   open	   to	   debate.	   In	   addition,	   no	   RCT	   has	   evaluated	   whether	   CEA	   under	  
locoregional	   anaesthesia	   is	   equivalent	   to	   (or	   safer)	   than	   CAS	   in	   symptomatic	   patients	   with	  
severe	  cardiac	  or	  pulmonary	  disease.	  
	  
2.3.9.1	  	  Age	  
Age	  >80	   is	   frequently	   cited	  as	  a	   ‘high-­‐risk	   for	  CEA’	   criterion.	  However,	  meta-­‐analyses	  of	  data	  
from	   symptomatic	   patients	   in	   ICSS,	   CREST,	   EVA-­‐3S	   and	   SPACE196	   showed	   that	   increasing	   age	  
(especially	   >70)	   was	   associated	   with	   increased	   stroke	   risks	   after	   CAS,	   but	   not	   CEA	   (section	  
2.3.4.1.2).	  Possible	  explanations	  for	  the	  higher	  stroke	  rates	  after	  CAS	  in	  older	  patients	  include	  
increased	  atherosclerotic	  burden,	   increased	  aortic	  arch	  calcification	  and	  wall	  disease,	  changes	  
in	  vascular	  anatomy	  and	  increasing	  carotid	  plaque	  vulnerability255.	  
	  
2.3.9.2	  	  	  Radiation	  Therapy	  
Previous	   cervical	   radiation	   therapy	   is	   frequently	   cited	   as	   being	   associated	   with	   poorer	  
outcomes	   after	   CEA.	   However,	   in	   a	   systematic	   review	   of	   27	   studies	   (533	   patients)	   who	  
underwent	  CAS	  (n=361)	  or	  CEA	  (n=172),	  the	  perioperative	  risk	  for	  “any	  cerebrovascular	  adverse	  
event”	  was	  3.9%	  (95%	  CI,	  2.3%–6.7%)	  following	  CAS	  versus	  3.5%	  (95%	  CI,	  1.5%–8.0%)	  after	  CEA	  
(P=0.77)256.	   However,	   the	   risk	   of	   temporary	   CNI	   after	   CEA	   was	   9.2%	   (95%	   CI,	   3.7%–21.1%)	  
versus	  none	  after	   CAS.	  After	   the	  peri-­‐operative	  period,	   recurrent	   TIA/stroke	  was	   significantly	  
more	   common	   after	   CAS	   (4.9/100	   person	   years)	   versus	   2.8/100	   person	   years	   after	   CEA	  
(p=0.014).	  In	  addition,	  restenosis	  >50%	  was	  significantly	  more	  common	  after	  CAS	  (p<0.003).	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2.3.9.3	  Restenosis	  after	  ipsilateral	  carotid	  endarterectomy	  
A	  meta-­‐analysis	   of	   observational	   patient	   data	   observed	   that	   in	   patients	  with	   restenosis	   after	  
CEA,	   CAS	  was	   not	   superior	   to	   redo	   CEA	   regarding	   perioperative	   stroke/death	   rate	   or	   further	  
restenosis257.	  Thirteen	  studies	  involving	  1132	  patients	  who	  were	  treated	  by	  CAS	  (n=653)	  or	  redo	  
CEA	   (n=479)	   reported	   that	   peri-­‐operative	   death/stroke	   did	   not	   differ	   between	   CAS	   and	   redo	  
CEA	  (2.3%	  vs	  2.7%,	  OR	  0.8	  (95%CI	  0.4–1.8).	  The	  risk	  of	  developing	  a	  second	  restenosis	  (median	  
follow-­‐up	  13	  months)	  was	  similar	  for	  both	  groups	  (HR	  1.4,	  (95%	  CI	  0.9–2.2).	  The	  prevalence	  of	  
CNI	  was	  5.5%	  after	  redo	  CEA,	  but	  the	  rate	  of	  permanent	  CNI	  was	  less	  than	  1%.	  Restenosis	  after	  
CEA	  is	  discussed	  in	  greater	  detail	  in	  section	  2.6.2.2.5.	  
	  
2.3.9.4	  	  	  Implementing	  ‘high-­‐risk’	  criteria	  in	  population	  based	  studies	  	  
The	  Centre	  for	  Medicare	  and	  Medicaid	  Services	  (CMS)	  defines	  physiologic	  high-­‐risk	  variables	  as	  
age	  >80	  years,	  New	  York	  Heart	  Association	  class	  III,	  CCF,	  left	  ventricular	  ejection	  fraction	  <30%,	  
unstable	   angina,	   MI	   ≤30	   days,	   contralateral	   ICA	   occlusion,	   recent	   coronary	   artery	   bypass	  
grafting	   or	   valve	   repair	   and	   haemodialysis.	   Anatomical	   risk	   factors	   included;	   contralateral	  
laryngeal	  nerve	  palsy,	  restenosis	  after	  CEA,	  a	  history	  of	  cervical	  radiotherapy,	  high	  or	  low	  placed	  
carotid	  lesions	  and	  previous	  neck	  surgery258.	  	  
	  
Symptomatic	   ‘high-­‐risk’	  patients	  had	  a	  9.1%	  risk	  of	  death/stroke	  or	  MI	   following	  CAS	  vs	  7.3%	  
after	  CEA	  (OR,	  1.3	  (95%CI	  0.95-­‐1.73)	  p=0.11).	  Amongst	  CEA	  patients,	  age	  >80	  (OR	  1.4	  (95%	  CI	  
1.02-­‐1.8)),	   congestive	   heart	   failure	   (OR	   1.7	   (95%CI	   1.03-­‐2.8)),	   ejection	   fraction	   <30%	   (OR	   3.5	  
(95%CI	   1.6-­‐7.7)),	   angina	   (OR	  3.9	   (95%CI	   1.6-­‐9.9)),	   contralateral	   occlusion	   (OR	  3.2	   (95%CI	   2.1-­‐
4.7))	  and	  high	  anatomic	   lesions	   (OR	  2.7	   (95%CI	  1.33-­‐5.6))	  predicted	  an	   increased	   risk	  of	  peri-­‐
operative	  stroke,	  MI	  or	  death.	  The	  authors	  observed	  that	  while	  certain	  CMS	  ‘high-­‐risk’	  criteria	  
could	   identify	   patients	   at	   higher-­‐risk	   for	   suffering	   adverse	   events	   after	   CEA,	   some	   ‘high-­‐risk’	  
criteria	  were	  more	   important	   than	  others.	  They	  concluded	  that	  CEA	  appeared	  safer	   than	  CAS	  
for	  the	  majority	  of	  ‘high-­‐risk	  for	  CEA’	  patients,	  while	  the	  benefits	  for	  CAS	  appeared	  to	  be	  limited	  
to	  patients	  with	  restenosis	  and	  prior	  radiation	  therapy259.	  
	  
The	   Vascular	   Study	  Group	   of	   New	   England	   performed	   a	  multivariate	   analysis,	  which	   showed	  
that	   independent	   risk	   factors	   for	   an	   increased	   risk	  of	   stroke,	  MI	  or	  death	  at	  one-­‐year	   in	  CEA	  
patients	   included;	   increasing	   age,	   preadmission	   residence	   in	   a	   nursing	   home,	   CHF,	   diabetes,	  
chronic	  pulmonary	  disease,	  any	  prior	  history	  of	  cerebrovascular	  disease	  and	  contralateral	   ICA	  
occlusion.	   Three	   SAPPHIRE	   criteria	   (abnormal	   stress	   test,	   restenosis	   after	   CEA	   and	   history	   of	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radiotherapy)	   were	   not	   associated	   with	   an	   increased	   late	   risk260.	   These	   conflicting	   data,	  
therefore,	  suggest	  that	  there	  is	  still	  no	  consensus	  regarding	  what	  constitutes	  being	  ‘high-­‐risk	  for	  
CEA’.	  SAPPHIRE	  criteria	  should	  not	  be	  used	  uncritically	   to	  exclude	  symptomatic	  patients	   from	  
CEA.	  Management	  decisions	  must	  be	  made	  on	  an	  individual	  patient	  basis,	  based	  upon	  patient	  
co-­‐morbidities,	  anatomical	  features,	  and	  the	  experience	  of	  CAS	  practitioners	  locally.	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In	  recently	  symptomatic	  patients	  with	  50-­‐99%	  stenoses	  and	  
anatomical	  and/or	  medical	  co-­‐morbidities	  that	  are	  considered	  by	  
the	  multidisciplinary	  team	  to	  make	  them	  ‘higher-­‐risk	  for	  carotid	  
endarterectomy’,	  carotid	  stenting	  should	  be	  considered	  as	  an	  
alternative	  to	  endarterectomy,	  provided	  the	  documented	  
procedural	  death/stroke	  rate	  is	  <6%.	  
IIa	  
	  




2.4	  	  Carotid	  surgical	  techniques:	  
	   	   	   	   	  	  
2.4.1	  	  Carotid	  endarterectomy	  
2.4.1.1	  	  Pre-­‐operative	  check	  list	  
The	  surgeon	  should	  ensure	  that	  the	  answers	  to	  a	  number	  of	  key	  questions	  are	  documented	  in	  
the	   patient’s	   case	   notes	   before	   performing	   CEA261.	   The	   aim	   is	   to	   minimise	   avoidable	  
morbidity/mortality	  and	  to	  lessen	  the	  risk	  of	  medico-­‐legal	  censure.	  Questions	  to	  be	  answered	  
include:	  has	   the	   indication	   for	   surgery	  been	  documented?	   	  Are	   there	  atypical	   symptoms	   that	  
require	   further	   investigation?	   Is	   the	   degree	   of	   stenosis	   appropriate	   for	   recommending	   CEA?	  
Have	   the	   procedural	   risks	   quoted	   to	   the	   patient	   been	   documented?	   Is	   the	   patient	   receving	  
optimal	   BMT?	   Is	   high	   carotid	   disease	   anticipated?	   Are	   there	   any	   pre-­‐existing	   CNIs?	   	   Has	   the	  
operative	  side	  been	  marked	  with	  an	  indelible	  pen?	  
Of	   these,	   four	   are	   particularly	   important.	   First,	   did	   the	   surgeon	   quote	   his/her	   own	   peri-­‐
operative	  risks	  to	  the	  patient	  during	  the	  consent	  process,	  rather	  than	  using	  outcome	  data	  from	  
RCTs?	   Second,	   if	   the	   patient	   has	   previously	   undergone	   carotid	   surgery	   (especially	   to	   the	  
contralateral	  side),	  or	  has	  previously	  undergone	  a	  total/partial	  thryroidectomy	  or	  radical	  neck	  
surgery,	  it	  is	  essential	  that	  the	  patient	  undergoes	  indirect	  laryngoscopy	  to	  ensure	  that	  there	  is	  
no	  evidence	  of	  a	  contralateral	  vocal	  cord	  palsy.	  Bilateral	  recurrent	   laryngeal	  nerve	  palsies	  can	  
be	   fatal	   (as	   can	   bilateral	   hypoglossal	   nerve	   palsies).	   If	   a	   contralateral	   vocal	   cord	   palsy	   is	  
identified,	   the	   reason	   for	   performing	   CEA	   should	   be	   urgently	   reviewed.	   If	   the	   patient	   was	  
asymptomatic,	  the	  procedure	  should	  be	  cancelled	  and	  CAS	  considered	  as	  an	  alternative.	  If	  the	  
patient	  was	   recently	   symptomatic,	   then	   CAS	   should	   still	   be	   considered.	   If,	   however,	   it	   is	   not	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possible	   to	   perform	   CAS	   and	   the	   indication	   for	   intervening	   remains	   compelling,	   the	   patient	  
should	   be	   warned	   about	   the	   consequences	   of	   bilateral	   recurrent	   laryngeal	   nerve	   palsies	  
(permanent	  tracheostomy)	  and	  an	  Ear	  Nose	  and	  Throat	  (ENT)	  surgeon	  should	  be	  present	  at	  the	  
time	   of	   extubation.	   In	   addition,	   the	   surgeon	   should	   not	   use	   a	   retrograde	   approach	   to	   the	  
bifurcation,	   as	   this	   is	   associated	   wth	   a	   significantly	   higher	   risk	   of	   recurrent	   laryngeal	   nerve	  
injury	  (section	  2.4.1.6).	  Third,	  it	  is	  important	  to	  ensure	  that	  the	  patient	  is	  receiving	  appropriate	  
antiplatelet	  and	  statin	   therapy	  and	   that	   systolic	  BPs	  >180mmHg	  have	  been	  excluded	   (section	  
2.3.2.4.1).	  Finally,	  it	  is	  essential	  that	  the	  surgeon	  anticipates	  the	  likelihood	  of	  having	  to	  mobilise	  
the	  upper	   ICA.	   If	   this	   is	  anticipated,	   the	  surgeon	  should	   take	  steps	   to	  ensure	   that	   this	  can	  be	  
achieved	   safely.	   For	   less	   experienced	   surgeons,	   it	   might	   be	   appropriate	   to	   ask	   a	   more	  
experienced	  colleague	  to	  either	  assist	  or	  take	  over	  the	  case.	  Alternatively,	  it	  may	  be	  necessary	  
to	  plan	  for	  a	  more	  complicated	  exposure	  technique	  (section	  2.4.1.14).	  The	  risks	  associated	  with	  
dissection	  of	  the	  upper	   ICA	  are	  higher	   (especially	  CNI)	  and	  this	  needs	  to	  have	  been	  discussed	  
with	  the	  patient	  beforehand.	  
	  
2.4.1.2	  Staged	  or	  synchronous	  bilateral	  carotid	  interventions	  
A	  proportion	  of	  patients	  will	  present	  with	  bilateral	  70-­‐99%	  stenoses.	  Most	  will	  be	  either	  totally	  
asymptomatic,	  or	  have	  one	  stenosis	  symptomatic	  and	  the	  other	  asymptomatic.	  It	  is	  extremely	  
rare	   for	   bilateral	   severe	   ICA	   stenoses	   to	   be	   symptomatic,	   either	   simultaneously	   or	   within	   a	  
short	   period	   of	   each	   other.	   The	   question	   arises	   as	   to	   whether	   synchronous	   bilateral	   CEAs	  
should	  ever	  be	  considered.	  Whilst	  it	  is	  feasible	  to	  undertake	  bilateral	  synchronous	  CEAs262,	  the	  
most	   dangerous	   complication	   is	   inadvertent	   injury	   to	   both	   recurrent	   laryngeal	   and/or	  
hypoglossal	  nerves,	  which	  can	  be	  fatal.	  Accordingly,	  if	  bilateral	  (synchronous)	  revascularisations	  
are	  deemed	  absolutely	  necessary,	   it	  may	  be	  better	   to	   consider	  bilateral	   CAS	  procedures.	   For	  
most	  patients,	  however,	  staged	  bilateral	  CEAs	  would	  seem	  more	  appropriate,	  especially	  in	  the	  
patient	  with	  a	  symptomatic	  50-­‐99%	  stenosis	  on	  one	  side	  and	  an	  asymptomatic	  70-­‐99%	  stenosis	  
on	  the	  other.	  
	  
2.4.1.3	  	  General	  versus	  locoregional	  anaesthesia	   	  
A	   meta-­‐analysis	   of	   41	   non-­‐randomised	   studies	   (25,000	   CEAs)	   reported	   that	   CEA	   under	  
locoregional	   anaesthesia	   (LRA)	   was	   associated	   with	   a	   40%	   RRR	   in	   30-­‐day	   death/stroke,	  
compared	  with	  CEA	  under	  general	  anaeathesia	  (GA),	  as	  well	  as	  significant	  reductions	  in	  MI	  and	  
respiratory	   complications263.	   The	   General	   Anaesthesia	   Local	   Anaesthesia	   (GALA)	   trial	   (3526	  
patients)	   is	   the	   largest	   RCT	   to	   date	   and	   reported	   no	   significant	   difference	   regarding	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perioperative	  death,	  stroke,	  or	  MI	  between	  GA	  (4.8%)	  and	  LRA	  (4.5%)264.	  An	  updated	  Cochrane	  
review265,	  which	  combined	  data	  from	  14	  RCT´s	  (4596	  patients),	  showed	  that	  CEA	  under	  LRA	  did	  
not	  confer	  significant	  reductions	  in	  30-­‐day	  stroke	  (3.2%),	  compared	  to	  CEA	  under	  GA	  (3.5%).	  
	  
Most	   studies	  on	  CEA	  under	   LRA	   include	  patients	  on	  aspirin	  monotherapy.	  However,	  with	   the	  
increasing	  use	  of	  DAPT	  (especially	  in	  the	  early	  time	  period	  after	  onset	  of	  symptoms),	  there	  are	  
concerns	   about	   haematoma	   formation.	   In	   a	   systematic	   review	   of	   69	   studies	   (n=10,081	  
patients),	   combined	   deep	   and	   superficial	   cervical	   plexus	   blockade	   was	   associated	   with	   a	  
significantly	   higher	   risk	   of	   major	   complications	   (OR	   2.13,	   p=0.006),	   when	   compared	   with	  
superficial/intermediate	   blockade266.	   However,	   the	   ‘major	   complications’	   were	   inadvertent	  
intravascular	   injection	   and	   respiratory	   failure/distress	   secondary	   to	   phrenic	   nerve	   and/or	  
recurrent	  laryngeal	  nerve	  paralysis.	  There	  was	  no	  specific	  mention	  as	  to	  whether	  deep	  cervical	  
plexus	  blockade	  was	  associated	  with	  an	   increased	  risk	  of	  haematoma	  formation.	   In	  a	  working	  
party	   consensus	   on	   LRA	   in	   patients	   with	   coagulation	   abnormalities,	   there	   was	   no	   mention	  
about	  any	  adverse	  effect	  relating	  to	  DAPT	  and	  no	  specific	  mention	  about	  whether	  it	  was	  safe	  to	  
undertake	  deep	  cervical	  plexus	  blockade	  in	  CEA	  patients267.	  Moreover,	  guidelines	  published	  by	  
the	  American	  Society	  of	  Regional	  Anesthesia	  refer	  mainly	  to	  spinal/epidural	  anaesthesia	  (with	  
no	  reference	  to	  deep	  cervical	  plexus	  blockade)	  and	  they	  provide	  no	  advice	  regarding	  DAPT.	  In	  
most	   clinical	   situations,	   the	   guidelines	   recommended	   cessation	   of	   antiplatelet	   therapy	  
(especially	  clopidogrel)	  wherever	  possible268.	  
	  
Accordingly,	  there	  are	  no	  published	  data	  on	  whether	  it	  is	  safe	  to	  perform	  deep	  cervical	  plexus	  
blockade	   in	   CEA	   patients	   on	   DAPT269.	   With	   the	   likelihood	   that	   an	   increasing	   proportion	   of	  
recently	   symptomatic	  patients	  will	   undergo	  CEA,	  whilst	   on	  DAPT,	   surgeons	   and	  anaesthetists	  
who	   prefer	   to	   perform	   CEA	   under	   LRA	   will	   need	   to	   clarify	   local	   protocols	   regarding	   peri-­‐
operative	  antiplatelet	  strategies	  and	  choice	  of	  anaesthesia.	  It	  would,	  however,	  be	  inappropriate	  
to	   stop	   clopidogrel	   and	   delay	   CEA	   for	   7-­‐10	   days,	   as	   this	   will	   increase	   the	   likelihood	   of	   the	  
patient	   suffering	  an	  early	   recurrent	  embolic	   stroke	   (section	  2.3.5).	   Intra-­‐operative	  ultrasound	  
may	   enable	   safer	   infiltration	   of	   local	   anaesthetic,	   as	   it	   permits	   visualisation	   of	   the	   cervical	  
transverse	  processes	  and	  VA.	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It	   is	   recommended	   that	   choice	   of	   anaesthesia	   for	   carotid	  
endarterectomy	   (general	   versus	   locoregional)	   be	   left	   to	   the	  
surgeon/anaesthetists	  discretion	  	  




2.4.1.4	  	  	  Volume	  outcome	  relationship	  
A	  meta-­‐analysis	   of	   25	   studies	   (>900,000	   CEAs	   from	   around	   the	   world,	   but	  mainly	   the	   USA),	  
found	  a	  significant	  relationship	  between	  CEA	   in	  higher-­‐volume	  centres	  and	   lower	  rates	  of	  30-­‐
day	  death,	  stroke	  and	  death/stroke,	  with	  a	  critical	  threshold	  of	  79	  cases	  per	  year	  per	  unit270.	  In	  
another	   study,	   analysing	   outcomes	   following	   18,248	   CEAs	   in	   England,	   there	   was	   also	   a	  
significant	  volume	  outcome	  relationship	  favouring	  higher-­‐volume	  centres,	  with	  respect	  to	  lower	  
mortality	  and	  reduced	  length	  of	  stay271.	  In	  the	  latter	  meta-­‐analysis,	  the	  critical	  threshold	  was	  35	  
CEAs	  per	  centre,	  per	  year.	  The	  most	  likely	  explanation	  for	  the	  difference	  between	  35	  CEAs	  per	  
year	  in	  the	  UK	  analysis	  and	  79	  in	  the	  previous	  meta-­‐analysis	  is	  probably	  because	  about	  85%	  of	  
CEAs	  in	  the	  UK	  are	  undertaken	  in	  symptomatic	  patients	  (associate	  with	  higher	  procedural	  risks),	  
while	   the	   former	   meta-­‐analysis	   will	   have	   included	   a	   greater	   proportion	   of	   asymptomatic	  
patients	  (associated	  with	  lower	  procedural	  risks).	  	  
AbuRahma	  analysed	  the	  effect	  of	   surgeon	  volume	  on	  30-­‐day	  stroke/death	   in	  953	  CEAs.	  High-­‐
volume	   surgeons	   (>30	   CEAs	   per	   year)	   had	   significantly	   lower	   30-­‐day	   stroke/death	   rates,	  
compared	   to	   lower-­‐volume	   surgeons.	   Death/stroke	   was	   significantly	   higher	   in	   non-­‐vascular	  
surgeons	   (general/cardiac	   surgeons	   vs	   vascular	   surgeons)	   in	   asymptomatic	   patients	   (3.2%	   vs.	  
0.72%)272.	   In	   a	  meta-­‐analysis	   looking	   at	   outcomes	   stratified	   by	   hospital	   and	   surgeon	   volume,	  
7/9	  studies	  showed	  a	  significant	  inverse	  relationship	  for	  individual	  surgeon	  volume273,	  while	  7/8	  
studies	   reported	   that	   specialist	   vascular	   training	   was	   associated	   with	   significantly	   lower	  
death/stroke	  rates	  after	  CEA,	  compared	  with	  general,	  cardiac	  and	  neurosurgical	  specialties,	  but	  
only	  for	  lower	  volume	  surgeons.	  For	  high-­‐volume	  surgeons,	  surgical	  specialty	  had	  no	  impact	  on	  
outcome273.	  
	  
2.4.1.5	  	  Transverse	  or	  longitudinal	  incision?	  
The	  traditional	  approach	  to	  the	  bifurcation	  is	  via	  a	  longitudinal	  anterior	  sternomastoid	  incision.	  
Alternatively,	   CEA	   can	   be	   performed	   via	   a	   transverse	   incision,	   guided	   by	   pre-­‐operative	   DUS	  
marking	  of	   the	  bifurcation.	  Bastounis	   reported	   that	   transverse	   incisions	  gave	  better	   cosmetic	  
results	  with	   fewer	  CNIs274.	  By	   contrast,	  Marcucci	   reported	  no	  difference	   in	   the	  prevalence	  of	  
CNI	   and	   commented	   that	   it	   was	  more	   difficult	   to	   insert	   a	   shunt	   if	   a	   transverse	   incision	  was	  
used275.	  Ascher	  proposed	  a	  modified	  approach	  wherein	  DUS	  is	  used	  to	  identify	  the	  bifurcation	  
and	   a	   smaller	   longitudinal	   incision	   is	   made,	   which	   can	   be	   extended	   as	   required.	   This	  
significantly	   reduced	   incision	   length,	   offered	   good	   cosmesis,	   with	   no	   excess	   CNI	   risk276.	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Surgeons	   can,	   therefore,	   use	   whichever	   incision	   they	   prefer.	   If	   DUS	   suggests	   that	   the	  
bifurcation	   is	   not	   too	  high	  and	   there	   is	   a	   focal	   stenosis,	   a	   transverse	   skin	   crease	   incision	  will	  
probably	  give	  the	  best	  cosmetic	  result.	  If,	  however,	  there	  is	  any	  question	  about	  the	  bifurcation	  
being	  high,	  or	  if	  the	  lesion	  is	  extensive,	  a	  longitudinal	  incision	  remains	  preferable.	  	  
	  
2.4.1.6	  	  Antegrade	  or	  retrojugular	  exposure	  	  
Retrojugular	   exposure	   avoids	   mobilizing	   the	   hypoglossal	   nerve	   and	   may	   be	   associated	   with	  
shorter	   operating	   times	   and	  may	   optimise	   access	   to	   the	   upper	   ICA.	   A	   retrojugular	   approach	  
facilitates	   access	   to	   the	   upper	   ICA	   by	   sweeping	   anteriorly	   structures	   such	   as	   the	  
sternocleidomastoid	   artery,	   hypoglossal	   nerve	   and	   ansa	   cervicalis277.	   A	  meta-­‐analysis	   of	   four	  
non-­‐randomised	   trials	   and	   two	   RCTs	   (740	   CEAs)	   found	   no	   evidence	   that	   retrojugular	   (versus	  
antegrade)	  exposure	  was	  associated	  with	  reductions	  in	  peri-­‐operative	  death	  (0.6%	  vs	  0.5%)	  or	  
stroke	   (0.9%	   vs	   0.7%).	   However,	   the	   retrojugular	   approach	   was	   associated	   with	   significantly	  
higher	   rates	   of	   recurrent	   laryngeal	   nerve	   palsy	   (8.1%	   vs	   2.2%),	  with	   no	   evidence	   of	   reduced	  
rates	  of	  hypoglossal	  nerve	  injury	  (1.3%	  vs	  1.3%)278.	  	  
	  
Recommendation	  50	   Class	   Level	   References	  
The	   choice	   of	   carotid	   exposure	   (antegrade/retrojugular)	   should	  
be	  left	  to	  the	  discretion	  of	  the	  operating	  surgeon.	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2.4.1.7	  	  Carotid	  sinus	  nerve	  blockade	  
The	  rationale	  that	  routine	  carotid	  sinus	  nerve	  (CSN)	  blockade	  reduces	  haemodynamic	  instability	  
during/after	  CEA,	  was	  not	  supported	  by	  a	  meta-­‐analysis	  of	  4	  RCTs,	  which	  reported	  no	  evidence	  
that	  CSN	  blockade	  reduced	  hypotension,	  hypertension	  or	  arrhythmias	  after	  CEA279.	  
	  
	  
Recommendation	  51	   Class	   Level	   References	  
Routine	   carotid	   sinus	   nerve	   blockade	   is	   not	   recommended	  
as	   there	   is	   no	   evidence	   that	   it	   reduces	   the	   prevalence	   of	  
peri-­‐operative	  hypotension,	  hypertension	  and	  arrhythmias	  
III	   A	   279	  
	  
	  
2.4.1.8	  	  Anticoagulation	  and	  protamine	  reversal	   	  
In	   an	   ECST	   subgroup	   analysis,	   ‘no	   heparin’	   administration	   prior	   to	   carotid	   clamping	   was	  
associated	   with	   a	   significant	   increase	   in	   peri-­‐operative	   stroke280.	   There	   has	   been	   much	  
controversy	  about	  whether	   it	   is	   safe	   to	   reverse	  heparin	   (using	  protamine),	   the	  concern	  being	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that	   any	   reduction	   in	   neck	   haematomas	   might	   be	   offset	   by	   a	   higher	   risk	   of	   post-­‐operative	  
thrombotic	   stroke.	   Only	   one,	   small	   RCT	   addressed	   this	   question,	   but	   was	   abandoned	   after	  
recruiting	   only	   64	   patients	   because	   two	   patients	   randomised	   to	   protamine	   suffered	   a	   stroke	  
due	  to	  early	  thrombosis281.	  	  	  
The	  proportion	  of	  US	  surgeons	  using	  protamine	   increased	   from	  43%	   in	  2003	   to	  62%	  by	  2010	  
and	   the	   Vascular	   Study	  Group	   of	   New	   England	   Registry	   (10,059	   CEAs)	   reported	   that	   heparin	  
reversal	  with	  protamine	  was	   associated	  with	   significant	   reductions	   in	   re-­‐exploration	   for	   neck	  
haematoma	  (0.6%	  vs	  1.4%;	  p=0.001),	  without	  any	  increase	  in	  peri-­‐operative	  stroke/death	  (1.1%	  
vs	  1.0%)	  or	  peri-­‐operative	  MI	  (1%	  vs	  1.2%)282.	  A	  similar	  finding	  was	  made	  in	  a	  post-­‐hoc	  analysis	  
of	   2107	   CEA	   patients	   randomised	   within	   the	   GALA	   trial283.	   A	   systematic	   review	   and	   meta-­‐
analysis	   of	   outcomes	   in	   3817	   CEA	   patients	   receiving	   protamine	   and	   6070	   CEA	   patients	   not	  
receiving	  protamine	  observed	  that	  protamine	  administration	  was	  associated	  with	  a	  significant	  
reduction	  in	  the	  prevalence	  of	  neck	  haematoma	  requiring	  re-­‐exploration	  (OR	  0.42	  (95%CI	  0.22-­‐
0.8),	  p=0.008)	  and	  no	  evidence	   that	  protamine	  was	  associated	  with	  an	   increased	  risk	  of	  peri-­‐
operative	  stroke	  (OR	  0.71	  (95%CI0.49-­‐1.03),	  p=0.07)	  284.	  
	  
Recommendation	  52	   Class	   Level	   References	  
Protamine	  reversal	  of	  heparin	  should	  be	  considered	  in	  order	  
to	  prevent	  neck	  haematomas	  requiring	  re-­‐exploration.	  
IIa	   B	   282-­‐284	  
	  
2.4.1.9	  	  Shunting:	  routine,	  never,	  selective?	   	   	   	  
Temporary	  interruption	  of	  cerebral	  perfusion	  during	  carotid	  clamping	  can	  cause	  haemodynamic	  
neurological	  deficits,	  which	  can	  be	  avoided	  by	  shunt	   insertion.	  Surgeons	   tend	  to	  be	   ‘routine’,	  
‘selective’	  or	  ‘never’	  shunters,	  usually	  based	  on	  their	  training.	  There	  is	  a	  paucity	  of	  quality	  data	  
for	  guiding	  practice.	  Whilst	  there	  are	  various	  methods	  for	  monitoring	  cerebral	  perfusion	  during	  
carotid	   clamping	   (electroencephalograpy	   (EEG),	   stump	   pressure,	   back	   flow,	   TCD),	   the	   only	  
modality	  that	  is	  100%	  reliable	  is	  the	  patient’s	  neurological	  status	  when	  CEA	  is	  performed	  under	  
LRA.	  A	  Cochrane	  review	  of	  6	  RCTs	  (1270	  CEAs)	  concluded	  that	  (based	  on	  poor	  quality	  data)	  no	  
meaningful	  recommendations	  could	  be	  made	  regarding	  routine,	  selective	  or	  never	  shunting285.	  
Bennett	   evaluated	   3153	   CEA	   patients	   from	   the	   National	   Surgical	   Quality	   Improvement	  
Programme	  (NSQIP)	  database	  (2023	  without	  and	  1130	  with	  a	  shunt)	  and	  found	  no	  differences	  
regarding	  peri-­‐operative	  TIA/stroke	  (3.4%	  without	  vs.	  3.7%	  with	  shunt).	  A	  subgroup	  analysis	  of	  
patients	   with	   contralateral	   severe	   stenosis	   or	   occlusion	   revealed	   higher	   rates	   of	   TIA/stroke	  




Recommendation	  53	   Class	   Level	   References	  
It	  is	  recommended	  that	  the	  choice	  of	  shunting	  (routine,	  selective,	  
never)	  be	  left	  to	  the	  discretion	  of	  the	  operating	  surgeon.	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2.4.1.10	  	  Carotid	  Patching:	  routine,	  never,	  selective?	  
Surgeons	  tend	  to	  be	   ‘routine’,	   ‘selective’	  or	   ‘never’	  patchers.	  Meta-­‐analyses	  of	  10	  RCTs	  (2157	  
patients)	   comparing	   routine	  patching	  with	   routine	  primary	   closure	  observed	   that	   (i)	   patching	  
was	   associated	   with	   significant	   reductions	   in	   peri-­‐operative	   ipsilateral	   stroke	   (patch	   1.5%	   vs	  
4.5%	   primary	   closure;	   OR	   0.2	   (95%CI	   0.1-­‐0.6)	   p=0.001);	   (ii)	   patching	   was	   associated	   with	  
significant	   reductions	   in	   30-­‐day	   ICA	   thrombosis	   (0.5%	   patch	   vs	   3.1%	   primary	   closure;	  OR	   5.6	  
(95%CI	   2.4-­‐12.5)	   p=0.0011));	   (iii)	   patients	   randomised	   to	   primary	   closure	   were	   three	   times	  
more	  likely	  to	  return	  to	  theatre	  within	  30-­‐days	  (3.1%	  primary	  closure	  vs	  1.1%	  patched;	  OR	  2.9	  
(95%CI	  1.3-­‐6.3)	  p=0.01);	  (iv)	  there	  was	  no	  significant	  difference	  between	  routine	  patching	  and	  
routine	  primary	  closure	  regarding	  peri-­‐operative	  death,	  fatal	  stroke,	  death/stroke	  and	  CNI	  and	  
(v)	  patch	  type	  (polyester,	  Polytetrafluoroethylene	  (PTFE),	  autologous	  vein,	  bovine	  pericardium)	  
did	  not	   influence	  early	   outcomes287,288.	   Vein	  patch	   rupture	   is	   an	   extremely	   rare	   complication	  
and	  is	  more	  likely	  if	  smaller	  calibre	  saphenous	  veins	  have	  been	  harvested	  from	  the	  ankle289.	  
With	   regard	   to	   long-­‐term	   outcomes,	   routine	   patching	   (versus	   routine	   primary	   closure)	   was	  
associated	  with	  significant	  reductions	   in	   (i)	   late	   ipsilateral	  stroke	  (1.6%	  patch	  vs	  4.8%	  primary	  
closure;	  OR	  0.3	  (95%CI	  0.2-­‐0.6)	  p=0.001);	  (ii)	  any	  stroke	  (2.4%	  patch	  vs	  4.6%	  primary	  closure;	  OR	  
0.49	  (95%CI	  0.3-­‐0.9)	  p=0.002)	  and	  	  (iii)	  restenosis	  (4.3%	  patch	  vs	  13.8%	  primary	  closure;	  OR	  0.2	  
(95%CI	   0.2-­‐0.3)	   p<0.01).	   No	   RCTs	   have	   compared	   routine	   with	   selective	   patching287,288	   and	  
there	  is	  no	  consensus	  on	  criteria	  for	  selective	  patching.	  
	  
Recommendation	  54	   Class	   Level	   References	  
Routine	   patching	   is	   recommended,	   rather	   than	   routine	  
primary	   closure.	   There	   is	   no	   evidence	   that	   patch	   type	  
influences	  outcome	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2.4.1.11	  Eversion	  vs	  traditional	  endarterectomy	   	   	  
During	   eversion	   CEA	   (eCEA),	   the	   ICA	   is	   transected	   obliquely	   at	   its	   origin	   and	   a	   cylinder	   of	  
atheroma	   ‘expelled’	  via	  eversion	  of	   the	  outer	  media	  and	  adventitia.	  The	  distal	   intimal	   step	   is	  
examined	   for	   residual	   flaps,	   which	   are	   then	   excised.	   The	   ICA	   is	   shortened	   (as	   required)	   and	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reanastomosed	  to	  the	  CCA.	  Advantages	  include	  no	  risk	  of	  prosthetic	  infection,	  it	  is	  quicker	  than	  
patched	   CEA,	   bifurcation	   geometry	   is	   preserved	   and	   it	   is	   possible	   to	   shorten	   the	   distal	   ICA	  
where	  necessary.	  Disadvantages	  are	  that	  a	  shunt	  cannot	  be	  inserted	  until	  eversion	  is	  completed	  
and	  there	  may	  be	  problems	  accessing	  the	  upper	  ICA	  if	  distal	  disease	  has	  been	  underestimated.	  
A	  meta-­‐analysis	  has	  reported	  that	  eCEA	  was	  associated	  with	  a	  significantly	  higher	  incidence	  of	  
post-­‐CEA	  hypertension	  (OR	  2.75	  (95%CI	  1.82-­‐4.16),	  compared	  with	  conventional	  CEA	  (cCEA).	  By	  
contrast,	   cCEA	   was	   associated	   with	   a	   significantly	   higher	   incidence	   of	   peri-­‐operative	  
hypotension	  (OR	  11.37	  (95%CI	  1.95-­‐66.46)290.	  	  
In	   a	  meta-­‐analysis	   of	   21	   randomised	   and	   non-­‐randomised	   studies	   comparing	   cCEA	   (n=7721)	  
with	  eCEA	   (n=8530),	   eCEA	  was	  associated	  with	   significant	   reductions	   in	  peri-­‐operative	   stroke	  
(OR	  0.46	  (95%CI	  0.35-­‐0.62)),	  peri-­‐operative	  death	  (OR	  0.49	  (95%CI	  0.34-­‐0.69))	  and	  a	  significant	  
reduction	   in	   late	   carotid	   occlusion	   (OR	   0.48	   (95%CI	   0.25-­‐0.90))291.	   However,	   in	   a	   Cochrane	  
review	  of	  five	  RCTs	  (2590	  CEAs)292,	  there	  were	  no	  statistically	  significant	  differences	  regarding	  
(i)	  30-­‐day	  death/stroke,	   (ii)	  peri-­‐operative	   thrombosis,	  and	   (iii)	   late	   stroke.	  However,	  patients	  
randomised	   to	  eCEA	  had	  a	   two	   fold	   reduction	   in	   late	   restenosis	  >50%	  (2.5%),	  compared	  with	  
patients	  undergoing	  cCEA	   (5.2%)	   (OR	  0.3	   (95%CI	  0.1-­‐0.8)).	  When	  the	  meta-­‐analysis	  compared	  
eCEA	  with	  patched	  CEA,	  however,	  there	  were	  no	  differences	   in	   late	  restenosis	  (2.5%	  eversion	  	  
vs	   3.9%	   patched	   	   (HR	   0.52	   (0.2	   –	   1.7))292.	   These	   data	   would,	   therefore,	   suggest	   that	   eCEA	  
provides	  equivalent	  outcomes	  to	  cCEA,	  provided	  the	  arteriotomy	  is	  closed	  with	  a	  patch.	  
	  
Recommendation	  55	   Class	   Level	   References	  
Eversion	   endarterectomy	   is	   recommended	   over	   routine	  
primary	  arteriotomy	  closure.	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Recommendation	  56	   Class	   Level	   References	  
It	  is	  recommended	  that	  the	  choice	  between	  eversion	  and	  
patched	   endarterectomy	   be	   left	   to	   the	   discretion	   of	   the	  
operating	  surgeon.	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2.4.1.12	  Treatment	  of	  coils	  and	  kinks	  
The	   management	   of	   patients	   with	   ICA	   coils/kinks	   in	   the	   absence	   of	   significant	   stenoses	   is	  
controversial.	   Incidental	   coils/kinks	   are	   found	   in	   up	   to	   16%	   of	   patients	   and	   half	   will	   have	  
histological	   features	   consistent	   with	   fibromuscular	   dysplasia293.	   One	   RCT	   compared	   surgical	  
correction	   versus	   BMT	   in	   182	   patients	  with	   hemispheric/non-­‐hemispheric	   symptoms	  with	   an	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isolated	   coil/kink	   of	   the	   ICA,	   where	   neurologists	   performed	   post-­‐operative	   assessments290.	  
Patients	   randomised	   to	  surgical	   correction	  had	  a	  0%	  rate	  of	  occlusion	  at	  a	  mean	  of	  5.9	  years	  
follow-­‐up,	  compared	  with	  5.5%	  in	  those	  treated	  medically	  (p=0.02).	  The	  risk	  of	  late	  stroke	  was	  
0%	   in	   surgically	   treated	  patients,	   compared	  with	  6.6%	   in	  medically	   treated	  patients	   (p=0.01).	  
Unfortunately,	  meaningful	  interpretation	  of	  the	  data	  was	  confounded	  by	  the	  fact	  that,	  41%	  of	  
the	   medically	   treated	   patients	   crossed	   over	   to	   surgical	   treatment	   because	   of	   recurrent	  
hemispheric	  or	  ongoing	  non-­‐hemispheric	  symptoms.	  	  
	  
Recommendation	  57	   Class	   Level	   References	  
Surgical	   intervention	   for	   asymptomatic	   isolated	   coils/kinks	  
of	  the	  internal	  carotid	  artery	  is	  not	  recommended.	  	  
	  
III	   C	   	  
	  
Recommendation	  58	   Class	   Level	   References	  
Symptomatic	   patients	   with	   isolated	   coils/kinks	   may	   be	  
considered	   for	   surgical	   correction,	   but	   only	   following	  
multidisciplinary	  team	  review	  and	  provided	  no	  other	  cause	  
for	   transient	   ischaemic	   attack	   or	   stroke	   symptoms	   can	   be	  
identified.	  	  
IIb	   B	   293	  
	  
	  
2.4.1.13	  	  Role	  of	  monitoring	  and	  quality	  control	  after	  carotid	  endarterectomy	  
There	   is	  no	  consensus	  as	  to	  whether	  a	  policy	  of	  monitoring	  or	  quality	  control	   reduces	  30-­‐day	  
death/stroke	  after	  CEA.	  Some	  have	  argued	  that	  outcomes	  are	  no	  different294,	  while	  others	  have	  
argued	  that	  this	  is	  because	  of	  a	  simple	  failure	  to	  ask	  the	  right	  questions170.	  	  
	  
Quality	   control	   is	   not	   the	   same	   as	  monitoring.	   The	   role	   of	  monitoring	   is	   to	   ensure	   adequate	  
brain	  perfusion,	  especially	  during	  carotid	  clamping	  and	  shunting.	  This	  can	  be	  achieved	  by	  using	  
TCD,	   or	   by	   performing	   CEA	   under	   LRA,	   measuring	   stump	   pressure,	   performing	   a	   subjective	  
assessment	  of	  ICA	  backflow	  following	  carotid	  clamping	  and	  near	  infra-­‐red	  spectroscopy.	  Loss	  of	  
cerebral	  electrical	  activity	  is	  assessed	  by	  somatosensory	  evoked	  potentials	  and	  	  EEG.	  The	  onset	  
of	   	   any	   intra-­‐operative	   neurological	   deficit	   can	   be	   accurately	   identified	   by	   performing	   CEA	  
under	  LRA.	  	  
	  
Quality	  control	  techniques	  aim	  to	  modify	  operative	  strategies	  in	  order	  to	  identify	  and	  prevent	  
technical	  error,	  including	  embolisation	  during	  carotid	  dissection	  using	  TCD,	  	  to	  ensure	  that	  the	  
shunt	   is	   functioning	   (TCD,	  CEA	  under	   LRA),	   to	   identify	   residual	   luminal	   thrombus	  before	   flow	  
restoration	   (angioscopy),	   to	   identify	   residual	   luminal	   thrombus	   after	   flow	   restoration	   (DUS,	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angiography),	   to	   diagnose	   large	   intimal	   flaps	   (angioscopy,	   DUS,	   angiography)	   to	   diagnose	  
residual	   (untreated)	   stenoses	   (DUS,	   angiography)	   and	   to	   diagnose	   the	   very	   rare	   patient	  who	  
thromboses	   the	   operated	   ICA	   during	   neck	   closure	   (diagnosed	   by	   increasing	   rates	   of	  
embolisation	  followed	  by	  declining	  MCAV	  using	  TCD)170.	  
	  
Evidence	   suggests	   that	   targeted	   monitoring	   and	   quality	   control	   strategies	   may	   reduce	   peri-­‐
operative	  death/stroke170,295,	  but	  reliance	  on	  a	  single	  monitoring	  or	  quality	  control	  strategy	   is	  
unlikely	   to	   make	   any	   difference,	   due	   to	   the	   multiple	   causes	   of	   peri-­‐operative	   stroke	  
(hypoperfusion,	  embolism,	  thrombosis,	  intracranial	  haemorrhage,	  hyperperfusion	  syndrome).	  
	  
Recommendation	  59	   Class	   Level	   References	  
Targeted	  monitoring	  and	  quality	   control	   strategies	  may	  be	  
considered	  to	  reduce	  the	  risk	  of	  peri-­‐operative	  stroke	  
	  
IIb	   C	   170,295	  
	  
	  
2.4.1.14	  	  Treatment	  of	  high	  internal	  carotid	  artery	  lesions	  
A	  high	  bifurcation	  or	  a	  stenosis	  extending	  behind	  the	   jaw	  can	  represent	  a	  technical	  challenge	  
and	  increase	  the	  risk	  of	  CNI.	  If	  the	  person	  performing	  DUS	  assessment	  cannot	  image	  above	  the	  
lesion,	   corroborative	   CTA/MRA	   imaging	   must	   be	   performed	   to	   evaluate	   operability.	   The	  
presence	  of	  distal	  disease	  extension	  should	  prompt	  the	  surgeon	  to	  reconsider	  whether	  CEA	  is	  
appropriate	   (eg	   in	   asymptomatic	   patients).	   If	   the	   patient	   is	   recently	   symptomatic	   and	   the	  
surgeon	   is	   concerned	   about	   his/her	   ability	   to	   complete	   the	   procedure,	   CAS	   should	   be	  
considered	  as	  an	  alternative.	  	  
	  
There	   are	   several	   options	   for	   improving	   access	   to	   the	   upper	   ICA,	   including	   division	   of	   the	  
sternocleidomastoid	   artery	   (which	   tethers	   the	   hypoglossal	   nerve),	   division	   of	   the	   occipital	  
branch	  of	  the	  external	  carotid	  artery	  (ECA),	  transection	  of	  the	  ansa	  cervicalis	  (which	  also	  tethers	  
the	  hypoglossal	  nerve),	  division	  of	  digastric	  and	  transection	  of	  the	  styloid	  process.	  	  
	  
In	   the	   presence	   of	   distal	   disease	   extension,	   advance	   planning	   is	   essential.	   Nasolaryngeal	  
intubation	  enables	   the	  mouth	   to	  be	   closed	  which	   then	  opens	  up	   the	  angle	  between	   jaw	  and	  
mastoid	  process	  for	  distal	  access.	  Temporomandibular	  subluxation	  cannot	  be	  undertaken	  once	  
the	  operation	  is	  underway.	  An	  alternative	  strategy	  (which	  can	  be	  performed	  once	  the	  operation	  
is	   underway)	   involves	   extending	   the	   incision	   anterior	   to	   the	   ear	   with	   mobilisation	   of	   the	  
 77 
superficial	   lobe	   of	   the	   parotid.	   This	   greatly	   increases	   access	   to	   the	   upper	   ICA,	   but	   usually	  	  
requires	  the	  assistance	  of	  a	  specialist	  ENT	  or	  parotid	  surgeon296.	  
	  
Recommendation	  60	   Class	   Level	   References	  
It	   is	   recommended	   that	   the	   surgeon	   should	   anticipate	   the	  
presence	   of	   distal	   disease	   extension	   and	   plan	   for	   this	   in	  
advance.	  	  
	  




2.4.1.15	  	  	  Wound	  drainage	  
	  
The	  rationale	   for	  placing	  a	  drain	   in	   the	  deeper	   tissues	   following	  CEA	   is	   that	   it	   should	  prevent	  
haematoma	  formation,	  which	  could	  compromise	  the	  airway	  in	  the	  early	  post-­‐operative	  period	  
and	   also	   predispose	   to	   abscess	   formation	   and/or	   late	   patch	   infection.	   There	   is,	   however,	  
controversy	  as	  to	  whether	  drains	  make	  any	  difference.	  An	  RCT	  observed	  that	  routine	  drainage	  
yielded	  a	  mean	  volume	  of	  42mls	  of	  blood,	  plus	  a	  median	  residual	  neck	  haematoma	  volume	  of	  
25mls	  on	  DUS	  assessment	  (range	  5-­‐65).	  By	  contrast,	  the	  median	  residual	  haematoma	  volume	  in	  
patients	   randomised	   to	   ‘no	   drains’	   was	   31mls	   (range	   3-­‐72)297.	   Observational	   studies	   have	  
reported	   that	   small	   calibre	   drains	   (10F)	   are	   ineffective,	   while	   14F	   drains	   significantly	   reduce	  
neck	  haematoma	  formation298.	  This	  is	  another	  area	  of	  surgical	  practice	  where	  surgeons	  tend	  to	  
practice	  what	  they	  were	  taught,	   rather	  than	  being	  based	  on	  evidence.	  Despite	  the	  single	  RCT	  
(which	  suggested	  that	  routine	  drainage	  was	  ineffective),	   it	   is	   likely	  that	  most	  surgeons	  remain	  
‘more	  comfortable’	  about	  routinely	  or	  selectively	  inserting	  a	  wound	  drain	  after	  CEA.	  
	  
	  
2.4.1.16	  	  Ward,	  high	  dependency	  or	  intensive	  care	  post-­‐operatively?	  
	  
All	  CEA	  and	  CAS	  patients	  benefit	  from	  3-­‐6	  hours	  neurological	  and	  intra-­‐arterial	  BP	  monitoring	  in	  
the	   Recovery	   Area	   of	   theatre	   or	   angio	   suite	   following	   CEA.	   Relatively	   few	   patients	   require	  
routine	  post-­‐operative	  monitoring	  in	  a	  high	  dependency	  unit	  (HDU)	  or	  intensive	  care	  unit	  (ICU).	  
The	  majority	  can	  be	   transferred	  back	   to	   the	  vascular	  ward	   for	  ongoing	  surveillance,	   involving	  
hourly	   non-­‐invasive	   BP	   and	   neurological	   monitoring	   for	   the	   first	   24	   hours	   and	   four	   hourly	  
thereafter	  until	  discharge.	  	  
Evidence	  suggests	  that	  up	  to	  40%	  of	  patients	  may	  require	  treatment	  for	  post-­‐CEA	  hypertension	  
in	  the	  early	  post-­‐operative	  period299.	  Half	  of	  these	  will	  require	  treatment	  in	  the	  first	  three	  post-­‐
operative	  hours,	  but	  most	  require	  only	  a	  single	  bolus	  of	   intravenous	   labetalol	  to	  control	  their	  
BP	  (section	  2.6.1.3.3).	  If	  there	  are	  no	  further	  spikes	  of	  hypertension,	  these	  patients	  can	  usually	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return	  to	  the	  vascular	  ward	  2-­‐3	  hours	  later.	  Patients	  who	  require	  intravenous	  therapy	  to	  control	  
BP	   should	   either	   remain	   in	   the	   Recovery	   Area	   of	   theatre	   (with	   ongoing	   intra-­‐arterial	   BP	  
monitoring)	   or	   be	   transferered	   to	   the	   HDU	   for	   continued	   intra-­‐arterial	   BP	   monitoring.	   Two	  
hours	   after	   intravenous	   treatment	   has	   completed	   and	   with	   no	   further	   surges	   in	   BP,	   it	   is	  
reasonable	   to	   transfer	   the	   patient	   back	   to	   the	   vascular	   ward	   for	   ongoing	   monitoring.	   Any	  
patient	  who	  suffers	  a	  major	   intra-­‐operative	  cardiac	  event	   should,	  however,	  be	   transferred	   to	  




2.4.2	  Carotid	  bypass	   	   	   	  
2.4.2.1	  	  Indications	  	  
Bypass	   is	   indicated	   in	   the	   following	   situations:	   extensive	   atherosclerotic	   disease,	   excessive	  
coiling/kinking	  of	   the	   ICA	  above	  a	   stenosis,	  previous	   radiotherapy	   causing	   fibrosis	  of	   the	   ICA,	  
excessive	   arterial	   wall	   thinning	   after	   CEA,	   large	   intimal	   flap	   on	   completion	   imaging,	  
revascularisation	   following	  enbloc	  excision	  of	  a	   carotid	  body	   tumour,	   treatment	  of	  prosthetic	  
patch	   infection,	   treatment	   of	   restenosis	   after	   CEA,	   treatment	   of	   fibromuscular	   dysplasia	   and	  
treatment	  of	  aneurysms300-­‐306.	  
	  
2.4.2.2	  	  Technique	  	  
Options	   include	   (i)	   an	   interposition	   graft;	   (ii)	   end-­‐to-­‐side	   anastomosis	   to	   the	   distal	   CCA	  with	  
end-­‐to-­‐side	  or	  end-­‐to-­‐end	  anastomosis	  to	  the	  distal	  ICA	  with	  ECA	  exclusion	  and	  (iii)	  bifurcation	  
reconstruction	  (retaining	  the	  ECA)	  with	  a	  distal	  end-­‐to-­‐end	  anastomosis	  to	  the	  ICA.	  The	  Pruitt	  
shunt	   is	   ideal	   for	   performing	   a	   bypass,	   as	   the	   reversed	   vein	   or	   prosthetic	   conduit	   can	   be	  
positioned	  over	  the	  distal	  limb	  prior	  to	  shunt	  insertion.	  The	  shunt	  then	  ensures	  that	  the	  distal	  
anastomosis	   is	   aligned	   and	   easy	   to	   complete.	   Conduits	   include	   reversed	   saphenous	   vein	  
harvested	  from	  the	  thigh301,302,305,PTFE300,301,303,304	  or	  polyester306.	  Early	  and	  late	  outcomes	  are	  
summarised	  in	  table	  19.	  
	  
These	  data	   suggest	   that	   carotid	  bypass	  can	  be	  performed	  with	   low	  procedural	   risks	  and	  with	  
good	   long-­‐term	   patency.	   Notwithstanding	   the	   lack	   of	   RCTs,	   late	   patency	   with	   prosthetic	  
conduits	  appear	  to	  be	  as	  good	  as	  with	  vein,	  (possibly	  better).	  Interestingly,	  only	  three	  late	  graft	  






Table	  19:	  early	  and	  late	  outcomes	  following	  carotid	  interposition	  bypass	  grafting	  
author	   n=	   conduit	  
type	  






Ricco300	   198	   PTFE	   1/198	  	  (0.5%)	   98%	  @	  10y	   none	  
Dorafshar301	   31	   PTFE	   1/31	  	  (3.2%)	   90%	  @	  4	  y	   1/31	  
Roddy303	   22	   PTFE	   0/22	  	  (0.0%)	   95%	  @	  2y	   none	  
Veldenz304	   51	   PTFE	   1/51	  	  (1.9%)	   96%	  @	  2y	   none	  
Dorafshar301	   10	   vein	   1/10	  	  (10%)	   80%	  @	  4y	   n/a	  
Lauder302	   50	   vein	   3/50	  	  (6.0%)	   83%	  @	  3y	   n/a	  
Koncar306	   292	   polyester	   	  19/292	  (6.5%)	   96%	  @	  32m	   2/292	  
Branchereau305	   212	   vein	   14/212	  (6.6%)	   92%	  @10y	   n/a	  
	  
	  
2.4.3	  	  Extracranial	  to	  intracranial	  bypass	  
The	  rationale	  underpinning	  extracranial	  to	  intracranial	  bypass	  (EC-­‐IC)	  is	  that	  in	  patients	  with	  an	  
extracranial	   ICA	  occlusion,	  a	  bypass	   (usually	   from	  the	  superficial	   temporal	  artery	  to	  the	  MCA)	  
will	  reduce	  the	  long-­‐term	  risk	  of	  ipsilateral	  ischaemic	  stroke.	  A	  1985	  RCT	  concluded	  that	  EC-­‐IC	  
bypass	  conferred	  no	  benefit	  over	  BMT307.	  The	  trial	  was,	  however,	  criticised	  regarding	  selection	  
criteria,	  method	   of	   randomisation,	   the	   large	   number	   of	   patients	   operated	   upon	   outwith	   the	  
trial	   and	   the	   lack	   of	   haemodynamic	   criteria	   for	   trial	   entry.	   A	   subsequent	   Cochrane	   review,	  
which	   included	   2	   RCTs	   and	   19	   observational	   studies	   (n=2591),	   concluded	   that	   EC-­‐IC	   bypass	  
conferred	  no	  benefit	  over	  BMT	  in	  terms	  of	  late	  stroke	  prevention	  (RCTs:	  (OR	  0.99	  (95%CI	  0.79-­‐
1.23),	  p=0.91));	  non-­‐RCTs	  (OR	  0.80	  (95%CI	  0.54-­‐1.18),	  p=0.25))308.	  A	  third	  RCT	  was	  undertaken,	  
which	   only	   included	   patients	   with	   a	   recently	   symptomatic	   extracranial	   ICA	   occlusion	   plus	  
evidence	   of	   haemodynamic	   impairment	   in	   the	   ipsilateral	   cerebral	   hemisphere	   (increased	  
oxygen	  extraction	  fraction	  using	  Positron	  Emission	  Tomography)309.	  The	  2-­‐year	  risk	  of	  ipsilateral	  
stroke	  (including	  peri-­‐operative	  stroke/death)	  was	  21.0%	  (95%CI	  12.8-­‐29.2)	  after	  EC-­‐IC	  bypass,	  
versus	  22.7%	  (95%CI	  13.9-­‐31.6)	   in	  patients	  randomised	  to	  BMT	  (p=0.78).	  Accordingly,	  there	   is	  
still	   no	   role	   for	   EC-­‐IC	  bypass	   in	   the	   routine	  management	  of	   patients	  with	   atherosclerotic	   ICA	  
occlusion.	  The	  only	  exception	  might	  be	  the	  patient	  with	  persisting	  clinical	  and	  haemodynamic	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  61	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   References	  
Extracranial	  to	  Intracranial	  bypass	  surgery	  is	  not	  
recommended	  in	  patients	  with	  an	  extracranial	  internal	  
carotid	  occlusion.	  
	  




2.5	  	  Carotid	  Artery	  Stenting	  
2.5.1	  	  Adjuvant	  medical	  therapy	  
Pre-­‐intervention	   statin	   therapy	  may	   reduce	  procedural	   complications	   (section	   2.3.2.3.3).	   It	   is	  
recommended	  to	  start	  DAPT	  with	  aspirin	  (300mg	  initially	  for	  up	  to	  14	  days	  followed	  by	  75mg	  
daily	  if	  not	  already	  taking	  aspirin)	  and	  clopidogrel	  (75mg	  daily)	  three	  days	  prior	  to	  CAS.	  Aspirin	  
and	  clopidogrel	  should	  be	  continued	  for	  at	  least	  one	  month,	  followed	  by	  clopidogrel	  thereafter,	  
unless	   the	   treating	   physician	   opts	   for	   an	   alternative	   long-­‐term	   antiplatelet	   regimen	   (section	  
2.3.2.1.3).	  Most	   operators	   administer	   5000IU	   of	   intravenous	   heparin	   prior	   to	   the	   procedure	  
and	   0.6-­‐1.2mg	   of	   atropine	   (or	   0.6mg	   Glycopyrrolate)	   in	   order	   to	   prevent	   hypotension	   and	  
bradycardia/asystole	  prior	  to	  balloon	  inflation310,311.	  	  
	  
Recommendation	  62	   Class	   Level	   References	  
It	   is	   recommended	   that	   atropine	   or	   glycopyrrolate	   be	  
administered	   prior	   to	   balloon	   inflation	   to	   prevent	  
hypotension,	  bradycardia	  or	  asystole	  
	  
I	   B	   310,311	  
	  
2.5.2	  	  Access	  (femoral,	  cervical,	  radial)	  
The	   commonest	   access	   is	   via	   the	   common	   femoral	   artery	   (CFA),	   although	   direct	   CCA	   and	  
brachial/radial	   artery	   access	   are	   alternatives.	   The	   latter	   may	   be	   preferable	   in	   patients	   with	  
aorto-­‐iliac	  tortuosity/occlusion.	  Direct	  CCA	  access	  via	  a	  cut	  down	  has	  recently	  been	  advocated	  
as	  this	  avoids	  manipulation	  of	  wires	  and	  catheters	  within	  the	  aortic	  arch.	  
	  
2.5.3	  	  Choice	  of	  wires,	  access	  catheters,	  stent	  design	  
For	   access	   into	   the	   CCA,	   a	   0.035”	   guide	   wire	   is	   used.	   For	   stent	   placement	   and	   balloon	  
angioplasty	  (requiring	  rapid	  exchange	  systems)	  0.014”	  floppy	  tip	  guide	  wires	  are	  advised.	  Long	  
sheaths	   or	   guiding	   catheters	   (6F-­‐8F)	   are	   used	   to	   obtain	   a	   stable	   position	   in	   the	   CCA.	   ICSS	  
reported	   significantly	   lower	   30-­‐day	   risks	   of	   death/stroke	   in	   CAS	   patients	   where	   closed	   cell	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designed	   stents	   were	   used	   (5.1%),	   versus	   9.5%	   in	   patients	   where	   open	   cell	   designed	   stents	  
were	  used	  (OR	  10.53	  (95%CI	  0.31-­‐0.91),	  p=0.024)312.	  There	  is	  currently	  no	  evidence	  that	  micro-­‐
mesh	  or	  dual	  layer	  stents	  reduce	  procedural	  risks	  after	  CAS.	  
	  
2.5.4	  	  Role	  of	  pre-­‐dilatation	  
Predilation	   is	   only	   undertaken	   in	   patients	   with	   high-­‐grade	   stenoses	   (>80%),	   when	   it	   is	  
anticipated	   that	   the	   stent	   or	   filter	   protection	   device	   cannot	   cross	   the	   lesion313,	   because	  
predilatation	  may	  be	  associated	  with	  higher	  procedural	  stroke	  rates.	  
	  
2.5.5	  	  Use	  of	  cerebral	  protection	  devices	  
There	   is	   conflicting	   evidence	   (and	   opinion)	   regarding	   the	   role	   of	   cerebral	   protection	   devices	  
(CPDs)	   in	   preventing	   stroke	   after	   CAS,	   despite	   the	   fact	   that	   it	   is	   not	   unusual	   to	   find	   embolic	  
material	   in	   retrieved	   distal	   filters314.	   A	   meta-­‐analysis	   of	   22	   studies	   (n=11,655)	   reported	  
significantly	   lower	   rates	   of	   perioperative	   stroke/death	   favouring	   the	   use	   of	   CPDs	   (OR	   0.57	  
(95%CI	   0.43-­‐0.76),	   p<0.01)315.	   In	   addition,	   the	   best	   CAS	   results	  within	   RCTs	  were	   reported	   in	  
CREST	   and	   ACT-­‐1,	   where	   CPDs	   were	  mandatory	   and	   CAS	   practitioners	   were	   trained	   in	   their	  
use97,189.	   By	   contrast,	   a	  meta-­‐analysis	   of	   30-­‐day	   stroke	   in	   patients	   randomised	   to	   CAS	  within	  
EVA-­‐3S,	  SPACE	  and	  ICSS	  found	  no	  evidence	  that	  CPD	  usage	  was	  associated	  with	  reduced	  peri-­‐
operative	  stroke	  rates	  (OR	  0.95	  (95%CI	  0.38-­‐2.41),	  p=0.92)195.	  Proximal	  CPDs	  protect	  the	  brain	  
by	   stopping	   or	   reversing	   blood	   flow	   within	   the	   carotid	   bifurcation.	   Their	   main	   advantages	  
include	  being	  able	  to	  cross	  the	  stenosis	  with	  protection	  already	  in	  place	  and	  the	  avoidance	  of	  
distally	   placed	   CPDs	   (such	   as	   filters),	   which	   may	   be	   associated	   with	   spasm	   or	   distal	   ICA	  
dissection.	  It	  is	  advised,	  however,	  that	  proximal	  CPDs	  should	  be	  avoided	  in	  patients	  with	  severe	  
ECA/CCA	   disease316.	   Overall,	   30%	   will	   not	   tolerate	   proximal	   occlusion317	   and	   will	   develop	  
neurological	   symptoms.	   In	   a	   series	   of	   600	   patients,	   the	   only	   clinical	   predictive	   factor	   of	   not	  
being	  able	  to	  tolerate	  proximal	  occlusion	  was	  contralateral	  ICA	  occlusion317.	  	  
	  
These	  contradictory	   reports	  and	   the	   lack	  of	  high-­‐quality	  data	  have	   led	   to	  conflicting	  opinions	  
among	  CAS	  practitioners,	  with	   some	  claiming	   that	  CPDs	  are	  unnecessary,	  while	  others	  would	  
never	   perform	   an	   unprotected	   CAS	   procedure.	   Given	   the	   lack	   of	   high-­‐quality	   data,	   the	  
recommendation	  in	  these	  guidelines	  is	  based	  on	  a	  broad	  consensus	  amongst	  CAS	  practitioners	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The	  use	  of	  embolic	  protection	  devices	  should	  be	  considered	  in	  
patients	  undergoing	  CAS	  
IIa	   B	   	  	  	  	  97,189,315,318	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Proximal	  protection	  devices	  are	  not	  recommended	  in	  patients	  
with	   advanced	   common	   carotid	   disease,	   or	   those	   with	  
external	  carotid	  artery	  disease	  (where	  an	  occlusion	  balloon	  is	  
to	  be	  positioned	  in	  the	  external	  carotid	  artery)	  or	   in	  patients	  
with	  contralateral	  occlusion	  and	  insufficient	  collateralization.	  
	  
III	   C	   316	  
	  
	  
2.5.6	  	  Role	  of	  peri-­‐procedural	  monitoring	  
The	   presence	   of	   an	   experienced	   anaesthesiologist	   or	   physician	   capable	   of	   maintaining	  
haemodynamic	  stability	   is	  mandatory	  and	  haemodynamic	  monitoring	  should	  be	  continued	  for	  
at	  least	  6	  hours	  after	  the	  procedure.	  	  
	  
2.5.7	  	  Learning	  curve	  and	  the	  volume	  outcome	  relationship	  
As	  with	  CEA,	  there	  are	  conflicting	  data	  regarding	  a	  volume	  outcome	  relationship	  following	  CAS.	  
In	  a	  systematic	  review	  of	  outcomes	  from	  four	  large	  case	  series	  and	  one	  registry,	  it	  was	  observed	  
that	  in	  ‘active’	  CAS	  centres,	  it	  took	  almost	  two	  years	  of	  experience	  before	  30-­‐day	  death/stroke	  
rates	  fell	  below	  5%319.	   In	  an	  analysis	  of	  data	  derived	  from	  the	  Healthcare	  Cost	  and	  Utilization	  
Project’s	   Nationwide	   Inpatient	   Sample	   from	   2006	   to	   2010,	   greater	   operator	   volume	   was	  
associated	  with	  a	   lower	   rate	  of	  postoperative	  mortality	  and	  complications,	  as	  well	   as	   shorter	  
lengths	   of	   stay	   and	   lower	   hospitalization	   costs320.	   In	   a	   large	   ‘high-­‐risk	   for	   CEA’	   Registry,	   a	  
lifetime	  experience	  of	  72	  CAS	  procedures	  was	  necessary	  to	  achieve	  a	  30-­‐day	  death/stroke	  rate	  
<3%	   in	   asymptomatic	   non-­‐octogenarian	   patients321.	   In	   an	   analysis	   of	   outcomes	   in	   Medicare	  
beneficiaries,	   30-­‐day	  mortality	  was	   significantly	   higher	  when	   practitioners	   performed	   <6	   CAS	  
procedures	  per	  year,	   compared	  with	  >24	   (OR	  1.9	   (95%CI	  1.4-­‐2.7),	  p<0.001)322.	   In	  a	  very	   large	  
single	  centre	  series	  involving	  2124	  successful	  CAS	  procedures,	  a	  lifetime	  experience	  of	  >100	  CAS	  
interventions	   was	   associated	   with	   significantly	   fewer	   peri-­‐operative	   strokes	   (OR	   0.81	   (95%CI	  
0.67-­‐0.95)),	  whilst	  a	  lifetime	  experience	  of	  <50	  CAS	  procedures	  was	  a	  significant	  predictor	  of	  an	  
increased	   risk	  of	   peri-­‐operative	   stroke	   (p<0.001)323.	   Finally,	   in	   a	  post-­‐marketing	  evaluation	  of	  
outcomes	   in	   5841	   patients	   in	   the	   CHOICE	   Registry	   (carotid	   stenting	   for	   high	   surgical	   risk	  
patients:	   evaluating	   outcomes),	   the	   most	   important	   predictive	   feature	   for	   30-­‐day	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death/stroke/MI	  was	  an	  increased	  time	  interval	  between	  individual	  CAS	  procedures324.	  
	  
An	  individual	  patient	  meta-­‐analysis	  was	  undertaken	  in	  recently	  symptomatic	  patients	  who	  were	  
randomised	  to	  CAS	  in	  EVA-­‐3S,	  SPACE	  and	  ICSS325.	  In	  contrast	  to	  what	  was	  reported	  (above),	  the	  
30-­‐day	   risk	  of	  death/stroke	  was	  not	   influenced	  by	   lifetime	  CAS	  experience	   (p=0.8).	  However,	  
compared	   to	   high	   annual	   volume	   CAS	   operators	   (mean	   >5.6	   cases	   per	   year)	  who	   incurred	   a	  
5.1%	   risk	  of	  death/stroke,	  30-­‐day	  death/stroke	  was	   significantly	  higher	   in	  operators	  with	   low	  
annual	  CAS	  experience	  (mean	  3.2	  cases	  per	  year),	  who	  incurred	  a	  10%	  rate	  of	  death/stroke	  (OR	  
2.3	  (95%CI	  1.36-­‐3.87).	  Intermediate	  volume	  operators	  (mean	  3.2-­‐5.6	  cases	  pr	  year)	  incurred	  an	  
8.4%	  risk	  of	  death/stroke	  (OR	  1.93	  (95%CI	  1.14-­‐3.27)325.	  	  
	  
The	   authors	   of	   the	   pooled	   individual	   patient	   meta-­‐analysis	   of	   1546	   recently	   symptomatic	  
patients	  randomised	  within	  ICSS,	  EVA-­‐3S	  and	  SPACE	  concluded	  that	  CAS	  practitioners	  should	  be	  
performing	  at	  least	  6	  CAS	  procedures	  each	  year325.	  By	  contrast,	  the	  Society	  for	  Cardiovascular	  
Angiography	  and	  Interventions	  and	  the	  Society	  for	  Vascular	  Medicine	  advise	  that	  “in	  an	  era	  of	  
low	  CAS	  volumes”,	  25	   lifetime	  CAS	  procedures	   is	   reasonable	   for	  achieving	  competency,	  along	  
with	   10-­‐15	   CAS	   procedures	   annually	   to	   maintain	   competency326,	   provided	   that	   the	   3%	  
(asymptomatic)	  and	  6%	  (symptomatic)	  thresholds	  are	  maintained.	  
	  
	  
2.6	  	  Complications	  following	  carotid	  interventions	  	  
2.6.1	  	  The	  first	  30	  days	  
2.6.1.1	  	  Stroke	  after	  carotid	  endarterectomy	   	  
2.6.1.1.1	  	  Intraoperative	  stroke	  
An	  intra-­‐operative	  stroke	  is	  defined	  as	  any	  new	  focal	  neurological	  deficit	  (or	  worsening	  of	  a	  pre-­‐
existing	  deficit),	  which	  is	  apparent	  immediately	  following	  recovery	  from	  anaesthesia	  and	  whose	  
symptoms	   last	   for	   >24	   hours.	   In	   practice,	   the	   majority	   follow	   intra-­‐operative	   embolisation	  
(during	  carotid	  dissection/mobilisation,	  following	  shunt	  insertion,	  following	  restoration	  of	  flow,	  
following	  accumulation	  of	  platelet	  thrombi	  on	  the	  endarterectomy	  zone	  during	  neck	  closure)	  or	  
(less	   commonly)	   hypoperfusion,	   which	   may	   be	   associated	   with	   carotid	   clamping	   or	   shunt	  
malfunction.	   In	   a	   recent	   25-­‐year	   audit,	   most	   intra-­‐operative	   strokes	   appeared	   to	   follow	  
embolisation	  of	  retained	  luminal	  thrombus	  following	  restoration	  of	  flow,	  despite	  irrigation	  with	  
heparinised	   saline	   prior	   to	   flow	   restoration170.	   The	   source	   of	   the	   emboli	   was	   bleeding	   from	  
transected	   vasa	   vasorum	   following	   plaque	   removal.	   The	   ensuing	   thrombus	   is	   often	   densely	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adherent	  to	  the	  endarterectomy	  zone	  and	  can	  be	  resistant	  to	  blind	  irrigation.	  It	  can,	  however,	  
be	  identified	  using	  completion	  angioscopy	  (prior	  to	  flow	  restoration)	  and	  removed170.	  	  	  
	  
One	  of	  the	  advantages	  of	  performing	  CEA	  under	  LRA	  is	  that	  the	  timing	  of	  any	  new	  neurological	  
deficit	  can	  be	  accurately	  determined.	  For	  patients	  undergoing	  CEA	  under	  GA,	  an	  abrupt	  change	  
in	  the	  EEG	  can	  also	  predict	  the	  most	  likely	  time	  of	  onset	  of	  a	  new	  neurological	  deficit327.	  If	  the	  
patient	   exhibits	   the	   triad	   of	   hemiplegia,	   homonymous	   hemianopia	   and	   higher	   cortical	  
dysfunction	   (aphasia/visuospatial	   neglect)	   upon	   recovery	   from	   anaesthesia,	   it	   is	   highly	   likely	  
that	  either	  the	  ICA	  or	  MCA	  mainstem	  is	  occluded.	  If	  only	  one	  or	  two	  components	  of	  the	  triad	  
are	  present,	  this	  is	  more	  likely	  to	  represent	  occlusion	  of	  one	  or	  more	  MCA	  branches328.	  
	  
It	   is	   currently	   accepted	   practice	   that	   anyone	   recovering	   from	   anaesthesia	   with	   a	   new	  
neurological	   deficit	   should	   undergo	   immediate	   re-­‐exploration,	   to	   exclude	   accumulation	   of	  
thrombus	  within	  the	  endarterectomy	  zone329.	  In	  a	  sub-­‐analysis	  of	  the	  causes	  of	  stroke	  in	  ACST-­‐
1,	   the	  rate	  of	  disabling/fatal	  stroke	   in	  patients	  who	  underwent	   immediate	  re-­‐exploration	  was	  
similar	  to	  those	  who	  did	  not	  undergo	  re-­‐exploration330.	  However,	  the	   immediate	  priority	   is	  to	  
identify	   patients	   with	   ICA	   thrombosis,	   as	   they	   will	   benefit	   from	   immediate	   exploration.	  
Provided	  flow	  is	  restored	  within	  1	  hour,	  good	  neurological	  recovery	  can	  be	  expected.	  Although	  
re-­‐exploration	   will	   not	   benefit	   patients	   with	   MCA	   mainstem	   or	   branch	   embolism	   or	  
haemodynamic	  stroke	  (other	  than	  being	  able	  to	  remove	  a	  source	  of	  embolisation),	  this	  cannot	  
be	   avoided.	   For	   those	  with	   access	   to	   TCD,	   decision-­‐making	   is	   easier	   as	   ICA	   occlusion	  will	   be	  
associated	   with	   MCA	   velocities	   identical	   to	   those	   seen	   during	   carotid	   clamping170.	   DUS	   can	  
assist	   in	   confirming	   whether	   there	   is	   flow	   within	   the	   endarterectomy	   zone,	   but	   air	   in	   the	  
subcutaneous	   tissues	   often	   makes	   it	   difficult	   to	   interpret	   the	   findings	   in	   the	   early	   post-­‐
operative	   period.	   At	   re-­‐exploration,	   the	   artery	   should	   be	   opened	   carefully	   and	   thrombus	  
removed.	  If	  thrombus	  extends	  distally,	  this	  may	  be	  retrieved	  by	  careful	  retraction.	  If	  a	  Fogarty	  
catheter	   is	  utilised,	   care	  must	  be	   taken	   to	  avoid	  distal	   trauma.	  Following	   thrombectomy,	  any	  
technical	  errors	   should	  be	  corrected	  and	  a	  completion	  angiogram	  performed	   to	  ensure	  distal	  
patency.	   Several	   small	   series	  have	   suggested	   that	  patients	   suffering	  embolic	  occlusion	  of	   the	  
ipsilateral	   anterior	   or	  MCA	   arteries	   during	   (or	   immediately	   after)	   CEA	   can	   be	   treated	   by	   re-­‐
exploration	  (to	  remove	  any	  residual	  thrombus	  within	  the	  endarterectomy	  zone)	  followed	  by	  an	  
intra-­‐operative	  intra-­‐arterial	  infusion	  of	  500,000331,32	  or	  1	  million	  units	  of	  urokinase333,	  without	  
incurring	   significant	   bleeding	   complications	   (section	   2.6.1.2.1).	   Urgent	   mechanical	  
thrombectomy	  should	  also	  now	  be	  considered	   in	  patients	  with	  embolic	  occlusion	  of	   the	  MCA	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mainstem,	   especially	   as	   some	  CEA	   patients	  may	   not	   be	   eligible	   for	   intravenous	   thrombolysis	  
(section	  2.6.1.2.1).	  	  
	  
It	   would	   clearly	   be	   preferable	   to	   prevent	   intra-­‐operative	   stroke.	   Whilst	   no	   RCTs	   have	   been	  
undertaken,	   targeted	   monitoring	   (TCD,	   EEG)	   and	   quality	   control	   assessment	   (completion	  
angioscopy,	   DUS,	   angiography)	   have	   been	   associated	   with	   significant	   reductions	   in	   intra-­‐
operative	   embolisation,	   identification	   of	   luminal	   thrombus	   prior	   to	   restoration	   of	   flow	   and	   a	  
decline	  in	  intra-­‐operative	  stroke	  rates170,295,327.	  
	  
2.6.1.1.2	  	  Post-­‐operative	  stroke	  
This	   is	   defined	   as	   any	   new	   focal	   neurological	   deficit	   (or	   worsening	   of	   a	   pre-­‐existing	   deficit),	  
following	   full	   recovery	   from	  anaesthesia	   and	  whose	   symptoms	   last	  more	   than	  24	  hours.	   The	  
aetiology	  varies	  with	  the	  time	  interval	  from	  surgery.	  In	  the	  first	  6	  hours,	  the	  most	  likely	  cause	  is	  
ICA	   thrombosis	   or	   embolism	   from	  mural	   thrombus	   in	   the	   endarterectomy	   zone.	   After	   12-­‐18	  
hours	   have	   elapsed,	   stroke	   due	   to	   the	   hyperperfusion	   syndrome	   (HS)	   or	   ICH	   become	   more	  
likely170.	   Accordingly,	   if	   a	   neurological	   deficit	   becomes	   apparent	   in	   the	   first	   6	   post-­‐operative	  
hours,	  thromboembolic	  stroke	  should	  be	  assumed	  and	  the	  patient	  should	  return	   immediately	  
to	   theatre	   for	   re-­‐exploration,	   the	   rationale	   and	   management	   being	   the	   same	   as	   for	   intra-­‐
operative	  stroke327.	  A	  number	  of	  studies	  have	  shown	  that	   it	  may	  be	  possible	  to	  prevent	  early	  
post-­‐operative	   thromboembolic	   stroke	   by	   starting	   DAPT	   pre-­‐operatively	   (aspirin	   75mg,	  
clopidogrel	  75mg)128,170,327.	  
However,	  patients	  developing	  new	  neurological	  symptoms	  after	  six	  hours	  have	  elapsed	  require	  
emergency	  extracranial	  and	  intracranial	  CTA.	  This	  will	  exclude	  ICA	  thrombus	  (which	  should	  be	  
removed	   at	   re-­‐exploration)	   or	   (more	   likely),	   intracerebral	   oedema,	   ICH	   or	   parenchymal	  
haemorrhage.	   ICH	  may	   require	   craniotomy	   in	   selected	   cases,	   but	   the	  majority	   are	  managed	  
conservatively.	  Hyperperfusion	  syndrome	  stroke	  complicates	  about	  1%	  of	  CEAs	  and	   is	  usually	  
associated	  with	   post-­‐CEA	   hypertension,	   headache,	   atypical	  migrainous	   phenomena	   and	   focal	  
onset	  seizures334.	  The	  neurological	  deficit	  with	  HS	  can	  either	  be	  due	  to	  breakthrough	  oedema	  
or	  haemorrhage,	  or	   it	  can	  be	  ischaemic,	  possibly	  due	  to	  activation	  of	  the	  coagulation	  cascade	  
and	   inhibition	   of	   endothelial	   fibrinolysis335.	   HS	   is	   often	   associated	   with	   the	   development	   of	  
patchy	  white	  matter	   vasogenic	   oedema	   on	   CT/MRI.	   This	   is	   sometimes	  mistaken	   for	   evolving	  
ischaemia	   on	   CT,	   but	   DWI-­‐MRI	   will	   show	   that	   the	   oedema	   is	   vasogenic	   (as	   opposed	   to	  
cytotoxic),	  while	  MRI	   perfusion	   imaging	  will	   show	  normal	   perfusion	  within	   the	   area	  of	  white	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matter	   oedema336.	   For	   some	   reason,	   the	   patchy	   white	   matter	   vasogenic	   oedema	   may	   also	  
affect	   the	  vertebrobasilar	   territory.	  Patients	  exhibiting	  symptoms	  suspicious	  of	  HS	  will	  usually	  
have	   elevated	   BP	   and	   this	   should	   be	   actively	   treated	   (section	   2.6.1.3.3).	   Seizures	   should	   be	  
controlled	  with	   intravenous	   titrated	   doses	   of	   lorazepam	   and	   appropriate	   anti-­‐epileptic	   drugs	  




2.6.1.1.3	  	  Predictors	  of	  stroke	  after	  carotid	  endarterectomy	  
ECST	   reported	   various	   features	   that	  were	   associated	  with	   an	   increased	   risk	   of	   peri-­‐operative	  
stroke	   including	   (i)	   female	   gender	   (10.4%	   vs	   5.8%,	   p=0.0001);	   (ii)	   peripheral	   vascular	   disease	  
(12.0%	  vs	  6.1%,	  p=0.0001);	  (iii)	  systolic	  BP	  (<120mmHg	  =	  3.4%;	  121-­‐159	  =	  6.5%;	  160-­‐180	  =	  7.7%;	  
>180mmHg	   =	   13.0%,	   p=	   0.04)	   and	   (iv)	   the	   type	   of	   presenting	   cerebrovascular	   event	   (retinal	  
(3.2%),	  hemispheric	  stroke	  (6.3%),	  hemispheric	  TIA	  (9.1%)	  p=	  0.006)169.	  
	  
NASCET	  also	  reported	  clinical/imaging	  features	  associated	  with	  a	  significant	   increase	  in	  stroke	  
after	  CEA	  including	  (i)	  hemispheric	  versus	  retinal	  events	  (6.3%	  vs	  2.7%;	  OR	  2.3	  (95%CI	  1.1-­‐5.0));	  
(ii)	  left	  vs	  right	  CEA	  (6.7%	  vs	  3.0%;	  OR	  2.3	  (95%CI	  1.4-­‐3.6)));	  (iii)	  contralateral	  occlusion	  (9.4%	  vs	  
4.4%;	  OR	  2.2	  (95%CI	  1.1-­‐4.5));	  (iv)	  ipsilateral	  CT/MR	  infarct	  	  (6.3%	  vs	  3.5%;	  OR	  1.8	  (95%CI	  1.2-­‐
2.8))	  and	  (v)	  irregular	  as	  opposed	  to	  smooth	  plaque	  (5.5%	  vs	  3.7%;	  OR	  1.5	  (95%CI	  1.1-­‐2.3))337.	  A	  
meta-­‐analysis	   of	   170	   studies	   (>70,000	   patients)	   observed	   that	   contralateral	   occlusion	   was	  





2.6.1.2	  	  Stroke	  after	  carotid	  artery	  stenting	   	  
Although	  CPDs	  are	  frequently	  used,	   intra-­‐procedural	  distal	  embolisation	  can	  still	  occur	  due	  to	  
incomplete	  deployment	  and/or	  malpositioning	  of	  the	  filter,	  or	  because	  of	  incomplete	  aspiration	  
of	  debris	  when	  using	  balloon	  protection	  devices.	  In	  a	  limited	  number	  of	  cases,	  CPDs	  cannot	  be	  
used	  because	  of	  technical	  reasons	  or	  patient	  intolerance.	  	  
	  
2.6.1.2.1	  	  Mechanical	  thrombectomy	  and	  intra-­‐arterial	  thrombolysis	  
Techniques	   for	   treating	   patients	   who	   develop	   a	   new	   neurological	   deficit	   during	   CAS	   include	  
mechanical	   thrombectomy	   and/or	   intra-­‐arterial	   thrombolysis.	   Safe	   mechanical	   removal	   of	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embolic	  material	  from	  the	  main	  branches	  of	  the	  ICA	  (out	  to	  the	  distal	  M2-­‐segment)	  is	  possible	  
using	  dedicated	  neuro-­‐interventional	  retrieval	  devices339.	  With	  the	  recently	  published	  positive	  
results	  of	  various	  RCTs	  evaluating	  mechanical	  thrombectomy	  in	  acute	  ischaemic	  stroke249,	  most	  
interventionists	   now	   advocate	   the	   use	   of	   stent-­‐retrievers	   or	   thrombus	   aspiration	   in	   patients	  
who	   experience	   an	   acute,	   new	   stroke	   during	   CAS	   secondary	   to	   acute	   ICA,	  M1	  or	  M2	  branch	  
occlusion	  (section	  2.3.5.3).	  	  
	  
Thrombolysis	   in	   the	   setting	   of	   acute	   distal	   ICA	   occlusion	   due	   to	   embolisation	   during	   CAS	   is	  
rarely	  beneficial,	  because	  the	  embolus	  usually	  comprises	  plaque,	  rather	  than	  fibrin	  clot.	  In	  the	  
event	   of	   acute	   stent	   thrombosis,	   thrombolysis	   should	   be	   considered.	   Thrombolytic	   agents	  
currently	  in	  use	  include	  urokinase	  and	  recombinant	  Tissue	  Plasminogen	  Activator	  (rTPA),	  which	  
are	   delivered	   through	   the	   guiding	   catheter,	   diagnostic	   catheter	   or	   a	   super-­‐selectively	   placed	  
microcatheter	   (ensuring	   that	   the	   catheter	   is	   positioned	   within	   the	   thrombus).	   High-­‐dose	  
urokinase	   regimens	   are	   generally	   administered	   (500,000units	   of	   urokinase),	   with	   half	   being	  
administered	   as	   an	   initial	   bolus.	  Alternatively,	   a	   continuous	   infusion	   (without	  bolus)	   of	   up	   to	  
1,250,000	  units	  of	  urokinase	  over	  90	  minutes	  can	  be	  performed.	  	  
	  
rTPA	  can	  be	  given	  as	  a	  5mg	  bolus,	  followed	  by	  slow-­‐infusion	  (maximum	  dose	  20mg).	   If	  any	  of	  
the	  proximal	   thrombus	  dissolves,	   the	   tip	  of	   the	  microcatheter	  needs	   to	  be	  advanced	   into	   the	  
proximal	   portion	   of	   any	   residual	   thrombus.	   Selective	   intra-­‐arterial	   administration	   of	   5mg	  
abciximab	   followed	   by	   a	   bolus	   of	   5mg	   abciximab	   intravenously	   has	   been	   effective	   in	   the	  
treatment	  of	  neurological	  sequelae	  due	  to	  distal	  embolisation	  after	  CAS339.	   	  
	  
No	   RCTs	   have	   addressed	   the	   treatment	   of	   acute	   stroke	   due	   to	   ICA	   thrombosis,	   or	   M1/M2	  
segment	  embolic	  occlusions	  after	  CAS.	  The	  management	   should,	  however,	  be	  no	  different	   to	  
stroke	   occurring	   without	   a	   prior	   carotid	   intervention.	   Accordingly,	   eligible	   patients	   with	  
thromboembolic,	   ischaemic	   stroke	   after	   CAS	   should	   be	   considered	   for	   mechanical	  
thrombectomy	   using	   neuro-­‐interventional	   thrombectomy	   devices,	   provided	   they	   fulfil	   the	  
criteria	  for	  inclusion	  in	  those	  trials	  (section	  2.3.5.3).	  
	  
	  
2.6.1.2.2	  	  Predictors	  of	  stroke	  after	  carotid	  artery	  stenting	  
A	  Delphi	  consensus	  identified	  various	  imaging	  criteria	  that	  were	  associated	  with	  an	  increase	  in	  
difficulty	  for	  ‘novices’	  undertaking	  CAS	  including	  (i)	  type	  III	  aortic	  arch;	  (ii)	  bovine	  arch;	  (iii)	  arch	  
atheroma;	   (iv)	  diseased	  ECA;	   (v)	  markedly	  angulated	  distal	   ICA;	   (vi)	  a	   long	  stenosis	  and	   (vii)	  a	  
 88 
pinhole	  stenosis340.	   In	  CAVATAS,	   increasing	  stenosis	   length	  was	  an	   independent	  risk	  factor	  for	  
procedural	   stroke/death341.	   In	   a	   pooled	   analysis	   from	   EVA-­‐3S,	   SPACE	   and	   ICSS,	   CAS	   was	  
associated	  with	  a	  threefold	  excess	  risk	  of	  death/stroke	  (compared	  with	  CEA)	  when	  performed	  
in	  the	  first	  seven	  days	  after	  onset	  of	  symptoms	  (9.4%	  vs	  2.8%;	  OR	  3.4	  (95%	  CI:	  1.01-­‐11.8))	  after	  
adjusting	  for	  age,	  sex,	  and	  nature	  of	  qualifying	  event224.	  A	  post	  hoc	  analysis	  of	  ICSS	  data	  showed	  
that	  CAS	  patients	  who	  had	  an	  age-­‐related	  white-­‐matter	  change	  (ARWMC)	  score	  of	  >7	  on	  pre-­‐
operative	  CT/MRI	  faced	  an	  increased	  risk	  of	  peri-­‐operative	  stroke,	  compared	  to	  patients	  whose	  
ARWMC	   score	   was	   <7	   (HR	   2.76	   (95%	   CI	   1.17-­‐6.51)	   p	   =	   0.021).	   There	   was	   no	   association	  
between	   ARWMC	   scores	   and	   peri-­‐operative	   stroke	   in	   patients	   treated	   by	   CEA	   (HR	   1.18,	   0.4-­‐
3.55)	  p	  =	  0.76)342.	   CAS	  was	  associated	  with	  a	   significantly	  higher	   risk	  of	  peri-­‐operative	   stroke	  
(compared	  with	  CEA)	   in	  patients	  with	  an	  ARWMC	  score	  of	  >7	  or	  more	   (HR	  2.98	   (1.29	  –	  6.93)	  
p=0.011),	  but	  there	  was	  no	  difference	  in	  risk	  between	  CEA	  and	  CAS	  in	  patients	  whose	  ARWMC	  
score	   was	   <7342.	   More	   recently,	   CREST	   has	   reported	   that	   peri-­‐operative	   stroke	   rates	   were	  
significantly	  higher	  after	  CAS	  in	  patients	  whose	  lesion	  length	  was	  >13mm	  and	  sequential	  lesions	  




2.6.1.3	  	  Post-­‐intervention	  haemodynamic	  instability	  
2.6.1.3.1	  	  Post-­‐stenting	  hypotension	  
In	   a	   meta-­‐analysis	   of	   27	   studies	   (n=4204),	   12%	   (95%CI	   7-­‐18)	   required	   treatment	   for	   peri-­‐
procedural	   hypotension,	   12%	   (95%CI	   7-­‐19)	   required	   treatment	   for	   bradycardia,	   while	   13%	  
(95%CI	   8-­‐17)	   were	   treated	   for	   both	   hypotension	   and	   bradycardia.	   Persistent	   haemodynamic	  
instability	  (>1	  hour	  vasopressor	  support)	  affected	  19%	  (95%CI	  13-­‐27)	  of	  CAS	  patients344.	  There	  
was	  a	  statistically	  significant	  association	  between	  increasing	  age	  and	  haemodynamic	  instability.	  
Lesions	   <10mm	   of	   the	   carotid	   bifurcation	   and	   the	   site	   of	   minimum	   lumen	   diameter	   were	  
associated	   with	   bradycardia	   and	   there	   was	   a	   statistically	   significant	   association	   between	   a	  
history	  of	  ipsilateral	  CEA	  and	  persistent	  haemodynamic	  instability	  after	  CAS344.	  Haemodynamic	  
instability	  after	  CAS	  usually	  resolves	  and	   its	  clinical	  significance	  seems	  relatively	  minor.	  Meta-­‐
analyses	   have	   not	   shown	   any	   statistically	   significant	   differences	   between	   patients	   with	   or	  
without	  haemodynamic	  instability	  after	  CAS	  in	  terms	  of	  peri-­‐operative	  death	  (OR	  2.99	  (95%	  CI	  
0.34-­‐26.06));	  stroke	  (OR	  1.0	  (95%	  CI	  0.57-­‐1.75));	  stroke/death	  (OR	  1.51	  (95%	  CI	  0.98-­‐2.33));	  TIA	  
(OR	  0.86	  (95%	  CI	  0.47-­‐1.61)),	  or	  any	  major	  adverse	  event	  rate	  (OR	  1.31	  (95%	  CI	  0.73-­‐2.34))344.	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Measures	  for	  preventing	  haemodynamic	  instability	  include	  adequate	  hydration	  and	  withholding	  
antihypertensive	  medications	  on	  the	  morning	  of	  CAS.	  Continuous	  ECG	  monitoring,	  invasive	  BP	  
monitoring	  and	  venous	  access	  are	  mandatory.	  Glycopyrrolate	  (a	  synthetic	  atropine	  derivative)	  
was	   compared	  with	   atropine	   in	   a	   retrospective	   study	   (115	  CAS	  procedures)	   and	   found	   to	   be	  
more	  effective	  in	  preventing	  postoperative	  bradycardia	  and	  hypotension	  (30%	  vs	  72%,	  p=0.002	  
and	  2.5%	  vs	  36%,	  p=0.001)	   respectively.	   In	  addition,	   there	  were	   lower	   rates	  of	  postoperative	  
hypertension	  (2.5%	  vs	  16%,	  p=0.047).	  However,	  glycopyrrolate	  conferred	  no	  benefit	  regarding	  
peri-­‐procedural	   tachycardia,	   BP	   changes,	   vasopressor	   use	   or	   cardiac	   complications.	   No	  
significant	  differences	  in	  procedural	  neurologic	  and	  access	  site	  complications	  were	  observed345.	  	  
	  
The	   treatment	  of	  post-­‐CAS	  hypotension	   requires	  administration	  of	   iv	   crystalloids	  plus	  volume	  
expanders.	   This	   strategy	  may,	   however,	   be	   inadequate	   due	   to	   decreased	   peripheral	   vascular	  
resistance	  (secondary	  to	   loss	  of	  sympathetic	  tone)	  and	  not	  underlying	  hypovolaemia.	  Titrated	  
intravenous	   vasopressors	   (dobutamine,	   dopamine,	   norepinephrine,	   phenylephrine)	   may	   be	  
necessary	   to	  maintain	  systolic	  BP	  >90mmHg.	  The	   influence	  of	  vasopressor	   type	   (on	  outcome)	  
was	  evaluated	   in	   a	   retrospective	   study	   involving	  42	  patients	   requiring	   vasopressor	   treatment	  
after	  CAS346.	  The	  mean	  vasopressor	   infusion	  time	  was	  32	  hours	  for	  dopamine,	  compared	  with	  
24	   hours	   for	   norepinephrine	   (p=0.052)	   and	   22	   hours	   (p=0.028)	   for	   phenylephrine.	   The	  mean	  
length	  of	  stay	  in	  the	  coronary	  care	  unit	  was	  47	  hours	  for	  dopamine,	  compared	  with	  37	  hours	  for	  
the	   norepinephrine/phenylephrine	   groups	   combined	   (p=0.056).	   Major	   adverse	   events,	  
including	   MI,	   arrhythmias	   and	   cardioversion	   were	   significantly	   more	   common	   in	   patients	  
receiving	   dopamine,	   than	   in	   patients	   receiving	   norepinephrine	   or	   phenylephrine	   (p=0.04).	  
Midodrine	  (a	  selective	  α-­‐1	  agonist)	  that	  causes	  arteriolar	  and	  venous	  vasoconstriction	  without	  
stimulating	   cardiac	  β-­‐adrenergic	   receptors	   is	  well	   tolerated	  and	   is	   as	  effective	  as	   intravenous	  
dopamine	  in	  the	  treatment	  of	  hypotension	  after	  CAS347.	  	  
	  
2.6.1.3.2	  	  Post-­‐endarterectomy	  hypotension	  
Post-­‐CEA	  hypotension	   has	   been	   attributed	   to	   exposure	   of	   carotid	   sinus	   baroreceptors	   to	   the	  
pulse	  pressure,	  without	  the	  dampening	  effect	  of	  the	  excised	  plaque348.	  The	  clinical	  relevance	  of	  
post-­‐CEA	  hypotension	   is	   variable,	  with	   some	   reporting	   that	   it	   increases	   peri-­‐operative	   stroke	  
and	  MI349,	   whereas	   others	   believe	   it	   to	   be	   a	   benign	   phenomenon348.	   There	   is	   no	   consensus	  
regarding	   what	   BP	   threshold	   should	   be	   used	   for	   treatment.	   The	   management	   of	   post-­‐CEA	  




Recommendation	  65	   Class	   Level	   References	  
First-­‐line	   treatment	  of	  post-­‐carotid	   intervention	  hypotension	  
should	   be	   the	   administration	   of	   intravenous	   crystalloids	  
together	   with	   volume	   expanders.	   If	   this	   fails	   to	   improve	  	  
blood	   pressure,	   titrated	   intravenous	   vasopressors	  
(dobutamine,	   dopamine,	   noradrenaline,	   phenylephrine)	  
should	   be	   considered	   to	   maintain	   systolic	   blood	   pressure	  
>90mmHg.	  	  
IIa	   C	   346	  
	  
2.6.1.3.3	  	  Post-­‐endarterectomy	  hypertension	  
Postoperative	  hypertension	  affects	  up	  to	  two	  thirds	  of	  patients	  undergoing	  CEA,	  depending	  on	  
the	   definition	   used299.	   Several	   theories	   have	   been	   proposed,	   including	   denervation	   of	   the	  
carotid	   bulb	   and	   increased	   cerebral	   norepinephrine	   and/or	   renin	   production	   by	   the	   central	  
nervous	   system350-352.	   Post-­‐CEA	   hypertension	   is	   associated	   with	   preoperative	  
hypertension299,353,	  GA263	  and	  eCEA290	  .	  The	  association	  between	  GA	  and	  post-­‐CEA	  hypertension	  
is	   attributed	   to	   increased	   neuroendocrine	   stress	   hormone	   levels.	   The	   association	   between	  
eversion	  CEA	  and	  post-­‐CEA	  hypertension	   is	   attributed	   to	  denervation	  of	   the	   carotid	  bulb,	   via	  
circumferential	  transection	  at	  the	  origin	  of	  the	  ICA354.	  About	  65%	  of	  patients	  submitted	  to	  eCEA	  
will	  require	  vasodilators	  postoperatively,	  compared	  with	  40%	  of	  patients	  submitted	  to	  cCEA290.	  
In	   a	   recent	   prospective	   study	   involving	   100	   CEA	   patients,	   Newman	   observed	   that	   poorly	  
controlled	   pre-­‐operative	   BP	   and	   impaired	   baroreceptor	   function	   (but	   not	   impaired	  
autoregulation)	   were	   associated	   with	   a	   significantly	   higher	   prevalence	   of	   post-­‐CEA	  
hypertension299.	   Intra-­‐operative	   variables	   that	  predicted	  a	   significantly	   increased	   risk	  of	  post-­‐
CEA	  hypertension	  included	  poorly	  controlled	  or	  labile	  hypertension	  at	  induction	  of	  anaesthesia.	  
No	  other	  variable	  (including	  the	  magnitude	  of	  MCA	  velocity	  increase	  with	  flow	  restoration)	  was	  
predictive	  of	  post-­‐CEA	  hypertension355.	  
	  
Poorly	  treated	  post-­‐CEA	  hypertension	  has	  been	  associated	  with	  post-­‐operative	  TIA/stroke353,356	  
and	  is	  a	  risk	  factor	  for	  neck	  haematoma	  formation,	  HS	  and	  ICH170,334,357.	  There	  are	  a	  variety	  of	  
strategies	   for	   treating	   post-­‐CEA	   hypertension170,358,	   but	   the	   need	   for	   intravenous	  
antihypertensive	   therapy	   becomes	   less	   common	   once	   the	   patients	   resume	   their	   normal	  
antihypertensive	  medications.	  Vascular	  Units	   should	  have	  written	   guidance	   for	   treating	  post-­‐
CEA	  hypertension	  in	  order	  that	  treatment	  decisions	  are	  not	  delayed.	  
	  
	  
2.6.1.3.4	  	  Post-­‐stenting	  hypertension	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As	  with	   CEA,	  most	   patients	  with	   post-­‐CAS	   hypertension	  were	   treated	  with	   anti-­‐hypertensive	  
drugs	  prior	  to	  the	  procedure.	  Symptomatic	  post-­‐CAS	  hypertension	  (HS,	  ICH)	  is	  reported	  in	  up	  to	  
3%	  of	  patients359.	  The	  management	  is	  the	  same	  as	  for	  CEA.	  
	  
Recommendation	  66	   Class	   Level	   References	  
It	   is	   recommended	   that	   intra-­‐arterial	   blood	   pressure	  
monitoring	  be	   continued	   for	   the	   first	   3-­‐6	  hours	   after	   carotid	  
endarterectomy,	   followed	   by	   hourly	   noninvasive	   blood	  
pressure	  monitoring	  for	  the	  first	  24	  hours.	  	  
I	   C	   	  
	  
Recommendation	  67	   Class	   Level	   References	  
It	  is	  recommended	  that	  vascular	  units	  have	  written	  criteria	  for	  
treating	  post-­‐	  carotid	  intervention	  hypertension.	  	  
I	   C	   170	  
	  
	  
2.6.1.4	  	  Wound	  haematoma	  after	  carotid	  endarterectomy	  
The	   Vascular	   Surgery	   Group	   of	   New	   England	   (VSGNE)	   reported	   that	   re-­‐exploration	   for	   neck	  
haematoma	  was	  required	  in	  1.2%	  of	  CEA	  patients	  on	  aspirin,	  0.7%	  on	  clopidogrel	  and	  1.4%	  in	  
patients	   taking	   aspirin	   and	   clopidogrel360.	   ICSS	   reported	   that	   the	   prevalence	   of	   haematoma	  
requiring	  re-­‐exploration	  was	  3.4%361.	  There	  is	  no	  evidence	  that	  aspirin	  and	  clopidogrel	  therapy	  
significantly	   increases	   the	   risk	   of	   haematoma132,360,362.	   The	   role	   of	   protamine	   reversal	   in	  
reducing	  re-­‐exploration	  for	  neck	  haematoma	  formation	  after	  CEA	  has	  been	  discussed	  in	  section	  
2.4.1.8.	   Small	   calibre	   suction	   drains	   do	   not	   appear	   to	   reduce	   the	   prevalence	   of	   haematoma,	  
while	  larger	  calibre	  drains	  may	  help298	  (section	  2.4.1.15).	  Most	  haematomas	  occur	  in	  the	  first	  6	  
hours	  after	  CEA,	  often	  after	  a	  period	  of	  untreated	  hypertension357.	  Any	  evidence	  of	  stridor	  or	  
tracheal	  deviation	  mandates	  immediate	  evacuation.	  
	  
Recommendation	  68	   Class	   Level	   References	  
It	   is	   recommended	   that	   any	   patient	   who	   develops	   a	   post-­‐
operative	   neck	   haematoma	   in	   association	   with	   stridor	   or	  
tracheal	  deviation	  must	  be	  re-­‐explored	  immediately.	  	  
	  
I	   C	   	  
	  
	  
2.6.1.5.	  Cranial	  nerve	  injury	  
In	  a	  meta-­‐analysis	  of	  16,749	  CEA	  patients	   from	  four	  RCTs,	  8	  prospective	  and	  14	  retrospective	  
studies,	   the	   prevalence	   of	   CNI	   was	   4.2%	   for	   the	   recurrent	   laryngeal	   nerve,	   3.8%	   for	   the	  
hypoglossal	   nerve,	   1.6%	   for	   the	   mandibular	   branch	   of	   the	   facial	   nerve,	   0.2%	   for	   the	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glossopharyngeal	   nerve	   and	   0.2%	   for	   the	   spinal	   accessory	   nerve363.	   Significant	   predictors	   for	  
CNI	   were	   urgent	   procedures	   and	   re-­‐exploration	   for	   bleeding/neurological	   deficit.	   The	   meta-­‐
analysis	   observed	   that	   the	   prevalence	   of	   CNI	   had	   diminished	   significantly	   over	   the	   last	   30	  
year363.	  
In	   ICSS,	   the	   incidence	   of	   CNI	  was	   5.5%	   in	   821	   CEA	   patients361.	   However,	   only	   11	   (1.3%)	   had	  
symptoms	   at	   30	   days	   and	   the	   CNI	   was	   disabling	   in	   only	   one	   patient	   (0.12%)	   at	   6	   months	  
(modified	   Rankin	   Score	   >3).	   In	   CREST,	   the	   prevalence	   of	   CNI	  was	   4.3%	   in	   1151	   patients,	   the	  
commonest	  injuries	  being	  glossopharyngeal/vagus	  (41%),	  mandibular	  branch	  of	  the	  facial	  nerve	  
(30%)	  and	  hypoglossal	  (25%).	  Horner’s	  syndrome	  complicated	  4%	  of	  CEAs.	  In	  CREST,	  one	  third	  
of	  CNIs	   resolved	  within	  30	  days,	  with	  81%	  resolved	  by	  1	  year.	   In	   terms	  of	  HRQoL	  analyses	   in	  
CREST,	  CNI	  had	  an	   impact	  on	  eating	  and	  swallowing	  at	  2-­‐4	  weeks,	  but	  not	   thereafter364.	   This	  
would	   suggest	   that	   while	   CNI	   is	   more	   common	   after	   CEA	   and	   is	   responsible	   for	  
eating/swallowing	  problems	  in	  the	  first	  2-­‐4	  weeks,	  few	  are	  disabling	  in	  the	  long	  term.	  
CNIs	  can	  be	  avoided	  by	  good	  anatomical	  knowledge,	  by	  dissecting	  close	  to	  the	  arterial	  wall	  and	  
by	   careful	   use	   of	   forceps,	   retractors,	   cautery	   and	   clamps.	   A	   useful	   manoeuver	   to	   minimise	  
injury	  to	  the	  hypoglossal	  nerve	  is	  division	  of	  the	  sternocleidomastoid	  artery,	  which	  tethers	  the	  
nerve.	  The	  hypoglossal	  nerve	  can	  then	  be	   indirectly	  retracted	  by	  applying	  a	  tie	  to	  the	  divided	  
ansa	   cervicalis.	   Injuries	   to	   the	   mandibular	   branch	   of	   the	   facial	   nerve	   can	   be	   minimised	   by	  
avoiding	  jaw	  retraction	  and	  by	  curving	  the	  skin	  incision	  posteriorly	  toward	  the	  mastoid	  process.	  
In	  a	  RCT	  involving	  1,126	  CEA	  patients,	  perioperative	  administration	  of	  dexamethasone	  reduced	  




2.6.1.6	  	  New	  post-­‐operative	  cerebral	  ischaemic	  lesions	  
ICSS	  undertook	  a	  substudy	  where	  CEA	  and	  CAS	  patients	  underwent	  DWI-­‐MRI	  1–7	  days	  before	  
treatment,	   followed	  by	  a	   second	  scan	  1–3	  days	  after	   treatment	  and	  a	   third	  27–33	  days	  after	  
treatment366,	   each	   analysed	   by	   blinded	   investigators.	   Sixty-­‐two	   of	   124	   patients	   (50%)	  
undergoing	  CAS	  and	  18/107	  CEA	  patients	   (17%)	  had	  at	   least	  one	  new	  DWI	   lesion	  on	   the	   first	  
post-­‐treatment	  scan	  (OR	  5·∙21	  (95%CI	  2·∙78–9·∙79),	  p<0·∙0001).	  When	  the	  scans	  were	  repeated	  at	  
1	   month,	   there	   were	   persisting	   changes	   on	   fluid-­‐attenuated	   inversion	   recovery	   (FLAIR)	   MR	  
sequences	  in	  28/86	  CAS	  patients	  (33%),	  compared	  with	  6/75	  CEA	  patients	  (8%)	  (OR	  5.93	  (95%	  
CI	   2.25–15.62),	   p=0.0003)366.	   In	   a	  meta-­‐analysis	   of	   two	  RCTs	   and	   18	   non-­‐randomized	   studies	  
(CAS=989;	  CEA=1115),	  the	  incidence	  of	  new	  DWI-­‐MRI	  cerebral	  lesions	  was	  significantly	  greater	  
after	  CAS	  than	  CEA	  (40%	  vs	  12%;	  OR	  5.17	  (95%	  CI	  3.31-­‐8.06),	  p<0.00001)365.	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The	   clinical	   relevance	   of	   new	   DWI-­‐MRI	   lesions	   is	   unknown.	   There	   is	   no	   evidence	   that	   these	  
lesions	  predispose	  towards	  cognitive	  impairment,	  but	  this	  would	  require	  long-­‐term	  studies	  and	  
large	  numbers	  of	  patients.	  ICSS	  published	  follow-­‐up	  data	  in	  the	  cohort	  who	  underwent	  pre-­‐	  and	  
post-­‐operative	  MRI	  imaging368.	  The	  5-­‐year	  incidence	  of	  recurrent	  stroke/TIA	  was	  22.8%	  in	  CAS	  
patients	   with	   new	   DWI	   lesions,	   compared	   with	   8.8%	   in	   CAS	   patients	   with	   no	   new	   DWI-­‐MRI	  
lesions	  (HR	  2.85	  (95%	  CI	  1.05-­‐7.72),	  p=	  0.04).	  ICSS	  concluded	  that	  new	  ischaemic	  brain	  lesions	  
after	  CAS	  may	  be	  a	  marker	  for	  an	   increased	  risk	  of	  recurrent	  cerebrovascular	  events	  and	  that	  
DWI	  positive	  patients	  might	  benefit	  from	  more	  aggressive	  and	  prolonged	  DAPT368.	  	  
	  
	  
2.6.2	  	  Late	  Complications	  After	  Carotid	  Interventions	  
2.6.2.1	  	  Prosthetic	  patch	  infection	  
In	  a	  review	  of	  30	  published	  case	  series	  (130	  patients),	  patch	  infection	  complicated	  0.4-­‐1.8%	  of	  
CEAs369.	   One-­‐third	   presented	   within	   two	   months	   of	   the	   original	   procedure	   (usually	   with	   a	  
preceding	   wound	   complication),	   while	   two	   thirds	   presented	   after	   6-­‐months	   had	   elapsed,	  
usually	   with	   a	   chronic	   sinus	   or	   pseudoaneurysm	   formation.	   Patch	   rupture	   or	   anastomotic	  
dehiscence	   was	   relatively	   rare	   and	   mostly	   involved	   infections	   occurring	   within	   the	   first	   two	  
months367.	   Staphylococci	   and	  Streptococci	  were	   the	  underlying	   infective	  organisms	   in	  90%	  of	  
cases.	   Because	   an	   increasing	   proportion	   of	   coagulase	   negative	   staphylococci	   are	   resistant	   to	  
Flucloxacillin,	   it	   is	   reasonable	   to	   start	   patients	   on	   intravenous	   vancomycin	   (or	   Teicoplanin)	  
whilst	  awaiting	  definitive	  cultures.	  	  
DUS	   is	   the	   first-­‐line	   investigation	   and	   can	   reveal	   patch	   corrugation	   (which	  may	   precede	   the	  
diagnosis	   of	   overt	   infection	   by	   11	   months370),	   the	   presence	   of	   deep	   collections	   and/or	  
pseudoaneurysm	  formation.	  DUS	  should,	  however,	  be	  supplemented	  by	  CTA	  in	  patients	  being	  
considered	   for	   open	   exploration	   or	   insertion	   of	   a	   covered	   stent.	   Patch	   excision	   and	   arterial	  
reconstruction	   with	   autologous	   vein	   (patch/bypass)	   is	   the	   ‘gold-­‐standard’	   treatment.	   Patch	  
excision	  and	  reconstruction	  with	  prosthetic	  material	  should	  be	  avoided	  because	  of	  high	  rates	  of	  
reinfection367.	   There	   have	   been	   limited	   reports	   (n=5)	   of	   using	   covered	   stents	   to	   treat	   patch	  
infection	  (good	  initial	  results),	  but	  no	  long-­‐term	  data	  are	  available369.	  	  
	  
	  
Recommendation	  69	   Class	   Level	   References	  
Patch	   excision	   and	   autologous	   venous	   reconstruction	   is	  
recommended	   for	   most	   patients	   with	   prosthetic	   patch	  
infection.	  
I	   C	   369,371	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Recommendation	  70	   Class	   Level	   References	  
Insertion	  of	  a	   covered	  stent	  may	  be	  considered	   in	   selected	  
‘high-­‐risk	   for	   surgery’	   patients	   with	   suspected	   prosthetic	  
patch	  infection	  
IIb	   C	   369	  
	  
	  
Recommendation	  71	   Class	   Level	   References	  
Patch	   excision	   and	   prosthetic	   reconstruction	   is	   not	  
recommended	  for	  patients	  with	  patch	  infection	  after	  carotid	  
endarterectomy.	  




2.6.2.2	  	  Restenosis	  after	  carotid	  interventions	  
2.6.2.2.1	  	  Pathophysiology	  	  
‘Recurrent’	   lesions	  within	   4-­‐6	  weeks	  of	   CEA	   represent	   residual	   atherosclerotic	   lesions,	   rather	  
than	   restenoses.	   Restenosis	   usually	   begins	   3-­‐6	   months	   postoperatively,	   secondary	   to	  
neointimal	  hyperplasia.	  Restenoses	  developing	  after	  24	  months	  most	  likely	  represent	  recurrent	  
atherosclerosis.	   Factors	   associated	   with	   restenosis	   include;	   smoking,	   hypertension,	   female	  
gender,	  diabetes,	  small	  carotid	  diameter,	  residual	  stenoses	  and	  primary	  closure	  after	  CEA73,99.	  
	  
2.6.2.2.2	  	  Surveillance	  after	  endarterectomy	  and	  stenting	  
DUS	  criteria	  for	  diagnosing	  restenoses	  after	  CEA	  and	  CAS	  are	  different	  to	  imaging	  an	  untreated	  
carotid	  artery	  (section	  2.1.5).	  Following	  CEA,	   it	  has	  been	  proposed	  that	  the	  PSV	  threshold	  for	  
diagnosing	   a	   >50%	   restenosis	   should	   be	   213cm/sec	   and	   274cm/sec	   for	   diagnosing	   a	   >70%	  
restenosis372.	  DUS	  criteria	  for	  diagnosing	  ‘instent	  restenosis’	  after	  CAS	  are	  summarised	  in	  table	  
20.	  As	   can	   be	   seen,	   PSV	   threshold	   velocities	   are	  much	   higher	   than	   after	   CEA	   for	   diagnosing	  
>50%	   and	   >70%	   restenoses373,374.	   However,	   the	   need	   to	   use	   higher	   PSV	   thresholds	   for	  
diagnosing	  >50%	  ICA	  restenoses	  after	  CAS	  was	  not	  confirmed	  in	  a	  recent	  substudy	  from	  ICSS375.	  
	  








>50%	   >220cm/sec	   	   >2.5	  
>70%	   >300cm/sec	   >90	  cm/sec	   >3.8	  
Based	  on	  data	  from	  Lal	  and	  Stanziale373,374	  
	  
DUS	   surveillance	  enables	  monitoring	  of	  disease	  progression	   in	   the	   contralateral	   ICA,	  which	   is	  
more	   common	   than	   ipsilateral	   restenosis,	   with	   progression	   being	   dependent	   upon	   disease	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severity	  at	   the	  time	  of	  CEA.	  The	  data	  are,	  however,	  conflicting	  as	  to	   its	  benefit.	  Patients	  with	  
>50%	  contralateral	  stenoses	  have	  been	  reported	  to	  be	  five	  times	  more	  likely	  to	  progress	  during	  
follow-­‐up375,376.	   Ballotta	   undertook	   serial	   surveillance	   of	   contralateral	   ACS	   following	   CEA	   and	  
reported	  that	  progression	  from	  a	  moderate	  (50%	  to	  69%)	  to	  a	  severe	  (70%	  to	  99%)	  stenosis	  was	  
associated	   with	   an	   increased	   risk	   of	   TIA/stroke,	   with	   >80%	   of	   events	   occurring	   in	   the	   latter	  
patient	  group378.	  No	  data,	  however,	  were	  provided	  for	  ipsilateral	  stroke	  rates	  alone.	  
	  
By	  contrast,	  in	  a	  series	  of	  151	  CEA	  patients	  who	  underwent	  serial	  post-­‐operative	  imaging	  of	  the	  
non-­‐operated	  ICA,	  cumulative	  freedom	  from	  stroke	  in	  the	  non-­‐operated	  hemisphere	  was	  99%,	  
96%	  and	  86%	  at	  1,	  5	  and	  10	  years	  respectively	  (mean	  stroke	  incidence	  =	  1%	  per	  annum).	  Only	  
one	  stroke	  in	  the	  contralateral	  hemisphere	  was	  preceded	  by	  a	  TIA	  and	  no	  stroke	  was	  associated	  
with	  a	  severe	  (>70%)	  ICA	  stenosis.	  Ten	  patients	  	  (7%)	  whose	  contralateral	  stenosis	  was	  <50%	  at	  
baseline	  progressed	  to	  a	  severe	  stenosis	  during	  follow-­‐up,	  but	  only	  three	  became	  symptomatic.	  
In	   each	   case,	   however,	   onset	   of	   symptoms	  preceded	   recognition	  of	   disease	  progression.	   The	  
study	   concluded	   that	   none	   of	   the	   observed	   strokes	   could	   have	   been	   prevented	   by	  
postoperative	  surveillance379.	  
	  
2.6.2.2.3	  	  	  Prevalence	  of	  restenosis	  	  
A	  recent	  meta-­‐analysis	  identified	  11	  RCTs	  which	  reported	  rates	  of	  restenosis	  >70%	  or	  occlusion	  
after	   CEA	   and	   CAS380.	   RCTs	   were	   used	   (rather	   than	   observational	   studies)	   because	   they	   are	  
prospective,	  they	  are	  conducted	  with	  greater	  scientific	  rigour,	  selection	  bias	  is	  reduced	  through	  
randomisation	   and	   independent	   observers	   adjudicate	   most	   endpoints378.	   The	   weighted	  
incidence	  of	  ‘restenosis	  >70%	  or	  occlusion’	  is	  detailed	  in	  table	  21.	  
	  
Table	  21.	  Meta-­‐analysis	  of	  the	  prevalence	  of	  restenosis	  >70%	  or	  occlusion	  in	  surveillance	  data	  
from	  RCTs	  involving	  CEA	  and	  CAS*	  
	  
	   no	  of	  
RCTs	  




restenosis	  >70%	  or	  
occlusion	  	  
%	  (95%CI)	  
any	  CEA	   11	   4249	   47	   5.8%	  	  
(4.1-­‐8.2)	  




6	   2916	   60	   10.3%	  	  
(6.4-­‐16.4)	  
CAS	   5	   2716	   62	   10.0%	  	  
(6.0-­‐16.3)	  
	   *	  data	  derived	  from	  Kumar	  et	  al380.	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A	   previous	   meta-­‐analysis	   reported	   that	   CAS	   was	   associated	   with	   significantly	   higher	   >70%	  
restenosis	   rates	   than	   after	   CEA	   (OR	   2.41	   (95%	   CI	   1.28-­‐4.53),	   p	   =	   0.007)195.`	   In	   CAVATAS,	  
however,	   most	   patients	   randomised	   to	   endovascular	   therapy	   were	   treated	   by	   balloon	  
angioplasty.	  When	  the	  meta-­‐analysis	  was	  confined	  to	  the	  five	  RCTs	  using	  primary	  stenting,	  the	  
difference	  in	  severe	  restenosis	  rates	  between	  CEA	  and	  CAS	  was	  not	  statistically	  significant	  (OR	  
1.97	  (95%	  CI	  0.67-­‐5.79)195.	  	  
	  
2.6.2.2.4	  	  	  Restenosis	  and	  recurrent	  ipsilateral	  symptoms	  
There	  are	  conflicting	  data	  about	  whether	  there	  is	  any	  association	  between	  restenosis	  after	  CEA	  
or	  CAS	  and	  recurrent	  ipsilateral	  symptoms.	  Table	  22	  summarises	  surveillance	  data	  from	  7	  RCTs	  
involving	   CEA	   patients	   (n=2839)	   and	   4	   RCTs	   involving	   CAS	   patients	   (n=1964).	   The	   Principle	  
Investigators	   of	   each	   RCT	  were	   asked	   to	   check	  whether	   the	   diagnosis	   of	   restenosis	   >70%	   or	  
occlusion	  was	  made	  before	  or	  after	  stroke	  onset	  and	  to	  provide	  details	  about	  the	  status	  of	  the	  
asymptomatic	  ipsilateral	  ICA	  stenosis	  on	  the	  last	  DUS	  surveillance	  scan	  immediately	  preceding	  
stroke	  onset380.	  	  
	  
Table	  22:	  meta-­‐analysis	  of	  the	  prevalence	  of	  late	  ipsilateral	  stroke	  in	  CEA/CAS	  patients	  with	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*	  	  	  data	  derived	  from	  Kumar	  et	  al380.	  
**	  all	  restenoses	  had	  been	  asymptomatic	  prior	  to	  stroke	  onset.	  
	  
There	   was	   no	   association	   between	   a	   previously	   asymptomatic	   ‘restenosis	   >70%’	   and	   late	  
ipsilateral	  stroke	  in	  CAS	  patients.	  Only	  1/125	  patients	  with	  a	  restenosis	  >70%	  after	  CAS	  (0.8%)	  
at	  50	  months	  follow-­‐up	  suffered	  a	  late	  ipsilateral	  stroke,	  compared	  with	  37/1839	  (2.0%)	  in	  CAS	  
patients	  who	  did	  not	  develop	  a	  restenosis	  >70%	  (OR	  0.87	  (95%CI	  0.24-­‐3.21),	  p=0.8339).	  Overall,	  
97%	  of	  all	  late	  ipsilateral	  strokes	  after	  CAS	  occurred	  in	  patients	  without	  a	  restenosis	  >70%380.	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By	  contrast,	  a	  severe	  asymptomatic	  restenosis	  >70%	  after	  CEA	  did	  appear	  to	  be	  associated	  with	  
a	   significantly	   higher	   risk	   of	   late	   ipsilateral	   stroke.	   Seven	   of	   135	   patients	   (5.2%)	   with	   a	  
previously	  asymptomatic	  restenosis	  >70%	  prior	  to	  stroke	  onset	  suffered	  a	  late	  ipsilateral	  stroke	  
at	   a	   median	   of	   37	   months	   follow-­‐up,	   compared	   with	   40/2704	   (1.2%)	   in	   patients	   without	   a	  
restenosis	   >70%	   (OR	   4.77	   (95%CI	   2.29-­‐9.92),	   p<0.0001380.	   However,	   85%	   of	   late	   ipsilateral	  
strokes	  after	  CEA	  occurred	  in	  patients	  without	  a	  restenosis	  >70%380.	  There	  was	  insufficient	  data	  
to	  perform	  subgroup	  analyses	  in	  patients	  undergoing	  patched	  or	  eversion	  CEA.	  
	  
2.6.2.2.5	  	  Management	  of	  restenosis	  
2.6.2.2.5.1	  Symptomatic	  restenoses	  
No	  RCTs	   have	   evaluated	  whether	   symptomatic	   restenoses	   should	  be	   treated	  medically	   or	   by	  
redo	  CEA/CAS.	   It	  has,	  however,	  become	  customary	  to	  adopt	  the	  same	  treatment	  criteria	  that	  
are	  used	  to	  select	  symptomatic	  patients	  with	  primary	  atherosclerotic	  stenoses	  (section	  2.3.3).	  
Accordingly,	   if	   a	   patient	   reports	   ipsilateral	   carotid	   territory	   symptoms	   and	   has	   a	   50-­‐99%	  
restenosis	  after	  CEA	  or	  CAS,	  they	  should	  undergo	  redo	  CEA	  or	  CAS	  within	  14	  days	  of	  symptom	  
onset.	  Supervising	  clinicians	  should	  ensure	  that	  all	  patients	  receive	  optimal	  medical	  treatment	  
(section	   2.2.1).	   Recently	   symptomatic	   patients	   with	   a	   <50%	   ipsilateral	   restenosis	   should	   be	  
treated	   medically,	   in	   much	   the	   same	   manner	   as	   if	   they	   had	   presented	   without	   having	  
undergone	   a	   previous	   CEA	   or	   CAS	   (section	   2.3.3).	   The	   choice	   of	   redo	   CEA	   or	   CAS	   should	   be	  
based	  on	  MDT	  review,	  local	  surgeon/interventionist	  experience	  and	  patient	  choice.	  In	  a	  meta-­‐
analysis	   of	   13	   studies	   (n=1132	   patients),	   there	   was	   no	   difference	   in	   30-­‐day	   death/stroke	  
between	  CAS	  (3.1%)	  and	  redo	  CEA	  (3.7%)	  when	  treating	  recently	  symptomatic	  patients	  with	  50-­‐
99%	  restenoses	  (OR	  0.8	  (95%CI	  0.3-­‐2.6))257.	  
	  
2.6.2.2.5.2	  	  Asymptomatic	  restenoses	  
This	   remains	   a	   highly	   controversial	   subject.	   No	   RCT	   has	   evaluated	   whether	   BMT	   or	   redo	  
CEA/CAS	   (+BMT)	   is	   the	   optimal	   treatment	   strategy	   for	   patients	   with	   asymptomatic	   >70%	  
restenoses	  after	  CEA	  or	  CAS.	  Despite	  an	  intuitive	  belief	  that	  most	  asymptomatic	  restenoses	  are	  
benign,	  a	   recent	  meta-­‐analysis	   reported	  that	   two	  thirds	  of	  patients	  undergoing	  treatment	   for	  
restenoses	   were	   asymptomatic257,	   ie	   many	   surgeons	   and	   interventionists	   clearly	   remain	  
uncomfortable	  about	  not	  intervening	  in	  asymptomatic	  patients	  with	  restenoses	  >70%.	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Kumar’s	  meta-­‐analysis	   suggested	   that	   patients	   developing	   an	   asymptomatic	   restenosis	   >70%	  
after	  CAS	  would	  gain	  little	  or	  no	  benefit	  from	  re-­‐intervention,	  as	  the	  risk	  of	  stroke	  is	  very	  small	  
(0.8%	  over	  4	  years)380	  (table	  22).	  However,	  the	  presence	  of	  an	  asymptomatic	  >70%	  restenosis	  
after	  CEA	  was	  associated	  with	  a	  significantly	  higher	  risk	  of	  late	  ipsilateral	  stroke,	  compared	  with	  
patients	  without	  a	   severe	   restenosis	   (table	  22).	   So,	   should	  all	  patients	  with	  an	  asymptomatic	  
restenosis	  >70%	  after	  CEA	  be	  offered	  a	  redo	  CEA	  or	  CAS?	  
	  
The	  meta-­‐analysis	  observed	  that,	  based	  on	  the	  data	  in	  table	  22,	  approximately	  6%	  of	  patients	  
undergoing	  CEA	  will	  develop	  a	  restenosis	  >70%	  (or	  occlusion)	  over	  a	  mean	  of	  47	  months.	  This	  
means	  that	  approximately	  1700	  CEA	  patients	  would	  need	  to	  undergo	  DUS	  surveillance	  in	  order	  
to	  identify	  100	  patients	  with	  an	  asymptomatic	  restenosis	  >70%.	  The	  presence	  of	  an	  untreated,	  
asymptomatic	  restenosis	  >70%	  after	  CEA	  was	  associated	  with	  a	  5%	  risk	  of	  late	  ipsilateral	  stroke	  
(table	  22).	   If	  one	  assumes	  that	  all	  undergo	  reintervention,	  a	  maximum	  of	  5	   ipsilateral	  strokes	  
will	  be	  prevented.	  However,	  95/100	  would	  ultimately	  undergo	  an	  unnecessary	  reintervention,	  
2-­‐3	   would	   suffer	   a	   peri-­‐operative	   stroke	   following	   CAS	   or	   redo	   CEA257	   and	   about	   5%	   would	  
suffer	  a	  CNI	  after	  redo	  CEA257.	  In	  effect,	  a	  policy	  of	  aggressively	  intervening	  in	  100	  patients	  with	  
an	   asymptomatic	   >70%	   restenosis	   after	   CEA	   could	   only	   ever	   prevent	   about	   2-­‐3	   ipsilateral	  
strokes	  in	  the	  long-­‐term.	  Moreover,	  despite	  serial	  surveillance	  and	  reinterventing	  in	  all	  patients	  
with	  asymptomatic	  70-­‐99%	  restenoses	  after	  CEA,	  85%	  of	  all	  late	  ipsilateral	  strokes	  destined	  to	  
happen	  would	  still	  occur	  in	  patients	  with	  no	  evidence	  of	  a	  restenosis	  >70%	  (table	  22).	  
	  
However,	  two	  subgroups	  of	  patient	  with	  asymptomatic	  restenoses	  >70%	  after	  CEA/CAS	  warrant	  
DUS	   surveillance	   and	   reintervention.	   The	   first	   would	   be	   any	   patient	   developing	   neurological	  
symptoms	   during	   carotid	   clamping	   under	   LRA,	   or	   during	   balloon	   inflation	   (proximal	   flow	  
reversal)	  during	  CAS.	  The	  second	  would	  be	  patients	  whose	  mean	  MCA	  velocities	  fell	  below	  15	  
cm/sec	  on	  TCD	  monitoring	  during	  carotid	  clamping	  under	  GA.	  A	  threshold	  of	  15cm/sec	  has	  been	  
shown	  to	  correlate	  with	  loss	  of	  cerebral	  electrical	  activity381.	  In	  both	  subgroups,	  progression	  to	  
occlusion	  may	  be	  more	  likely	  to	  be	  associated	  with	  a	  major	  haemodynamic	  stroke.	  
	  
2.6.2.2.5.3	  	  Redo	  endarterectomy	  or	  stenting?	  
If	  a	  decision	  has	  been	  made	  to	   intervene,	   there	  are	   two	  options	   including	  surgery	   (redo	  CEA,	  
bypass)	   or	   CAS,	   neither	   of	  which	   have	   been	   subjected	   to	   randomised	   comparison.	   In	   a	   2015	  
meta-­‐analysis	   of	   13	  observational	   studies,	  where	   redo	  CEA	  was	   compared	  with	  CAS256,	   there	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was	  no	  difference	   in	  30-­‐day	  stroke/death	  (2.3%	  (CAS)	  vs	  2.7%	  (redo	  CEA)	   (OR	  0.8	   (95%CI	  0.4-­‐
1.8)).	  There	  was	  also	  no	  difference	  in	  the	  prevalence	  of	  recurrent	  restenosis	  >70%	  (4%	  after	  CAS	  
vs	  7.7%	  after	  redo	  CEA).	  Redo	  CEA	  was	  associated	  with	  a	  5.5%	  risk	  of	  CNI	  (mostly	  temporary)	  
and	  a	  2.7%	   risk	  of	  bleeding	  complications.	  CAS	  was	  associated	  with	  access	   site	   complications	  






Recommendation	  72	   Class	   Level	   References	  
It	   is	   recommended	   that	   patients	   suffering	   a	   late	   ipsilateral	  
stroke/TIA	  in	  the	  presence	  of	  an	  ipsilateral	  50-­‐99%	  restenosis	  
should	   undergo	   redo	   carotid	   endarterectomy	   or	   carotid	  
artery	  stenting.	  
	  
I	   A	   172	  
Recommendation	  73	   Class	   Level	   References	  
It	   is	   recommended	   that	   patients	   suffering	   a	   late	   ipsilateral	  
stroke/transient	   ischaemic	   attack	   in	   the	   presence	   of	   an	  
ipsilateral	  <50%	  restenosis	  should	  be	  treated	  medically.	  
I	   A	   172	  
Recommendation	  74	   Class	   Level	   References	  
Reintervention	  may	  be	  considered	  in	  carotid	  endarterectomy	  
patients	  with	  an	  asymptomatic	  70-­‐99%	   restenosis,	   following	  
multidisciplinary	  team	  review.	  
IIb	   B	   380	  
Recommendation	  75	   Class	   Level	   References	  
It	   is	   recommended	   that	   carotid	   stent	   patients	  who	   develop	  
an	  asymptomatic	  restenosis	  >70%	  are	  treated	  medically.	  
I	   A	   380	  
Recommendation	  76	   Class	   Level	   References	  
Serial	   surveillance	   and	   reintervention	   for	   asymptomatic	  
restenoses	  >70%	  is	  recommended	  in	  patients	  who	  developed	  
neurological	   symptoms	   during	   carotid	   clamping	   under	   local	  
anaesthesia,	   or	   during	   balloon	   inflation	   (or	   proximal	   flow	  
reversal)	  during	  carotid	  stenting	  
I	   C	   	  
Recommendation	  77	   Class	   Level	   References	  
Serial	   surveillance	   and	   reintervention	   for	   asymptomatic	  
restenoses	  >70%	  is	  recommended	  in	  carotid	  endarterectomy	  
patients	   whose	   mean	   middle	   cerebral	   artery	   velocities	   fell	  
below	  15	   cm/sec	   on	   transcranial	  Doppler	  monitoring	   during	  








2.7	  	  Management	  of	  concurrent	  coronary	  &	  carotid	  disease	  	  
The	  presence	  of	  carotid	  stenosis/occlusion	  is	  associated	  with	  an	  increased	  risk	  of	  peri-­‐operative	  
stroke	  in	  patients	  undergoing	  coronary	  artery	  bypass	  (CABG),	  but	  whether	  carotid	  disease	  is	  a	  
risk	  factor,	  rather	  than	  an	  aetiological	  factor,	  has	  been	  the	  subject	  of	  considerable	  debate.	  
	  
2.7.1	  	  	  	  Is	  carotid	  disease	  an	  important	  cause	  of	  stroke	  during	  cardiac	  surgery?	  
The	  prevalence	  of	  stroke	  after	  CABG	  is	  1-­‐2%,	  while	  the	  prevalence	  of	  carotid	  ‘stenosis	  >50%’	  in	  
unselected	   CABG	  patients	   is	   9%.	   The	   prevalence	   of	   ‘stenosis	   >80%’	   is	   7%382.	   A	  meta-­‐analysis	  
reported	  that	  CABG	  patients	  with	  ‘50–100%’	  carotid	  stenoses	  faced	  a	  7%	  risk	  of	  perioperative	  
stroke,	  increasing	  to	  9%	  in	  patients	  with	  80-­‐100%	  stenoses383.	  High	  as	  these	  risks	  might	  seem,	  it	  
is	   important	  to	  consider	  how	  occlusion	  and	  the	  patient’s	  neurological	  status	   influences	  stroke	  
risk	  after	  CABG.	  CABG	  patients	   reporting	  a	  prior	  history	  of	  TIA/stroke	  and	   those	  with	   carotid	  
occlusion	   incur	   a	  much	  higher	   risk	  of	   post-­‐CABG	   stroke.	  D’Agostini	   observed	   that	   the	   rate	  of	  
post-­‐CABG	   stroke	   was	   18%	   in	   patients	   with	   a	   previously	   symptomatic	   unilateral	   carotid	  
stenosis,	   increasing	   to	   26%	   in	   symptomatic	   patients	   with	   bilateral	   stenoses	   who	   then	  
underwent	   isolated	   CABG384.	   A	   systematic	   review	   suggested	   that	   CABG	  patients	  with	   carotid	  
occlusion	  incurred	  an	  11%	  risk	  of	  stroke	  after	  CABG382.	  	  
After	  excluding	  patients	  with	  symptomatic	  carotid	  disease	  (who	  are	  definitely	  at	  higher	  risk	  of	  
post-­‐CABG	   stroke)	   and	   those	   with	   occlusion	   (who	   cannot	   undergo	   CEA),	   the	   risk	   of	   peri-­‐
operative	   stroke	   in	   a	   recent	   systematic	   review	   fell	   to	   <2.0%	   in	  CABG	  patients	  with	  unilateral	  
(non-­‐operated)	   asymptomatic	   50-­‐99%,	   70-­‐99%	   and	   80-­‐99%	   carotid	   stenoses383.	   In	   the	   same	  
systematic	   review,	  6.5%	  of	  patients	  with	  bilateral	  ACS	   suffered	  a	  peri-­‐operative	   stroke,	  while	  
9.1%	  either	  died	  or	  had	  a	  stroke	  during	  CABG383.	  	  
The	   aetiology	   and	   laterality	   of	   peri-­‐operative	   stroke	   in	   4674	   CABG	   patients	   screened	   pre-­‐
operatively	   for	   carotid	   disease	   found	   that	   86%	   of	   strokes	   could	   not	   be	   attributed	   to	   carotid	  
carotid	  clamping	  under	  general	  anaesthesia.	  
Recommendation	  78	   Class	   Level	   References	  
When	   a	   decision	   has	   been	   made	   to	   undertake	  
revascularisation	   in	   patients	   with	   a	   restenosis	   it	   is	  
recommended	   that	   the	   choice	   of	   redo	   endarterectomy	   or	  
stenting	   should	   be	   based	   on	  multidisciplinary	   team	   review,	  
local	  surgeon/interventionist	  preference	  and	  patient	  choice.	  
I	   C	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disease382.	   In	   a	   pooled	   series	   of	   23,557	   patients	   undergoing	   CABG	   without	   prophylactic	  
CEA/CAS,	   95%	  of	  476	  post-­‐operative	   strokes	   could	  not	  be	  attributed	   to	   carotid	  disease385-­‐387.	  
Accordingly,	   most	   of	   the	   available	   evidence	   suggests	   no	   causal	   relationship	   between	   a	  
significant,	   asymptomatic	   unilateral	   stenosis	   and	   post-­‐CABG	   stroke,	   suggesting	   other	  
aetiologies	  may	  play	  a	  more	  important	  role,	  particularly	  aortic	  arch	  atheroembolism.	  As	  CABG	  
patients	   increase	   in	   age,	   so	   too	   does	   the	   prevalence	   of	   severe	   carotid	   disease,	   severe	   aortic	  
arch	  disease	  and	  post-­‐CABG	  stroke	  (table	  23).22,382,388	  	  
	  
Table	  23:	  Prevalence	  of	  post-­‐CABG	  stroke	  and	  its	  association	  with	  age	  and	  prevalence	  of	  





Prevalence	  of	  stenosis	  
>70%	  on	  screening*	  22	  
Prevalence	  of	  aortic	  
arch	  disease388	  
50-­‐59	   1-­‐2%	   0.2%	  M	  :	  0.1%	  F	   9%	  
60-­‐69	   2-­‐3%	   0.8%	  M	  :	  0.2%	  F	   18%	  
70-­‐79	   4-­‐7%	   2.1%	  M	  :	  1.0%	  F	   22%	  
>80	   8-­‐9%	   3.1%	  M	  :	  0.9%	  F	   33%	  
	  
M	  =	  males;	  F	  =	  females	  
*	  prevalence	  of	  carotid	  stenosis	  based	  on	  population	  screening,	  not	  screening	  in	  CABG	  patients	  
	  
Interestingly,	  the	  presence	  of	  a	  carotid	  bruit	  was	  the	  only	  significant	  predictor	  of	  severe	  aortic	  
arch	  atherosclerotic	  disease389,	  while	  a	  >70%	  carotid	  stenosis	  on	  DUS	  was	  also	  an	  independent	  
predictor	  of	  severe	  aortic	  arch	  disease390.	  In	  a	  2015	  systematic	  review	  of	  predictors	  associated	  
with	  stroke	  after	  CABG,	  Mao	  found	  seven	  variables	  associated	  with	  an	   increased	  risk	  of	  post-­‐
CABG	   stroke	   including	   increasing	   age,	   prior	   stroke/TIA,	   carotid	   stenosis,	   history	   of	   PAD,	  
unstable	  angina,	  prolonged	  cardiopulmonary	  bypass	  and	  post-­‐operative	  atrial	  fibrillation)391.	  
	  
	  
2.7.2	  	  	  What	  is	  the	  value	  of	  screening	  patients	  undergoing	  cardiac	  surgery?	  
Given	  the	  low	  prevalence	  of	  stroke	  after	  CABG,	  routine	  screening	  for	  ACS	  before	  CABG	  cannot	  
be	   supported.	   Clinical/imaging	   factors	   associated	   with	   an	   increased	   likelihood	   of	   finding	   a	  
severe	  carotid	  stenosis	   in	  CABG	  patients	   include	   increasing	  age,	  carotid	  bruit,	  history	  of	  prior	  
stroke/TIA	  and	  left	  main	  stem	  disease382,392.	  	  
	  
2.7.3	  	  	  Are	  carotid	  interventions	  indicated	  in	  cardiac	  surgery	  patients?	  	  
Due	   to	   the	   many	   different	   causes	   of	   stroke	   during	   CABG	   and	   the	   lack	   of	   a	   clear	   causal	  
association	   with	   ACS,	   routine	   prophylactic	   carotid	   revascularization	   is	   unlikely	   to	   reduce	   the	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prevalence	   of	   post-­‐CABG	   stroke.	   However,	   some	   CABG	   patients	   will	   benefit	   from	   a	  
staged/synchronous	  carotid	  intervention.	  The	  literature	  supports	  staged	  or	  synchronous	  carotid	  
interventions	   in	   CABG	   patients	   with	   a	   history	   of	   stroke/TIA384,	   but	   is	   less	   supportive	   of	  
prophylactic	  CEA/CAS	   in	  CABG	  patients	  with	  unilateral	  70-­‐99%	  asymptomatic	  stenoses,	  where	  
the	  stroke	  risk	  may	  only	  be	  about	  2%383,393.	  The	  evidence	  would,	  however,	  support	  prophylactic	  
CEA	   (or	   CAS)	   in	   patients	  with	   bilateral	   asymptomatic	   70-­‐99%	   stenoses,	   or	   a	   70-­‐99%	   stenosis	  
with	  contralateral	  occlusion383.	  
	  
However,	  an	  RCT	  has	  challenged	  this	  interpretation	  of	  the	  literature394.	  	  Illuminati	  randomized	  
185	   CABG	   patients	   with	   unilateral,	   asymptomatic	   70-­‐99%	   carotid	   stenoses	   to	  
staged/synchronous	   CEA	   prior	   to	   CABG	   or	   isolated	   CABG	   followed	   by	   CEA	   at	   a	   later	   date	  
(deferred	  CEA).	  Thirty-­‐day	  mortality	  was	  1%	  in	  each	  group,	  while	  30-­‐day	  death/stroke	  rate	  was	  
4%	   (deferred	   CEA))	   and	   1%	   (staged/synchronous	   CEA)	   (p=ns).	   Interestingly,	   the	   90-­‐day	  
death/stroke	   rate	   was	   9%	   with	   deferred	   CEA	   versus	   1%	   for	   staged/synchronous	   CEA.	   The	  
authors	   concluded	   that	   prophylactic	   CEA	   was	   potentially	   beneficial	   in	   CABG	   patients	   with	  
unilateral	   asymptomatic	   70-­‐99%	   carotid	   stenoses	   in	   order	   to	   reduce	   the	   90-­‐day	   risk	   of	  
ipsilateral	  stroke,	  rather	  than	  peri-­‐operative	  stroke394.	  	  
	  
2.7.4	  	  	  What	  carotid	  surgical/endovascular	  options	  are	  available?	  
Interventional	  strategies	   include:	   (1)	  staged	  CEA	  followed	  by	  CABG;	   (2)	  staged	  CABG	  followed	  
by	  CEA;	   (3)	  synchronous	  CEA	  and	  CABG;	   (4)	  staged	  CAS	   followed	  by	  CABG	  and	  (5)	   ‘same	  day’	  
CAS	  +	  CABG.	  Table	  24	  summarises	  the	  findings	  of	  several	  meta-­‐analyses	  published	  over	  the	  last	  
two	  decades.	   The	  majority	   of	   patients	   (>80%)	  would	   have	  been	  neurologically	   asymptomatic	  
with	  unilateral	  ICA	  stenoses	  and	  the	  majority	  reported	  30-­‐day	  death/stroke	  rates	  of	  7-­‐8%.	  	  
	  
Table	  24:	  Meta-­‐analyses	  of	  pooled	  30-­‐day	  outcomes	  from	  different	  revascularization	  
strategies	  in	  patients	  with	  combined	  carotid	  and	  cardiac	  disease	  
	  















































































































































































































*	  synch	  =	  synchronous	  
	  
MI:	  myocardial	  infarction;	  CABG:	  Coronary	  artery	  bypass	  graft;	  CAS:	  carotid	  stenting;	  CEA:	  carotid	  
endarterectomy;	  off	  pump	  means	  CABG	  done	  without	  cardiopulmonary	  bypass;	  pre-­‐bypass,	  on	  
bypass	  indicates	  when	  CEA	  was	  performed	  relative	  to	  cardiopulmonary	  bypass	  
	  
	  
Table	   25	   presents	   similar	   data,	   this	   time	   from	   administrative	   dataset	   registries,	   which	   are	  
more	   likely	   to	   reflect	   ‘real	   world’	   practice.	   30-­‐day	   death/stroke	   ranged	   from	   6-­‐10%	   in	  
predominantly	   asymptomatic	   patients,	   with	   the	   highest	   procedural	   risks	   being	   observed	   in	  
patients	  with	   a	   history	   of	   stroke/TIA	  who	  underwent	   either	   staged/synchronous	  CEA+CABG	  




Table	  25:	  30-­‐day	  procedural	  risks	  after	  CEA+CABG	  stratified	  for	  treatment	  strategy	  from	  large	  








NIS	  1993-­‐2002	  	  
staged/synch	  CEA	  +	  CABG	   all	  cases	   7,073	   5.6%	   4.9%	   9.7%	  
Timaran	  2008404	  
NIS	  2000-­‐2004	  
staged/synch	  CEA	  +	  CABG	  
staged	  CAS	  +	  CABG	  









	   staged/synch	  CEA+CABG	  	  










staged	  CEA	  +	  CABG	  
synchronous	  CEA+CABG	  








staged	  CEA	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  CABG	  














synchronous	  CEA	  +	  CABG	  











NIS	  =	  National	  Inpatient	  Sample,	  synch	  =	  synchronous;	  all	  cases	  =	  symptomatic	  and	  asymptomatic;	  off	  
bypass	  =	  CABG	  was	  done	  off	  bypass	  
	  
	  
One	   systematic	   review400	   suggested	   that	  performing	  CABG	  off-­‐pump	  was	  associated	  with	   the	  
lowest	   rates	   of	   post-­‐CABG	   stroke,	   attributed	   to	   no	   cannulation	   of	   a	   diseased	   aortic	   arch.	  
However,	  Gopaldas406	   found	  no	  evidence	  to	  support	  this	   in	  patients	  undergoing	  either	  staged	  
or	  synchronous	  carotid	  interventions	  (table	  25).	  	  	  
	  
CAS	  might	  be	  a	  alternative	  to	  CEA.	  In	  an	  updated	  meta-­‐analysis	  (table	  24),	  which	  included	  2727	  
patients	  who	  underwent	  staged	  or	  'same	  day'	  CAS-­‐CABG,	  the	  overall	  30-­‐day	  death/stroke	  rate	  
was	   7.9%401.	   The	  majority	   (80%)	   were	   neurologically	   asymptomatic	   with	   a	   unilateral	   carotid	  
stenosis,	   in	   whom	   the	   30-­‐day	   death/stroke	   rate	   was	   6.7%	   after	   CAS+CABG	   with	   a	  
death/stroke/MI	   rate	   of	   8.5%.	   Given	   the	   low	   rates	   of	   stroke	   in	   asymptomatic	   patients	   with	  
unilateral	  stenoses	  undergoing	  isolated	  CABG,	  it	  is	  unlikely	  that	  CAS+CABG	  (or	  CEA+CABG)	  will	  
benefit	  the	  asymptomatic	  patient	  with	  unilateral	  stenoses.	  Another	  important	  finding	  from	  the	  
systematic	  review	  was	  that	  performing	  staged	  or	  same-­‐day	  CAS+CABG	  in	  patients	  with	  a	  prior	  
history	  of	  TIA/stroke	  was	  associated	  with	  a	  15%	  30-­‐day	  risk	  of	  death/stroke401.	  	  
	  
Using	  propensity	  scoring,	  Shishehbor	  evaluated	  three	  approaches	  to	  carotid	  revascularization	  in	  
CABG	   patients	   with	   predominantly	   asymptomatic	   carotid	   disease,	   staged	   CEA-­‐CABG	   (n=45),	  
staged	  CAS-­‐CABG	  (n=110)	  and	  combined	  CEA-­‐CABG	  (n=195).	  Staged	  CAS-­‐CABG	  and	  combined	  
CEA-­‐CABG	  were	  associated	  with	  similar	   rates	  of	  death,	   stroke	  and	  MI	   in	   the	  short	   term,	  with	  
both	   being	   better	   than	   staged	   CEA-­‐CABG407.	   Mortality	   was	   comparable	   across	   all	   treatment	  
strategies	  in	  the	  early	  period,	  whereas	  higher	  stroke	  rates	  were	  observed	  in	  the	  combined	  CEA-­‐
CABG	   group	   and	   higher	   MI	   rates	   in	   the	   staged	   CEA-­‐CABG	   group	   at	   1-­‐year.	   Outcomes	  
significantly	  favoured	  staged	  CAS-­‐CABG	  after	  the	  first	  year407.	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The	  requirement	  for	  DAPT	  after	  CAS	  can	  be	  a	  problem	  for	  the	  staged	  CAS-­‐CABG	  approach,	  as	  it	  
increases	   the	   risk	   of	  MI	   between	   the	   two	   procedures,	   as	  well	   as	   increasing	   the	   risk	   of	   peri-­‐
operative	   bleeding	   during	   urgent	   or	   emergency	   CABG.	   However,	   evidence	   suggests	   that	   CAS	  
can	  be	  performed	  on	   the	  same	  day	  as	  CABG	  using	  aspirin/heparin	  cover,	  with	   thienopyridine	  
antiplatelet	  agents	  being	  started	  6–12	  hours	  after	  CABG401,408,409.	  	  
	  
	  
2.7.5	  	  	  Managing	  patients	  with	  unstable	  coronary	  artery	  disease?	  	  
The	  Carotid	  Artery	  Revascularization	  and	  Endarterectomy	  (CARE)	  registry	  involved	  255	  patients	  
who	  underwent	  CAS	  and	  196	  who	  underwent	  CEA	  prior	  to	  urgent	  cardiac	  surgery.	  The	  30-­‐day	  
rate	   of	   death/stroke	   and	  MI	  was	   15%	   after	   CAS	   and	   22%	   after	   CEA410,	  which	   is	   considerably	  
higher	  than	  reported	   in	  tables	  24	  and	  25.	  CARE	  did	  not,	  however,	  separate	  staged	  CEA-­‐CABG	  
and	   combined	   CEA+CABG	   and	   significant	   regional	   variations	   in	   practice	   existed,	  with	   60%	   of	  
carotid	  interventions	  being	  undertaken	  in	  asymptomatic	  patients.	  	  
	  
Recommendation	  79	   Class	   Level	   References	  
Routine	  screening	  for	  carotid	  disease	  prior	  to	  open-­‐heart	  
surgery	  is	  not	  recommended.	  	  
III	   C	   	  
	  
Recommendation	  80	   Class	   Level	   References	  
Ultrasound	  screening	  for	  carotid	  disease	  prior	  to	  coronary	  
bypass	  should	  be	  considered	  in	  patients	  aged>70	  years,	  
those	  with	  a	  history	  of	  transient	  ischaenic	  attack	  or	  stroke,	  a	  
carotid	  bruit	  or	  left	  mainstem	  disease	  so	  that	  the	  patient	  can	  
be	  better	  informed	  of	  the	  increased	  risks	  associated	  with	  
coronary	  artery	  bypass	  surgery	  in	  patients	  with	  concurrent	  
carotid	  disease.	  	  
IIa	   C	   382,392	  
	  
Recommendation	  81	   Class	   Level	   References	  
Staged	  or	  synchronous	  carotid	  intervention	  should	  be	  
considered	  in	  coronary	  artery	  bypass	  surgery	  patients	  with	  a	  
recent	  history	  of	  stroke	  or	  transient	  ischaemic	  attack	  and	  a	  
50-­‐99%	  carotid	  stenosis	  	  
IIa	   B	   382,384	  
	  
Recommendation	  82	   Class	   Level	   References	  
Staged	  or	  synchronous	  carotid	  endarterectomy	  should	  be	  
considered,	  instead	  of	  stenting	  plus	  coronary	  bypass,	  in	  
patients	  with	  a	  recent	  history	  of	  stroke	  or	  transient	  
ischaemic	  attack	  and	  a	  50-­‐99%	  carotid	  stenosis	  	  
IIa	   B	   397,399,401,404	  
	  
Recommendation	  83	   Class	   Level	   References	  
A	  staged	  or	  synchronous	  carotid	  intervention	  is	  not	  
recommended	  in	  coronary	  artery	  bypass	  patients	  with	  an	  
asymptomatic	  unilateral	  70-­‐99%	  carotid	  stenosis	  for	  the	  
prevention	  of	  peri-­‐operative	  stroke	  
III	   B	   383	  
	  
Recommendation	  84	   Class	   Level	   References	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A	  staged	  or	  synchronous	  carotid	  intervention	  may	  be	  
considered	  in	  coronary	  artery	  bypass	  patients	  with	  bilateral	  
asymptomatic	  70-­‐99%	  carotid	  stenoses,	  or	  a	  70-­‐99%	  stenosis	  
with	  contralateral	  occlusion.	  
IIb	   C	   383	  
	  
Recommendation	  85	   Class	   Level	   References	  
The	  choice	  between	  carotid	  endarterectomy	  and	  carotid	  
stenting	  in	  asymptomatic	  patients	  in	  whom	  a	  carotid	  
intervention	  is	  deemed	  necessary	  prior	  to	  coronary	  artery	  
bypass	  should	  be	  based	  on	  the	  urgency	  of	  performing	  
surgery,	  choice	  of	  antiplatelet	  strategy	  during	  coronary	  
bypass,	  individual	  patient	  characteristics,	  symptom	  status	  
and	  local	  expertise.	  





2.8	  	  Carotid	  disease	  and	  major	  ‘non-­‐cardiac’	  surgery	  
Vascular	   surgeons	   are	   often	   asked	   to	   advise	   on	   how	   to	  manage	   a	   patient	   undergoing	  major	  
non-­‐cardiac	   surgery	   who	   has	   a	   concurrent	   severe	   ACS.	   Should	   prophylactic	   CEA	   or	   CAS	   be	  
considered	  to	  reduce	  the	  risk	  of	  peri-­‐operative	  stroke?	  	  
	  
2.8.1	  	  Prevalence	  of	  stroke	  after	  major	  ‘non-­‐cardiac’	  surgery	  
The	  prevalence	  of	  perioperative	  stroke	  depends	  upon	  the	  nature	  and	  complexity	  of	  the	  surgical	  
procedure,	  the	  presence	  of	  risk	  factors	  and	  (most	  particularly)	  the	  timing	  of	  major	  surgery	  after	  
a	  recent	  TIA	  or	  stroke	  (table	  26).	  
	  
Table	  26:	  Prevalence	  of	  peri-­‐operative	  stroke	  stratified	  for	  type	  of	  procedure	  
	  
Author	   Population	   n=	   stroke	  risk	  
Axelrodt	  2004411	   major	  vascular	  surgery	   	  	  5296	  aortic	  
	  	  7299	  lower	  limb	  bypass	  




Sharifpour	  2014412	   major	  vascular	  surgery	   	  	  8077	  major	  amputation	  
	  	  21,962	  lower	  limb	  
bypass	  
	  	  7888	  open	  aortic	  





Jorgensen	  2014413	   non-­‐cardiac,	  including	  
vascular	  
	  	  481,113	   0.1%	  
Sonny	  2014414	   non-­‐cardiac	  including	  
vascular	  
	  	  2110	   2.6%	  
Kikura	  2008415	   general,	  orthopaedic,	  
thoracic,	  non-­‐carotid	  
vascular	  
	  	  36,634	   0.3%	  
Parvizi	  2007416	   knee	  arthroplasty	   	  	  1636	   0.4%	  




	  	  201,235	  
	  	  39,339	  
0.2%	  
0.6%	  
Huang	  2010418	   caesarian	  section	   	  303,862	   0.05%	  
Mashour	  2011419	   non-­‐cardiac	  (low	  risk)	  
general,	  orthopaedic,	  
urology,	  ENT,	  plastics,	  
thoracic,	  gynaecology	  
	  523,059	   0.1%	  
Biteker	  2014420	   non-­‐cardiac,	  non-­‐vascular	   	  	  1340	   2.3%	  
*	  EVAR	  =	  endovascular	  aortic	  aneurysm	  repair	  
	  
The	  prevalence	  of	  peri-­‐operative	  stroke	  was	  <1%	  in	  all	  but	  two	  cohorts	  undergoing	  major	  (non-­‐
cardiac	  operations)	  in	  table	  26,	  suggesting	  that	  (for	  the	  vast	  majority	  of	  patients)	  peri-­‐operative	  
stroke	  during	  major	  non-­‐cardiac	  surgery	  is	  rarely	  a	  major	  problem.	  
	  
2.8.2	  	  	  	  Prediction	  of	  stroke	  after	  major	  non-­‐cardiac	  surgery.	  
Table	  27	   summarises	   features	  associated	  with	  an	   increased	  risk	  of	  peri-­‐operative	  stroke	  after	  
non-­‐cardiac	   surgical	   procedures.	   The	   most	   consistent	   were	   increasing	   age	   and	   a	   history	   of	  
previous	  stroke.	  
	  
Table	  27;	  Predictors	  for	  peri-­‐operative	  stroke	  following	  major	  non-­‐cardiac	  procedures	  
	  
Author	   Population	   Stroke	  predictors	   OR	  (95%CI)	  	  
Axelrodt	  2004411	   major	  vascular	  surgery	   aortic	  operation	   1.7	  (1.0-­‐2.8)	  
Sharifpour	  
2014412	  
major	  vascular	  surgery	   each	  1	  yr	  increase	  in	  age	  
cardiac	  history	  
females	  
history	  of	  stroke	  






Parvizi	  2007416	   knee	  arthroplasty	   age	  
BMI	  
1.2	  (1.0-­‐201.2)	  	  
1.0	  (1.0-­‐1.1),	  	  
Kikura	  2008415	   general,	  orthopaedic,	  
thoracic,	  non-­‐carotid	  
vascular	  
age	  >70	  yrs	  



































ENT,	  plastics,	  thoracic,	  
acute	  renal	  failure	  
history	  of	  stroke	  















Biteker	  2014420	   non-­‐cardiac,	  non-­‐
vascular	  
age	  





non-­‐cardiac	   stroke	  <3	  months	  
stroke	  3-­‐6	  months	  




*	  BMI	  =	  body	  mass	  index	  
	  
	  
2.8.3	  	  	  	  Timing	  of	  major	  surgery	  after	  recent	  stroke	  
One	  of	   the	  main	   findings	   from	   table	  27	  was	  how	  the	   timing	  of	  major	  non-­‐cardiac	  operations	  
after	   a	   recent	   stroke	   impacted	   on	   peri-­‐operative	   stroke.	   In	   a	   large	   Danish	   national	   study	   of	  
adult	   patients	   undergoing	   481,183	   elective,	   non-­‐cardiac	   operations,	   7137	   (1.5%)	   were	  
undertaken	   in	   patients	   with	   a	   prior	   history	   of	   stroke.	   In	   the	   latter	   cohort,	   the	   risk	   of	   peri-­‐
operative	  stroke	  was	  11.9%	  when	  elective	  non-­‐cardiac	  operations	  were	  performed	  within	  three	  
months	  of	  stroke	  onset,	  declining	  to	  4.5%	  where	  3-­‐6	  months	  had	  elapsed	  and	  1.8%	  where	  6-­‐12	  
months	  had	  elapsed.	  This	  compares	  with	  0.1%	  in	  patients	  who	  had	  no	  history	  of	  prior	  stroke413.	  	  
	  
2.8.4	  	  	  Is	  there	  a	  role	  for	  prophylactic	  endarterectomy	  or	  stenting?	  
Patients	  undergoing	  non-­‐cardiac,	  non-­‐vascular	  major	  surgery	  with	  three	  or	  four	  cardiovascular	  
risk	   factors	   (age,	   coronary	  disease,	   renal	   failure,	  hypertension,	  diabetes,	   smoking,	  body	  mass	  
index	   >35kg/m2,	   chronic	   obstructive	   pulmonary	   disease,	   previous	   TIA)	   incurred	   a	   0.7%	  
incidence	  of	  perioperative	  stroke.	  With	  five	  or	  more	  risk	  factors,	  the	  incidence	  of	  peri-­‐operative	  
stroke	  increased	  to	  1.9%419,420.	  It	  is	  therefore	  important	  to	  review	  the	  overall	  cardiovascular	  risk	  
profile	   in	  patients	  undergoing	  major	  non-­‐cardiac,	   non-­‐vascular	   surgical	   procedures	   as	  part	   of	  
the	  consent	  process418,421.	  Most	  perioperative	  strokes	  are	   ischaemic	  and	  secondary	  to	  cardiac	  
embolism.	   The	   perioperative	   period	   also	   involves	   complex	   haemodynamic	   stresses	   involving	  
hypercoagulable	   and	   systemic	   inflammatory	   responses,	   all	   of	  which	   increase	   the	   risk	   of	   peri-­‐
operative	  stroke,	  especially	  if	  anticoagulation	  or	  antiplatelet	  therapies	  need	  to	  be	  withdrawn.	  	  
The	  role	  of	  prophylactic	  carotid	  revascularization	   in	  patients	  with	  ACS	  undergoing	  major	  non-­‐
cardiac,	   non-­‐vascular	   surgical	   procedures	   has	   been	   evaluated	   in	   one	   RCT	   and	   one	   non-­‐
randomised	  study.	  Ballotta	  randomised	  79	  patients	  with	  severe	  ACS	  to	  prophylactic	  CEA	  within	  
one	  week	  of	  the	  major	  surgical	  procedure	  (n=40),	  versus	  a	  deferred	  CEA	  after	  the	  major	  surgical	  
procedure	  (n=39).	  There	  were	  no	  perioperative	  deaths	  or	  strokes	  in	  either	  group.	  Two	  deferred	  
patients	   (5%)	   suffered	   a	   minor	   stroke	   65	   and	   78	   days	   after	   their	   major	   surgical	   procedure,	  
whilst	  awaiting	  CEA422.	  	  
 109 
	  
Sonny	  performed	  a	  retrospective	  study	  to	  determine	  whether	  the	  presence	  of	  ACS	  predisposed	  
patients	   who	   were	   undergoing	   non-­‐cardiac,	   non-­‐carotid	   surgery	   to	   a	   heightened	   risk	   of	  
perioperative	  stroke.	  During	  a	  5-­‐year	  period,	  2,110	  patients	  had	  carotid	  DUS	  performed	  within	  
6	  months	  before	  or	  1	  month	  after	  their	  operation.	  Thirty-­‐seven	  percent	  of	  patients	  had	  at	  least	  
one	  ACS	  >50%,	  while	  13%	  had	  >70%	  stenoses.	  Of	   the	  2,110	  patients	   included,	  112	   (5%)	  died	  
within	  30	  days	  and	  54	  (3%)	  suffered	  a	  postoperative	  stroke.	  Neither	  of	  the	  stenosis	  thresholds	  
(>50%,	  >70%)	  was	  associated	  with	  an	  increased	  risk	  of	  peri-­‐operative	  stroke414.	  
	  
Recommendation	  86	   Class	   Level	   References	  
It	  is	  recommended	  that	  patients	  undergoing	  elective,	  non-­‐
cardiac	  surgery	  with	  a	  history	  of	  stroke	  or	  transient	  ischaemic	  
attack	  within	  the	  preceding	  six	  months	  should	  undergo	  carotid	  
artery	  imaging.	  	  
	  
I	   B	   413	  
	  
Recommendation	  87	   Class	   Level	   References	  
It	  is	  recommended	  that	  patients	  with	  a	  history	  of	  stroke	  or	  
transient	  ischaemic	  attack	  in	  the	  preceding	  6	  months	  who	  are	  
to	  undergo	  elective,	  non-­‐cardiac	  surgery	  with	  an	  ipsilateral	  50-­‐
99%	  carotid	  stenosis	  should	  undergo	  carotid	  revascularisation	  
before	  elective	  non-­‐cardiac	  surgery.	  
I	   A	   172,413	  
	  
	  
Recommendation	  88	   Class	   Level	   References	  
It	  is	  recommended	  that,	  where	  possible,	  elective	  non-­‐cardiac	  
surgery	  should	  be	  delayed	  for	  6	  months	  in	  patients	  with	  a	  
history	  of	  recent	  stroke	  and	  no	  significant	  carotid	  disease.	  The	  
decision	  to	  proceed	  with	  semi-­‐urgent	  elective	  surgery	  will	  
have	  to	  be	  individualized,	  based	  upon	  the	  underlying	  
pathology	  
I	   B	   413	  
	  
Recommendation	  89	   Class	   Level	   References	  
Routine	  carotid	  imaging	  in	  asymptomatic	  patients	  undergoing	  
non-­‐cardiac	  surgery	  procedures	  is	  not	  recommended	  	  
III	   B	   411,412	  
	  
	  
Recommendation	  90	   Class	   Level	   References	  
Patients	  undergoing	  major	  non-­‐cardiac,	  non-­‐vascular	  surgical	  
procedures	   should	   undergo	   a	   comprehensive	   cardiovascular	  
risk	  assessment	  to	  aid	  the	  consent	  process	  regarding	  the	  risk	  
of	  peri-­‐operative	  stroke	  
I	   B	   419,421	  
	  
Recommendation	  91	   Class	   Level	   References	  
Where	   ever	   possible,	   statin	   and	   antiplatelet	   therapy	   should	  
not	   be	   stopped	   prior	   to	   major	   non-­‐vascular	   surgical	  
procedures	   in	   patients	   with	   asymptomatic	   50-­‐99%	   carotid	  
stenoses.	  Anticoagulant	  therapy	  withdrawal	  should	  be	  based	  
on	  an	  assessment	  of	  thromboembolic	  and	  haemorrhagic	  risks	  
III	   B	   423	  
	  
Recommendation	  92	   Class	   Level	   References	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Prophylactic	  carotid	  endarterectomy	  and	  carotid	  stenting	  are	  
not	  recommended	  in	  patients	  with	  asymptomatic	  carotid	  
stenoses	  prior	  to	  major	  non-­‐cardiac,	  non-­‐vascular	  surgical	  
procedures	  	  





2.9	  Occlusive	  disease	  of	  the	  proximal	  common	  carotid	  and	  innominate	  
arteries	  
	  
2.9.1	  	  	  Introduction	  
The	   incidence	   of	   significant	   stenosis	   or	   occlusion	   affecting	   the	   origins	   of	   aortic	   arch	   branch	  
vessels	   is	   0.5-­‐6.4%,	   with	   a	   relatively	   higher	   frequency	   affecting	   the	   innominate	   or	   left	  
subclavian	   arteries,	   as	   opposed	   to	   the	   left	   CCA424.	   Total	   CCA	   occlusion	   is	   relatively	   rare,	  
affecting	  2-­‐4%	  of	  patients	  undergoing	  angiography	  for	  symptomatic	  cerebrovascular	  disease425.	  
Patients	   with	   a	   symptomatic	   arch	   origin	   stenosis	   have	   a	   2.3%	   annual	   risk	   of	   developing	   a	  
stenosis	  affecting	  another	  arch	  branch	  vessel424,	  while	   tandem	  occlusive	  disease	  affecting	  the	  
carotid	  bifurcation	  may	  be	  present	  in	  up	  to	  17%	  of	  patients.	  
	  
2.9.2	  	  	  Clinical	  presentation	  
Left	  CCA	  lesions	  give	  rise	  to	  left	  hemispheric	  and	  left	  retinal	  symptoms.	  Left	  subclavian	  lesions	  
give	  rise	  to	  vertebrobasilar	  and/or	  left	  upper	  extremity	  symptoms,	  while	  innominate	  lesions	  can	  
involve	   three	   territories	   (right	   carotid,	   vertebrobasilar	   and	   right	   upper	   extremity).	   Occlusive	  
lesions	   involving	   branches	   of	   the	   aortic	   arch	   are	   generally	   atherosclerotic,	   but	   arteritis	  
(Takayasu’s,	  radiation)	  and	  dissection	  should	  be	  considered	  in	  younger	  patients.	  	  
	  
2.9.3	  	  Indications	  for	  revascularization.	  
Indications	   for	   revascularizing	   arch	   branch	   origin	   lesions	   are	   similar	   to	   those	   for	   performing	  
CEA.	  The	  natural	  history	  of	   isolated	  CCA	  or	   innominate	  stenoses	   is	  unknown.	   In	  patients	  with	  
neurological	   sequelae	   or	   upper	   extremity	   ischemia,	   the	   indication	   for	   revascularization	   is	  
relatively	  straightforward.	  There	  is	  no	  evidence	  supporting	  open	  or	  endovascular	  interventions	  
in	  asymptomatic	  patients.	  
	  
2.9.4	  	  Endovascular	  versus	  open	  surgical	  reconstruction	  
There	   is	   controversy	   regarding	   the	   optimal	   intervention	   for	   patients	   with	   innominate	   artery	  
disease,	   as	   there	   is	   frequently	   multivessel	   involvement.	   Until	   thirty	   years	   ago,	   supra-­‐aortic	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occlusive	  disease	   could	  only	   be	   treated	  by	  open	   surgery.	   Transposition	  of	   the	  CCA	  on	   to	   the	  
subclavian	   artery	   provides	   direct	   autogenous	   revascularization,	   but	   this	   may	   not	   always	   be	  
feasible.	  Open	  CCA	  endarterectomy	  can	  be	  performed	  via	  an	  open	  or	   retrograde	  semi-­‐closed	  
endarterectomy.	  However,	  with	   recent	  advances	   in	  hybrid	   interventions,	  most	   innominate	  or	  
proximal	   CCA	   stenoses/occlusions	   are	   now	   treated	   by	   open	   retrograde	   angioplasty	   and	  
stenting424.	  In	  the	  largest	  published	  series	  of	  primary	  stenting	  for	  145	  aortic	  side	  branch	  origin	  
lesions	  in	  114	  patients,	  the	  technical	  success	  rate	  was	  97%	  and	  there	  were	  no	  strokes	  or	  deaths	  
at	  30-­‐days.	  During	  a	  mean	  follow-­‐up	  of	  52	  months	  (range	  2-­‐163),	  restenosis	   free	  survival	  was	  
96%	  and	  83%	  at	  12	  and	  60	  months	  respectively424.	  	  
	  
	  
2.9.5	  	  Open	  revascularisation:	  cervical	  versus	  transthoracic	  
Techniques	  for	  reconstructing	  arch	  vessels	  include	  bypass	  via	  a	  transthoracic	  or	  extra-­‐thoracic	  
(cervical)	   approach.	   The	   transthoracic	   approach	   involves	   a	   median	   sternotomy	   or	   the	   less	  
invasive	   ‘trap-­‐door’	   technique.	   Cervical	   reconstructions	   are	   less	   invasive	   and	   are	   associated	  
with	  fewer	  procedural	  risks.	   	  Patients	  with	  an	  isolated	  subclavian	  or	  CCA	  lesion	  (with	  a	  patent	  
ipsilateral	   carotid	   or	   subclavian	   artery)	   should	   undergo	   transposition	   or	   bypass	   via	   a	   cervical	  
approach.	   Saphenous	   vein	   was	   previously	   the	   first-­‐choice	   conduit,	   but	   vein	   grafts	   are	   often	  
small	   in	  calibre	  and	  more	  prone	  to	  kinking/angulation	  than	  prosthetic	  grafts,	  which	  otherwise	  
offer	   durable	   patency	   and	   low	  morbidity426.	   At	   the	   other	   end	   of	   the	   spectrum	   is	   the	   patient	  
with	  involvement	  of	  all	  three	  arch	  branches,	  where	  graft	  outflow	  must	  arise	  from	  the	  aorta	  via	  
a	   median	   sternotomy.	   Transthoracic	   reconstructions	   can	   be	   performed	   with	   acceptably	   low	  
morbidity/mortality,	  which	  can	  be	  similar	  to	  those	  involving	  a	  cervical	  approach.	  Moreover,	  the	  
transthoracic	  approach	  is	  associated	  with	  significantly	  better	  long-­‐term	  patency427.	  	  
	  
2.9.6	  	  	  Tandem	  proximal	  inflow	  and	  internal	  carotid	  artery	  disease	  
‘Tandem	  disease’	  involves	  lesions	  affecting	  the	  innominate	  artery	  or	  proximal	  CCA,	  in	  addition	  
to	   significant	   disease	  within	   the	   ipsilateral	   ICA.	  Historically,	  most	  were	   treated	  by	   total	   open	  
procedures,	   but	   most	   now	   undergo	   a	   hybrid	   approach	   where	   open	   retrograde	  
angioplasty/stenting	  of	  the	  innominate	  or	  proximal	  CCA	  is	  followed	  by	  CEA428.	  
	  
Recommendation	  93	   Class	   Level	   References	  
Open	  or	  endovascular	  interventions	  to	  treat	  proximal	  
common	  carotid	  artery	  or	  innominate	  artery	  
stenoses/occlusions	  are	  not	  recommended	  in	  asymptomatic	  







2.10	  Unresolved	  issues	  relating	  to	  managing	  carotid	  artery	  disease	  	  	  
	  
The	  Writing	  Group	  identified	  key	  issues	  relating	  to	  the	  investigation	  and	  management	  of	  carotid	  
artery	  disease	  that	  need	  to	  be	  addressed	  to	  better	  inform	  future	  guidelines.	  These	  include:	  
	  
Should	   the	   ‘accepted’	   risk	   thresholds	   for	   performing	   CEA	   or	   CAS	   be	   reduced	   from	   6%	   in	   symptomatic	  
patients	  and	  3%	  in	  asymptomatic	  patients?	  
	  
Should	  the	  time	  threshold	  for	  a	  patient	  being	  defined	  as	  ‘recently	  symptomatic’	  (currently	  6-­‐months)	  be	  
reduced?	  
	  
The	  need	  to	  develop	  a	  validated	  algorithm	  for	   identifing	  ‘high	  risk	  for	  stroke’	  asymptomatic	  patients	   in	  
whom	  to	  target	  CEA	  and	  CAS.	  
	  
To	  determine	  whether	  asymptomatic	  carotid	  disease	  contributes	  towards	  cognitive	  decline	  and	  whether	  
CEA/CAS	  can	  reverse	  or	  prevent	  this.	  
	  
Whether	  measurement	  of	  plasma	  biomarkers	  to	  evaluate	  excessive	  endothelial	  and	  coagulation	  system	  
activation	  has	  any	  potential	  for	  guiding	  risk	  stratification	  in	  patients	  with	  asymptomatic	  carotid	  disease.	  
	  
Should	   all	   recently	   symptomatic	   patients	   be	   started	   on	   dual	   antiplatelet	   therapy	   once	   parenchymal	  
haemorrhage	  is	  excluded	  on	  CT/MRI	  and	  then	  be	  continued	  throughout	  the	  peri-­‐operative	  period?	  
	  
Is	  there	  a	  role	  for	  clinical	  and	  imaging	  surveillance	  after	  CEA	  or	  CAS?	  
	  
Relevance	   of	   new	   DW-­‐MRI	   lesions	   after	   CEA	   and	   CAS.	   Do	   these	   contribute	   towards	   a	   higher	   rate	   of	  
recurrent	  stroke	  or	  cognitive	  decline?	  
	  
In	  patients	  undergoing	  emergency	  stent	  retrieval	  thrombectomy	  for	  acute	  ischaemic	  stroke	  due	  to	  an	  ICA	  
or	  MCA	  (M1/M2)	  occlusion,	  is	  it	  safe	  to	  perform	  CAS	  to	  treat	  concurrent	  extracranial	  ICA	  stenoses	  during	  
the	  same	  procedure?	  
	  
Which	  recently	  symptomatic	  patients	  with	  0-­‐49%	  ICA	  stenoses	  might	  benefit	  from	  urgent	  CEA	  or	  CAS?	  
	  
What	  is	  the	  optimal	  timing	  for	  performing	  CEA	  or	  CAS	  after	  intravenous	  thrombolysis?	  
	  
How	   should	   the	   presence	   of	   a	   tandem	   distal	   ICA	   severe	   stenosis	   influence	   management	   decisions	   in	  
recently	  symptomatic	  patients	  with	  50-­‐99%	  ICA	  stenoses?	  
	  
Can	  we	  accurately	  define	  patients	  who	  really	  are	   ‘high-­‐risk	   for	  CEA’	   in	  whom	  one	  should	  preferentially	  
perform	  CAS?	  
	  
Can	  we	  accurately	  define	  patients	  who	  really	  are	   ‘high-­‐risk	   for	  CAS’	   in	  whom	  one	  should	  preferentially	  
perform	  CEA?	  
Recommendation	  94	   Class	   Level	   References	  
Most	  proximal	  common	  carotid	  artery	  and	  innominate	  
stenoses	  should	  be	  considered	  for	  treatment	  via	  open	  
retrograde	  angioplasty	  and	  stenting.	  
IIa	   C	   424	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What	  is	  the	  optimal	  method	  for	  protecting	  the	  brain	  during	  CAS;	  none,	  distal	  filter,	  proximal	  protection,	  
transcarotid	  approach?	  
	  
Is	  it	  safe	  to	  perform	  CEA	  under	  locoregional	  anaesthesia	  if	  the	  patient	  is	  taking	  dual	  antiplatelet	  therapy?	  
	  
Does	  intravenous	  heparin	  therapy	  confer	  any	  additional	  benefit	  over	  mono	  or	  dual	  antiplatelet	  therapy	  
in	  patients	  who	  present	  with	  crescendo	  TIAs?	  
	  
Is	   CEA	   under	   locoregional	   anaesthesia	   safer	   than	   CAS	   in	   ‘hig-­‐	   risk	   for	   CEA’	   patients	   with	   significant	  
cardiac	  or	  chronic	  pulmonary	  disease?	  
	  




Section	  3:	  Vertebral	  artery	  disease	  
	  
3.1	  	  Introduction	  
3.1.1	  	  Burden	  of	  vertebrobasilar	  stroke	  
One	   fifth	   of	   ischaemic	   strokes	   affect	   the	   vertebrobasilar	   territory,	   otherwise	   termed	   the	  
posterior	  circulation429.	  Vertebrobasilar	  events	  receive	  much	  less	  attention	  that	  those	  affecting	  
the	   carotid	   territory,	   but	   data	   suggest	   they	   are	   associated	  with	   a	   similarly	   high-­‐risk	   of	   early	  
recurrent	  stroke.	  	  
	  
3.1.2	  	  Aetiology	  of	  vertebrobasilar	  stroke	  
The	  causes	  of	  vertebrobasilar	  stroke/TIA	  are	  similar	  to	  those	  affecting	  the	  anterior	  circulation430	  
including	   cardioembolism,	   large	   artery	   thromboembolism	   and	   small	   artery	   disease.	  
Atherosclerosis	   of	   the	   vertebral	   or	   basilar	   arteries	   accounts	   for	   20-­‐25%	  of	   strokes.	   	   Stenoses	  
mostly	   occur	   at	   the	   VA	   origins,	   but	   they	   can	   affect	   the	   distal	   VA	   and	   basilar	   arteries.	  	  
Intracranial	  stenoses	  are	  more	  common	  in	  individuals	  with	  a	  sub-­‐Saharan	  African	  or	  East	  Asian	  
ethnic	  origin,	  compared	  with	  Caucasians.	  Thromboembolism	  appears	  to	  be	  the	  main	  cause	  of	  
ischaemia	  in	  patients	  with	  VA	  stenoses.	  	  This	  is	  supported	  by	  the	  detection	  of	  circulating	  emboli	  
on	   TCD	   distal	   to	   the	   stenosis	   and	   by	   the	   temporal	   risk	   profile	   in	   patients	   with	   symptomatic	  
stenoses,	   which	   shows	   a	   high	   early	   risk	   of	   recurrent	   stroke	   followed	   by	   a	   much	   lower	   risk,	  
despite	  the	  continued	  presence	  of	  a	  stenosis.	  	  	  
	  
Haemodynamic	   compromise	  was	   previously	   thought	   to	   be	   the	  main	   cause	  of	   vertebrobasilar	  
symptoms.	  However,	  studies	  suggest	  that	  this	   is	   less	  common	  than	  previously	  thought.	   In	  the	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New	  England	  posterior	  circulation	  registry,	  only	  13/407	  patients	  (3%)	  had	  symptoms	  secondary	  
to	   haemodynamic	   ischaemia	   and	   this	   was	   most	   commonly	   seen	   in	   patients	   with	   bilateral	  
intracranial	   VA	   disease431.	   Cardiac	   embolism,	   usually	   from	   atrial	   fibrillation,	   accounted	   for	   a	  
quarter	  of	  posterior	  circulation	  strokes/TIAs.	  An	  additional	  quarter	  were	  due	  to	  disease	  of	  the	  
small	  penetrating	  arteries,	  resulting	  in	  lacunar	  stroke.	  	  These	  penetrating	  arteries	  arise	  from	  the	  
intracranial	  vertebral,	  basilar	  and	  posterior	  cerebral	  arteries431.	  	  	  
	  
3.1.3	  	  Symptoms	  attributable	  to	  vertebral	  artery	  disease	  
The	   vertebrobasilar	   system	   supplies	   the	   brainstem,	   cerebellum,	   occipital	   lobes	   and	   (in	  most	  
patients)	  the	  inferior	  temporal	  lobes	  and	  most	  of	  the	  thalami.	  	  Accordingly,	  ischaemia	  can	  give	  
rise	  to	  a	  wide	  range	  of	  symptoms,	  including	  vertigo,	  ataxia,	  eye	  movement	  disorders,	  bilateral	  
limb	   weakness,	   complete	   visual	   loss	   (cortical	   blindness)	   and	   hemianopia430.	   	   However,	  
vertebrobasilar	  events	  can	  also	  include	  symptoms	  that	  are	  classically	  attributable	  to	  presumed	  
anterior	   circulation	   ischaemia,	   including	   unilateral	   weakness	   or	   numbness.	   In	   a	   consecutive	  
series	   of	   407	  patients	  with	   posterior	   circulation	   stroke	   in	   a	   tertiary	   referral	   centre,	   the	  most	  
common	   symptoms	   were	   dizziness	   47%,	   unilateral	   limb	   weakness	   41%,	   dysarthria	   31%,	  
headache	   28%	   and	   nausea/vomiting	   in	   27%.	   The	   most	   frequent	   signs	   were:	   unilateral	   limb	  
weakness	   38%,	   gait	   ataxia	   31%,	   unilateral	   limb	   ataxia	   30%,	   dysarthria	   28%	   and	   nystagmus	  
24%432.	  	  	  
	  
3.1.4	  	  Imaging	  strategies	  in	  vertebral	  artery	  disease	  
MRI	  is	  more	  sensitive	  than	  CT	  for	   imaging	  posterior	  circulation	  ischaemia/infarcts,	  particularly	  
in	  the	  brainstem433.	   	  This	  reflects	  the	  higher	  resolution	  of	  MRI	  over	  CT	  for	   identifying	  infarcts,	  
especially	  small	  ones	  in	  the	  brainstem	  or	  cerebellum,	  because	  MRI	  is	  less	  prone	  to	  artefact	  than	  
CT.	  DWI	   is	  the	  most	  sensitive	  MRI	  technique	  for	  detecting	  acute	   ischaemia	  or	   infarction.	  DW-­‐
MRI	  may	  be	  positive	  for	  up	  to	  2	  weeks	  after	  onset	  of	  ischaemia,	  although	  it	  can	  occasionally	  be	  
negative,	  particularly	  with	  very	  small	  brainstem	  infarcts434.	  
	  
DUS	  is	  less	  sensitive	  at	  detecting	  VA	  stenoses	  than	  carotid	  stenoses435.	  	  The	  VA	  can	  often,	  but	  
not	  always,	  be	  visualised	  on	  DUS,	  but	  the	  more	  distal	  VA	  segments	  cannot	  be	  imaged	  directly	  
and	   the	   presence	   of	   a	   stenosis	   is	   often	   only	   inferred	   from	   waveform	   abnormalities.	   	   If	  
waveform	   abnormalities	   are	   present,	   however,	   they	   have	   a	   high	   specificity436.	   DUS	   provides	  
direct/indirect	  evidence	  of	  abnormal	  VA	  flow,	  including	  lesions	  located	  proximally	  or	  distally437.	  
DUS	   can	   estimate	   VA	   size	   and	   direction	   of	   flow	   and	   can	   differentiate	   between	   hypoplasia,	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stenosis,	   occlusion	   and	   aplasia	   of	   the	   VA.	   However,	   it	   has	   low	   sensitivity,	   especially	   for	   the	  
deeply	   located	   proximal	   VA	   segment436,438.	   DUS	   can	   also	   indirectly	   suggest	   the	   presence	   of	  
subclavian	  steal	  syndrome	  with	  pre-­‐steal	  (transient	  mid-­‐systolic	  flow	  deceleration),	  partial	  steal	  
(flow	   reversal	   during	   systole)	   and	   complete	   subclavian	   steal	   (retrograde	   flow	   persisting	  
throughout	  the	  cardiac	  cycle).	  	  
	  
In	  the	  presence	  of	  a	  VA	  origin	  occlusion,	  flow	  through	  collaterals	  may	  be	  seen,	  while	  stenoses	  
may	  be	  visualized	  as	  turbulent	  flow	  or	  waveform	  dampening.	  An	  intra-­‐stenotic	  to	  post-­‐stenotic	  
PSVVA	   ratio	   >2.2	   has	   been	   validated	   as	   the	   optimal	   criterion	   for	   diagnosing	   a	   proximal	   VA	  
stenosis	   ≥50%,	   with	   a	   sensitivity	   and	   specificity	   of	   96%	   and	   89%,	   respectively439.	   Beyond	  
stenosis	   grading,	   VA	   diameters	   that	   differ	   by	   >25%	   are	   considered	   non-­‐symmetrical440.	  
Hypoplasia	  in	  the	  V2	  segment	  is	  defined	  as	  a	  diameter	  ≤2.5mm	  or	  a	  difference	  compared	  with	  
the	  contralateral	  side	  of	  >1:1.7	  and	  a	  significant	  decrease	   in	  flow	  velocities	  as	  compared	  with	  
the	  contralateral	  side	  and	  an	  increase	  in	  ipsilateral	  flow	  resistance	  index	  ≥0.85442.	  	  
	  
Historically,	  intra-­‐arterial	  angiography	  was	  the	  ‘gold	  standard’	  for	  diagnosing	  atherosclerotic	  VA	  
disease.	  However,	  because	  of	  angiography-­‐related	  stroke,	  it	  has	  been	  replaced	  by	  non-­‐invasive	  
imaging,	   especially	   CEMRA	   and	   CTA.	   Both	   allow	   visualisation	   of	   the	   entire	   vertebrobasilar	  
system,	   thereby	   enabling	   simultaneous	   detection	   of	   extra-­‐	   and	   intracranial	   VA	   and	   basilar	  
stenoses.	   CEMRA	  provides	   better	   visualisation	   of	   the	   vertebrobasilar	   system,	   particularly	   the	  
proximal	  VA,	  than	  non-­‐contrast	  MRA	  techniques,	  such	  as	  time	  of	  flight	   imaging435.	   	   In	  a	  study	  
comparing	  CTA,	  CEMRA,	  and	  DUS,	  against	  the	  ‘gold	  standard’	  of	  intra-­‐arterial	  digital	  subtraction	  
angiography,	   CEMRA	   and	   CTA	   were	   found	   to	   have	   high	   sensitivity	   and	   specificity	   and	   were	  
better	  than	  DUS	  for	  evaluating	  the	  VAs439.	  	  
	  
Recommendation	  95	   Class	   Level	   References	  
Colour	  Duplex	  ultrasound	   is	   recommended	  as	  the	   first	   line	   imaging	  
strategy	   in	   patients	   with	   suspected	   vertebrobasilar	   ischaemia,	   but	  
must	  be	   followed	  by	  either	  contrast	  enhanced	  magnetic	   resonance	  
angiography	   or	   computed	   tomography	   angiography	   before	   any	  
decisions	  on	  intervention	  are	  made.	  




3.2	  Secondary	  prevention	  in	  asymptomatic	  patients	  
3.2.1	  	  	  	  Optimal	  medical	  therapy	  
3.2.1.1	  Risk	  factor	  control	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There	  have	  been	  no	   specific	  RCTs	  evaluating	   the	  effect	  of	   risk	   factor	   control	   in	  patients	  with	  
asymptomatic	  VA	   stenoses.	  Accordingly,	   it	   is	   reasonable	   to	  adopt	   the	   same	  strategy	   that	  has	  
been	  recommended	  for	  ACS	  (section	  2.2.1.1).	  	  
Recommendation	  96	   Class	   Level	   References	  
A	   healthy	   diet,	   smoking	   cessation	   and	   physical	   activity	   are	  
recommended	   for	   all	   patients	  with	   asymptomatic	   vertebral	  
artery	  disease	  
I	   C	   	  
	  
3.2.1.2	  Antiplatelet	  therapy	  
There	  have	  been	  no	  specific	  RCTs	  evaluating	  the	  effect	  of	  antiplatelet	  therapy	  in	  patients	  with	  
asymptomatic	  VA	   stenoses.	  Accordingly,	   it	   is	   reasonable	   to	  adopt	   the	   same	  strategy	   that	  has	  
been	  recommended	  for	  ACS	  (section	  2.2.1.2).	  	  
	  
Recommendation	  97	   Class	   Level	   References	  
Low	   dose	   aspirin	   (75-­‐325mg	   daily)	   (or	   clopidogrel	  
(75mg	   daily)	   if	   aspirin	   intolerant)	   is	   recommended	   in	  
asymptomatic	  patients	  with	  vertebral	  stenoses	  for	  the	  
prevention	  of	  myocardial	  infarction	  and	  other	  vascular	  
events.	  
I	   C	   	  
	  
3.2.1.3	  Lipid	  lowering	  therapy	  
There	   have	   been	   no	   specific	   RCTs	   evaluating	   the	   effect	   of	   statin	   therapy	   in	   patients	   with	  
asymptomatic	  VA	   stenoses.	  Accordingly,	   it	   is	   reasonable	   to	  adopt	   the	   same	  strategy	   that	  has	  
been	  recommended	  for	  ACS	  (section	  2.2.1.3).	  	  
Recommendation	  98	   Class	   Level	   References	  
Statin	  therapy	  is	  recommended	  for	  the	  prevention	  of	  
stroke,	   myocardial	   infarction	   and	   other	  
cardiovascular	  events	  in	  patients	  with	  asymptomatic	  
vertebral	  artery	  stenoses.	  
I	   C	   	  
	  
3.2.1.4	  Treatment	  of	  hypertension	  
There	  have	  been	  no	  specific	  RCTs	  evaluating	  the	  effect	  of	  antihypertensive	  therapy	  in	  patients	  
with	  asymptomatic	  VA	  stenoses.	  Accordingly,	   it	   is	  reasonable	  to	  adopt	  the	  same	  strategy	  that	  
has	  been	  recommended	  for	  ACS	  (section	  2.2.1.4).	  	  
Recommendation	  99	   Class	   Level	   References	  
Antihypertensive	   treatment	   is	   recommended	   for	  
patients	   with	   hypertension	   and	   asymptomatic	  
extracranial	   vertebral	   artery	   stenoses	   to	   maintain	  
long	  term	  blood	  pressure	  <140/90mmHg	  
I	   C	   	  
	  
3.2.1.5	  Treatment	  in	  diabetic	  patients	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There	  have	  been	  no	  specific	  RCTs	  evaluating	  the	  effect	  of	  therapy	  for	  diabetes	  in	  patients	  with	  
asymptomatic	  VA	   stenoses.	  Accordingly,	   it	   is	   reasonable	   to	  adopt	   the	   same	  strategy	   that	  has	  
been	  recommended	  for	  ACS	  (section	  2.2.1.5).	  	  
Recommendation	  100	   Class	   Level	   References	  
In	   diabetic	   patients	   with	   asymptomatic	   vertebral	  
artery	   stenoses,	   strict	   glycaemic	   control	   is	  
recommended	  
I	   C	   	  
	  
Recommendation	  101	   Class	   Level	   References	  
In	   diabetic	   patients	   with	   asymptomatic	   vertebral	  
artery	  stenoses,	  the	  target	  blood	  pressure	  should	  be	  
<140/85mmHg	  
I	   B	   48	  
	  
	  
3.2.2	  Screening	  for	  asymptomatic	  vertebral	  artery	  disease	  
There	   have	   been	   no	   specific	   RCTs	   evaluating	   the	   effect	   of	   screening	   in	   patients	   with	  
asymptomatic	  VA	   stenoses.	  Accordingly,	   it	   is	   reasonable	   to	  adopt	   the	   same	  strategy	   that	  has	  
been	  recommended	  for	  ACS	  (section	  2.2.2).	  	  
Recommendation	  102	   Class	   Level	   References	  
Population	  screening	  for	  asymptomatic	  vertebral	  artery	  stenoses	  
is	  not	  recommended	  	  
III	   C	   	  
	  
	  
3.2.3	  	  Interventions	  for	  asymptomatic	  vertebral	  artery	  disease	  
The	   risk	   of	   stroke	   in	   patients	   with	   asymptomatic	   VA	   stenoses	   is	   much	   lower	   than	   for	  
symptomatic	   VA	   stenoses.	   In	   a	   hospital-­‐based	   study	   of	   3,717	   patients	   with	   atherosclerotic	  
arterial	  disease,	  7.6%	  had	  asymptomatic	  VA	  stenoses	  of	  >50%	  on	  DUS442.	  The	  annual	  stroke	  risk	  
was	  0.2%	  in	  patients	  with	  isolated	  asymptomatic	  VA	  stenoses	  and	  0.8%	  for	  those	  with	  VA	  and	  
carotid	  artery	  stenoses.	  	  	  
Recommendation	  103	   Class	   Level	   References	  
It	   is	   recommended	   that	   asymptomatic	   vertebral	   artery	  
atherosclerotic	   lesions	   should	   not	   be	   treated	   by	   open	   or	  
endovascular	  interventions	  
III	   C	   442	  
	  
	  
3.3	  Tertiary	  prevention	  in	  recently	  symptomatic	  patients	  
3.3.1	  	  	  	  Optimal	  medical	  therapy	  
 118 
3.3.1.1	  Risk	  factor	  control	  
There	  have	  been	  no	   specific	  RCTs	  evaluating	   the	  effect	  of	   risk	   factor	   control	   in	  patients	  with	  
symptomatic	   VA	   stenoses.	   Accordingly,	   it	   is	   reasonable	   to	   adopt	   the	   same	   strategy	   that	   has	  
been	  recommended	  for	  symptomatic	  carotid	  stenoses	  (section	  2.3.2.1).	  	  
	  
Recommendation	  104	   Class	   Level	   References	  
A	   healthy	   diet,	   smoking	   cessation	   and	   physical	   activity	   are	  
recommended	   for	   all	   patients	   with	   symptomatic	   vertebral	  
artery	  disease	  
I	   C	   	  
	  
3.3.1.2	  Antiplatelet	  therapy	  
There	  have	  been	  no	  specific	  RCTs	  evaluating	  the	  effect	  of	  antiplatelet	  therapy	  in	  patients	  with	  
symptomatic	   VA	   stenoses.	   Accordingly,	   it	   is	   reasonable	   to	   adopt	   the	   same	   strategy	   that	   has	  
been	  recommended	  for	  symptomatic	  carotid	  stenoses	  (section	  2.3.2.2).	  	  
	  
Recommendation	  105	   Class	   Level	   References	  
Antiplatelet	   therapy	   is	   recommended	   in	  
symptomatic	   patients	   with	   50-­‐99%	   stenoses	   not	  
undergoing	   vertebral	   interventions.	   First	   choice	  
therapy	   is	   clopidogrel	   75mg	   daily	   or	   aspirin	   75mg	  
daily	  plus	  modified	   release	  dipyridamole	  200mg	  bd.	  
If	   intolerant	   of	   dipyridamole	   or	   clopidogrel,	   aspirin	  
monotherapy	   (75-­‐325mg)	   should	   be	   used.	   If	   aspirin	  
and	   clopidogrel	   intolerant,	   use	   dipyridamole	   MR	  
200mg	  bd.	  	  
I	   A	   121-­‐124,126	  
	  
Recommendation	  106	   Class	   Level	   References	  
It	  is	  recommended	  that	  patients	  undergoing	  
vertebral	   artery	   stenting	   should	   receive	   dual	  
antiplatelet	   therapy	   with	   aspirin	   (75-­‐325mg	   daily)	  
and	   clopidogrel	   (75mg	   daily).	   Clopidogrel	   should	   be	  
started	  at	  least	  3	  days	  prior	  to	  stenting	  or	  as	  a	  single	  
300mg	   loading	   dose	   in	   urgent	   cases	   followed	   by	  
75mg	   daily.	   Aspirin	   and	   clopidogrel	   should	   be	  
continued	   for	   at	   least	   4	   weeks	   after	   stenting	   and	  
then	   optimal	   long-­‐term	   secondary	   preventive	  
antiplatelet	   therapy	   should	   be	   continued	  
indefinitely.	  	  	  	  
I	   C	   	  
	  
	  
Recommendation	  107	   Class	   Level	   References	  
Long-­‐term	   aspirin	   plus	   clopidogrel	   therapy	   is	   not	  
recommended	   in	   symptomatic	   patients	   undergoing	  
open	  surgery	  or	  stenting	  of	  vertebral	  artery	  stenoses	  
unless	  indicated	  for	  cardiac	  reasons	  
III	   C	   	  
	  
	  
Recommendation	  108	   Class	   Level	   References	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Concurrent	   gastro-­‐protection	   therapy	   or	   proton	  
pump	   inhibition	   with	   pantoprazole	   should	   be	  
considered	   in	   patients	   prescribed	   clopidogrel	   who	  
have	  one	  or	  more	  factors	  that	  increase	  the	  patient’s	  
risk	   of	   gastrointestinal	   bleeding	   (prior	   history	   of	  
gastrointestinal	   bleeding,	   older	   age,	   helicobacter	  
pylori	  infection,	  concomitant	  use	  of	  aspirin,	  or	  other	  
non-­‐steroidal	   anti-­‐inflammatory	   agents,	  
anticoagulants,	   selective	   serotonin	   re-­‐uptake	  
inhibitors	  and	  steroids).	  
IIa	   B	   148-­‐151	  
	  
3.3.1.3	  Lipid	  lowering	  therapy	  
There	  have	  been	  no	   specific	  RCTs	  evaluating	   the	  effect	  of	   risk	   factor	   control	   in	  patients	  with	  
symptomatic	   VA	   stenoses.	   Accordingly,	   it	   is	   reasonable	   to	   adopt	   the	   same	   strategy	   that	   has	  
been	  recommended	  for	  symptomatic	  carotid	  stenoses	  (section	  2.3.2.3).	  	  
Recommendation	  109	   Class	   Level	   References	  
Statin	  therapy	  is	  recommended	  for	  the	  prevention	  of	  
stroke,	   myocardial	   infarction	   and	   other	  
cardiovascular	   events	   in	   patients	  with	   symptomatic	  
vertebral	  artery	  stenoses.	  
I	   C	   	  
	  
3.3.1.4	  Treatment	  of	  hypertension	  
There	  have	  been	  no	  specific	  RCTs	  evaluating	  the	  effect	  of	  antihypertensive	  therapy	  in	  patients	  
with	   symptomatic	  VA	   stenoses.	  Accordingly,	   it	   is	   reasonable	   to	  adopt	   the	   same	   strategy	   that	  
has	  been	  recommended	  for	  symptomatic	  carotid	  stenoses	  (section	  2.3.2.4).	  	  
Recommendation	  110	   Class	   Level	   References	  
Antihypertensive	   treatment	   is	   recommended	   for	  
patients	   with	   hypertension	   and	   symptomatic	  
extracranial	   vertebral	   artery	   stenoses	   to	   maintain	  
long	  term	  blood	  pressure	  <140/90mmHg	  
I	   A	   45,47	  
	  
	  
3.3.1.5	  Treatment	  in	  diabetic	  patients	  
There	  have	  been	  no	  specific	  RCTs	  evaluating	  the	  effect	  of	  therapy	  for	  diabetes	  in	  patients	  with	  
symptomatic	   VA	   stenoses.	   Accordingly,	   it	   is	   reasonable	   to	   adopt	   the	   same	   strategy	   that	   has	  
been	  recommended	  for	  symptomatic	  carotid	  stenoses	  (section	  2.3.2.5).	  	  
Recommendation	  111	   Class	   Level	   References	  
In	   diabetic	   patients	   with	   symptomatic	   vertebral	  
artery	   stenoses,	   strict	   glycaemic	   control	   is	  
recommended	  
I	   C	   	  
	  
Recommendation	  112	   Class	   Level	   References	  
In	   diabetic	   patients	   with	   symptomatic	   vertebral	   I	   B	   48	  
 120 




3.3.2	  Interventions	  in	  recently	  symptomatic	  patients	  
It	  was	  previously	  thought	  that	  vertebrobasilar	  events	  had	  a	  more	  benign	  prognosis	  than	  carotid	  
events.	   Consequently,	   patients	   were	   less	   rigorously	   investigated	   and	   did	   not	   always	   receive	  
intensive	   secondary	   prevention.	   Recent	   evidence,	   however,	   suggests	   that	   VA	   stenoses	   are	  
associated	  with	  higher	  rates	  of	  early	   recurrent	  stroke,	  with	  a	  risk	  profile	  similar	   to	   (or	  worse)	  
than	  that	  for	  carotid	  disease.	  Evidence	  suggests	  that	  the	  90-­‐day	  risk	  of	  recurrent	  stroke	  is	  7%	  in	  
patients	  with	  no	  VA	  stenoses,	  16%	  in	  patients	  with	  extracranial	  VA	  stenoses,	  and	  33%	  in	  those	  
with	  intracranial	  VA	  or	  basilar	  artery	  stenoses443.	  	  	  
	  
The	  evidence	  would,	   therefore,	   suggest	   that	  any	   intervention	   in	   symptomatic	   vertebrobasilar	  
patients	   should	   probably	   be	   undertaken	   early	   after	   symptom	   onset443.	   This	   is	   not,	   however,	  
reflected	   in	   several	   RCTs.	   In	   CAVATAS,	   the	   mean	   interval	   between	   symptom	   onset	   and	  
randomization	  was	  92	  days	  (range	  5-­‐376),	  while	  the	  mean	  interval	  between	  randomization	  and	  
endovascular	   treatment	   was	   45	   days	   (range	   7-­‐148	   days)444.	   In	   the	   Stenting	   of	   Symptomatic	  
Atherosclerotic	   Lesions	   in	   the	   Vertebral	   or	   Intracranial	   Arteries	   (SSYLVIA)	   study445,	   the	  mean	  
delay	  between	  qualifying	  event	  and	  stenting	  was	  73	  days	  (median	  29,	  range	  1-­‐959	  days).	  In	  the	  
Vertebral	   Artery	   Stenting	   Trial	   (VAST),	   the	   median	   interval	   between	   last	   symptom	   and	  
randomisation	  was	  25	  days	  (IQR	  11–50),	  while	  the	  delay	  between	  randomisation	  and	  stenting	  
was	  7	  days	  (0–12)446.	  For	  a	  summary	  of	  the	  key	  findings	  of	  the	  various	  RCTs,	  see	  section	  3.3.4.1.	  	  
	  
3.3.2.1	  Role	  of	  vertebral	  revascularisation	  in	  ‘positional	  vertigo’	  
It	  is	  not	  unusual	  for	  a	  diagnosis	  of	  ‘positional’	  vertebrobasilar	  ischaemia	  to	  be	  made	  in	  patients	  
presenting	  with	  dizziness	  or	  vertigo	  during	  lateral	  neck	  rotation	  or	  extension.	  Historically,	  these	  
symptoms	   have	   been	   attributed	   to	   VA	   ‘nipping’	   in	   the	   bony	   foramina	   of	   the	   transverse	  
processes	   of	   the	   cervical	   vertebrae.	   However,	   while	   occasional	   diagnoses	   have	   been	  
corroborated	  using	  CTA/MRA/DSA,	  most	  are	  probably	  made	  without	  any	  further	  investigation.	  
As	  a	  consequence,	  patients	  may	  then	  be	  turned	  down	  for	  major	  surgery	  on	  the	  mistaken	  belief	  
that	   they	   might	   be	   high-­‐risk	   for	   peri-­‐operative	   stroke	   because	   of	   a	   misdiagnosis	   of	  
vertebrobasilar	   ischaemia.	   A	   systematic	   review	   of	   the	   literature447	   observed	   that	   out	   of	   20	  
published	   studies,	   seven	   reported	  no	   changes	   in	  VA	  or	   posterior	   cerebral	   artery	   (PCA)	   blood	  
flow,	   while	   13	   described	   varying	   changes	   (reversal,	   complete	   occlusion,	   reduced	   flow).	   In	   a	  
 121 
series	   of	   46	   patients	   with	   an	   accessible	   window	   for	   TCD	   and	   who	   presented	   with	  
dizziness/vertigo	  on	  head	  movement,	  none	  exhibited	  any	  change	  in	  extracranial	  VA	  flow	  during	  
head	  turning/extension	  and	  none	  had	  reversal	  of	  VA	  flow.	  There	  were	  also	  no	  changes	  in	  PCA	  
flow	  characteristics	  (directionality/flow	  velocities)	  during	  head	  turning.	  In	  this	  series,	  74%	  were	  
referred	  to	  a	  Balance	  Clinic,	  where	  94%	  noted	  an	  improvement	  following	  entry	  into	  a	  vestibular	  
rehabilitation	   programme448,	   presumably	   due	   to	   successful	   treatment	   for	   benign	   positional	  
vertigo.	  
	  
3.3.3	  	  Open	  surgical	  management	  
Access	   to	   the	   VA	   is	   less	   easy	   than	   for	   the	   ICA.	   This	   is	   the	   main	   reason	   why	   surgery	   is	   less	  
commonly	  undertaken	  to	  treat	  symptomatic	  stenoses430.	  Surgical	  approaches	  to	  lesions	  at	  the	  
VA	  origin	  include:	  transposition	  to	  the	  ipsilateral	  CCA,	  VA	  re-­‐implantation,	  vein	  bypass	  grafting	  
from	   the	   subclavian	   artery	   and	   trans-­‐subclavian	   vertebral	   endarterectomy.	   Reconstruction	  of	  
the	   distal	   VA	   can	   treat	   stenoses	   or	   occlusions	   within	   the	   V2/V3	   segments,	   but	   worldwide	  
experience	  is	  limited.	  	  
A	  variety	  of	  techniques	  for	  reconstructing	  the	  distal	  VA	  V3	  segment	  (from	  C2	  to	  where	  the	  VA	  
perforates	  the	  dura)	  have	  been	  reported.	  These	   include	  transposition	  (suitable	  only	  for	  C1-­‐C2	  
reconstructions)	  and	  bypass	  grafting.	  Transposition	  procedures	  using	  the	  ECA	  or	  occipital	  artery	  
rely	  on	  the	  size	  and	  patency	  of	  the	  donor	  artery	  and	  are	  indicated	  if	  there	  is	  no	  suitable	  graft	  
available.	   Graft	   conduits	   include	   reversed	   saphenous	   vein,	   prosthetic	   and	   other	   autologous	  
grafts	   (eg	   radial	   artery)449	   The	   only	   available	   data	   available	   are	   from	   non-­‐controlled	   studies,	  
which	  are	  vulnerable	   to	  publication	  bias	  and	   selective	   reporting	  of	   favourable	   results.	   	   These	  
have	   reported	  early	   complication	   rates	  of	  2.5-­‐25%	   for	  VA	   reconstructions,	  with	  perioperative	  
mortality	  rates	  of	  0-­‐4%	  and	  mortality	  rates	  of	  2-­‐8%	  for	  distal	  artery	  reconstruction449-­‐452.	  	  	  
	  
3.3.4	  	  Endovascular	  treatment	  
3.3.4.1	  	  Stenting	  vs	  medical	  therapy	  
Little	  data	  are	  available	  regarding	  extracranial	  VA	  stenting	  in	  the	  early	  time	  period	  after	  onset	  
of	  symptoms.	  A	  review	  of	  600	  cases	  of	  symptomatic	  VA	  stenoses	  (symptoms	  within	  6	  months)	  
treated	  with	   angioplasty	   +/-­‐	   stenting	   stratified	   the	   stenoses	   according	   to	  whether	   they	  were	  
proximally	  or	  distally	  located453.	  	  Stenting	  of	  the	  proximal	  VA	  was	  technically	  successful	  in	  99%,	  
with	  a	  mortality	  of	  0.3%	  and	  a	  peri-­‐operative	  stroke	  rate	  of	  1.3%.	  	  Following	  stenting,	  there	  was	  
a	   low	   rate	   of	   annual	   recurrent	   stroke	   (0.6%),	   although	   there	  was	   a	   25%	   restenosis	   rate.	   	   By	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contrast,	  stenting	  or	  angioplasty	  of	  the	  distal	  VA	  was	  associated	  with	  higher	  morbidity	  (10.6%	  
for	  stenting,	  7.1%	  for	  angioplasty),	  with	  mortality	  rates	  of	  3.2%	  and	  3.7%	  respectively453.	  	  	  
	  
A	  systematic	   review,	   involving	  1,000	  patients	  undergoing	  extracranial	  VA	  stenting,	   reported	  a	  
periprocedural	  stroke	  risk	  of	  1.1%454.	  However,	  high	  restenosis	  rates	  (25-­‐30%)	  complicated	  VA	  
origin	  stenting.	  The	  systematic	   review	  observed	  that	   the	  use	  of	  drug	  eluting	  stents	   (DES)	  was	  
associated	  with	  lower	  rates	  of	  restenosis	  compared	  with	  bare	  metal	  stents	  (BMS)	  (11%	  vs	  30%)	  
after	   a	   mean	   follow-­‐up	   of	   24	   months453,	   although	   not	   all	   case	   series	   have	   shown	   this	  
association455,456.	   The	   available	   data	   suggest	   that	   interventions	   involving	   intracranial	   VA	  
stenoses	  were	   associated	  with	  higher	   procedural	   risks	   than	   for	   extracranial	   lesions.	  However	  
this	   has	   to	   be	   balanced	   against	   the	   much	   higher	   risk	   of	   recurrent	   stroke	   for	   patients	   with	  
intracranial	  VA	  stenoses443.	  	  	  
	  
There	   is	   little	  RCT	  data	  to	  guide	  practice.	  CAVATAS	  randomised	  16	  patients	  with	  symptomatic	  
VA	  stenoses	  to	  angioplasty	  or	  BMT444.	  None	  developed	  recurrent	  symptoms,	  but	  many	  patients	  
were	   recruited	   months	   after	   their	   last	   TIA/stroke,	   ie	   well	   beyond	   the	   high-­‐risk	   period	   for	  
recurrent	  stroke.	  	  
	  
The	   VAST	   study	   randomised	   115	   symptomatic	   patients	   with	   >50%	   intra-­‐	   or	   extracranial	   VA	  
stenoses.	  Fifty-­‐seven	  were	   randomised	   to	  stenting	  and	  58	   to	  BMT446.	   	  Three	  stented	  patients	  
suffered	   a	   stroke,	  MI	   or	   vascular	   death	  within	   30	   days	   of	   treatment,	   versus	   one	   in	   the	   BMT	  
group.	   	  During	  a	  median	  3-­‐year	   follow-­‐up,	   seven	  stented	  patients	   (12%)	  and	   four	   (7%)	   in	   the	  
BMT	  group	  experienced	  a	   stroke	   in	   the	   territory	  of	   the	   symptomatic	  VA446.	  During	   follow-­‐up,	  
there	  were	   eight	   ‘any’	   strokes	   in	   the	   stented	   group	   and	   seven	   in	   the	   BMT	   group.	   VAST	  was	  
stopped	  prematurely	  due	  to	  regulatory	   issues	  and	  was	  underpowered	  to	  show	  any	  significant	  
difference	  between	  stenting	  and	  BMT.	  There	  was	  no	  evidence	  of	  any	  benefit	  favouring	  stenting.	  
It	  did,	  however,	  suggest	  that	  the	  risk	  of	  stenting	  for	  patients	  with	  intracranial	  VA	  stenoses	  was	  
relatively	   high.	   	   This	   is	   very	   similar	   to	   data	   from	   the	   Stenting	   and	   Aggressive	   Medical	  
Management	   for	   Preventing	   Recurrent	   Stroke	   and	   Intracranial	   Stenosis	   Trial	   (SAMMPRIS)457.	  
SAMMPRIS	  compared	  stenting	  (Wingspan	  stent)	  against	  BMT	  in	  450	  patients	  with	  symptomatic	  
intracranial	   stenoses,	   of	   whom	   60	   (13%)	   had	   stenoses	   of	   the	   VA	   or	   basilar	   arteries.	   Basilar	  
artery	  stenoses	  were	  associated	  with	  particularly	  high	  rates	  of	  periprocedural	  ischaemic	  stroke	  
following	  stenting	  (21%	  versus	  7%	  for	  other	  arteries)	  458.	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A	   systematic	   review,	   involving	   672	   symptomatic	   patients	   in	   4	   RCTs	   and	   6	   non-­‐randomised	  
studies	   between	   2007-­‐2015,	   and	   which	   compared	   outcomes	   between	   percutaneous	  
transluminal	   angioplasty	   (PTA)	   plus	   BMT	   versus	   BMT	   alone,	   observed	   no	   significant	   benefit	  
from	  PTA	  +	  BMT	  over	  BMT	  alone	  (table	  28)459.	  	  
	  
Table	   28:	   30-­‐day	   and	   long-­‐term	  outcomes	   in	   a	  meta-­‐analysis	   of	   PTA	   +	   BMT	   versus	   BMT	   in	  
patients	  with	  symptomatic	  vertebral	  artery	  stenoses*.	  
	  
Endpoint	   30-­‐day	   Long	  term	  
	   PTA+BMT	   BMT	   PTA+BMT	   BMT	  
posterior	  circulation	  	  
TIA	  
16.7%	   0.0%	  p=0.09	   10%	   38%	  p=0.11	  
posterior	  circulation	  infarction	   1.8%	   1.7%	  p=0.99	   6%	   12%	  p=0.51	  
*	  data	  derived	  from	  Feng	  et	  al459	  	  
	  
Not	   included	   in	  Feng’s	  meta-­‐analysis	  was	  the	  Vertebral	  Artery	   Ischaemia	  Stenting	  Trial	   (VIST),	  
which	   presented	   its	   results	   at	   the	   European	   Stroke	  Organisation	   Conference	   in	   2016460.	   VIST	  
randomised	  182	  patients	  with	  symptomatic	   intra-­‐	  and	  extracranial	  VA	  stenoses	  between	  BMT	  
versus	   angioplasty	  with	   or	  without	   stenting.	  Almost	   all,	   however,	   underwent	   stenting.	   It	   had	  
been	  hoped	  to	  recruit	  540	  patients,	  but	  funding	  was	  stopped	  due	  to	  slow	  recruitment.	  Of	  the	  
91	  patients	   randomised	  to	  stenting,	   the	  procedure	  was	  not	  performed	   in	  30	   (33%).	  The	  main	  
reason	   in	   23	   patients	   (77%))	   was	   the	   finding	   of	   a	   stenosis	   <50%	   on	   DSA	   at	   the	   time	   of	   the	  
planned	  stenting.	  Selection	  prior	  to	  randomisation	  had	  been	  on	  the	  basis	  of	  CTA	  or	  MRA.	  Of	  the	  
61	  patients	  in	  the	  stent	  group,	  the	  stenosis	  was	  extracranial	  in	  48	  (79%)	  and	  intracranial	  in	  13	  
(21%).	  Mean	   follow-­‐up	  was	  3.5	  years.	  The	  primary	  endpoint	  was	  any	   stroke	  during	   follow-­‐up	  
and	  on	  an	  ‘intention	  to	  treat’	  analysis,	  this	  occurred	  in	  5	  patients	  (including	  one	  fatal	  stroke)	  in	  
the	  stent	  group	  and	  in	  12	  patients	  (including	  two	  fatal	  strokes)	   in	  the	  medical	  group	  (HR	  0.40	  
(95%CI	  0.14-­‐1.13),	   p=0.08),	  which	   trended	   in	   favour	  of	   stenting.	  However,	   after	   adjusting	   for	  
time	  from	  last	  symptom	  to	  randomisation,	  which	  was	  significantly	  shorter	  in	  the	  stented	  arm,	  
the	  results	  became	  significant	  with	  a	  HR	  of	  0.34	  (95%CI	  0.12-­‐0.98)	  p=0.04).	  Due	  to	  the	  majority	  
of	   patients	   in	   VIST	   having	   extracranial	   stenoses,	   drawing	   firm	   conclusions	   on	   the	   benefit	   of	  
stenting	  intracranial	  stenoses	  was	  not	  possible,	  but	  the	  risk	  of	  peri-­‐procedural	  stroke	  appeared	  
to	   be	   higher	   for	   intracranial	   stenoses	   (zero	   for	   stenting	   of	   extracranial	   stenoses,	   2/13	   (15%)	  
following	   stenting	   of	   intracranial	   stenoses.	   Higher	   stroke	   risks	   associated	   with	   stenting	   of	  
intracranial	  stenoses	  was	  also	  observed	  in	  the	  SAMMPRIS	  study457.	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The	   fact	   that	   VIST	   (like	   VAST	   before	   it)	   stopped	   early,	   means	   that	   they	   were	   inevitably	  
underpowered	  to	  make	  definitive	  conclusions.	  However,	  whilst	  awaiting	  corroboration	  in	  larger	  
RCTs,	  the	  VIST	  findings	  suggest	  that	  stenting	  of	  recently	  symptomatic	  extracranial	  VA	  stenoses	  
may	  be	  appropriate	  in	  selected	  patients,	  especially	  those	  with	  recurrent	  symptoms,	  despite	  risk	  
factor	  modification	  and	  optimal	  BMT460,462.	  
	  
Recommendation	  113	   Class	   Level	   References	  
Patients	  with	  recurrent	  vertebrobasilar	  territory	  symptoms	  (despite	  
best	  medical	  therapy)	  and	  who	  have	  a	  50-­‐99%	  extracranial	  vertebral	  
artery	  stenosis	  may	  be	  considered	  for	  revascularisation	  
IIb	   B	   446,449,451,460,461	  
	  
	  
Recommendation	  114	   Class	   Level	   References	  
No	  one	  should	  have	  a	  diagnosis	  of	  ‘positional	  vertigo’	  attributed	  to	  
nipping	   of	   the	   vertebral	   arteries	   on	   head	   movements,	   unless	  
corroborated	   by	   computed	   tomographic,	   magnetic	   resonance	   or	  
digital	  subtraction	  angiography.	  	  
III	   C	   447,448	  
	  
	  
3.3.4.2	  	  Adjuvant	  medical	  therapy	  
Protocols	  regarding	  dual	  antiplatelet	  therapy,	  statins	  and	  intravenous	  heparin	  are	  the	  same	  as	  
for	  CAS	  (sections	  2.3.2.2.3	  and	  2.3.2.2.3).	  	  
	  
3.3.4.3	  	  Access	  
Most	  procedures	  are	  performed	  via	  a	  femoral	  approach	  (93%),	  although	  transbrachial	  (3%)	  and	  
trans-­‐radial	   access	   (5%)	   have	   been	   used462.	   The	   procedure	   is	   usually	   performed	   under	   LA,	  
thereby	  enabling	  continuous	  neurologic	  monitoring.	  
	  
3.3.4.4	  	  Choice	  of	  wires,	  access	  catheters,	  stent	  design	  	  
A	  5F/6F	  guiding	   catheter	  or	   long-­‐access	   sheath	   (when	  working	   via	   the	  CFA)	   is	  navigated	   to	  a	  
stable	   position	   in	   the	   subclavian	   artery.	   The	  VA	  ostium	   is	   cannulated	   and	   the	   stenotic	   lesion	  
crossed	  with	  0.014-­‐	  or	  0.018-­‐inch	  guide	  wires	  and	   treated	  using	   small	   coronary	  balloons	  and	  
stents.	   Both	   monorail	   and	   over-­‐the-­‐wire	   systems	   are	   available,	   but	   the	   former	   has	   the	  
advantage	   of	   using	   standard-­‐length	   wires,	   making	   catheter	   exchange	   simpler.	   Despite	   high	  
technical	   success	   rates,	   VA	   angioplasty	   (alone),	   especially	   when	   used	   for	   the	   treatment	   of	  
disease	  at	  the	  VA	  origin,	  appears	  to	  have	  high	  rates	  of	  restenosis463.	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Angioplasty	  with	   stent	  placement	   seems	   to	  aid	  durability.	   Specifically	  designed	   stents	   for	   the	  
VA	  are	  not	  available	  and	  coronary	  balloon-­‐expandable	   stents	  are	   typically	  used	  because	   they	  
have	   a	   low	   crossing	   profile,	   limited	   foreshortening,	   and	   easy	   navigation	   through	   tortuous	  
vessels.	   Although	   self-­‐expanding	   stents	   are	   more	   difficult	   to	   deploy	   as	   precisely	   as	   balloon-­‐
expandable	  stents	  (especially	  in	  ostial	  lesions),	  they	  can	  be	  reserved	  for	  extracranial	  VA	  stenting	  
in	  vessels	  with	  too	  large	  a	  diameter	  for	  using	  coronary	  stents	  (>4mm).	  Late	  stent	  fracture	  with	  
in-­‐stent	   restenosis	   is	   a	   problem	  with	  endoluminal	   therapies	   at	   the	  VA	  origin.	  A	   recent	  meta-­‐
analysis	  of	  non-­‐randomised	  studies	  suggested	  that	   there	  was	  no	  difference	  between	  DES	  and	  
BMS	   regarding	   technical	   success,	   clinical	   success	   and	   peri-­‐procedural	   complications	   in	   the	  
treatment	  of	  extracranial	  VA	   stenoses.	  However,	   (compared	  with	  DES),	  BMS	   treated	  patients	  
had	   significantly	   higher	   rates	   of	   recurrent	   symptoms	   (2.8%	   vs	   11.3%	   (OR	   3.3,	   p=0.01)	   and	  
restenoses	  (15.5%	  vs	  33.6%	  (OR	  0.38),	  p=0.001)	  464	  (section	  3.4.2).	  
	  
3.3.4.5	  	  Cerebral	  protection	  devices	  
Procedures	  can	  be	  performed	  with	  or	  without	  CPDs,	  although	  VAs	  are	  sometimes	  too	  small	  to	  
accommodate	  them.	  One	  large	  review	  found	  distal	  protection	  was	  only	  used	  in	  2%	  of	  cases462.	  	  
	  
3.3.4.6	  	  Predilatation	  
The	  risks	  associated	  with	  pre-­‐dilatation	  in	  extracranial	  VA	  stenting	  have	  never	  been	  reported.	  It	  
is	  reasonable	  to	  perform	  pre-­‐dilatation	  when	  the	  stent	  cannot	  pass	  through	  the	  VA	  stenosis.	  
	  
	  
3.4	  	  Complications	  after	  vertebral	  interventions	  
3.4.1	  	  procedural	  risks	  following	  open	  surgical	  reconstructions	  
Relatively	   few	   surgeons	   have	   experience	   of	   performing	   significant	   numbers	   of	   open	   VA	  
reconstructions.	   Accordingly,	   the	   results	   reported	   from	   large	   personal	   series	   by	   the	   small	  
number	  who	  do,	  may	  not	  actually	  represent	  ‘real	  world’	  practice.	  Table	  29	  details	  30-­‐day	  rates	  
of	   death,	   stroke	   (including	   laterality)	   and	   death/stroke	   after	   proximal	   and/or	   distal	   VA	  
reconstructions	  in	  the	  contemporary	  literature.	  	  
	  
Patency	   rates	   ranged	   from	   84	   to	   100%	   at	   30	   days449,451,465-­‐467,	   with	   one	   series	   of	   352	   VA	  
reconstructions	  reporting	  early	  occlusion	  rates	  of	  7%449.	  While	  30-­‐day	  death/stroke	  rates	  after	  
proximal	   and/or	   distal	   VA	   reconstructions	   (table	   29)	   were	   relatively	   low	   (2-­‐7%),	   there	   was	  
evidence	  of	   a	   trend	  across	   all	   published	   series	   that	   procedural	   risks	  were	   significantly	   higher	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when	  vertebral	  reconstructions	  were	  combined	  with	  carotid	  procedures	  (30-­‐day	  death/stroke	  
rate	   8-­‐11%).	   Paralysis	   of	   the	   spinal	   accessory	   nerve	   complicated	   1-­‐13%	   of	   procedures,	  
averaging	   7%,	   while	   Horner’s	   syndrome	   (temporary	   or	   permanent)	   complicated	   2-­‐21%	   of	  
procedures449,465-­‐467.	  	  	  
	  
Table	  29:	  morbidity	  and	  mortality	  after	  vertebral	  artery	  reconstructions	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3.4.2	  	  Procedural	  risks	  following	  vertertal	  artery	  stenting	  
In	  a	  review	  of	  outcomes	  in	  20	  non-­‐randomised	  studies	  involving	  1767	  undergoing	  VA	  stenting,	  
only	   5	   strokes	   (0.3%)	   were	   reported	   as	   occurring	   in	   the	   peri-­‐operative	   period.	   The	   rate	   of	  
procedural	   TIA	  was	  9/1767	   (0.5%),	  while	   access	   complications	  occurred	   in	  13	  patients	   (0.7%)	  
and	  8	  procedures	  (0.5%)	  were	  complicated	  by	  dissection469.	  	  In	  this	  series,	  peri-­‐operative	  stroke	  
was	   extremely	   rare.	   In	   the	   absence	   of	   specific	   studies	   on	   the	   treatment	   of	   stroke	   after	   VA	  
stenting,	   no	   specific	   recommendations	   can	   be	   made	   other	   than	   advising	   that	   they	   should	  
probably	  be	  treated	  in	  the	  same	  way	  as	  after	  CAS	  (section	  2.6.1.2).	  
	  
Recommendation	  115	   Class	   Level	   References	  
Combined	   carotid	   and	   vertebral	   artery	   revascularisations	   should	  
not	  be	  performed	  during	  the	  same	  procedure	  
III	   C	   449,	  451,	  465,466	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3.4.3	  Restenosis	  after	  vertebral	  artery	  stenting	  
Risk	  factors	  for	  instent	  restenosis	  (ISR)	  include	  tortuosity	  of	  the	  extracranial	  VA,	  diameter	  of	  the	  
stent470,	   diabetes	  mellitus,	   smoking,	   small	   VA	   diameters	   and	   long	   stenoses	   (>10mm)471.	   The	  
SSYLVIA	  study	  enrolled	  61	  patients,	  where	  18	  had	  stenoses	  located	  within	  the	  extracranial	  VA.	  
SSYLVIA	   observed	   that	   43%	   of	   BMS	   that	   were	   placed	   in	   the	   extracranial	   VA	   had	   ISR	   after	   6	  
months.	  The	  proportion	  with	   ISR	  was	  considerably	  higher	   in	  ostial	  VA	   lesions,	  compared	  with	  
pre-­‐posterior	  inferior	  cerebellar	  artery	  VA	  lesions	  and	  intracranial	  lesions	  (67%,	  25%,	  and	  32%,	  
respectively)445.	  	  
	  
In	  meta-­‐analyses,	   the	   prevalence	   of	   >50%	   ISR	   after	   VA	   stenting	   varied	   from	   0	   to	   45%454,4712	  
reflecting	  heterogeneity	   regarding	  study	  duration,	   type	  of	   follow-­‐up	   imaging,	  post-­‐procedural	  
medical	  therapy	  and	  technical	  factors	  such	  as	  stent	  diameter.	  Table	  30	  summarises	  the	  findings	  
from	   four	   systematic	   reviews	   on	   predominantly	   retrospective,	   single	   centre	   case	   studies.	  
Eberhardt	   combined	   data	   from	   over	   300	   endovascular	   interventions	   for	   symptomatic	  
atherosclerotic	   disease	   of	   extracranial	   VAs	   and	   reported	   that	   26%	   had	   significant	   ISR	   at	   12	  
months453.	  Stayman454	  combined	  27	  studies	   (980	  patients)	  and	  observed	  that	  restenosis	  rates	  
were	  lower	  with	  DES	  than	  with	  BMS	  (11.2%	  versus	  30%).	  In	  a	  more	  recent	  systematic	  review	  of	  
42	  studies	  published	  between	  1981	  and	  2011	  (1099	  patients),	   ISR	  was	  23%.	  However,	  among	  
151	   patients	   treated	   with	   DES,	   only	   12%	   developed	   a	   significant	   restenosis462.	   Langwieser	  
analysed	  nine	  studies	  comparing	  BMS	  and	  DES473.	  DES	  were	  associated	  with	  significantly	  lower	  
rates	  of	  restenosis	  (8.2%),	  compared	  to	  BMS	  (23.7%)	  (p=0.0001)	  and	  significantly	  lower	  rates	  of	  
symptomatic	   restenosis	   (4.7%)	   compared	   with	   BMS	   (11.6%)	   (p=0.005).	   In	   a	   more	   recent	  
systematic	   review	   of	   studies	   published	   between	   2006	   and	   2012,	   when	   compared	   with	   DES,	  
BMS	   had	   significantly	   higher	   rates	   of	   recurrent	   symptoms	   (2.8%	   vs	   11.3%	   (OR3.32)	   p=0.011)	  
and	  restenoses	  (OR	  0.38,	  p=0.001)464.	  
	  
Table	  30:	  Meta-­‐analysis	  on	  rates	  of	  restenosis	  after	  VA	  stenting	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3.5	  Surveillance	  strategies	  after	  vertebral	  revascularisation	  
Open	   revascularisation	   procedures	   for	   proximal	   VA	   lesions	   are	   associated	  with	   high	   rates	   of	  
symptomatic	  improvement	  and	  low	  rates	  of	  recurrent	  stenoses.	  Hanel	  reported	  late	  outcomes	  
in	   29	   patients	   undergoing	   proximal	   VA	   reconstructions.	   Only	   two	   developed	   recurrent	  
symptoms	  attributable	   to	  vertebrobasilar	   insufficiency,	  while	  only	  one	  of	   fourteen	  patients	   in	  
surveillance	  developed	  a	   recurrent	  VA	  stenosis467.	   	  Kakino	  reported	  no	  cases	  of	   restenosis	  on	  
follow-­‐up	  angiography	  and	  no	  recurrent	  strokes	  during	  a	  mean	  follow-­‐up	  of	  54	  months	  after	  VA	  
to	  subclavian	  artery	   transposition474.	  Recurrent	  stroke	  rates	  after	  endovascular	   treatment	  are	  
detailed	  in	  table	  30.	  
	  
The	  relationship	  between	  VA	  restenoses	  and	  recurrent	  symptoms	  is	  unclear.	  After	  VA	  stenting,	  
ISR	   affects	   11–45%	   of	   patients454,472,	   while	   stent	   fracture	   is	   not	   uncommon	   and	   has	   been	  
associated	   with	   a	   higher	   prevalence	   of	   recurrent	   events471.	   The	   pathophysiology	   of	   stent	  
fracture	   and	   ISR	   is	   probably	   mechanical	   irritation	   from	   the	   fractured	   struts	   causing	   smooth	  
muscle	   proliferation	   and	   impaired	   re-­‐endothelization	   within	   the	   proximal	   VA.	   However,	   in	  
another	  study,	  3/12	  patients	  developed	  stent	  fractures	  and	  all	  remained	  asymptomatic.475	  
	  
Although	   DUS	   can	   identify	   proximal	   VA	   stenoses,	   the	   resolution	   of	   currently	   available	  
ultrasound	   equipment	   is	   sub-­‐optimal	   for	   the	   assessment	   of	   recurrent	   stenoses,	   especially	  
within	   stented	   vessels.	   Hence,	   unlike	   with	   recurrent	   stenoses	   after	   CEA/CAS,	   surveillance	  
imaging	   after	   VA	   endovascular	   interventions	   is	   challenging.	   While	   DSA	   remains	   the	   ‘gold	  
standard’,	   its	   routine	   use	   cannot	   be	   justified,	   especially	   as	   recurrent	   events	   after	   VA	  
interventions	  are	  very	  low.	  Accordingly,	  for	  those	  who	  advocate	  imaging	  surveillance	  after	  VA	  
interventions,	  DUS	  may	  be	  performed	  after	  VA	  stenting	  of	  ostial	  or	  proximal	  VA	  segments	  at	  6	  
Recommendation	  116	   Class	   Level	   References	  
When	  extracranial	  vertebral	  artery	  stenting	  is	  being	  considered,	  drug	  
eluting	  stents	  should	  be	  considered	  in	  preference	  to	  bare	  metal	  stents	  
IIa	   C	   462,464,473	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and	  12	  months	  and	  yearly	  thereafter.	  Any	  suspected	  lesions	  should	  be	  corroborated	  by	  CTA	  or	  




3.6	  Unresolved	  issues	  relating	  to	  vertebral	  artery	  disease	  
The	   Writing	   Group	   identified	   a	   number	   of	   key	   issues	   relating	   to	   the	   investigation	   and	  
management	  of	  atherosclerotic	  VA	  disease	  that	  need	  to	  be	  addressed	  in	  order	  to	  better	  inform	  
future	  guidelines.	  These	  include:	  
	  
Is	  there	  a	  role	  for	  early	  stenting	  in	  recently	  symptomatic	  patients	  with	  extracranial	  VA	  stenoses?	  
	  
What	   is	   the	   optimal	  way	   to	  manage	   a	   recently	   symptomatic	   patient	  with	   an	   intracranial	   VA	  
stenosis?	  
	  
Should	   all	   recently	   symptomatic	   patients	   with	   vertebrobasilar	   TIA/stroke	   be	   started	   on	   dual	  
antiplatelet	  therapy	  once	  parenchymal	  haemorrhage	  has	  been	  excluded?	  
	  
Does	   the	   location	   of	   VA	   stenoses	   in	   symptomatic	   patients	   influence	   decisions	   regarding	  
intervention	  or	  medical	  therapy?	  
	  
What	  is	  the	  optimal	  method	  of	  detecting	  VA	  restenosis	  (CEMRA	  or	  CTA)	  after	  stenting	  with	  BMS	  
or	  DES?	  
	  
How	  best	  to	  manage	  patients	  with	  >70%	  asymptomatic	  restenoses	  after	  VA	  stenting?	  
Recommendation	  117	   Class	   Level	   References	  
Digital	   angiography	   for	   serial	   surveillance	   after	   vertebral	   artery	  
interventions	  is	  not	  recommended	  
III	   B	   454,462	  
	  
Recommendation	  118	   Class	   Level	   References	  
Serial	   non-­‐invasive	   imaging	   of	   the	   extracranial	   vertebral	   arteries	  may	  
be	   considered	   in	   patients	  who	   have	   undergone	   open	   or	   endovascular	  
interventions	  
IIb	   C	  	  	  	   	  	  454,462	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